



Vrije Universiteit Brussel

Faculty of Medicine and Pharmacy

Department of Pharmaceutical and Pharmacological Sciences (FARM)

Research Group of In Vitro Toxicology and Dermato-Cosmetology (IVTD)

Prof. Dr. Pharm. V. Rogiers

Detailed Curriculum Vitae

Prof. Vera Rogiers



CONTENTS

1. GENERAL INFORMATION.....	1
2. FORMATION.....	2
3. FUNCTIONS AND ACTIVITIES IN FACULTY AND UNIVERSITY STRUCTURES	2
3.1. CAREER AT THE VUB	2
3.2. TEACHING DUTIES	3
3.2.1. Academic mandates.....	3
3.2.2. Promotership and co-promotership of doctoral theses at VUB.....	4
3.2.3. Member of the Jury of doctoral and PhD theses at the VUB.....	6
3.2.4. Member of the jury of PhD theses at other universities.....	10
3.2.5. Promoter of theses at pre-doctoral level (over the years).....	11
3.3. OTHER FUNCTIONS AT THE UNIVERSITY (VUB)	13
3.4. ASSIGNMENTS IN COMMITTEES OF OTHER UNIVERSITIES/RESEARCH CENTRES.....	14
4. DESCRIPTION OF RESEARCH ACTIVITIES	14
4.1. BIOCHEMICAL RESEARCH	14
4.2. EXPERIMENTAL IN VITRO TOXICOLOGICAL RESEARCH.....	15
4.3. DERMATO-COSMETIC RESEARCH.....	27
5. SCIENTIFIC HONORS AND AWARDS	31
6. PATENTS.....	33
7. STAYS AT OTHER RESEARCH CENTRES	34
8. MEMBERSHIPS AND EXPERTISE	35
9. NAMES OF SCIENTISTS WHO CAN EVALUATE MY ACHIEVEMENTS	38
10. SCIENTIFIC PUBLICATIONS.....	39
10.1. ARTICLES IN PEER-REVIEWED INTERNATIONAL JOURNALS	39
10.2. ARTICLES IN PEER-REVIEWED NATIONAL JOURNALS.....	65
10.3. BOOKS, ARTICLES IN BOOKS	66
11. ACTIVE PARTICIPATION IN CONGRESSES	74
11.1. ORGANISATION OF CONGRESSES.....	74
11.2. INVITED SPEAKER/LECTURER	78
11.3. ORAL AND POSTER COMMUNICATIONS	97
12. REFEREE FOR JOURNALS - MEMBER OF THE EDITORIAL BOARD.....	129
13. MENTIONS/CITATIONS IN THE MEDIA	129

Curriculum vitae

Prof. Vera Rogiers



1. GENERAL INFORMATION

Family name: **ROGIERS**

First Names: **Vera, Maria**

Born: in Lokeren, Belgium, on February 10, 1952

Sex: female

Nationality: Belgian

Identity Card: 591-6288804-08

Married: on May 2, 1975

Husband: Name: Claes, Luc (†4th April, 1997)
Born: in Leuven, Belgium, on March 31, 1951
Nationality: Belgian
Profession: Vice-President European Development - Avia Partners

Children: Name: Claes, Leen
Born: Jette, November 16, 1981

Address: Kraaivenstraat 43, B-2820 Bonheiden, Belgium

Telephone: Home: +32-15-51-6072
Work: +32-2-477-4516

Fax: +32-2-477-4582

E-mail: vrogiers@vub.ac.be
verarogiers@yahoo.com

Url: <http://www.ivtd-fafy.be>
<http://www.dermatocosmeticcourse.eu>
<http://www.safetycourse.eu>

2. FORMATION

Secondary Education

July 1969: Latin-Mathematics, Koninklijk Atheneum Lokeren, Highest distinction

University

1970: 1st candidature in Pharmaceutical Sciences, University of Ghent, Highest distinction
1971: 2nd candidature in Pharmaceutical Sciences, University of Ghent, High distinction
1972: 1st degree in Pharmaceutical Sciences, University of Ghent, Highest distinction
1973: 2nd degree in Pharmaceutical Sciences, University of Ghent, High distinction
1974: 3rd degree in Pharmaceutical Sciences, University of Ghent, High distinction
1980: Doctoral Degree, Doctor in Pharmaceutical Sciences, Vrije Universiteit Brussel, Highest Distinction. Title of thesis: "*Bijdrage tot de studie van het patroon der niet-veresterde langketenvetzuren in plasma en de vetzuur-samenstelling van de fosfo-lipidenfrakties der erythrocytaire membranen bij kinderen - Uitgewerkt bij cystic fibrosis*"
2000: Master in Applied Toxicology, University of Guilford (UK), Distinction
Master thesis on cultures of hepatocytes

Additional titles or certificates

- Industrial pharmaceutical chemist
- Clinical Biology, certificate A
- Registered in the European Register of Toxicologists (ERT) since 2010.

3. FUNCTIONS AND ACTIVITIES IN FACULTY AND UNIVERSITY STRUCTURES

3.1. Career at the VUB

1974-1980: Assistant in the Department of Biochemistry, Faculty of Medicine and Pharmacy, VUB
1980-1985: First assistant in the Department of Toxicology, Faculty of Medicine and Pharmacy, VUB
1985-1992: Workleader in the Department of Toxicology, Faculty of Medicine and Pharmacy, VUB
1992-1997: "ZAP" member, degree "head docent" in the Department of Toxicology, Faculty of Medicine and Pharmacy, VUB
Since 2000: Head of the Department of Toxicology, Faculty of Medicine and Pharmacy, VUB

- 1997-2001: Professor and Head of Toxicology, Faculty of Medicine and Pharmacy, VUB
- Since 2001: Ordinary Professor and Head of the Department of Toxicology, Dermato-Cosmetology and Pharmacognosy, Faculty of Medicine and Pharmacy, VUB
- Since 2011: Head of Research Cluster "Lever & Celbiologie & Toxicologie", Consortium consisting of the research groups IVTD, *in vitro* Toxicology and Dermato-Cosmetology (previous name FAFY), LIVR (Liver Cell Biology Lab) and SKIN (Skin Research and Physiology).
- Since 2014: Chair of FARM: Farmaceutische en Farmacologische Wetenschappen (all pharmaceutical groups together)

3.2. Teaching duties

3.2.1. Academic mandates

- 1974-1980: Practical courses "Biochemistry", 2nd candidature of Medicine
- 1980-2000: Practical course "Toxicology" (135 hrs), 2nd year in Pharmaceutical Sciences
- 1984-1998: Professor of the course "Bromatology, second part: Chemical quality and toxicity of cosmetics", 2nd year in Pharmaceutical Sciences
- Since 1987: Professor of the course "Introduction to Cosmetic Sciences" (15 hrs + 15 hrs practical courses), 3rd year in Pharmaceutical Sciences
- Since 1987: Regular teacher for UPV, iPAVUB, AZ-VUB, Wetenschapsweek VUB,
- 1988-2000: Professor of the course "Medical Terminology" (30 hrs), 1st candidature in Medical-Social Sciences
- 1988-2000: Professor of the course "Medical Terminology" (30 hrs) in the short programme B (1 year), candidate Medical-Social Sciences
- 1988-1992: Organiser of and lecturer at the course "Getuigschrift in Dermato-Cosmetische Wetenschappen" (60 hrs) at the VUB. A Saturday mornings-course for specialization in Dermato-Cosmetic Sciences. Only to be followed by students in the possession of a university degree
- Since 1989: Responsible for the course "Bijzondere Methodenleer" (45 hrs). On demand of the dean, not officially rewarded
- Since 1992: Organizer and lecturer of the "Intensive Course in Dermato-Cosmetic Sciences (30 hrs) at the VUB. A one-week course to form specialists for the European cosmetic industry (iPAVUB-course since 1998).
- Since 1993: Professor of the course "Pharmaceutical Technology - Dermatologic Preparations" (20 hrs theory and 60 hrs practice), 2nd year in Pharmaceutical Sciences
- 1994-1995: Lecturer in the course "Biomedical Research Technology - Part: The use of cell cultures in toxicological research", 1st and 2nd year Biomedical Sciences
- In 1996: Lecturer in the PhD program for Medical Sciences "Biotransformation of Drugs" at the Heymans Institute, Rijksuniversiteit Gent, with the lecture "Methodology for *in vivo* metabolism studies"
- 1997- 2000: Lecturer in a study program for teachers of secondary high schools in BE

- Since 1998: Professor of the course "Quality and toxicity of cosmetics" (15 hrs theory, 30 hrs practice), 3rd year in Pharmaceutical Sciences
- Since 1998: Professor of the course "Cosmetic Dossier" (30 hrs theory), 3rd year in Pharmaceutical Sciences
- Since 2000: Organizer of and lecturer in the iPAVUB-course "Safety Assessment of Cosmetics in the EU" (60 hrs) at the VUB, a one-week course to form safety assessors for the cosmetic industry. This course is included in an official risk assessment program of Trisk at the European level.
- Since 2001: Professor of the course "Toxicology" (45 hrs theory + 105 hrs practice), 2nd year in Pharmaceutical Sciences
- Since 2002: Lecturer of the course "Toxicology", 2nd and 3rd year Medical Doctor
- In 2003: Lecturer in the course "Intensive training course EU-candidate countries" organized by TAIEX and Colipa (1 week)
- In 2006: Organisation of a Course on Toxicology (Part I) and Ecotoxicology (Part II) in collaboration with VITO, for the Belgian Federal Government, Division Security of the Food Chain and Environment
- Since 2008: Guest Professorship at the Universiteit Gent (5%), responsible for the course on Cosmetic Sciences for Master Pharmacy students.

3.2.2. Promotership and co-promotership of doctoral theses at VUB

- 1989: co-promoter of the doctoral thesis in Pharmaceutical Sciences of Yves VANDENBERGHE "Activity, expression and regulation of glutathione S-transferase isoenzymes in cultured hepatocytes"
- 1994: promoter of the doctoral thesis in Pharmaceutical Sciences of Miranda CORNET "Contribution to the study of the biotransformation and toxicity of 2-methylpropene (isobutene)"
- 1994: promoter of the doctoral thesis in Pharmaceutical Sciences of Sandra COECKE "Hormonal regulation of flavin-containing monooxygenase and glutathione S-transferase in rat liver. An *in vitro* approach"
- 1996: co-promoter of the doctoral thesis in Pharmaceutical Sciences of Karen MERTENS "Glutation-afhankelijke detoxicatie van hydroperoxiden in culturen van hepatocyten"
- 1998: promoter of postdoctoral work of Dr. Pharm Betty GHERARDI "Argiles: les nouveaux biomatériaux" (sponsored by C. Dior)
- 2000: co-promoter of the doctoral thesis in Pharmaceutical Sciences of Karen DE SMET "Collagen gel cultures of rat hepatocytes as *in vitro* tools in pharmaco-toxicology. An evaluation of phase I biotransformation"
- 2000: promoter of the doctoral thesis in Pharmaceutical Sciences of Tamara VANHAECKE "Hormonal regulation and zonation of glutathione S-transferase in rat hepatocyte cultures"
- 2000: promoter of the doctoral thesis in Pharmaceutical Sciences of Sonja BEKEN "Characterisation and optimisation of collagen gel cultures of hepatocytes as *in vitro* tools in pharmaco-toxicology"
- 2001: promoter of the doctoral thesis in Pharmaceutical Sciences of Kristien DE PAEPE "Evaluation of the efficacy of dermato-cosmetic products"

- 2004: promoter of the doctoral thesis in Pharmaceutical Sciences of Peggy PAPELEU (OZR-researcher) "Hydroxamate histone deacetylase inhibitors and their effects on cell cycle-related signal transduction in primary rat hepatocytes - Implications for *in vitro* toxicology and drug development"
- 2005: promoter of the doctoral thesis in Pharmaceutical Sciences of Greetje ELAUT (FWO-researcher) "Pharmaco-toxicological screening of hydroxamic acid-based histone deacetylase inhibitors in primary hepatocyte cultures"
- 2005: co-promoter of the doctoral thesis in Medical Sciences of J.P. HACHEM, MD (UZ-VUB) "The two-compartment model of the stratum corneum: biochemical aspects and pathophysiological implications"
- 2006: promoter of the doctoral thesis in Pharmaceutical Sciences of Mathieu VINKEN (FWO-researcher) "The effects of hydroxamate histone deacetylase inhibitors on the expression of connexins in primary cultures of rat hepatocytes"
- 2007: promoter of the doctoral thesis in Pharmaceutical Sciences of Evi HOUBEN "The barrier function of the skin in relation to epidermal ceramidase activity"
- 2007: promoter of the doctoral thesis in Pharmaceutical Sciences of Sarah SNYKERS (IWT-bursary) "*In vitro* differentiation of postnatal progenitor cells into functional hepatocytes"
- 2008: promoter of the doctoral thesis in Pharmaceutical Sciences of Tom HENKENS "Effects of hydroxamate-based histone deacetylase inhibitors on the xenobiotic biotransformation capacity of cultured primary rat hepatocytes"
- 2008: promoter of the doctoral thesis in Pharmaceutical Sciences of Marleen PAUWELS "Critical evaluation of the current EU regulatory framework for the safety assessment of cosmetics"
- 2011: co-promoter of the doctoral thesis in Biomedical Sciences of Inge MANNAERTS "The role of histone deacetylases during hepatic stellate cell activation and fibrinogenesis" (promoter: Prof. Leo Van Grunsven, LIVR)
- 2011: promoter of the doctoral thesis in Pharmaceutical Sciences of Feras AL BATTAH (Erasmus Mondus) "Contribution to the isolation and hepatic differentiation of postnatal stem/progenitor cells from human adipose tissue"
- 2012: promoter of the doctoral thesis in Pharmaceutical Sciences of Joanna FRACZEK "Study of the epigenetic modification of gene expression by interference with histone acetylation and DNA methylation in cultured rat hepatocytes"
- 2012: promoter of the doctoral thesis in Pharmaceutical Sciences of Tatyana Yordanova DOKTOROVA "Evaluation of carcinogen-modified global gene expression profiles in live-based *in vitro* models with focus on primary hepatocyte cultures"
- 2012: promoter of the doctoral thesis in Pharmaceutical Sciences of Joery DE KOCK "Differentiation of adult progenitor cells (human, rat) into hepatocyte-like cells: potential new *in vitro* models for preclinical research"
- 2015: promoter of the doctoral thesis in Pharmaceutical Sciences of Robim. MARCELLINO RODRIGUES "Human skin-derived precursors as a novel cell source for the *in vitro* prediction of drug-induced liver injury".
- 2015: promoter of the doctoral thesis in Pharmaceutical Sciences of Bart DESMEDT - "Illegal Cosmetics on the Belgian Market"
- 2015: promoter of the doctoral thesis in Pharmaceutical Sciences of Eva RAMBOER - "Development of a differentiated hepatic *in vitro* system for long-term pharmacotoxicological studies based on (epi)genetic modification of primary hepatocytes".

Promotorship of ongoing doctoral research projects:

- *“Innovative microRNA-based differentiation strategy to develop metabolically stable long-term hepatocyte cultures applicable in early preclinical drug development”*
BOLLEYN Jennifer-Promoters: V. Rogiers and T. Vanhaecke-start 2009 as assistant (planned promotion 2016)
- *“Development of a differentiated hepatic in vitro system for long-term pharmacotoxicological studies base upon (epi)genetic modification of human primary hepatocytes”*
ATES Gamze-Promoters: V. Rogiers and T. Doktorova-start 2011 (planned promotion 2016)
- *“Differentiation of progenitor cells of umbilical cord skin and Wharton’s Jelly into functional hepatocytes: a new in vitro model in preclinical drug development”*
BUYL Karoline.-Promoters: V. Rogiers, J. De Kock and T. Vanhaecke-start 2011 (planned promotion 2016).
- *“PRIMISTRA: Ontwikkeling van een prioritariseringsstrategie voor de risico-evaluatie van voedingscontactmaterialen”*, VAN BOSSUYT Melissa. - VUB Promoters: V. Rogiers and T. Vanhaecke and WIV Promoters: B. Mertens and E. Van Hoeck.
- *“Characterisation of connexin43 and its hemichannels as biomarkers and pharmacological targets in acute liver failure: a combined in vitro-in vivo study”*
MAES Michael. - Promoters: M. Vinken, V. Rogiers and B. Cogliati-start 2014 (planned promotion 2017)
- *“Characterisation of connexins, pannexins and their hemichannels as biomarkers and pharmacological targets in liver steatosis: a combined in vitro-in vivo study”*
WILLEBRORDS Joost. - Promoters: M. Vinken, V. Rogiers and B. Cogliati-start 2014 (planned promotion 2018)
- *“Characterisation of connexins, pannexins and their hemichannels as biomarkers and pharmacological targets in liver fibrosis: a combined in vitro-in vivo study”*
YANGUAS CRESPO Sara. - Promoters: M. Vinken, V. Rogiers and B. Cogliati - start 2014 (planned promotion 2018)

3.2.3. Member of the Jury of doctoral and PhD theses at the VUB

- 1993: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of J. Jore "Formation of subviral particles by translation of subgenomic poliovirus RNAs in a cell-free system and *Saccharomyces cerevisiae*", Dept. of Microbiology and Hygiene, VUB (promoter Prof. A. Boeyé)
- 1994: member of the jury of the doctoral thesis in Biomedical Research of P. Clarys. "Non-invasive measurement of biophysical skin properties in the *in vivo* assessment of the percutaneous absorption of various topically applied compounds", Dept Human Biometry and Biomechanics (Prof A. Barel), VUB
- 1994: member of the jury of the doctoral thesis in Pharmaceutical Sciences of R. Kiekens "Assessment of the percutaneous absorption of various topically applied compounds", Dept. Human Biometry and Biomechanics (Prof. A. Barel), VUB
- 1994: "De pancreatische B-cel populatie: een heterogene celgroep met aanpassingsvermogen", VUB, Dept. Metabolism and Endocrinology, (Prof. D. Pipeleers)

- 1995: member of the jury of the doctoral thesis in Pharmaceutical Sciences of S. Sarre "Neurochemical and neuropharmacological studies in the monoaminergic mesotelencephalic neuron systems in rat brain using *in vivo* microdialysis", Dept. of Pharmaceutical Chemistry, VUB (promoters Prof. Y. Michotte, Prof. G. Ebinger)
- 1995: member of the jury of the doctoral thesis in Pharmaceutical Sciences of I. Vercruysse "Study of the influence of calcium antagonists on the disposition of propranolol", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoters Prof. A. Dupont and Prof. D.L. Massart)
- 1995: member of the jury of the doctoral thesis in Pharmaceutical Sciences of K. Van Belle "Study of the pharmacokinetics and pharmacology of antiepileptic drugs in rat, using *in vivo* microdialysis", Dept. of Pharmaceutical Chemistry, VUB (promoter Prof. Y. Michotte)
- 1995: member of the jury of the doctoral thesis in Pharmaceutical Sciences of Chr. Hartmann "Contribution to better practices in method validation - Evaluation of the bias of an analytical method", Department of Pharmaceutical and Biomedical Analysis, VUB (Prof. D.L. Massart)
- 1996: member of the jury of the doctoral thesis in Pharmaceutical Sciences of W. Penninckx "Tools for Method Development and Validation in Atomic Absorption Spectrometry", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. D. L. Massart)
- 1996: member of the jury of the doctoral thesis in Pharmaceutical Sciences of A. Matton "Influence of opiates and stress on the prolactin secretion *in vivo* in male rats", Dept. of Pharmacology, VUB (promoter Prof. L. Vanhaelst)
- 1997: member of the jury of the doctoral thesis in Pharmaceutical Sciences of K. Thorre "Neurochemical and neuropharmacological studies on the central serotonergic system", Dept. of Pharmaceutical Chemistry, VUB (Prof. Y. Michotte)
- 1998: member of the jury of the PhD thesis of Yuwande Patanawong in the Master Program in Medical and Pharmaceutical research "Encapsulation of morphine and bupivacaine in liposomes", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. J. A. Plaizier-Vercammen)
- 1998: member of the jury of the doctoral thesis in Pharmaceutical Sciences of P. Van Keerbergen "Development and implementation of a Run Suitability system for graphite furnace atomic absorption spectrometry", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. D. L. Massart)
- 1998: member of the jury of the doctoral thesis of E. Manou "Evaluation of the dermatocosmetic properties of essential oils from aromatic plants by means of skin bioengineering methods", Dept. Biometry and Biomechanics, VUB (promoter Prof. A. Barel)
- 1999: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of M. Griep "Health, nutritional and dental status interfere in the age-induced change of food odour perception and preference", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. D.L. Massart)
- 1999: member of the jury of the doctoral thesis in Medical Sciences of T. Niki, MD "Hepatic stellate cell - major fibroblast transition: Evaluation of antifibrogenic novel transdifferentiation markers", Dept. of Cell Biology and Histology, VUB (promoter Prof. A. Geerts)

- 2000: chair of the jury of the doctoral thesis of P. Izurieta "Cholinergic, dopaminergic and GABA-ergic interactions in striatum and substantia nigra: *in vivo* neurochemical effects of muscarinic antagonists", Dept. of Pharmaceutical Chemistry (promoters Prof. Y. Michotte, Prof. G. Ebinger, co-promoters S. Sarre and R. Vrijssen)
- 2000: member of the jury of the doctoral thesis of A.K.D. Ghopus Muhammad Khan "Neuropharmacological studies on focally-evoked pilocarpine-induced seizures: benzodiazepine and adenosine agonists-mediated depressant actions", Dept. of Pharmaceutical Chemistry, VUB (promoters Prof. Y. Michotte, Prof. G. Ebinger)
- 2000: member of the jury of A. Demuynck "De ontwikkeling van corrigerende producten voor de reiniging en verzorging van de vette en acné-gevoelige huid: galenische formulaties en efficiëntiemetingen" for the degree of Industrial Pharmacist, VUB (promoters: Prof. B. Rombaut, Dr. Y. Vander Heyden; co-promoter Dr. S. Lauwers)
- 2002: member of the doctoral thesis in Pharmaceutical Sciences of M. Brisaert "Chemical stability of erythromycin and tretinoin in topical preparations", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. J.A. Plaizier-Vercammen)
- 2002: member of the doctoral thesis in Medical Sciences of K. Rombauts, "Modulation of expression of fibrosis-related genes by pharmacologically induced hyperacetylation of histones", Dept. of Cell Biology and Histology, VUB (promoter Prof. A. Geerts)
- 2002: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Qian Guo "Dimension reduction in data mining", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoters Prof. D.L. Massart and Prof. J. Smeyers-Verbeke)
- 2003: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of J.A. Fernandez Pierna "Improvements in the multivariate calibration processes", Dept. of Pharmaceutical and Biomedical Analysis, VUB (promoter Prof. D.L. Massart)
- 2003: member of the jury of the doctoral thesis in Medical Sciences of Karine Hellemans "Expression of PPARs and RXRs during hepatic stellate cell transdifferentiation. Implications for liver fibrogenesis", Dept. of Cell Biology and Histology, VUB (promoter Prof. A. Geerts)
- 2004: member of the jury of the doctoral thesis in Dermatology of Truus Roelandt "Serine proteases inhibitors accelerate barrier recovery by protease-activated receptor-2 dependent mechanisms" (promoter Prof. D. Roseeuw; co-promoter Dr. J. P. Hachem)
- 2004: member of the jury of the doctoral thesis in Dermatology of Carol Huyghebaert "Stratum corneum acidification improves key epidermal barrier functions" (promoter Prof. D. Roseeuw; co-promoter Dr. J. P. Hachem)
- 2005: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Sébastien Gourvenec "Chemometric methods for batch process control using NIR spectroscopy", Dept. of Pharmaceutical and Biomedical Analyses (promoters Prof. D.L. Massart and Prof. J. Smeyers-Verbeke)
- 2005: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Ling Jin "Simplex local methods for multivariate calibration", Dept. of Pharmaceutical and Biomedical Analyses, VUB (promoters Prof. D. L. Massart and Prof. J. Smeyers-Verbeke)

- 2005: member of the jury of the doctoral thesis in Pharmaceutical Sciences of Elke Van Ghyseghem "Orthonogal chromatographic systems for the characterization of impurities in drugs", Dept. of Pharmaceutical and Biomedical Analyses, VUB (promoter Prof. Y. Vander Heyden)
- 2006: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Bart Stragier "Characterization of the interaction between angiotensin fragments and the central neurotransmitter systems" (promoters: Prof. Y. Michotte, Prof. S. Sarre, Prof. I. Smolders, Prof. Y. Vander Heyden)
- 2006: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Jan Luypaert "Data preprocessing methods to improve the results of qualitative and quantitative pharmaceutical applications on creams and green tea" (promoters: Prof. D.L. Massart, Prof. Y. Vander Heyden)
- 2007: member of the jury of the doctoral thesis in Pharmaceutical Sciences of Eric Deconinck "Tree-based modeling approaches to predict membrane passage properties of drugs" (Promoters: Prof. Y Vander Heyden, Prof. D. Coomans)
- 2010: member of the jury of the doctoral thesis in Pharmaceutical Sciences of Rui Yang "Investigation of the role of angiotensin IV and angiotensin A in blood pressure regulation and renal hemodynamics" (promoters: Prof. A. Dupont, Prof. I. Smolders)
- 2011: member of the jury of the doctoral thesis in Medical Sciences of Sandy Lenie "Characerization of an *in vitro* mouse follicle bioassay to study the effects of endocrine disrupters on ovarian homeostasis and gametogenesis" (promoter: Prof. C. Bourgain)
- 2011: member of the jury of the doctoral thesis in Pharmaceutical Sciences of Anneleen Schallier "Discovery of glutamate transporters as novel drug targets of epilepsy and Alzheimers disease" (promoter: Prof. Y. Michotte)
- 2012: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Christophe Tistaert "Data analysis of chromatographic fingerprints" (promoter: Prof. Y. Vander Heyden)
- 2012: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Ahmed Younes "Evaluation of recently introduced polysaccharide-based chiral stationary phases to update generic separation strategies in NPLC and RPLC" (promoters: Prof. Y. Vander Heyden and D. Mangelings)
- 2014: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Katrijn De Klerck "Chiral separations with polysaccharide-based stationary phases in supercritical fluid chromatography.-definition of a separation strategy for method development" (promoters: Prof.Y. Vander Heyden and D. Mangelings)
- 2015: chair of the jury of the doctoral thesis in Pharmaceutical Sciences of Jolien Van Schoors "UHPLC with electrochemical detection for *in vivo* monoamine measurements (promoters: Prof . A. Van Eeckhaut and I. Smolders)

3.2.4. Member of the jury of PhD theses at other universities

- 1991: invited expert member of the jury of the doctoral thesis of M. Cornelis "The use of keratinocytes as *in vitro* model for irritancy testing of pharmaceuticals", Dept. of Dermato-Pharmacology, University of Paris, Châtenay-Malabry, Paris, France (promoter Prof. Wepierre)
- 1993: invited expert member of the jury of the doctoral thesis of S. Thysman "La résorption transcutanée de médicaments par iontophorèse", Service de Pharmacie Galénique, Université Catholique de Louvain, Belgium
- 1994: member of the jury of the doctoral thesis of Florence Nicolas "Constitution et caractérisation fonctionnelle d'une banque d'hépatocytes humains, de singe et de chien cryopréservés", Université d'Aix-Marseille II, France (promoter Prof. J. P. Marty)
- 1994: member of the jury of the doctoral thesis of Nicole G.M. Palmen "Biological effects in human erythrocytes *in vitro* exposed to xenobiotics", Rijksuniversiteit Limburg, The Netherlands
- 1995: member of the jury of the doctoral thesis of G. Ciaramella, Dept. of Molecular Biology and Biochemistry, University College London, UK (promoter Prof. E. Shephard)
- 1995: invited member of the jury of the doctoral thesis of J.C. Ourlin "Transfection transitoire d'hépatocytes humains et de lignées cellulaires humaines: application à l'étude de la régulation des gènes CYP3A4 et CYP3A7", Dépt. de Biochimie et Biologie Moléculaire, Université de Montpellier II. Montpellier, France (promoter Dr. P. Maurel)
- 1996: invited member of the jury of the doctoral thesis of K. Kramer, Dept. Molecular Biology and Biochemistry, University College London, UK (promoter Prof. I. Phillips)
- 2000: invited member of the jury of the doctoral thesis of Mrs. D. Herriott, Dept. of Molecular Biology and Biochemistry, University College London, UK (promoter Prof. E. Shephard)
- 2000: invited member of the jury of the doctoral thesis of P. De Loecker, Faculty of Medicine and Pharmacie, Universitaire Instellingen Antwerpen, Antwerpen, Belgium
- 2000: invited member of the jury of the doctoral thesis of Ch. Lechanteur "Etude des effets thérapeutiques de l'administration de gènes suicides et de cytokines dans les carcinomatoses péritonéales", Université de Liège, Belgium
- 2001: invited member of the jury of the doctoral thesis of N. Carcia Carero "Caractérisation de la fonction barrière d'un type d'épiderme humain reconstruit", Faculté de Châtenay-Malabry, Université de Paris XI, France (promoter Prof. J.P. Marty)
- 2002: invited member of the jury of the doctoral thesis in Medical Sciences of Ann Don Porto Carero "The influence of environmental factors on the respiratory system; respiratory toxicity", Lab. Pneumologie K.U.L., Leuven, Belgium (promoter Prof. B. Nemery, KUL; co-promoter Dr. G. Schoeters, VITO)

- 2002: invited member of the jury of the doctoral thesis of A. De Smedt "Detectie van toxische effecten van PCB126 en PCB153 op het hemato-immuunsysteem door gebruik te maken van in vitro myeloïde, erythroïde en dendritische cellen", Universitaire Instelling Antwerpen, Antwerpen, Belgium (promoter Dr. G. Schoeters)
- 2005: invited member of the jury of the doctoral thesis in pharmaceutical sciences of Marijke Dhondt "Optimisation and validation of an alternative mucosal irritation test", Lab. of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Ghent University (promoter: Prof. J. P. Remon)
- 2006: invited member of the jury of the doctoral thesis of Bart De Wever "Reconstituted human epidermal, corneal and oral epithelial tissue models: alternatives to animal test models for the pre-clinical evaluation and risk assessment of topical products", Research Institute Growth and Development (GROW) and Dept. of Molecular Cell Biology, University Maastricht, Maastricht, The Netherlands.
- 2007: invited member of the jury of the doctoral thesis of Apr. Ruud Dirkx "Investigation of the interrelationship peroxisomes-mitochondria in hepatocytes", Faculty of Pharmacy, KUL, Leuven, Belgium (promoters: Prof. M. Baes, Prof. P. Van Veldhoven)
- 2010: invited member of the jury of the doctoral thesis of Apr. Caroline Vanparys "Development of in vitro screening systems for classification of endocrine disrupting compounds: an 'omics' approach" Universiteit Antwerpen (UA) (promoters: Prof. Dr. W. De Coen, Prof. Dr. R. Blust)
- 2014: invited member of the jury of the doctoral thesis of Mr. M.K. Prinsen "The isolated chicken eye test to replace the draize eye test in rabbits. From development to implementation: The long and winding road" Universiteit Wageningen, The Netherlands (promoters: Prof. Dr. R.A. Woutersen and Prof. Dr. C.F.M. Hendriksen, co-promotor: Dr. C. Krul)
- 2015 invited member of the jury of the doctoral thesis of T. Billiet "Gelatin Functionalizations for Cell Embedding in 3D Geometries using Rapid Prototyping Technology" University Ghent, Belgium (promoters: Prof. A.M. Maddar, Prof. P. Dubrueel and Prof. M. Cornelissen)

3.2.5. Promoter of theses at pre-doctoral level (over the years)

National: over all years of the whole carrier in toxicology, **per year:**

Promoter of 4-5 endworks of VUB master students in Pharmaceutical Sciences

Promoter of 1-2 endworks of VUB master students in Cell and Gene Technology,

Promoter of 1-2 endworks of students from Technical Schools (COOVI, Erasmus Hogeschool Brussel, etc.)

Promoter of 1-2 endworks of VUB master students in Biomedical Sciences

International:

- 1995: supervisor of the thesis of Linsey CHARLOTTE, University of Wolverhampton, School of Applied Sciences "The preservation of liver-specific functions of hepatocytes in primary culture using glutathione S-transferase" (Honours Project in Chemistry and Biochemistry)
- 1995: supervisor of the thesis of Kuldeep TANDA, University of Wolverhampton, School of Applied Sciences "The effects of different culture conditions on the biotransformation in rat hepatocytes" (Honours Project in Chemistry and Biochemistry)
- 1997: promoter of the master thesis of Domingo Ronald REAGAN S., University of Wolverhampton, School of Applied Sciences "Regulation of the expression of glutathione S-transferase isoenzymes in collagen gel sandwich and immobilisation cultures of rat hepatocytes" (Master Program in Medical and Pharmaceutical Research)
- 2003: promoter of the master thesis of Munira Abdul MUHAMMAD "Ceramidase activity in mammalian epidermis" (Master Program in Medical and Pharmaceutical Research, VUB)
- 2004: promoter of the thesis of K. KROEZE "De rol van epidermale ceramidase activiteit in de barrièrefunctie van de huid" (Biopharmaceutical Sciences student at the University of Leiden, Laboratory of Prof. J. Bouwstra, NL)
- 2004: promoter of the thesis of G. BAKALOVA "The role of epidermal ceramidase activity in desquamation" (Pharmacy student, Medical University of Sofia, Bulgaria)
- 2005: supervisor of master thesis of Vijay MORAMPUDI "The effect of liver-specific cytokines and Trichostatin A on the differentiation process of bone marrow stem cells into hepatocyte-like cells" (Master Program in Medical and Pharmaceutical Research, VUB)
- 2008: promoter of the master thesis of DRYANKOVA V., student of Medical University of Sofia (Erasmus/Socrates programme) "Effects of genotoxic carcinogens, non-genotoxic carcinogens and non-carcinogens on the expression of Cx32 in cultures of primary rat hepatocytes treated with the histone deacetylase inhibitor Trichostatin A"
- 2009: promoter of the master thesis of ALUANI S., student of Medical University of Sofia (Erasmus/Socrates program) "Biomarkers for detection of non-genotoxic hepatocarcinogens"
- 2010: promoter of the master thesis of TODOROVA S., student of Medical University of Sofia (Erasmus/Socrates programme) "Reactive oxygen species as possible biomarker for detection of non-genotoxic carcinogens"
- 2011: promoter together with collaborator M. Vinken of the master thesis of OGNQNOVA N., student of Medical University of Sofia (Erasmus/Socrates program) "The effect of genotoxic and non-genotoxic hepatocarcinogens on connexin 32 protein expression".
- 2012: promoter of the master thesis in Pharmaceutical Sciences of Pieter-Jan DE JONGHE "Karakterisatie van hepatische merkers in navelstreng afgeleide mesenchymale stamcellen"

- 2013: promoter of the master thesis in Pharmaceutical Sciences in the framework of the Erasmus/Socrates program of JG DIEZ, student from the University of Madrid, Spain. "Evaluation of the influence of liver-specific extracellular matrix substratum on the *in vitro* hepatogenic differentiation of human skin-derived precursors."
- 2013: promoter of the master thesis in Pharmaceutical Sciences of I. CASTRO, Universidade de Lisboa, Portugal, "Influence of different medium compositions in the generation and functionality of postnatal skin derived stem cells".
- 2013: promoter of the master thesis of Daphné BLANCHON of the Universidade de Lisboa, Portugal "The effect of acetaminophen (paracetamol) on the expression of Connexin 43 and pannexin1 in primary cultures of rat hepatocytes."

3.3. Other functions at the university (VUB)

- 1978-1985: Delegate of the assistants in the Faculty Commission of Medicine and Pharmaceutical Sciences
- Since 1980: Member of the Pharmaceutical Commission
- 1981-1993: Organizer of the Postacademic courses for Pharmacists at the Pharmaceutical Institute
- Since 1986: Member of the Faculty Commission as academic staff
- Since 1987: Member of the Research Council at the Campus Jette
- 1990-1993: Member of the Sub-commission Research Council
- Since 1996: Delegate of the Vrije Universiteit Brussel in the "Nationale Raad van de Orde van Apothekers"
- Since 1998: Member of the Pharmaceutical Commission of doctoral students
- 1998-2012: President of iPAVUB (Instituut voor Post-academische Vorming VUB)
- 1999-2014: Member of the Ethical Commission for the Protection of Animals
- Since 1999: Member of the Commission "Stage-apothekers"
- In 2000: Responsible for the Zomeruniversiteit, under iPAVUB coordination
- Since 2001: VUB Member of the "Geneeskundige Stichting Koningin Elisabeth"
- 2002-2014: Member of the VUB Commission "Ethisch Proefdiergebruik", Advisory Committee
- Since 2003: Member of the VUB Commission "Beroepscommissie AP"(Professional Commission for the Academic Staff), Advisory Committee
- 2003-2009: Member at the VUB of the "Commissie Geneesmiddelenonderzoek" (Commission for Drug Research) of the Flanders Fund for Scientific Research (FWO) (first mandate)
- 2004-2010 Member of VUB in Med1 and Chairman – "Expert panel Farmaceutische Wetenschappen en Eiwitchemie (Med1)"
- 2005-2015: Member of the VUB Senate
- Since 2008: Member of the Commission of Ordinary Professors responsible for advising on the evaluation, promotion and renewal of VUB academic staff
- 2009-2011: Member of the VUB Commission "Kenniss, Innovatie en Technologie Transfer (KITT)
- Since 2012: Substitute of Prof K. Vanderkerken (GF) as ZAP-member in the Research Council VUB
- Since 2012: Member of 'Industrial Research Fund' VUB (IOF council)
- In 2013: Member of Commission for Scientific Integrity (CWI) as expert in the field

- Since 2013: Elected member for Pharmaceutical Sciences in the Research Council VUB of Campus Jette, UMCOR
- Since 2013 Member of the Evaluation and Promotion Commission (EBC) of ZAP-members VUB
- Since 2013: Substitute at the Deontological Committee of the FAGG
- Since 2013: Member of the Hercules Advisory Board Commission of the VUB
- Since 2013: Substitute FWO-members of the Commission in the Biomedical Sciences
- Since 2014: Chair of Alliance Research Group VUB-UGent (contract renewal of 30/06/2011) “Connexin Signalling Research Group”
- 2014-2015: Representative of the faculty for maintaining the academic character in the Board of the University Hospital Brussels, RUZ (Raad van Bestuur)
- Since 2014: Chair of Cluster FARM (Pharmaceutical and Pharmacological Sciences), bringing all research groups of the pharmaceutical institute VUB together
- Since 2015 Member of the Innovation- and Valorisation committee (I&V) VUB
- Since 2015 Member of the Steering Committee Bright Core, VUB-ULB Alliance.

3.4. Assignments in committees of other universities/research centres

- March 2004: Invited member of the scientific committee for the evaluation of the candidatures for the career planning in the Department of "Longtoxicologie", at the K.U. Leuven (applicant Dr. P. Hoet)
- May 2011: Invited member of the scientific committee for the evaluation of the candidatures for the career planning of the Department of Toxicology at the University of Antwerp (applicant Dr. G. Schoeters)
- Dec 2011: Invited member of the scientific committee for the evaluation of the candidatures for the tenure track Toxicology at the University of Ghent.
- Since 2014: Mandate in “Wetenschappelijke Commissie Voeding, Geneesmiddelen en consumptiegoederen” (WIV-ISP)
- Oct 2015: Invited member of the “Evaluation and Promotion Commission” at the University of Ghent for ZAP promotions

4. DESCRIPTION OF RESEARCH ACTIVITIES

4.1. Biochemical research

To obtain a doctoral degree in Pharmaceutical Sciences the research carried out by Rogiers was situated in the field of the metabolism of lipids in children suffering from Cystic Fibrosis. The plasma free fatty acid pattern and the exchange process of fatty acids between blood and phospholipids and red cell membranes was studied in Cystic Fibrosis patients and in heterozygotes in comparison with healthy subjects. This research was internationally appreciated, shown by a number of international publications, a monograph, and participation in many international congresses and by being invited speaker abroad. *To this thesis the prize of the Belgian Cystic Fibrosis Association was awarded.*

4.2. Experimental *in vitro* toxicological research

The major research focus of Rogiers in the VUB department of Toxicology (FAFY, named now IVTD: *In Vitro* Toxicology and Dermato-Cosmetology) has always been situated in the field of experimental *in vitro* toxicology and is concerned with the **development of *in vitro* models for pharmaco-toxicological purposes as an alternative for the use of experimental animals** in biotransformation and toxicity studies of drugs, cosmetics and other chemical substances. In this context, **using the *in vitro* models developed, actually drug-induced liver injury (DILI) and the role of connexins, pannexins and hemi-channels in liver disease are being investigated. Also part of the work develops into the direction of translational research.**

Overview of the research over the passed years

Research has been carried out using liver cells of different species, including human cells. As such freshly isolated hepatocytes, stem cell-derived hepatocyte-like cells, their cultures and co-cultures have been explored. Sophisticated culture models including co-culture of hepatocytes with epithelial bile duct cells, collagen gel cultures (sandwich and immobilisation gel cultures), 3D-culture in a natural liver scaffold, etc. have been developed. Many of these methods are now used worldwide.

Over the past years, the focus on the lab was essentially on 3 major topics:

- (1) **Stabilisation of hepatocytes in culture:** When hepatocytes of different species, including man, are cultured, they dedifferentiate as a function of culture time and lose their specific phenotypic and functional properties.

In order to counteract dedifferentiation, different strategies were used. The initial strategy was based on mimicking the natural microenvironment of the cells. These include (i) *the reestablishment of cell-extracellular matrix interactions*; (ii) *the reintroduction of heterotypic cell-cell contacts* and (iii) the addition of differentiation promoting compounds to the cell culture medium. Onwards the (iv) *innovative strategy of epigenomic modification of cells* was introduced.

→ With respect to the reestablishment of *cell-extra cellular matrix interactions*, work was done using 2D- and 3D-cultures (collagen, mixtures of different matrix proteins) in order to maintain the polarity of the hepatocytes in culture. Sandwich and immobilisation gel cultures were successfully developed, but a major disadvantage was the hindered exchange of compounds between the cells and the culture medium.

Innovative methodological developments in our group were decellularisation of liver within 1 hour and the recellularisation of this 3D-natural scaffold with hepatocytes and other liver cell types of different origin. This model is oriented towards a humanised model to test important molecules, such as lead molecules within the pharmaceutical industry and could close the gap between the preclinical and clinical phase in drug development.

→ For *cell-cell contacts*, the IVTD-research focused on co-cultures of hepatocytes with liver epithelial cells of primitive biliary origin, which were later shown to be liver progenitor cells. They displayed a reproducible and well-characterized phenotype which reflected closely the *in vivo* situation.

→ For *medium components*, dedifferentiation of hepatocytes is best counteracted by adding differentiation-promoting compounds to the cultures. In that context compounds such as DMSO and corticoids could exert a positive effect on the functionality of hepatocytes in culture.

→ For *epigenetic modification of hepatocytes* to stabilize their functionality, focus was on histone deacetylase (HDAC) inhibitors added alone or in combination with DNA methyltransferase (DNMT) inhibitors. The former compounds (e.g. Trichostatin A) block the activity of the HDACs so that the histones remain largely acetylated making the DNA backbone more easily accessible for liver enriched transcription factors. It could be shown that the occurrence of spontaneous apoptotic cell death was delayed, functional expression of CYP iso-enzymes was kept and gap junction intercellular communication was enhanced. Together with DNMT inhibitors, a synergistic effect was observed providing as such a long-term hepatic *in vitro* model. Within the context of epigenetics, also the role of microRNAs was investigated and the effects that specific forms could exert on the functional stability of hepatocytes in culture.

(2) Generation of hepatocyte-like cells from stem cells / progenitors.

Human hepatocytes are the gold standard to build up a functional *in vitro* model reflecting *in vivo* xenobiotic biotransformation in human liver. Human liver cells, however, become scarce. Human stem cells / progenitor cells could represent an interesting alternative to generate functional hepatic cells and of these, postnatal stem cells pose the least ethical concerns. An innovative methodology was developed using *sequential exposure of postnatal stem cells to growth factors and cytokines to mimic the in vivo embryogenesis of the liver*. Experience was built up with progenitors of bone marrow, bile ducts, skin and adipose tissue of different species. Focus is now in particular on generating functional hepatic cells from adult progenitor cells derived from human skin. As human skin is obtained from young boys (2-5yrs) undergoing circumcision, also the youngest possible skin of both genders, namely skin of the umbilical cord of newborns and Wharton's Jelly is under study. Also neural crest cells could be isolated from human skin, creating the opportunity to enter the field of other target organs than the liver. For these unique cells a patent proposal has been filled.

(3) Generation of a hepatic cell line

A new immortalisation strategy was developed within IVTD by transduction of human hepatocytes with lentiviral vectors coding for cyclin D1, mutant cyclin-dependent kinase 4R24C (CDK4R24C) and human telomerase reverse transcriptase (hTERT) in a cyclisation recombination-locus of X over P1 construct, which allowed to reversibly induce infinite hepatocellular growth. Introducing CDK4R24C into hepatocytes in combination with cyclin D1 surmounted premature cell senescence induced by p16 and allowed the cells to proliferate *in vitro*. The generated cell line retained a number of key hepatic characteristics and can be further improved by refining culture conditions.

Actually ongoing research

(1) Human stem cell-derived hepatic cells in toxicology: stem cells isolated from human skin and differentiated towards hepatic cells are exposed to typical hepatotoxic compounds e.g. acetaminophen for acute liver failure; sodium valproate for steatosis; amiodarone for steatosis and phospholipidosis, etc. Characteristic hepatotoxic responses were observed for the already examined molecules and a similar predictive capacity for toxicant-induced liver damage as primary human hepatocytes was found. Furthermore the characteristics of the injury observed were similar as those observed in patients suffering from liver disease caused by the same compounds. This model is now further challenged with more reference molecules.

(2) **Human stem cell-derived hepatic cells in a translational strategy:** a specific stem cell population from human skin has been characterized for its favorable immunological properties. The cells have been transplanted successfully, before and after differentiation, in different animal models with pronounced liver insufficiency. The animals survived and showed impressive liver repair by the generation of functional human hepatic cells. A patent has been filed for the cells and methodology.

(3) **Role of connexins and pannexins in liver functionality:** *in vitro* models are applied to study key mechanisms in liver homeostasis in health and disease and to better define the building blocks of the Adverse Outcome Pathways (AOPs) of liver diseases such as cholestasis. Specific goals are (i) to test connexin hemichannels and pannexin channels as drug targets for the clinical therapy of liver disease and (ii) to test these proteins as biomarkers for the clinical diagnosis. These specific topics are developed by the Connect-team, headed by Prof. Mathieu Vinken, who has set up international collaborations with Brasil <http://www.vub.ac.be/en/research/project/connect-team>.

RESEARCH PROJECTS AND CONTRACTS IN RELATION TO THE RESEARCH TOPICS 4.1 AND 4.2

As administrative promotor:

- 1992-1992: A research fellowship of 12 months under the European Science Foundation programme of research fellowships and toxicology was obtained.
 - 1992, renewed 1993-1994: **EC DG XI** project (B91/B4 - 3081/013665)
Title: Cryopreserved human and animal hepatocytes as complementary or alternative models to the use of animals in pharmacotoxicological studies; establishment and characterisation of a cell bank by the EC", together with Roussel Uclaf, France; BIOPREDIC; Interm U49, France and Inserm U278, France
 - 1993-1993: a **BIOMED** pilot project, **EC DG XI** (nr BMH - CT 92-0005)
Title: "Inventory of the use, within Europe, of human cells in toxicological research on drugs. A first step in the creation of human cell banks for long-term projects" (Project leader: V. Rogiers)
 - 1993-1996: project leader of an **EC DDG XI** project, together with Prof. E. Shephard, University of London and firm Searle, Belgium (B92/B4 - 3063/11/009343)
Title: "Validation of co-cultures of hepatocytes with epithelial cells as an *in vitro* model for hepatotoxicity testing in drug development and chemical safety evaluation"
 - 1995: project PSS*0870 from the **EC DG XII** to organize a meeting with the pharmaceutical industry.
Title "Hepatocyte-based *in vitro* models and their application in pharmacotoxicology"
 - 1996-1997: promotor of **ECVAM** project 2963320747 (EU20787)
Title: "The development of standardised procedures for determining cytochrome P-450 depending enzyme activities. Study of the biotransformation and toxicity of isobutene, a monomer used in the preparation of plastics" In close collaboration with Prof. H.M. Bolt, University of Dortmund.
- 11.142,67 euro**
- 1997: promotor of **EC-ECVAM** contract 13480-97-11 F1ED ISPB
Title: "Potential use of non-invasive methods in safety testing of cosmetics"

- 1997: promotor of **OZR** project (OZRKAN102)
Title: "kredieten aan navorsers"
3.785,33 euro
- 1997-1999: promotor of **FWO** Research contract (FWPTM42)
Title: "Expressie en regulatie van sulfotransferasen in hepatocyten culturen"
48 man months
- 1998: promotor of **EC-ECVAM** contract 13430-97 F1ED ISPB (EU48)
Title: "Characterisation of proximal tubular cell lines and genetically engineered cell lines with respect to their biotransformation capacities"
48.815,19 euro
- 1998-2000: **Stichting Prins Laurent** (WDGO69)
Title: "Het ontwikkelen van het Belgisch Platform voor Alternatieve Methoden en Technologieën binnen de lokalen van de VUB-Campus Jette door middel van het aanwerven van een doctoraatstudente" (*The development of a Belgian Platform for Alternative Methods and Technologies within the rooms of the VUB Campus in Jette, by means of hiring a doctoral student or a doctor in Pharmaceutical Sciences*)
- 1997-2000: promotor of **FWO** Research Contract (FWOAL20)
Title: "Fundamenteel onderzoek naar en ontwikkeling van 3-dimensionele cultuurmodellen van hepatocyten als *in vitro* model voor biotransformatie- en toxiciteitsstudies van geneesmiddelen" (*Fundamental research and development of 3-dimensional culture models of hepatocytes as an in vitro model for biotransformation and toxicity studies*)
48 man months + 301.438,50 euro
- 1997-2000: promotor of **OZR** Research Contract (OZR50)
Title: "Fundamenteel onderzoek naar en ontwikkeling van 3-dimensionele cultuurmodellen van hepatocyten als *in vitro* model voor biotransformatie- en toxiciteitsstudies van geneesmiddelen" (*Fundamental research and development of 3-dimensional culture models of hepatocytes as an in vitro model for biotransformation and toxicity studies*)
12 man months + 113.163,41 euro
- 1999-2004: promotor of **FWO** Research Contract - aspirant (FWOTM137)
Title: "Geïsoleerde stellaatcellen en hepatocyten en hun culturen als *in vitro* model voor farmacotoxicologisch onderzoek van nieuwe antifibrogene geneesmiddelen" (*Isolated stellate cells and hepatocytes, and their cultures as in vitro models for pharmaco-toxicologic research of new antifibrogenic drugs*)
41 man months
- 2000-2001: promotor of **OZR** Research Contract (OZR484)
Title: "Fundamenteel onderzoek naar en ontwikkeling van 3-dimensionele cultuurmodellen van hepatocyten als *in vitro* model voor biotransformatie- en toxiciteitsstudies van geneesmiddelen" (*Fundamental research and development of 3-dimensional culture models of hepatocytes as an in vitro model for biotransformation and toxicity studies*)
22.310,42 euro

- 2001-2001: promotor of **FWO** Research contract (FWONL28-Nat.Lot)
 Title: "Invloed van histone deacetylase inhibitoren op het fenotype van hepatocyten in cultuur, en studie van de biotransformatie" (*Effect of histone deacetylase inhibitors on the phenotype of hepatocytes in culture, and study of the biotransformation*)
12 man months + 71.889,12 euro
- 2001-2004: promotor of **FWO** Research contract - doctorate (FWOAL163)
 Title: "Invloed van histone deacetylase inhibitoren op het fenotype van hepatocyten in cultuur, en studie van de biotransformatie" (*Effect of histone deacetylase inhibitors on the phenotype of hepatocytes in culture, and study of the biotransformation*)
48 man months + 246.901,92 euro
- 2001-2004: promotor of **OZR** Research Contract - doctorate (OZR630)
 Title: "Invloed van histone deacetylase inhibitoren op het fenotype van hepatocyten in cultuur, en studie van de biotransformatie" (*Effect of histone deacetylase inhibitors on the phenotype of hepatocytes in culture, and study of the biotransformation*)
64.558,10 euro
- 2000-2010: co-promotor of **FWO** Research Contract (FWOTM199)
 Title: "Nieuw *in vitro* model voor screening van niet-genotoxische hepatocyt-carcinogenen tijdens vroeg preklinisch geneesmiddelenonderzoek"
 (Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
108 man months + 12.000 euro
- 2002-2004: co-promotor of **FWO** project (FWOKN99)
 Title: "Zonale distributie en moleculaire regulatie van apoptose in organotypische hepatocyten culturen" (*Zonal distribution and molecular regulation of apoptosis in organotypic hepatocyte cultures*)
 (Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
49.789,35 euro
- 2002-2004: co-promotor of **OZR** project (OZR778)
 Title: "Zonale distributie en moleculaire regulatie van apoptose in organotypische hepatocyten culturen"
 (Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
43.831,48 euro
- 2003-2004: promotor of **OZR** Research Contract - aspirant (OZR894)
 Title: "Effect van Trichostatine A op de expressie van connexines in organotypische hepatocyten culturen" (*Effect of Trichostatin A on the expression of connexins in organotypical hepatocyte cultures*) (obtained but returned because of successful IWT application)
12 man months + 15.608 euro
- 2001-2005: promotor of **FWO** Research Contract - aspirant (FWOTM257)
 Title: "Effect van Trichostatine A op de expressie van connexines in organotypische hepatocyten culturen" (*Effect of Trichostatin A on the expression of connexins in organotypical hepatocyte cultures*)
48 man months

- 2003-2006: promotor of **IWT** Project - bursary (IWT183)
Title: "*In vitro* differentiatie van beenmergstamcellen tot hepatocyten: karakterisatie van de biotransformatie-capaciteit, regulatie door "liver enriched" transcriptiefactoren en invloed van Trichostatine A" (*In vitro differentiation of bone marrow stem cells to hepatocytes: characterisation of the biotransformation capacity, regulation by "liver-enriched" transcription factors and influence of Trichostatin A*)
24 man months + 14.873,66 euro
- 2004: promotor of **OZR** Research contract (OZR1168)
Title: "Modulatie van gentranscriptie door targeting van histone deacetylasen: de sleutel tot *in vitro* differentiatie van primaire hepatocyten"
16.409,21 euro
- 2004-2007: coordinator of **EU** Project FP6 **CONAM** (nr. 504776)
Title: "Consensus networking on alternative methods within Europe" (SSA-project) (EU 195)
150.000 euro
- 2004-2006: co-promotor of **FWO** Research Contract (FWOAL303)
Title: "De rol van serine proteasen bij huidpermeabiliteit homeostase en de pathogenese van atopische dermatitis"
45.000 euro
- 2004-2006: Research partner in **EU** Project FP6, **Predictomics** (nr. 504761)
Title: "Short-term *in vitro* assays for long-term toxicity" (STREP project) (EU200)
247.004,40 euro
- 2004-2009: member of the board of **EU** project FP6 **ReProTect** (EU199)
Title: "Development of a novel approach in hazard and risk assessment of reproductive toxicity"
291.504,99 euro
- 2004-2009: Research partner of **EU** project FP6 **ReProTect** (EU199)
Title: "Development of a novel approach in hazard and risk assessment of reproductive toxicity"
150.000 euro
- 2005: co-promotor of **OZR** project (OZR1164)
Title: "Trichostatin A en zijn hydroxyamaatanalogen als belangrijke regulatoren van apoptose in hepatocyten culturen"
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
10.000 euro
- 2005-2006: promotor of **OZR** project (OZR1332)
Title: "Effect van Trichostatin A op de expressie van connexines in primaire culturen van rathepatocyten"
43.109,08 euro
- 2005-2007: promotor of **Johnson & Johnson** Cooperation Agreement (WDGO449) - postdoc (P. Papeleu)
Title: "A culture system for highly differentiated hepatocytes and other primary cell types *in vitro* through direct targeting of histone deacetylases or their target genes"
24 man months

- 2005-2008: promotor of **OZR** Project (OZR1156)
Title: "Reorganisatie van het celkern-chromatine door histon deacetylase inhibitoren: mechanistisch onderzoek naar de regulatie van de dedifferentiatie/differentiatie in cultuur van primaire hepatocyten en beenmergstamcel-afgeleide hepatocyten"
48 man months + 100.000 euro
- 2005-2009: promotor of **FWO** Project (FWOAL309)
Title: "Reorganisatie van het celkern-chromatine door histon deacetylase inhibitoren: mechanistisch onderzoek naar de regulatie van de dedifferentiatie/differentiatie in cultuur van primaire hepatocyten en beenmergstamcel-afgeleide hepatocyten"
48 man months + 325.210 euro
- 2005-2011: member of the board and research partner of **EU** project FP6 **Sens-it-iv** (EU251) "Novel testing strategies for *in vitro* assessment of allergens"
150.000 euro
- 2006: co-promotor of **FWO** Project (FWOAL371)
Title: "Interacties tussen progenitors, hun voorbestemde dochtercellen, nichecellen en de extracellulaire matrix"
250.000 euro
- 2006: co-promotor of **OZR** Project (OZR1233)
Title: "Geneesmiddelen met histone deacetylase inhiberende activiteit als belangrijke regulatoren van apoptose"
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
15.000 euro
- 2006-2007: **IWT** Project (IWT289) - bursary (E. De Rop)
Title: "Epigenetische modificatie van de genexpressie door te interfereren met DNA-methylatie in culturen van primaire rathepatocyten" (*Epigenetic modification of gene expression by interfering with DNA methylation in primary rat hepatocyte cultures*)
24 man months + 7436,88 euro
- 2006-2007: co-promotor of **FWO** project (FWOKN167)
Title: "Geneesmiddelen met histone deacetylase inhiberende activiteit als belangrijke regulatoren van apoptose"
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
17.500 euro
- 2006-2009: promotor of **FWO** postdoc project (M. Vinken) (FWOTM411) Title: "Opheldering van de rol van connexine-eiwitten in de controle van hepatocellulaire homeostase: ontwikkeling van een op hepatocyten gebaseerd *in vitro* model voor pre-klinisch farmaco-toxicologisch onderzoek" (*Elucidation of the role of connexin proteins in the control of hepatocellular homeostasis: development of a hepatocyte-based in vitro model for pre-clinical pharmacotoxicological research*)
36 man months
- 2006-2010: promotor of **GOA** Research Contract (GOA48)
Title: "Epigenetic modification of gene expression by interference with histone acetylation" (co-promoters: K. Vanderkerken and A. Geerts)
1.200.000 euro

- 2006-2011: Research partner in **EU** project **CarcinoGENOMICS** (EU274), extended with 6 months
Title: "Development of a high throughput genomics-based test for assessing genotoxic and carcinogenic properties of chemical compounds *in vitro*"
637.444 euro
- 2007-2010: Research partner in **EU** project FP6 **LIINTOP** (EU280)
Title: "Optimization of liver and intestine *in vitro* models for pharmacokinetics and pharmacodynamics studies"
319.300 euro
- 2007-2011: promotor of **DWTC** project (DWTC236), IAP Project extern. Ref. (P6-VUB74IUAP6/36)
Title: "The hepatic progenitor cell niche under experimental conditions and in human liver disease"
902.000 euro
- 2008: co-promotor of **OZR** project (OZR1607BOF)
Title: "Opheldering van de rol van connexine eiwitten in hepatocellulaire apoptotische dood"
(Promotor: Prof. Mathieu Vincken, VUB-FAFY)
15.000 euro
- 2008-2009: promotor of **FWO** project (FWOTM487):
Title: "*In vitro* differentiatie van menselijke vetweefselstamcellen naar hepatocyten: een nieuw *in vitro* model voor het praktisch onderzoek van geneesmiddelen".
24 man months + 3720 euro
- 2008-2010: coordinator of **EU** project FP7 **START-UP** (EU305)
Title: "Identification of bottlenecks / strengths of 3Rs in different stages of drug development"
138.914,45 euro
- 2008-2013: Research partner in **EU** project FP7 **ESNATS** (EU317)
Title: "Embryonic stem cell-based novel alternative testing strategies".
639.294,40 euro
- 2008-2011: Research partner in **BruStem** project (BRGEOZ135)
Title: "Regenerative medicine of the liver using synergistic mixtures of immature or mature human hepatocytes with mesenchymal stem/progenitor cells or with hepatic stellate cells"
376.000 euro
- 2009-2012: promotor of **FWO** project (FWOAL517):
Title: "Ontwikkeling van functionele en stabiele hepatocytenculturen, inzetbaar in geneesmiddelenonderzoek, via epigenetische modificatiemechanismen"
48 man months + 257.104 euro
- 2009-2014: promotor of **IOF**-programma (IOF842) "Groeier"
550.000 euro
- 2009-2012: co-promotor of **OZR** project (OZR1799)
Title: "Nieuw *in vitro* model voor screening van niet-genotoxische hepatocarcinogenen tijdens vroeg preklinisch geneesmiddelenonderzoek"
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY).
90.000 euro

- 2007: promotor of **OZR** project (OZR1519)
Title: "*In vitro* differentiation of neonatal and adult progenitor cells into hepatocyte-like cells"
43.049,99 euro
- 2007-2011: promotor of **IWT** project (IWT336)
Title: "Differentiatie van progenitorcellen van humane huid en vetweefsels naar functionele hepatocyten: een nieuw *in vitro* model voor vroeg preklinisch geneesmiddelenonderzoek"
14.873,76 euro
- 2010: promotor of **OZR** project (OZR2069):
Title: "Epigenetische modificatie van genexpressie door interferentie met histon-acetylatie en DNA methylatie in gecultiveerde rat hepatocyten"
30.716,98 euro
- 2010: co-promotor of **FWO** project (FWOKN233)
Title: "De rol van connexine32 en connexine43 in de controle van hepatocellulaire homeostase: ontwikkeling van een lange-termijn primair hepatocytencultuursysteem voor farmaco-toxicologische studies"
(Promotor: Prof. Mathieu Vinken, VUB-FAFY)
16.400 euro
- 2010-2013: co-promotor of **FWO** project (FWOAL531)
Title: "Innovatieve microRNA-gebaseerde differentiatie strategie voor het ontwikkelen van metabool stabiele lange-termijn hepatocyten culturen, inzetbaar in vroeg pre-klinisch geneesmiddelenonderzoek"
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY).
60.000 euro
- 2010-2014: promotor of **FWO** project (FWOTM555)
Title: "Ontwikkeling van een gedifferentieerd hepatisch *in vitro* systeem voor lange-termijn farmaco-toxicologisch onderzoek gebaseerd op (epi)genetische modificatie van humane primaire hepatocyten" (Eva Ramboer).
48 man months + 14.880 euro
- 2010-2013: promotor of **OZR** project (OZR1925)
Title: "Ontwikkeling van functionele en stabiele hepatocyten culturen, inzetbaar in geneesmiddelenonderzoek, via epigenetische modificatiemechanismen"
110.441 euro
- 2011-2015: Research partner in **HeMeBio** (FP7/**Colipa** project) (EU 376-B)
Title: "Hepatic microfluidic bioreactor"
561.942,40 euro
- 2011-2016: Research partner in **DETECTIVE** (FP7/**Colipa** project) (EU 375)
Title: "Detection of endpoints and biomarkers for repeated dose toxicity using *in vitro* systems"
656.897,60 euro
- 2011: Research partner in EU project: EU-premium credit type B2c for **EU FP7** project (OZR 2266)
20.000 euro
- 2011: Research partner in EU project: EU-premium credit type B2c for **EU FP7** project **HeMiBio** (OZR 2312)
20.000 euro

- 2011: OZR2149 bridging **IWT** scholarship of **6 man months** and OZR 2219 **3 man months** to finish mandate of PhD student, J. Dekock
Title: “Differentiation of human and rat derived progenitor cells into functional hepatocyte-like cells: a potential new *in vitro* model for early preclinical research”
- 2011-2015: GOA78: promotor of **GOA** project
Title: “Interplay between epigenetic modification mechanisms and microRNAs (EPIGEN) (co-promoters: T. Vanden Driessche, K. Vanderkerken and L. van Grunsven)
1.200.000 euro
- 2012-2015: Promotor of **FWO** project (FWOAL643)
Title: “Recellularization of decellularized rat liver with human hepatic cells as a novel 3D culture model for pharmaco-toxicological research” (External ref. G016312N) Co-promoters: Komuta M. and Van den Oord J. (KU-Leuven)
180.800 euro
- 2011-2014: partner in **BruStem 2** (under Innoviris) (BRGEOZ135-B)
Title: “Regenerative medicine of the liver using synergistic mixtures of immature or mature human hepatocytes with mesenchymal stem / progenitor cells or with hepatic stellate cells”.
445.500 euro
- 2011-2016: promotor of tenior track **VUB/ZAP** mandate for post-doc collaborator M. Vinken
- 2010: co-promotor of **FWO** KN233 granted to M. Vinken as promotor
Title: “The role of connexin32 and connexin43 in the control of hepatocellular homeostasis: development of a long-term primary hepatocyte culture system for pharmaco-toxicological purposes”
16.400 euro
- 2011: recognition as **VUB-UGent** Alliance Research Group (VUB-UGent); promotor V. Rogiers - co-promotor: L. Leybaert.
2.500 euro
- 2010-2015: recognition as **FWO** research network (VUB, KUL, UGent)
Promotor: L. Leybaert; co-promoters: V. Rogiers and G. Bultynck.
50.000 euro
- 2011-2013: promotor of **WDG** research project (WDG0974) in collaboration with The Scientific Institute of Public Health (WIV-ISP) co-promotor : Peeters J.
48 man months
- 2012-2017: promotor of **DWTC** research project (DWTC280) external ref. n° IUAP7
Title: “Human liver disease: study of the hepatic stem cells and their niche, and development of novel systems (HEPRO-2)”
1.001.000 euro
- 2012-2015: co-promotor of **FWO** TM647 research project
Title: “Karakterisatie van *in vivo* gegenereerde hepatische cellen uitgaande van volwassen humane huidafgeleide voorlopercellen en evaluatie van hun potentieel gebruik in *in vitro* veiligheidsstudies van geneesmiddelen en leverziekte” (promotor: Joery De Kock, VUB-FAFY)
36 man months + 12.000 euro

- 2013: promotor of **OZR** grant (OZR2453) external ref. VOZ/R&D/2011-015
Title: “Combinatie van toxicogenomics en humane HepaRG™ culturen voor de identificatie van genotoxische stoffen”
12 man months
- 2013: promotor of **WDGO** research project (WDGO1033) in cooperation with Chesne Ch., Biopredic International – FR
Title: Services agreement Stabilization of the phenotypic properties of cryopreseved HepaRG (HPR116 cells)
7078,50 euro
- 2013: co-promotor of Willy Gepts Fonds (ADSI352)
Title: “Connexin hemichannels as drug targets in acute liver failure”
(Promotor: Prof. Mathieu Vinken, VUB-FAFY)
25.000 euro
- 2013-2016: co-promotor of **FWO** Research contract (FWOAL691)
Title: “Hepatocytachtige cellen, afgeleid van adulte humane huid progenitorcellen, als potentieel *in vitro* model voor het screenen van geneesmiddelen op mogelijke levertoxiciteit”
(Promotor: Prof. Tamara Vanhaecke, VUB-FAFY)
160.000 euro
- 2013-2017: co-promotor of **FWO** project (FWOAL723)
Title: "Karakterisatie van op connexine43- en pannexine1-gebaseerde hemikanalen als weefselbiomerkers en farmacologische doelwitten in acuut leverfalen: een gecombineerde *in vitro-in vivo* studie"
(Promotor: Prof. Mathieu Vinken, VUB-FAFY)
275.236 euro
- 2013-2017: co-promotor of **FWO** project (FWOAL732)
Title: "Hemikanalen als nieuw farmacologische doelwitten in leverfibrose"
(Promotor: Prof. Mathieu Vinken, VUB-FAFY)
360.000 euro
- 2013-2017: co-promotor of IWT mandate for aspirant Michaël Maes
Title: “Characterisation of connexin43 and pannexin1 and their hemichannels as biomarkers and pharmacological targets in acute liver failure: a combined *in vitro-in vivo* study”
(Promotor: Prof. Mathieu Vinken, VUB-FAFY).
48 man months
- 2013-2019: co-promotor of **ERC** project (EU457)
Title: "CONNECT: Connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver"
(Promotor: Prof. Mathieu Vinken, VUB-FAFY)
1.473.929 euro
- 2014: co-promotor of **FWO** project (FWOKN259)
Title: "Evaluatie van humane huidafgeleide voorlopercellen en hun *in vitro* bekomen hepatische cellen in experimentele leverziektmodellen bij de muis"
(Promotor: Prof. Joery De Kock, VUB-FAFY)
20.000 euro

- 2014: co-promotor of Willy Gepts Fonds (BOR14)
Title: “Exploration of translational potential of human skin-derived precursor cells and their *in vitro* generated hepatic derivatives in experimental liver disease models”
(Promotor: Prof. Joery De Kock, VUB-FAFY)
25.000 euro
- 2014-2017: co-promotor of **FWO** project (FWOAL732)
Title: “Hemikanalen als nieuwe farmacologische doelwitten in leverfibrose”
(promotor: Prof Vinken Mathieu VUB-FAFY)
360.000 euro
- 2014-2017: co-promotor of **FWO** project (FWOAL723)
Title: “Karakterisatie van op connexine43-en pannexine-gebaseerde hemikanalen als weefselbiomerkers en farmacologische doelwitten in acuut leverfalen: een gecombineerde *in vitro-in vivo* studie”. (promotor: Prof Vinken Mathieu VUB-FAFY)
275.236 euro
- 2014-2016: promotor of **WDGO** (WDGO1110) contract for a doctoral fellow with The Scientific Institute of Public Health (WIV-ISP) (4j. bursaal M. Van Bossuyt)
48 man months
- 2013-2014: promotor of **OZR** grant (OZR2497) co-financing via infrastructure funds Prof. J. Gutermuth
50.000 euro
- 2014-2019: promotor of **SRP** grant (SRP38)
Title: “Liver-based *in vitro* models for toxicity testing, and translational aspects”
450.000 euro
- 2014-2019: promotor of **HERCULES type I** grant (HERC26)
Affymetrix microarray genomics-transcriptomics platform
596.965,25 euro
- 2015-2019: co-promotor of **FWO** project
Title: “Connexine en pannexine kanalen: van moleculaire inzichten naar applicaties bij gezondheid en ziekte”
(promotor Prof Vinken Mathieu, VUB-FAFY)
62.500 euro

4.3. Dermato-Cosmetic research

In Dermato-Cosmetic sciences both fundamental and applied research are carried out.

Overview of the research over the passed years

a) Study of the barrier function of the stratum corneum in health and disease.

- The different lipid fractions of human skin barrier were analysed as a function of potential variables including age, gender, body site and skin pathology. Galenic preparations to normalize lipid abnormalities were developed.

- In collaboration with the laboratory of Prof. P. Elias and Prof. W. Holleran from the University of San Francisco, USA, the role of ceramidases and ceramides in the barrier function was examined at the molecular level. Also the ceramidase activity, namely the different isoforms expressed in human epidermis and in a relevant *in vitro* model were studied in human keratinocytes cultures. Parameters affecting the enzymatic activity, protein expression and mRNA level were measured.

- In collaboration with the WIV-ISP, illegal cosmetics (Ilcos) with focus on the group of skin bleaching products of the skin were examined. Several quantitative analytical techniques for the bleaching ingredients and perfumes used in these cosmetic products were developed and validated. Also the *in vitro* dermal absorption test was refined for use with human skin instead of pig skin.

b) safety and efficacy testing of cosmetic products.

- Postvalidation of alternative methods, using already existing *in vitro* and *in vivo* toxicological data on cosmetic ingredients, has been realised for the battery used to identify genotoxic substances. These data are retrieved from the SCCS (Scientific Committee on Consumer Safety) opinions on cosmetic ingredients present on the annexes of the EU cosmetic legislation,

- The safety of cosmetics is examined based on the toxicological profile of their ingredients, the chemical structure and exposure. A comprehensive database is set up containing all available information of potential cosmetic ingredients coming from the SCCS and predecessors, material safety data sheets (MSDS), own experimental results, literature and bibliographic data.

- The efficacy of cosmetics is carried out using non-invasive bioengineering methods. New methodologies are being developed and standardised. Available are: hydration measurements of the stratum corneum (capacity measurements), barrier function and barrier integrity (TEWL measurements), skin pH (pH measurements), skin surface lipids (sebumetry), elasticity (cutometer), skin colour (colorimetry), skin relief measurements (visiometer: light transmission methodology) and skin desquamation (squamometry).

Actually ongoing research

De-risking study of false positive in vitro genotoxicity results: this is a continuation of the FP7 EU project CarcinoGenomics in which HepaRG cells are exposed to known genotoxic and non-genotoxic compounds. In this study, cosmetic ingredients are used in an in vitro toxicogenomics approach and de-risking of potentially positive substances is obtained by interpretation of affymetrix whole genome expression and use of Ingenuity Pathway Analysis (transcriptomics).

PROJECTS AND CONTRACTS IN RELATION TO THE RESEARCH TOPIC 4.3

- 1998-1999 Project **WDGO80** (Christian Dior Parfums, Paris 8e, France) Title: Argiles: les nouveaux biomatériaux (*Clays: the new biomaterials*):
- 2001-2003 **OZR** Research Contract (OZR773) Title: "Kwantitatieve analyse van humane stratum corneum (DC) lipiden) na tape stripping in combinatie met niet-invasieve efficiëntiemetingen (*Quantitative analysis of SC lipids after stripping combined with non-invasive efficacy measurements*)
18.592,01 euro
- 2001-2003 Project **WDGO237** Title: Een vergelijking van de effecten van papieren zakdoekjes op de toestand van de huid van de neus en de perinasale zones (*Superfacial skin damage caused by rhinorrhea - clinical scoring, efficacy measurements and lipid analysis after tape stripping*)
- 2002-2005 **IWT** Research Contract - postdoc (IWT170) Title: "Ontwikkeling en efficiëntie-evaluatie van innovatieve dermato-cosmetische lotions met werking op de barrièrefunctie van de huid (*Development and innovation of dermato-cosmetic lotions focused on the human barrier function*).
23.470,64 euro
- 2011-2015 **WIV** contract Title: "Kwalificatie en toxicologische evaluatie van illegale en counterfeit dermatologische preparaten" Bart Desmedt

Over the years:

- "Vergelijkende studie van Biodermal NV en Galenco NV: Babyproducten", Biodermal BV, Zoetermeer (NL)
- "Face Gamma Galenco: Efficiëntiemetingen: hydraterend vermogen en effect op de huidbarrière. Vergelijkende studie van 3 dag- en 3 nachtcrèmes", Galenco NV, Paal (BE)
- "Effect of topical application of ceramide II containing preparations on SLS- and acetone-damaged skin", ICI Surfactants (Uniqema), Everberg (BE) and Quest, Kent (UK)
- "De ontwikkeling van een zetmeelsuspensie. Effect op de barrièrefunctie van de huid", Remy NV, Rijmenam (BE)
- "Het effect van rijstzetmeel toegevoegd als badwateradditief op de barrièrefunctie van een NaLS-beschadigde huid en de huid van atopische patiënten", Galenco NV, Paal (BE)
- "The validation and comparison of three different techniques to measure skin micro relief" (**WDGO143**), Institut de Recherche Pierre Fabre, Toulouse (FR)
- "Face en 50+ Gamma Galenco: efficiëntiemetingen: hydraterend vermogen en effect op de huidbarrière. Vergelijkende studie van een bodymelk en 2 dag- en nachtcrèmes", Galenco NV, Paal (BE)

- "Het effect van een cosmetische antischilfershampoo (climbazole) in een gebruikersunit", Candel NV, Zaventem (BE)
- "Contract Parfums Christian Dior "Effect of colloid PB: short-term, long-term, squamometry", Paris 8ème (FR)
- "Het hydraterend vermogen en effect op de barrièrefunctie van Dermalex medical body milk: korte termijnstudie", Galenco NV, Paal (BE)
- "Studie betreffende de efficiëntie van 48 verzorgende cosmetische producten, namelijk handcrèmes (metingen onder vorm van TEWL-metingen en capaciteitsmetingen)" (**WDGO155**), Verbruikersunie Test Aankoop, Brussel (BE)
- "Ontwikkeling van een reinigende waslotion en een verzorgende hydraterende crème voor een acnegevoelige huid", Galenco NV (BE)
- "Het effect van huididentieke lipiden op de barrièrefunctie van de huid", Cosmoferm (Gist Brocades), Delft (NL)
- "Ontwikkeling en efficiëntie van een sprayformulatie voor de barrièrefunctie van de huid", Galenco NV, Paal (NL)
- "Skin microrelief topography measurements of ageing skin", Institut de Recherche Pierre Fabre, Toulouse (FR)
- "De optimalisering van het cosmetisch aspect van een handontsmettende alcoholgel", Galenco NV, Paal (BE)
- "Nazicht van veiligheids- en efficiëntiedossiers van de cosmetische producten Biodermal, en eventueel aan te passen volgens de voorschriften van de Europese wetgeving" (**WDGO159**), Hans Schreuder Laboratoria, Baarn (NL)
- "The safe use of DMSO in the cryopreservation of keratinocytes/reconstructed epidermis", Scientific & Technical Consulting Cosmetology, Microbiology and Biochemistry, Louvain-la-Neuve (BE)
- "Nazicht van veiligheids- en efficiëntiedossiers van de cosmetische producten Galenco, en eventueel aan te passen volgens de voorschriften van de Europese Cosmetische Wetgeving" (**WDGO191**), Biodermal NV, Zoetermeer (NL)
- "Nazicht veiligheids- en efficiëntiedossiers van de cosmetische producten Biodermal, en eventueel aan te passen volgens de voorschriften van de Europese Cosmetische Wetgeving" (**WDGO245**), Biodermal NV, Zoetermeer (NL)
- "Nazicht van veiligheids- en efficiëntiedossiers van de cosmetische producten Galenco, en aanpassing volgens de voorschriften van de Europese Cosmetische Wetgeving" (**WDGO274**), Soprodal NV, Paal (BE)
- "Report on the preliminary examination of Proderm. Sunscreens SPF8-15-25-30" (**WDOO6301**), HDP Media, Ponsus Pharma AB, Stockholm (S)
- "Review of safety dossiers for three Ciba Vibracolor hair dyes" (**WDOO6301**), Ciba Specialty Inc., Basel (CH)
- "DMSO used as a cryoprotectant in CryoCeal®: safety aspects" (**WDOO6301**), Xcellentis, Merelbeke (BE)
- "Adviesvergadering Prof. Rogiers juli 2002" (**WDOO6301**), Ardoz Research BV (NL)
- "Lyphoderm: safety aspects, preliminary report" (**WDOO6301**), Xcellentis, Merelbeke (BE)
- "UlcoDress: safety aspects" (**WDOO6301**), Xcellentis, Merelbeke (BE)
- "UlcoDress: Safety aspects, complementary report" (**WDOO6301**), Xcellentis, Merelbeke (BE)

- "Review of a safety dossier for an imported cosmetic product" (**WDOO6301**), Laboratoires WECO (FR)
- "Review of a safety dossier for an important cosmetic product" (**WDGO315**), Avery Dennison (BE)
- "Advies met betrekking tot de ontwikkeling van een cosmetisch product (formuleren van een haargroeimiddel)" (**WDOO129**), De Laet Hans, Duffel (BE)
- "Opmaken van een veiligheidsdossier voor Spa Monopole verstuiver" (**WDOO129**), Spadel NV (BE)
- "Nazicht van veiligheids- en efficiëntiedossiers van cosmetische producten en aanpassing volgens voorschriften van de Europese cosmetische wetgeving" (**WDGO387**), Soprodal NV (BE)
- "Nazicht van veiligheids- en efficiëntiedossiers van cosmetische producten en aanpassing volgens voorschriften van de Europese cosmetische wetgeving" (**WDGO387**), Schreuder Research (NL)
- "Evaluation of the Estee Lauder Safety Testing Policy of Cosmetic Products" (**WDOO129**), Estee Lauder, New York (USA)
- "Risk assessment connected with the presence of phthalates in the different materials used in the production of diapers" (**WDGO382**), Edana (Procter & Gamble) (BE)
- "Consultancy and practical assistance for the drawing up of technical dossiers with regard to the use of melatonin in hair care cosmetic products" (**WDGO375**), Asatona AG, Zug (CH)
- (**WD0161**), US Food and Drug Administration, Dr. R.L. Bronaugh
Contract for a 2-day training course in safety assessment of cosmetics in Europe.
- (**WDG0376**), Asatona AG, Zug (CH)
Consultancy contract running from 2009 - today with respect to practical assistance for the drawing up of a technical dossier according to SCCS Notes of Guidance for melatonin.
- (**WDG0380**), Schreuder Research BV (NL)
Audit safety – and efficacy dossiers of cosmetic products and adaptation according to the European cosmetic regulatory requirements 2010.
- (**WDG0858**), Pierre Fabre Dermo-Cosmétique (FR)
Preparation of a SCCS dossier for a sunscreen 2010-2012.
- (**WDG0810**), Auriga Int. (NL)
2010-2013, giving assistance in making up a human safety dossier for a cosmetic ingredient according to the principles of the EU cosmetic legislation.
- (**WDG0845**), Centre Européen des Silicones CES
2010-2011, Effect op silicone-containing products on the TENL and hydration state of skin.
- (**WDG0PM72**), Nu Skin Belgium N.V. (BE)
2010-2013, Assistance in making cosmetic product dossier.
- (**WDG0786**), Omega Pharma Belgium N.V. (BE)
2009-2010, Skin efficacy and claim support of cosmetic products.
- (**WDG0890**), Philips Consumer Lifestyle B.V. (NL)
2011-2014, Research concerning the development of a food cleaner, whereby tap water is electrolysed to create alkaline water that can be used for washing and cleaning fruit and vegetables from pesticides.
- (**WDGO1033**), Service agreement: Stabilization of the phenotypic properties of cryopreserved HepaRG (HPR116 cells) Biopredic International (FR)

- **(WDGO1055)** 2013-2014 service agreement in cooperation with Carter R, EpiPharm AG (CH) - Preparation of the technical information file (PIF) for specific services upon demand on cosmetic products”.
- **(WDGO1054)** 2013-2017: service agreement in cooperation with Devrieze A., Takeda Belgium S.C.A. (BE) - Preparation of the technical information file (PIF) for specific services upon demand on cosmetic products”.
- **(WDGO1095)** 2014-2015: Service agreement with MA’OR ZE’EVI Dead Sea Laboratories LTD (IL) – “Determining whether the traces of heavy metals could present a risk for human health”.
- **(WDVO136)** 2014: Service agreement with British Standards Institution (UK), internship of 3 months of Chinese staff member of the Chinese FDA to study how to prepare a Product Information File for cosmetics in Europe.
- **(WDGO1279)** 2015: Service agreement with Chanel SAS – Presentation titled “Often misunderstood safety aspects of cosmetics and their ingredients”.
- **(WDGO1198)** 2015: Service agreement with Crea Cosme – Preparation of product information file (PIF) and/or consultancy for specific services upon demand on cosmetic products.
- **(WDGO1215)** 2015: Service agreement with Ontex – Preparation of product information file (PIF) and/or consultancy for specific services upon demand on cosmetic products.
- **(WDGO1186)** 2014-2017: Service agreement with Vemedia (Vision Healthcare) – Preparation of product information file (PIF) and/or consultancy for specific services upon demand on cosmetic products.

5. SCIENTIFIC HONORS AND AWARDS

- 1980-81: Prize of the Belgian Cystic Fibrosis Association for the thesis on "The lipid metabolism of Cystic Fibrosis patients", Belgium
- 1982: Laureate of the "Reisbeurzenwedstrijd", Belgium
- 1987: Laureate of the "Europese prijs voor de vervanging van dierexperimenten" ("European prize for the replacement of animal experiments"), organized by F.I.S.E.A., Luxemburg, for the thesis "Contribution to the study of the use of freshly isolated hepatocytes as an *in vitro* model for toxicity and biotransformation of xenobiotics", 500 000 BEF)
- 1989: Supporting award of FISEA for Yves Vandenberghe, for doctoral thesis done under promotership of V. Rogiers and A. Vercruysse, VUB
- 1994: Supporting award of FISEA for Sandra Coecke for doctoral thesis done under promotership of V. Rogiers and A. Vercruysse, VUB
- 1997: Sonja Beken, doctoral student of V. Rogiers, received the APMA Prize 1997 for the replacement of animal experiments, Belgium
- 1999: Tamara Vanhaecke, doctoral student of V. Rogiers, received the prize of the "Foundation Prince Louis doctoral student of V. Rogiers, de Polignac", Paris, France
- 1999: Kristien De Paepe, Laureate Rottendorf Europe Award 1999, Rottendorf Stiftung.
- 2000: Doerenkamp-Zbinden Award 2000. A prestigious prize from the Zbinden Foundation (CH) to be given for a whole career on the development of alternative methods for toxicology (500.000 BEF). It was the first time that a woman received

- this European prize. It was given by Prof. Van Zutphen (University of Utrecht) during INVITOX 2000 in Alicante, Spain (28/10/2000)
- 2000: Kristien De Paepe, doctoral student of V. Rogiers, was "Laureate Best Poster", 13th International Congress of the International Society of Bioengineering and Skin, Jerusalem, Israel
- 2000: Jean Pierre Hachem, MD, received the Roche Donation Prize 2000 as young researcher with the work "Epidermal barrier function and skin inflammatory diseases: Clinical approaches and implications" (research promoters: D. Roseeuw and V. Rogiers)
- 2005: P&G/Eurotox/HSI Animal Welfare and Alternatives Award 2005, scientific prize for research on alternatives to laboratory animals (25,000 €), received during the Eurotox congress in Krakow, Poland, on 12-14/09/2005 and donated to the Scientific Association ECOPA
- 2007: Sarah Snykers, doctoral student of V. Rogiers: Sequential Exposure to Cytokines Reflecting Embryogenesis: The Key for *in vitro* Differentiation of Adult Bone Marrow Stem Cells into Functional Hepatocyte-like Cells; SOT Award of the "Best paper published in Toxicological Sciences for 2007", Seattle, 16/03/2008.
- 2008: Marleen Pauwels, doctoral student of V. Rogiers, received the "Doerenkamp-Zbinden-Foundation Thesis Award" at the 15th Congress on Alternatives to Animal Testing, held in Linz, Austria, 19-21/09/2008.
- 2008 Vinken M., doctoral student of V. Rogiers: First Prize at Poster Competition Award of The European Partnership for Alternative Approaches to Animal Testing 2008 Conference (EPAA); Brussels, 03/11/2008.
- 2009: Poster award Manon Vivier and Vera Rogiers "European Partnership for Alternative Approaches to Animal Testing (EPAA), Brussels, 06/11/2009.
- 2010: Poster award for T. Doktorova, T. Vanhaecke, V. Rogiers and M. Vinken 4th Annual CarcinoGenomics meeting, Arona, Italy, 08-10/11/2010.
- 2012: Poster award for E. Ramboer, Vanhaecke T., Rogiers V., Vinken M., ESTIV2012 congress, Portugal, 16-19/10/2012.
- 2014: Award for young scientists' best oral presentation for Pharm Gamze Ates, PhD student under promotership of V Rogiers at the World Congress 9 on Alternative Methods, Prague, August 2014.
- 2014: 33e Forschungpreise zur Förderung methodischer Arbeiten mit dem Ziel der Einschränkung und des Ersatzes von Tierversuchen, award from the German Ministry of Food and Agriculture, Berlin, 04/12/2014, award for stem cell research for V Rogiers and stem cell team.

SPECIAL INVITATIONS

- 2010: Invitation by Food and Drug Administration (FDA), USA to train their staff in Safety Assessment of Cosmetics (how it is actually done in the EU)
- 2011: Invitation by National Agency of Drug and Food Control (NADFC) of Indonesia to explain their Authorities the key points of Cosmetics Product Information Files Auditing.
- 2012: Invitation by Health Canada to train their staff in Safety Assessment of Cosmetics in the EU.

- 2012: Invitation as expert in safety assessment of cosmetics in the EU, Beijing, China
- 2013: Invitation as expert in safety assessment of cosmetics in the EU, Beijing, China
- 2015: Invitation as expert in safety assessment of cosmetics in the EU, Beijing, China (3-day training course for Chinese competent authorities EUCCC organised by Home Office UK, Cosmetics Europe, European Commission and Chinese Authorities)

6. PATENTS

- PATENT SUBMISSION: PCT/EP2004/0012134, WO 2006/045331 "Differentiation of stem cells and stabilisation of phenotypical properties of primary cells".
Inventors: V. Rogiers, P. Papeleu, S. Snykers, T. Vanhaecke, M. Vinken, G. Elaut and T. Henkens - Applicant: VUB
- PATENT: DE69826839D for Shaving Liquid. Publication date: 2004/11/11. Inventors: P. Zegers, P. Vandamme and V. Rogiers. Applicant: Koninkl. Philips Electronics NV. Classification: International: A61K7/15; A61K7/50 - Also published as: W09847474 (A1) US5885563 (A1) - Application number: DE19986026839 19980312 - Priority numbers: EP19970201225 19970424; WO1998IB00339 19980312
- PATENT: EP0966255: for Shaving Liquid. Publication date: 1999/12/29. Inventors: CPG Zegers, P. Vandamme and V. Rogiers. Applicant: Koninkl. Philips Electronics NV. Classification: International A61K7/15; A61K7/50, B26B21/44 - Application number: EP19980905558 19980312 - Priority numbers EP19980905558 19980312; EP19970201225 19970424; WO19981B00339 19980312 Also published as EP0966255 (B1)
- PATENT number: AT278380T "Flüssiges Rasiermittel". Publication date: 2004/10/15.
Inventors: CPG Zegers, P. Vandamme, V. Rogiers. Applicant: Koninkl. Philips Electronics N.V. Classification: International: A61K7/15; A61K7/50; B26B21/44 - European: A61K7/15B. Application number: AT19980905558T 19980312 - Priority numbers: EP19970201225 19970424; WO19981B00339 19980312

The FAFY/ IVTD research in the area of liver-based *in vitro* modelling and stem cell technology is actually covered by 3 patent applications, a fourth one is under filing:

- VUB-014: PATENT number PCT/EP2004/0012134, WO2006/045331; EPO4822334.1, EP1824965; US11/577973, US2009/0130064a1 "Differentiation of stem cells and stabilization of phenotypical properties of primary cells". Inventors: V. Rogiers, T. Vanhaecke, S. Snykers, P. Papeleu, M. Vinken, G. Elaut and T. Henkens. Applicant: VUB (FAFY's core patent)
- VUB-026: PATENT number PCT/EP2007/055754, WO2007/144341; EPO7730081.2, EP2041272; US12/304117; US2010/278782a1 "Differentiation of rat liver epithelial cells into hepatocyte-like cells".
Inventors: V. Rogiers, T. Vanhaecke, S. Snykers, P. Papeleu, M. Vinken, T. Henkens, E. De Rop, J. Fraczek, J. De Kock and T. Doktorova; Applicant: VUB.

- VUB-022: PATENT number PCT/EP2008/0056706, WO2008/145736; EPO8760293.4, EP2158311; US12/602278, US2010/0196929 “Stabilization of the phenotypic properties of isolated primary cells”
Inventors: V. Rogiers, T. Vanhaecke, E. De Rop and J. Fraczek; Applicant: VUB.
- New patent application: A yet unknown multipotent stem cell population isolated from postnatal human skin with a geno- and phenotype closely resembling *in vivo* neural crest cells.
Inventors: V. Rogiers, Joery De Kock, Robim Rodrigues and Tamara Vanhaecke;
Applicant: VUB

7. STAYS AT OTHER RESEARCH CENTRES

PARTICIPATION IN COURSES AND WORKSHOPS

1. Stay at the Research Center and Kwashiorkor Hospital in Lwiro, Zaire, in order to study the fatty acid metabolism of the natives, 07/01-04/02/1978
2. Participation in a Refresher Course on Biochemistry of Membrane Function at the University of Nottingham, Great Britain, 23-30/09/1978
3. Stay at the Research Laboratories at the University of Cardiff, Wales, in the Department of Pediatrics on Prof. J.A. Dodge, 24-28/11/1980 *Organisation of a Workshop on Fatty Acids and of Prostaglandins in Cystic Fibrosis*
4. Stay at TNO, Rijswijk in the Department of Prof. Knook, in the Laboratories of Experimental Cytology and Cancerology; at the Université Libre de Bruxelles (ULB) and in the Department of Pharmacodynamics at the Katholieke Universiteit Leuven (KUL), in order to learn the isolation and perfusion techniques of liver tissues. Three weeks in 1982 and 1983
5. Participation in the course "Basic tissue culture" in Irvine, Scotland, 29/10-02/11/1982
6. Participation in the postgraduate course "Dermatology and cosmetology for pharmaceutical chemists", Dept. of Dermatology, Katholieke Universiteit Leuven, 1984-1985
7. Participation in workshop "Pedagogic Knowledge" organized by the VLIR in 1984-1985
8. Participation in the postgraduate course in Cosmetic Sciences organized by the Society of Cosmetic Scientists of Great-Britain, Bournemouth, Great-Britain, 13-19/03/1988
9. Stay at the laboratory of Dr. A. Guillouzo, Inserm, Unité de Recherches Hépatologiques U49, Rennes, France, in order to learn molecular biology techniques, 14/01-20/01/1990 and 29/01-03/02/1990
10. Participation in the course: Drug delivery & targeting systems. Prospects for the 90s. 05-06/12/1991, IBC, London
11. RITOX-M&T Symposium "Predictive Methods in Toxicology", Research Institute of Toxicology, Universiteit Utrecht, NL, 28/05/1997
12. *In Vitro* Toxicology Society (IVTS): Practice makes perfect. London, UK. 20/11/1997

13. The ECVAM Workshop "Availability and use of human nontransplantable tissue for biomedical research. Organized by IIAM (The International Institute for the Advancement of Medicine), Barnsdale, UK, 18-22/05/1998
14. From 1997-2000: Participation in the Modular Training Programme in Applied Toxicology (Master in Applied Toxicology), School of Biological Sciences, University of Surrey, UK. All obligatory 12 modules (one week per module) were followed and exams were successfully done. Thesis on "Cultures of hepatocytes".
15. Joint IVTS/ESTIV Teaching Workshop "The use of genomics and proteomics in *in vitro* toxicology", The University of Nottingham, UK, 10-11/04/2001
16. First Science Forum of BayerCropSciences AG "The molecular future of crop quality", Monheim, Germany, 10/10/2003
17. Several *ecopa* Board Meetings, of which the first was in Monheim, Germany, 28/04/2004
18. ECVAM/ecopa Stakeholders Workshop on the formation of national Consensus Platforms for 3R-Alternatives in the New Member States. JRC Enlargement action, Prague, Czech Republic, 04-06/06/2004
19. Participant at the EST Workshop "Review on the implementation of the EST" a joined collaboration between ReProTect project and ECVAM, Frankfurt, Germany, May 5th, 2008.
20. Participant at the "ESTIV2008" 15th International Congress on *In Vitro* Toxicology" Stockholm, 25-28/09/2008.
21. Participant at the LIINTOP Pre-meeting and General and MT meeting, Playa el Saler, Valencia, Spain, 14-17/01/2009.
22. Participation in most meetings/courses organised over the years 2009 to 2015 for the EU projects, CONAM, START-UP, CarcinoGenomics, ESNATS, Detective and HemiBio, organised in different EU countries.
23. Participant of the Scientific Advisory Board of "Innovative Systems Toxicology for Alternatives to Animal Testing" of InnoSystox organised by Zon MW together with the German Federal Ministry of Education and Research (BMBF) and Project leader Jülich, Frankfurt, Germany, 28/05/2015.

8. MEMBERSHIPS AND EXPERTISE

Membership of scientific societies

- Member of the Belgian Association for Biochemistry
- Member of the Belgian Association for Pharmaceutical Sciences
- Member of the Society of Cosmetic Scientists, Great Britain
- Member of the Belgian Association of Chemical Cosmetologists
- Member of the European Society of Biochemical Pharmacology
- Member of the Belgian Society of Toxicology (BELTOX)
- Member of ESTIV (European Society of *In Vitro* Toxicology)
- Member of the HUG Group (Hepatocytes User Group), UK
- Member of the European Society for Toxicology
- Foundation member of the Society of Cellular Pharmaco-Toxicology in France
- Foundation member of the Contact Group "Experimental Toxicology", FWO
- Foundation member of Badecos(Belgian Association of Dermato-Cosmetic Sciences)

- Foundation member of ECOPA(European Consensus Platform on 3R Alternative Methods)
- Co-founder and member of the Fund for Scientific Research – Flanders (FWO) groups of excellence “Connexin and pannexin channels: regulation, function and applications” (2010-2015)
- Included in the European Register of Toxicologists (ERT) (since 2010)

Technical and Scientific Committees

- Member of the Scientific Advisory Board of the European Society for Cosmetic & Aesthetic Dermatology, since 1999
- Scientific adviser for APB (Algemene Apothekersbond) concerning dermato-cosmetic preparations
- After being laureate of the FISEA prize, invited member of the jury of the FISEA-prize "Europese Prijs voor de vervanging van dierexperimenten" (European Prize for the Replacement of Experimental Animals), Luxemburg
- After receiving the prize for one of the PhD students under the promotorship of V Rogiers, invited member of the jury of the scientific prize "Princesse Jean de Mérode" (Belgian prize for alternative methods for the replacement of animal experiments), since 1989
- Official member of the working group "Cosmetics", section IV, Hoge Gezondheidsraad (Ministry of Health and Environment), since 1989
- Foundation member of BADECOS (Belgian Association of Dermato-Cosmetic Sciences), in 1989
- Chairperson of BADECOS (Belgian Association of Dermato-Cosmetic Sciences), not-for-profit scientific organization, national status, since 1989-2006
- Official member of the "Raad voor Dierenwelzijn", a commission of the Ministry of Agriculture and Justice, as scientific expert, 1990-1992
- Official member of the Belgian Pharmacopeia Commission, 1991
- Member of the scientific committee of the "Instituut voor Hygiëne en Epidemiologie", since 1991
- Member of the "Groupe de travail sur l'expérimentation animale et la procédure des médicaments" of the Ministry of Social Affairs, from 1992-1993
- Member of the "Working Party on Human Liver Quality and Characterisation for Europe", since 1995
- Representative for Belgium of ECVAM (European Center for the Validation of Alternative Methods) in ESAC (Scientific Advisory Committee of ECVAM, the European Center for the Validation of Alternative Methods), since 1993. From 2006, observer member of ESAC for ECOPA, since 2007 member of ESAC, 2011 - 2013 elected member of the renewed ESAC.
- Representative for Belgium of EEMCO (European Group for the Efficacy Measurements on Cosmetics and other Topical Products). Informational scientific group at the European level, from 1996-2002
- Member of ERGATT (European Research Group on Alternative Testing), from 1997-2003
- At the Commission level: Member of the SCCNFP (Scientific Committee of Cosmetic Products and Non-Food Products); since 1997, co-chair of SCCP (renamed), and further co-chair of SCCS (renamed) (Scientific Committee of Consumer Safety) until 2013; Chair of the subgroup Methodologies

- Invited member of the EC-DGIII Scientific Committee on Toxicity, Ecotoxicity and the Environment for the topic "Phthalates in Toys", in 1998
 - Scientific Director of the "Belgisch Platform voor Alternatieve Methoden - Plate-Forme Belge pour Méthodes Alternatives", Prince Laurent Foundation in the Department of Toxicology, VUB, Brussels, from 1998-2000
 - Member of the Scientific Advisory Board of the "Prince Laurent Foundation", from 1997-2000
 - Member of the Commission "Geneesmiddelenonderzoek" (Drug Research) of the FWO-Vlaanderen (Flemish Scientific Research Fund), 2003-2006 and 2006-2009
 - Member of the Editorial Board of SKIN, medical journal for dermatologists, since 1998
 - Board member of SusChem, horizontal action, 2005
 - Member of the "Deontologisch Comité" (Ministerieel besluit van 8 maart 2006, gepubliceerd in het Staatsblad op 4 april 2006), Afdeling Dierenwelzijn en CITES, Directoraat-generaal Dier, Plant en Voeding, FOD Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu (Belgian Federal Government), 2006
 - Since 2006, member of *epaa* (European Partnership for Alternative Approaches to Animal Testing) Mirror Group.
 - Member of the Solvay Animal Care and Use Committee (SACUC), 2007
 - Nominated by the Belgian Competent Authority as a toxicological expert (specialist) for the EChA (European Chemicals Agency)
 - Co-founder and member of the Fund for Scientific Research – Flanders (FWO) group of excellence “Connexin and pannexin channels: regulation, function and applications” (2010-2015)
 - Member of Deontologisch Comité, Federale Overheidsdienst (FOD) Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu (2013)
 - Member of the Scientific Advisory Board of “Innovative Systems Toxicology for Alternatives to Animal Testing” of InnoSysTox, organised by Zon MW together with the German Federal Ministry of Education and Research (BMBF) and Project Promotor Jülich, 2014-2015.
 - Member of SCCS {and predecessors SCCP, SCC(NF)P} until 2013, since then invited expert of SCCS (scientific Committee on Consumer Safety)
 - Since 2014: member of “Wetenschappelijke Commissie Voeding, Geneesmiddelen en consumptiegoederen” (WIV-ISP)
- **International collaborations in the context of EU research projects:**
- IVTD was research partner in the carcinoGENOMICS (FP6, IP) Project and a firm collaboration has been established with scientists from the University of Maastricht, Prof. J. Kleinjans and J. Van Delft and with scientists of the Franhofer Institute, DE.
 - IVTD was research partner in the ESNATS (FP7, IP) project. As such multiple collaborations on “Embryonic stem cell-based novel alternative testing strategies”, with European academic and industrial group exists, in particular those involved in liver research i.e. Prof. J. HESCHELER (the Institute of Neurophysiology of the University of Cologne, DE) who is the coordinator of ESNATS, and Prof. J. HENGSTLER (University of Dortmund (UoD)/Leibniz Research Centre for Working Environment and Human Factors (IFADO), DE).

- IVTD was research partner in the LIINTOP (FP6 STREP) project “Optimisation of liver and intestine *in vitro* models for pharmacokinetics and pharmacodynamics studies”. Multiple collaborations exist with the different European academic and industrial scientists, in particular with those involved in liver research i.e. Prof. J. CASTELL (University Hospital La Fe, Valencia, ES), Prof. C. GUGUEN-GUILLOUZO and Prof. A. GUILLOUZO, Unité Hépatologique, INSERM, Rennes, and the coordinator of LIINTOP (Prof. F. ZUCCO (Istituto Neurobiologia e Medicina Molecolare, University of Rome, IT).
- IVTD was the promoter of the CONAM (FP6) and START-UP (FP7 Support Action) projects and multiple contacts were established in particular with the pharmaceutical industry i.e. Prof. F. Pfannkuch (Roche, CH), Dr. H.J. Ahr (Bayer, DE) and Dr. J. Feyen (GALAPAGOS NV, BE) etc. and several regulatory bodies.
- IVTD is research partner in two actually running EU projects i.e. HeMiBio ("Hepatic Microfluidic Bioreactor"; coordinator Prof. C. VERFAILLIE, Stem Cell Institute KU Leuven, BE) and DETECTIVE ("Detection of endpoints and biomarkers of repeated dose toxicity using *in vitro* systems"; coordinator Prof. J. HESCHELER, the Institute of Neurophysiology of the University of Cologne, DE).
- V. Rogiers is member of the Advisory Committee of several EU projects, among these are PREDICT IV (IP, FP7 project), ReProTect (IP, FP6 project), COSMOS (IP, FP7 project) and ProSysTox (IP, FP7 project)

9. NAMES OF SCIENTISTS WHO CAN EVALUATE MY ACHIEVEMENTS

Universities in Belgium:

At the VUB: Prof. T. Vanden Driessche (Department of Gene Therapy and Regenerative Medicine), Prof. M. Chuah (Department of Gene Therapy and Regenerative Medicine), Prof. H. Thienpont (Photomics team, BPhot), Prof. L. Van Grunsven (LIVR, Liver Cell Biology), Prof. Y. Vander Heyden (FABY, Analytical Chemistry), Prof. J. Gutermuth (Dermatologie, UZ-VUB), Prof. A. Dupont (Dean faculty Medicine and Pharmacy, VUB), Prof. P. De Knop (Rector VUB)

At the RUG: Prof. J. Demeester and Prof. S. De Smedt (Laboratorium of General Biochemistry and Physical Pharmacy), Prof L. Leybaert (Laboratorium of Physiology), Prof. G. Leroux-Roels (CEVAC, Center for Vaccinology), Prof P. Dubrueel (PBM, Polymer Chemistry and Biomaterials)

At the KUL: Prof. T. Roskams (Department of Pathological analysis), Prof. A. Goossens (Department of Dermatology)

At the UA: Prof. G. Schoeters (Project Manager at VITO and Professor Biomedical Sciences at the University of Antwerp)

Universities abroad:


- Prof. J. Hescheler, Inst. of Neurophysiology, University of Köln
- Prof. A. Guillouzo Hépatologiques, INSERM U49, France
- Prof. J. Hengstler, Institut für Arbeitsphysiologie, Universität Dortmund, Germany
- Prof. J. Castell and Prof. M.J. Gomez-Lechon, University of Valencia, Hospital La Fe, Spain
- Prof. O. Pelkonen, Dept. Toxicology and Pharmacology, University of Oulu, Finland

10. SCIENTIFIC PUBLICATIONS


10.1. Articles in peer-reviewed international journals

Source items indexed within Web of Science Core Collection provide the follow overview (October 6, 2015)

- sum of the times cited: 5667
- sum of the times cited without self-citations: 4787
- citing articles: 4183
- citing articles without self-citations: 3975
- h-index: 39



Published Items in Each Year



Citations in Each Year

1. Rogiers V. (1977) The application of an improved gas-liquid chromatographic method for the determination of the long chain non-esterified fatty acid pattern of blood plasma in children. *Clinica Chimica Acta* **78**, 227-233.
2. Rogiers V. (1978) Stability of the long chain non-esterified fatty acid pattern in plasma and blood during different storage conditions. *Clinica Chimica Acta* **84**, 49-54.

3. Rogiers V. (1980) Gaschromatographic determination of the fatty acid pattern of red cell membrane plasmalogens in healthy children. *Journal of Chromatography* **182**, 27-33.
4. Rogiers V., Crockaert R. and Vis H.L. (1980) Altered phospholipid composition and changed fatty acid pattern of the various phospholipid fractions of red cell membranes of cystic fibrosis children with pancreatic insufficiency. *Clinica Chimica Acta* **105**, 105-115.
5. Rogiers V., Dab I., Crockaert R. and Vis H.L. (1980) Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. *Pediatric Research* **14**, 1088-1091.
6. Rogiers V. (1981) Long chain non-esterified fatty acid pattern in plasma of healthy children and young adults in relation to age and sex. *Journal of Lipid Research* **22**, 1-6.
7. Rogiers V., Mandelbaum I., Mozes N., Vertongen F., Dab I., Crockaert R. and Vis H.L. (1982) "In vitro" study of the incorporation and transport of non-esterified fatty acids into the phospholipids of the red blood cell membranes of cystic fibrosis patients. *Pediatric Research* **16**, 761-768.
8. Rogiers V., Dab I., Baran D. and Vercruysse A. (1983) Abnormal fatty acid pattern of the plasma cholesterol ester fraction of cystic fibrosis patients with and without pancreatic insufficiency. *European Journal of Pediatrics* **141**, 39-42.
9. Rogiers V., Dab Y., Michotte Y., Vercruysse A., Crockaert R. and Vis H.L. (1984). Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (*In vitro* study). *Pediatric Research* **18**, 704-709.
10. Rogiers V., Vercruysse A., Dab I., Crockaert R. and Vis H.L. (1984) Fatty acid pattern of platelet phospholipids in cystic fibrosis. *European Journal of Paediatrics* **142**, 305-306.
11. Rogiers V., Vandenberghe Y. and Vercruysse A. (1985) Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes. *Xenobiotica* **15**, 759-765.
12. Van Schravendijk C.F.H., Foriers A., Hooghe-Peters E.L., Rogiers V., De Meyts P., Sodoyez J.C. and Pipeleers D.G. (1985) Pancreatic hormone receptors on islet cells. *Endocrinology* **117**, 841-848.
13. Rogiers V. and Vercruysse A. (1985) Effect of organic solvents on 7-ethoxy coumarin O-deethylase activity. *Alternatives to Laboratory Animals (ATLA)* **13**, 123-124.
14. Rogiers V., Adriaenssens L., Vandenberghe Y. and Gepts E. (1986) Critical evaluation of 7-ethoxy coumarin O-deethylase activity measurement in intact isolated rat hepatocytes. *Xenobiotica* **16**, 817-826.
15. Rogiers V., Paeme G., Sonck W. and Vercruysse A. (1988) Metabolism of procyclidine in isolated rat hepatocytes: mechanism of diol formation. *Xenobiotica* **17**, 849-859.
16. Rogiers V., Vandenberghe Y., Sonck W., Maes V. and Vercruysse A. (1988) The inducing and inhibiting effects of sodium valproate *in vivo* on the biotransformation systems of xenobiotics studied with isolated rat hepatocytes. *Xenobiotica* **18**, 665-673.
17. Rogiers V. (1988) Toxicologische aspecten verbonden aan het gebruik van cosmetica. *Farmaceutisch Tijdschrift voor België* **8**, 52-57.
18. Vandenberghe Y., Ratanasavanh D., Rogiers V. and Guillouzo A. (1988) Glutathione S-transferase activity in cultured human hepatocytes. *Cell Biology Int. Rep.* **12**, 959-967.

19. Vandenberghe Y., Morel F., Foriers A., Vercruysse A., Guillouzo A. and Rogiers V. (1989) Effect of phenobarbital on the expression of GST isoenzymes in cultured rat hepatocytes. *FEBS Letters* **251**, 59-64.
20. Morel F., Vandenberghe Y., Pemble S., Taylor J.B., Ratanasavanh D., Rogiers V., Vercruysse A., Ketterer B. and Guillouzo A. Regulation of glutathione S-transferase subunits 3 and 4 in cultured rat hepatocytes. *FEBS Letters* **258**, 99-102.
21. Rogiers V. (1990) Liposomes: une forme galénique dans la dermato-cosmétique. *Cosmétique* **8/9**, 19-22.
22. Rogiers V., Vandenberghe Y., Callaerts A., Verleye G., Mertens K., Cornet M., Sonck W. and Vercruysse A. (1990) Phase I and phase II xenobiotic biotransformation in cultures and co-cultures of adult rat hepatocytes. *Biochemical Pharmacology* **40**, 1701-1706.
23. Rogiers V., Vandenberghe Y., Callaerts A., Sonck W. and Vercruysse A. (1990) Effects of DMSO on phase I and II biotransformation in cultured rat hepatocytes. *Toxicology In Vitro* **4**, 239-242.
24. Rogiers V., Derde M.P., Verleye G. and Roseeuw D. (1990) Standardized conditions needed for skin surface hydration measurements. *Cosmetics and Toiletries* **105**, 73-82.
25. Vandenberghe Y., Morel F., Taylor J., Rogiers V., Ratanasavanh D., Vercruysse A., Ketterer B. and Guillouzo A. (1990) Changes in expression of mRNA coding for glutathione S-transferase subunits 1-2 and 7 in cultured rat hepatocytes. *Molecular Pharmacology* **37**, 372-376.
26. Vandenberghe Y., Foriers A., Rogiers V. and Vercruysse A. (1990) Changes in expression and *de novo* synthesis of GST subunits in cultured adult rat hepatocytes. *Biochemical Pharmacology* **39**, 685-690.
27. Coecke S., Vandenberghe Y., Callaerts A., Sonck W., Verleye G., van Bezooijen C.F.A., Vercruysse A. and Rogiers V. (1990) Hepatic cytosolic GST activities in ageing brown Norway rats. Importance of sex differences and phenobarbital treatment for studies of ageing. *Mechanisms of Ageing and Development* **55**, 189-198.
28. Rogiers V. (1991) Liposomen een nieuwe galenische vorm in de dermato-cosmetologie. *Pharmakon* **86**, 52-58.
29. Rogiers V., Coecke S., Vandenberghe Y., Morel F., Callaerts A., Verleye G., van Bezooijen C.F.A., Guillouzo A. and Vercruysse A. (1991) Effect of the aging process on the gender and phenobarbital-dependent expression of glutathione S-transferase subunits in brown Norway rat liver. *Biochemical Pharmacology* **42**, 491-498.
30. Vandenberghe Y., Tee L., Morel F., Rogiers V., Guillouzo A. and Yeoh G. (1991) Regulation of glutathione S-transferase gene expression by PB in cultured adult rat hepatocytes. *FEBS Letters* **284**, 103-108.
31. Mertens K., Rogiers V., Sonck W. and Vercruysse A. (1991) Measurements of reduced and oxidized glutathione in cultures of adult rat hepatocytes. *Journal of Chromatography* **565**, 149-157.
32. Mertens K., Rogiers V., Sonck W. and Vercruysse A. (1991) Reduced and oxidized glutathione contents in adult rat hepatocytes under various culture conditions. *Cell Biology and Toxicology* **7**, 101-110.
33. Csanady G.A., Freise D., Denk B., Filser J.G., Cornet M., Rogiers V. and Laib R.J. (1991) Investigation of species differences in isobutene (2-methylpropene) metabolism between mice and rats. *Archives of Toxicology* **65**, 100-105.

34. Cornet M., Sonck W., Callaerts A., Csanady G., Vercruyssen A., Laib R. and Rogiers V. (1991) *In vitro* biotransformation of 2-methylpropene (isobutene): epoxide formation in mice liver. *Archives of Toxicology* **65**, 263-267.
35. Roseeuw D., Deconinck A., Neven A.M., Vandenberghe Y., Kets E., Verleye G. and Rogiers V. (1991) Fresh and cryopreserved cultured keratinocyte allografts for wound healing. *Toxicology in Vitro* **5**, 579-583.
36. Geerts A., Greenwel P., Cunningham M., De Bleser P., Rogiers V., Wisse E. and Rojkind M. (1991) Electron microscopical characterization of freshly isolated liver cells, and their use for Northern hybridization analysis of connective tissue protein transcripts. *Micron Microscopica Acta* **22**, 251-252.
37. Roberfroid M. and Rogiers V. (1991) Editorial. Brussels Symposium on Alternative Methods in Pharmacotoxicological research. *Journal of Alternative Laboratory Animals (ATLA)* **19**, 367-368.
38. Rogiers V., Akrawi M., Shephard E., Phillips I. and Vercruyssen A. (1992) Co-cultures of rat hepatocytes in the study of valproate toxicity. *Archives of Toxicology* **15**, 156-159.
39. Rogiers V., Callaerts A., Vercruyssen A., Akrawi M., Shephard E. and Phillips I. (1992) Effects of valproate on xenobiotic biotransformation systems in rat liver: *in vivo* and *in vitro* experiments. *Pharmaceutisch Weekblad, Scientific Edition* **14/3A**, 127-131.
40. Vandenberghe Y., Tee L., Rogiers V. and Yeoh G. (1992) Transcriptional and post-transcriptional dependent regulation of glutathione S-transferase expression in rat hepatocytes as a function of culture conditions. *FEBS Letters* **313**, 155-159.
41. Cornet M., Castelain P., Vercruyssen A., Laib R., Kirsh-Volders M. and Rogiers V. (1992) Mutagenicity of 2-methylpropene (isobutene) and its epoxide in a modified Ames Salmonella assay for volatile compounds. *Mutation Research* **271**, 213-221.
42. Coecke S., Mertens K., Segaert A., Callaert A., Vercruyssen A. and Rogiers V. Spectrophotometric measurement of flavin-containing monooxygenase activity in freshly isolated rat hepatocytes and their cultures. (1992) *Analytical Biochemistry* **205**, 285-288.
43. Rogiers V. and Vercruyssen A. (1993) Rat hepatocyte cultures and co-cultures in biotransformation studies of xenobiotics. *Toxicology* **82**, 193-208.
44. Mertens K., Rogiers V. and Vercruyssen A. (1993) Glutathione-dependent detoxication in adult rat hepatocytes under various culture conditions. *Archives of Toxicology* **67**, 680-685.
45. Mertens K., Rogiers V. and Vercruyssen A. (1993) Measurement of malondialdehyde in cultures of adult rat hepatocytes. *Toxicology in Vitro* **7**, 439-441.
46. Coecke S., Segaert A., Vercruyssen A. and Rogiers V. (1993) Expression of flavin-containing monooxygenase activity in conventional cultures and co-cultures of adult rat hepatocytes under various culture conditions. *Toxicology in Vitro* **7**, 487-491.
47. Geerts A., Greenwel P., Cunningham M., De Bleser P., Rogiers V., Wisse E. and Rojkind (1993) Identification of connective tissue gene transcripts in freshly isolated parenchymal, endothelial, Kupffer and fat-storing cells by northern hybridisation analysis. *Journal of Hepatology* **19**, 148-158.
48. Akrawi M., Shephard E.A., Phillips I.R., Vercruyssen A. and Rogiers V. (1993) Effects of Phenobarbital and valproate on the expression of cytochrome P-450 mediated mono-oxygenases in co-cultured rat hepatocytes. *Toxicology in Vitro* **7**, 477-480.

49. Castelain P., Criado B., Cornet M., Laib R., Rogiers V. and Kirsch-Volders M. (1993) Comparative mutagenicity of structurally related aliphatic epoxides in a modified Salmonella microsome assay. *Mutagenesis* **8**, 387-393.
50. Akrawi M., Rogiers V., Vandenberghe Y., Palmerc N.A., Vercruysse A., Shephard E. and Phillips I. (1993) Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P-450 mediated mono-oxygenase. *Biochemical Pharmacology* **45**, 1583-1591
51. Cornet M., Mertens K., Callaerts A., Sonck W., Vercruysse A. and Rogiers V. (1994) Age- and gender-related changes in the hepatic metabolism of 2-methylpropene and relationship to epoxide metabolizing enzymes. *Mechanisms of Ageing and Development* **74**, 103-115.
52. Akrawi M., Rogiers V., Vercruysse A., Phillips I.R. and Shephard E.A. (1994) Long-term preservation and induction of drug metabolizing enzymes in co-cultured rat hepatocytes. *Biochemical Society Transactions* **22/2**, 124S.
53. Leutbecher L., Cornet M., Rogiers V. and Bolt H.M. (1994) DNA binding study with inhaled [¹⁴C]2-methylpropene (isobutene). *Archives of Toxicology* **68**, 71-72.
54. Blaauboer B., Boobis A., Castell J., Coecke S., Guillouzo A., Groothuis G., Hall T., Hawksworth G., Lorenzon G., Miltenburger H., Rogiers V., Skett P., Villa P. and Wiebel F. (1994) The practical applicability of hepatocyte cultures in routine testing - Report of an ECVAM Workshop. *Alternatives to Laboratory Animals (ATLA)* **22**, 231-241.
55. Rogiers V. (1995) Efficacy claims of cosmetics in Europe must be scientifically substantiated from 1997 on. *Skin Research and Technology* **1**, 44-46.
56. Rogiers V., Blaauboer B., Maurel P., Phillips I. and Shephard E. (1995) Hepatocyte-based *in vitro* models and their application in pharmacotoxicology. Report of an EC DGXII meeting with representatives of the European pharmaceutical industry. *Toxicology in Vitro* **9**, 685-694.
57. Rogiers V., Akrawi M., Vercruysse A., Phillips I. and Shephard E. (1995) Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. *European Journal of Biochemistry* **231**, 337-343.
58. Rogiers V. (1995) Hepatocyte-based *in vitro* models in drug development: a priority for the European pharmaceutical industry. (Editorial) *TEN* **2**, 99.
59. Cornet M., Callaerts A., Jorritsma U., Bolt H., Vercruysse A. and Rogiers V. (1995) Species-dependent differences in biotransformation pathways of 2-methylpropene (isobutene). *Chemical Research in Toxicology* **8**, 987-992.
60. Cornet M., Callaerts A., Vercruysse A. and Rogiers V. (1995) *In vitro* biotransformation of 2-methylpropene (isobutene) in rat lung tissue in comparison with liver tissue. *Archives of Toxicology* **70**, 64-57
61. Debast G., Coecke S., Akrawi M., Foriers A., Vercruysse A., Phillips I., Shephard E. and Rogiers V. (1995) Effect of ethanol on glutathione S-transferase expression in co-cultured rat hepatocytes. *Toxicology in Vitro* **9**, 467-471.
62. Jorritsma U., Cornet M., Van Hummelen P., Bolt H., Vercruysse A., Kirsch-Volders M. and Rogiers V. (1995) Comparative mutagenicity of 2-methylpropene (isobutene), its epoxide 2-methyl-1,2-propane and propylene oxide in the *in vitro* micronucleus test using human lymphocytes. *Mutagenesis* **10**, 101-104.
63. Serup J., Masson P., Rodrigues L., Berardesca E., Leveque J., Loden J.L., Piérard G., Rogiers V., Salter D., Sauermann G. and Trullas-Cabanac C. (1995) EEMCO

- guidance for the assessment of dry skin (xerosis) and ichthyosis: clinical scoring systems. *Skin Research and Technology* **1**, 109-114.
64. De Bleser P., Jannes P., Van Buul-Offers SC., Hoogerbrugge C., Van Schravendijk C., Niki T., Rogiers V., Vandenbrande C., Wisse E. and Geerts A. (1995) Insulin-like growth factor II/mannose 6-phosphate receptor is expressed on CCl₄-exposed rat fat storing cells and facilitates activation of latent transforming growth factor- β in cocultures with sinusoidal endothelial cells. *Hepatology* **21**, 1429-1437.
 65. Mertens K., Vercruyse A., Rahmani R., Kaufman S. and Rogiers V. (1996) Interspecies differences in glutathione-dependent detoxication of hydroperoxides in short-term cultures of hepatocytes. *Toxicology in Vitro* **10**, 473-478.
 66. Mertens K., Kaufman S., Waterschoot S., Vercruyse A. and Rogiers V. (1996) Effect of testing butylhydroperoxide-induced oxidative stress on glutathione content and thiobarbituric acid reactive substances production in cultures and co-cultures of adult rat hepatocytes. *Toxicology in Vitro* **10**, 507-511.
 67. De Paepe K., Vandamme P., Roseeuw D. and Rogiers V. (1996) Ceramides/cholesterol/FFA containing cosmetics: the effect on barrier function. *SÖFW Journal* **122**, 199-204.
 68. Piérard G., Masson P., Rodrigues L., Berardesca E., Levêque J.L., Loden M., Rogiers V., Salter D., Sauermann G., Serup J. (1996) EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: evaluation by stratum corneum strippings. *Skin Research and Technology* **2**, 3-11.
 69. Rogiers V., Vandenberghé Y., Vanhaecke T., Geerts A., Callaerts A., Carleer J., Roba J. and Vercruyse A. (1997) Observation of hepatotoxic effects of 2-n-pentylaminoacetamide (milacemide) in rat liver by a combined *in vivo/in vitro* approach. *Archives of Toxicology* **71**, 271-282.
 70. Cornet M. and Rogiers V. (1997) Metabolism and toxicity of 2-methylpropene (isobutene). A review. *Critical Reviews in Toxicology* **27**, 223-232.
 71. Beken S., Pauwels M., Pahernik S., Koebe A.G., Vercruyse A. and Rogiers V. (1997) Collagen gel sandwich and immobilisation cultures of rat hepatocytes: problems encountered in expressing glutathione S-transferase activities. *Toxicology in Vitro* **11**, 741-752.
 72. Beken S., Tytgat T., Pahernik S., Koebe H.G., Vercruyse A. and Rogiers V. (1997) Cell morphology, albumin secretion and glutathione S-transferase expression in collagen gel sandwich and immobilisation cultures of rat hepatocytes. *Toxicology in Vitro* **11**, 409-416.
 73. Vanhaecke T., Vercruyse A. and Rogiers V. (1997) Effect of pyruvate on glutathione S-transferase expression in primary cultures of rat hepatocytes. *Toxicology in Vitro* **11**, 435-441.
 74. De Smet K., Callaerts A., Vercruyse A. and Rogiers V. (1997) Effect of phenobarbital on 7-ethoxycoumarin O-deethylase and microsomal epoxide hydrase activities in collagen gel cultures of rat hepatocytes. *Toxicology in Vitro* **11**, 459-463.
 75. De Bleser P.J., Niki T., Rogiers V. and Geerts A. (1997) Transforming growth factor- β gene. Expression in normal and fibrotic rat liver. *Journal of Hepatology* **26**, 886-893.
 76. De Bleser P.J., Niki T., Xu G.X., Rogiers V. and Geerts A. (1997) Localisation and cellular sources of activins in normal and fibrotic rat liver. *Hepatology* **26**, 905-912.

77. Xu G., Niki T., Virtanen I., Rogiers V., De Bleser P. and Geerts A. (1997) Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts. *Journal of Pathology* **183**, 90-98.
78. Coecke S., Callaerts A., Phillips I.R., Vercruyssen A., Shephard E.A. and Rogiers V. (1998) Effect of thyroid hormones on flavin-containing monooxygenase activity in co-cultured adult rat hepatocytes. *Toxicology in Vitro* **12**, 335-341. [IF₁₉₉₈ = 0.753]
79. Coecke S., Debast G., Phillips I.R., Vercruyssen A. and Rogiers V. (1998) Hormonal regulation of microsomal flavin-containing monooxygenase activity by sex steroids and growth hormone in co-cultured adult male rat hepatocytes. *Biochemical Pharmacology* **56**, 1047-1051. [IF₁₉₉₈ = 2.719]
80. Todd M., Garthoff B., Bernhardt G., Bodé G., Farr S., Kolar R., Lumley C., Pieters M., Rogiers V., Sauer U., Spielmann H., Straus J. and Warngard L. (1998). Issues related to the release of proprietary information and data for use in the validation of alternative methods. *Alternatives to Laboratory Animals (ATLA)* **26**, 13-20. [IF₁₉₉₈ = 1.471]
81. Anderson R., O'Hare M., Balls M., Brady M., Brahams D., Burt A., Chesne C., Combes R., Dennison A., Garthoff B., Hawksworth G., Kalter E., Lechat A., Mayer D., Rogiers V., Sladowski D., Southee J., Trafford J., van der Valk J. and van Zeller A.M. (1998) The availability of human tissue for biomedical research. *Alternatives to Laboratory Animals (ATLA)* **26**, 763-777. [IF₁₉₉₈ = 1.471]
82. Depreter M., Beken S., Tytgat T., Hallez F., Espeel M., Rogiers V. and Roels F. (1998) Hepatocyte polarity and differentiation of peroxisomes. *Cell Biology International* **22**, 62-63. [IF₁₉₉₈ = 0.884]
83. Rogiers V., Balls M., Basketter D., Berardesca E., Edward C., Elsner P., Ennen J., Leveque J.L., Loden M., Masson Ph., Parra J., Paye M., Piérard G., Rodrigues L., Schaefer H., Salter D. and Zuang V. (1999) The potential use of non-invasive methods in safety assessment of cosmetic products. The report and recommendations of an ECVAM/EEMCO Workshop. *Alternatives to Laboratory Animals (ATLA)* **27**, 515-537. [IF₁₉₉₉ = 1.526]
84. Rogiers V. (1999) Launch of the Belgian Platform for Alternative Methods. *Alternatives to Laboratory Animals (ATLA "Around the World")* **27**, 485-487. [IF₁₉₉₉ = 1.526]
85. Rogiers V. (1999) The barrier function of the skin by transepidermal water loss measurements. *Cosmétique* **23**, 23-25. [no IF₁₉₉₉]
86. Coecke S., Rogiers V., Bayliss M., Castell J., Doehmer J., Fabre G., Fry J., Kern A. and Westmoreland C. (1999) "The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: the current status. ECVAM hepatocytes and metabolically competent systems. Task Force Report I." *Alternatives to Laboratory Animals (ATLA)* **27**, 579-638. [IF₁₉₉₉ = 1.526]
87. Beken S., Slaus K., De Smet K., Depreter M., Roels F., Vercruyssen A. and Rogiers V. (1999) Effect of the extracellular matrix composition on the expression of glutathione S-transferase isoenzymes in organotypical hepatocyte cultures. *Toxicology in Vitro* **13**, 571-577. [IF₁₉₉₉ = 1.136]
88. De Smet K., Beken S., Depreter M., Roels F., Vercruyssen A. and Rogiers V. (1999) Effect of epidermal growth factor in collagen gel cultures of rat hepatocytes. *Toxicology in Vitro* **13**, 579-585. [IF₁₉₉₉ = 1.136]

89. De Paepe K., Vandamme P., Derde M.P., Roseeuw D. and Rogiers V. (1999) Body lotions enriched with skin identical lipids: a TEWL study of aged skin and SLS-induced scaly skin. *Eurocosmetics* **7**, 38-45. [no IF₁₉₉₉]
90. De Paepe K., Roseeuw D. and Rogiers V. (1999) Les céramides dans les préparations dermo-cosmétiques. *Journal de Médecine Esthétique et de Chirurgie Dermatologique* **26** (103) 179-184. [no IF₁₉₉₉]
91. Piérard F., Masson P., Rodrigues L., Rogiers V., Berardesca E., Elsner P., Leveque J.P., Loden M., Marks R., Parra J.L. and Trevethan M. (1999) EEMCO Guidance to the *in vivo* assessment of tensile functional properties of the skin. Part I: Relevance to the structures and ageing of the skin and subcutaneous tissues. EEMCO Review. *Skin Pharmacology and Applied Skin Physiology* **12**, 353-362. [IF₁₉₉₉= 0.711]
92. Leveque J.P., Masson P., Piérard G.E., Rodrigues L., Berardesca E., Gummer C.L., Loden M., Parra J.P., Rogiers V., Salter D. and Trevethan M. (1999) EEMCO Guidance for the assessment of skin topography. Review article. *Journal of the European Academy of Dermatology and Venereology* **12**, 103-114. [IF₁₉₉₉= 0.466]
93. De Bleser P.J., Xu G.X., Rombouts K., Rogiers V. and Geerts A. (1999) Glutathione levels discriminate between oxidative stress and transforming growth factor- β signaling in activated rat hepatic stellate cells. *Journal of Biological Chemistry* **274**, 48, 33881-33887. [IF₁₉₉₉= 7.666]
94. Geerts A. and Rogiers V. (1999) Sho-Saiko-to: the right blend of traditional oriental medicine and liver cell biology. *Hepatology* **29**, 282-284. [IF₂₀₀₅ = 9.792]
95. Niki T., Rombouts K., De Bleser P., De Smet K., Rogiers V., Schuppan D., Yoshida A.M., Gabbiani G. and Geerts A. (1999) A histone deacetylase inhibitor, Trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. *Hepatology* **29**, 858-864 [IF₁₉₉₉ = 7.344]
96. van der Valk J., Garthoff B., Schlitt A., Beken S., Rogiers V. and van Iersel A. (1999) Improving international co-operation between national organisations promoting the 3Rs. *ALTEX - Alternativen zu Tierexperimenten* **16**, 166-168. [no IF₁₉₉₉ ; IF₂₀₀₀= 0,158]
97. Coecke S., Vanhaecke T., Foriers A., Phillips I.R., Vercruysse A., Shephard E.A. and Rogiers V. (2000) Hormonal regulation of glutathione S-transferase expression in co-cultured adult rat hepatocytes. *Journal of Endocrinology* **166**, 363-371. [IF₂₀₀₀ = 2.663]
98. Depreter M., Tytgat T., Beken S., Espeel M., De Smet K., Rogiers V. and Roels F. (2000) "Effects of extracellular matrix on the expression of peroxisomes in primary rat hepatocyte cultures". *Journal of Hepatology* **32**, 381-391. [IF₂₀₀₀ = 3.761]
99. Vanhaecke T., Lindros K.O., Oinonen T., Coecke S., Debast G., Phillips I.R., Shephard E.A., Vercruysse A. and Rogiers V. (2000) Effect of ethanol on the expression of hepatic glutathione S-transferase: an *in vivo/in vitro* study, *Biochemical Pharmacology* **60**, 1491-1496. [IF₂₀₀₀ = 2.975]
100. Vanhaecke T., Lindros K.O., Oinonen T., Vercruysse A. and Rogiers V. (2000) Effect of long-term ethanol exposure on the acinar distribution of hepatic glutathione S-transferase, *Drug Metabolism and Disposition* **28** (12), 1470-1474. [IF₂₀₀₀ = 2.513]
101. De Smet K., Bruning T., Blaszkewicz, Bolt H., Vercruysse A. and Rogiers V. (2000) Biotransformation of trichloroethylene in collagen gel sandwich cultures of rat hepatocytes. *Archives of Toxicology* **74**, 587-592. [IF₂₀₀₀ = 2.006]

102. Rogiers V. (2000) Linea Guida SCCNFP. Valutazione Della Sicurezza Di Ingredienti e Prodotti Cosmetici. *Cosmetic Technology* **3,6** 22-27. [no IF₂₀₀₀]
103. Rogiers V. (2000) New challenges in safety assessment of cosmetics. *Eurocosmetics* **11/12** 32-36. [no IF₂₀₀₀]
104. De Paepe K., Derde M.P., Roseeuw D. and Rogiers V. (2000) Incorporation of ceramide 3B in dermato-cosmetic emulsions: effect on the transepidermal water loss of sodium lauryl sulphate-damaged skin. *Journal of the European Academy of Dermatology and Venereology* **14**, 272-279. [IF₂₀₀₀ = 0.675]
105. Roseeuw D. and De Paepe K. (2000) Water barrier function: what's new? *Journal of the European Academy of Dermatology and Venereology* **14**, 243-244. [IF₂₀₀₀ = 0.675]
106. De Paepe K., Derde M.P., Roseeuw D. and Rogiers V. (2000) Claim substantiation and efficiency of hydrating body lotions and protective creams. *Contact Dermatitis* **42**, 227-234. [IF₂₀₀₀ = 0.675]
107. De Paepe K., Lagarde J.H., Gall Y., Roseeuw D. and Rogiers V. (2000) Microrelief of the skin using a light transmission technique. *Archives of Dermatological Research* **292**, 500-510. [IF₂₀₀₀ = 1.346]
108. Depreter M., Walker T. De Smet K., Rogiers V., Roels F. and Beken S. (2000) Variable peroxisome expression in different primary hepatocyte cultures. *Molecular Biology of the Cell* **10** (109) 630. [IF₂₀₀₀ = 8.482]
109. Piérard G.E., Piérard-Franchimont C., Marks R., Paye M. and Rogiers V. (2000) EEMCO guidance for the *in vivo* assessment of skin greasiness. *Skin Pharmacology and Applied Skin Physiology* **13**, 372-389 (2000). [IF₂₀₀₀ = 0.940]
110. Depreter M., Tytgat T., Beken S., Espeel M., De Smet K., Rogiers V. and Roels F. (2000) Effects of extracellular matrix on the expression of peroxisomes in primary rat hepatocyte cultures. *Journal of Hepatology* **32/3**, 381-391. [IF₂₀₀₀ = 3.761]
111. Rogiers V., Masson P., Piérard G.E., Rodrigues L., Berardesca E., Elsner P., Lévêque J.L., Loden M., Marks R., Parra J.L., Trevethan M. and Zuang G. V. (2001) EEMCO-guidance for the assessment of transepidermal water loss (TEWL) in Cosmetic Sciences. *Skin Pharmacology and Applied Skin Physiology* **14/2**, 117-129. [IF₂₀₀₁ = 1.174]
112. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. (2000) Prevention of skin barrier damage in allergic contact dermatitis: An experimental model using contact allergy patch tests combined with TEWL measurements. *Journal of Investigative Dermatology* **115**, 551. [IF₂₀₀₀ = 4.539]
113. Vanhaecke T., Lindros K.O., Oinonen T., Vercruysse A. and Rogiers V. (2001) Triiodothyronine downregulates the periportal expression of α class glutathione S-transferase in rat liver, *FEBS Letters* **487**, 356-360. [IF₂₀₀₁ = 3.644]
114. Vanhaecke T., Derde M.-P., Vercruysse A. and Rogiers V. (2001) Hydroxypropyl- β -cyclodextrin as a delivery system for thyroid hormones, regulating glutathione S-transferase expression in rat hepatocyte co-cultures, *Biochemical Pharmacology* **61** (9), 1073-1078. [IF₂₀₀₁ = 3.340]
115. Vanhaecke T., Foriers A., Geerts A., Shephard E.A., Vercruysse A. and Rogiers V. (2001) Pyruvate-induced long-term maintenance of glutathione S-transferase in rat hepatocyte cultures, *Alternatives to Laboratory Animals (ATLA)* **29**, 335-346. [IF₂₀₀₁ = 1.788]
116. Vanhaecke T., Elaut G. and Rogiers V. (2001) Effect of oxygen concentration on the expression of glutathione S-transferase activity in periportal and perivenous rat hepatocytes. *Toxicology in Vitro* **15**, 387-392. [IF₂₀₀₁ = 0.839]

117. Hachem J.P., De Paepe K., Vanpee E. , Kaufman L., Rogiers V., Roseeuw D. (2001) The role of Corneotherapy in the treatment of skin barrier damage due to allergic contact dermatitis. *Journal of Investigative Dermatology* **117**, 532. [IF₂₀₀₁ = 4.645]
118. Hachem J.P., De Paepe K., Rogiers V., Roseeuw D. (2001) Prevention of skin barrier damage in allergic contact dermatitis. *Journal of the European Academy of Dermatology and Venereology* **15** suppl 2, 81. [IF₂₀₀₁ = 0.981]
119. Hachem J.P., De Paepe K., Rogiers V., Roseeuw D. (2001) Corneotherapeutic agents in the treatment of skin pathology. *Journal of the European Academy of Dermatology and Venereology* **15** suppl 2, 215. [IF₂₀₀₁ = 0.981]
120. Beken S., De Smet K., De Preter M., Roels F., Vercruysse A. and Rogiers V. (2001) Effects of L-proline on phase I and phase II biotransformation capacities of rat and human hepatocytes in long-term collagen gel cultures. *Alternatives to Laboratory Animals (ATLA)* **29**/1, 35-53. [IF₂₀₀₁ = 1.788]
121. De Smet K., Cavin C., Vercruysse A. and Rogiers V. (2001) Collagen type I gel cultures of adult rat hepatocytes as a screening induction model for cytochrome P450 dependent enzymes. *Alternatives to Laboratory Animals (ATLA)* **29**, 179-192. [IF₂₀₀₁ = 1.788]
122. De Smet K., Loyer P., Gilot D., Guguen-Guillouzo C., Vercruysse A. and Rogiers V. (2001) Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. *Biochemical Pharmacology* **61**, 1293-1303. [IF₂₀₀₁ = 3.340]
123. Slaus K., Coughtrie M.W.H., Sharp S., Vanhaecke T., Vercruysse A. and Rogiers V. (2001) Influence of culture system and medium enrichment on sulfotransferase and sulfatase expression in male rat hepatocyte cultures, *Biochemical Pharmacology* **61**, 1107-1117. [IF₂₀₀₁ = 3.340]
124. De Paepe K., J.P. Hachem, E. Vanpee, Goossens A., Germaux M.A., Lachapelle J.M., Lambert J., Matthieu L., Roseeuw D., Suys E., Van Hecke I. and Rogiers V. (2001) Beneficial effects of a skin tolerance-tested moisturising cream on the barrier function of experimentally elicited irritant and allergic contact dermatitis. *Contact Dermatitis* **44**, 337-343. [IF₂₀₀₁ = 1.016]
125. De Paepe K., Janssens K., Hachem J.P., Roseeuw D. and Rogiers V. (2001) Squamometry as screening method for the evaluation of hydrating products. *Skin Research and Technology* **7**, 184-192. [IF₂₀₀₂ = 0.859 (no IF₂₀₀₁ available)]
126. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. (2001) Combination therapy improves the recovery of the human skin barrier function: an experimental model using contact allergy patch test combined with TEWL measurements. *Dermatology* **202**, 314-319. [IF₂₀₀₁ = 0.972]
127. Rogiers V. (2002) Safety Evaluation of cosmetics in Europe. *Journal of the Society of Cosmetic Scientists of Korea* **28**/3, 111-124. [no IF₂₀₀₁]
128. Rogiers V. (2002) Ecopa: A powerful concept in the way forward for alternative methods. *Alternatives to Laboratory Animals (ATLA)* **30**/2, 199-202. [IF₂₀₀₂ = 2.022]
129. Rogiers V., Houben E. and De Paepe K. (2002) Safety and Efficacy of Cosmetics in the EU. *Revista Societati Romane a Chimistilor Cosmetologi (SRCC Magazine)* **1**, 32-37. [no IF₂₀₀₂]
130. De Paepe K., Roseeuw D. and Rogiers V. (2002) Repair of acetone-and sodium lauryl sulphate-damaged human skin barrier function using topically applied emulsions containing barrier lipids. *Journal of the European Academy of Dermatology and Venereology* **16**, 587-594. [IF₂₀₀₂ = 1.021]

131. De Paepe K., Hachem J.P., Vanpee E., Roseeuw D. and Rogiers V. (2002) Effects of rice starch as a bath additive on the barrier function of healthy, but SLS-damaged skin and skin of atopic patients. *Acta Dermato-Venereologica* **82**, 184-186. [IF₂₀₀₂ = 1.580]
132. Elaut G., Török G., Vinken M., Papeleu P., Tourwé D., Laus G. and Rogiers V. (2002) Major phase I biotransformation pathways of Trichostatin A in rat hepatocytes and in rat and human liver microsomes. *Drug Metabolism and Disposition* **30**, 1320-1328. [IF₂₀₀₂ = 3.277]
133. Depreter M., Walker T., De Smet K., Beken S., Kerckaert I., Rogiers V. and Roels F. (2002) Hepatocyte polarity and the peroxisomal compartment: a comparative study. *Histochemical Journal* **34/3-4**, 139-151. [IF₂₀₀₂ = 1.150]
134. Hachem J.P., De Paepe K., Vanpee E., Bogaerts M., Kaufman L., Rogiers V. and Roseeuw D. (2002) Efficacy of topical corticosteroids in nickel-induced contact allergy. *Clinical and Experimental Dermatology* **27**, 47-50. [IF₂₀₀₂ = 1.265]
135. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. (2002). The effect of two moisturisers on skin barrier damage in allergic contact dermatitis. *European Journal of Dermatology* **12**, 136-138. [IF₂₀₀₂ = 0.807]
136. Hachem J.P., De Paepe K., Sterckx G., Kaufman L., Rogiers V. and Roseeuw D. (2002) Evaluation of biophysical and clinical parameters of skin barrier function among hospital workers. *Contact Dermatitis* **46**, 220-223. [IF₂₀₀₂ = 0.928]
137. Berardesca E., Leveque J.L., Masson P. and the EEMCO Group (2002). EEMCO guidance for measurement of skin microcirculation. *Skin Pharmacology and Applied Skin Physiology* **15**, 442-456. [IF₂₀₀₂ = 0.948]
138. Rogiers V. (2003) Ecopa: actual status and plans. *Toxicology in Vitro* **17(5-6)**, 779-784. [IF₂₀₀₃ = 1.642]
139. Rogiers V. (2003) Safety assessment of cosmetic ingredients by the SCCNFP: general principles. *SÖFW Journal* **129/4**, 4-11. [no IF₂₀₀₃]
140. Papeleu P., Loyer P., Vanhaecke T., Elaut G., Geerts A., Guguen-Guillouzo C. and Rogiers V. (2003) Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. *Journal of Hepatology* **39(3)**, 374-382. [IF₂₀₀₃ = 5.283]
141. Houben E., De Paepe K., Hachem J.P., Roseeuw D. and Rogiers V. (2003) Cosmetische verzorging bij xerosis, deel 1: fundamentele aspecten. Soins cosmétiques dans la xérose, 1^{ère} partie: les fondamentaux. *Skin* **6/1**, 20-24. [no IF₂₀₀₃]
142. Houben E., De Paepe K., Hachem J.P., Roseeuw D. and Rogiers V. (2003) Cosmetische verzorging bij xerosis, deel 2: fundamentele aspecten. Soins cosmétiques dans la xérose, 2^{ème} partie. *Skin* **6/2**, 63-66. [no IF₂₀₀₃]
143. De Paepe K., Hachem J.P., Houben E., Lagarde J.M., Gall Y., Roseeuw D. and Rogiers V. (2003) Skin microrelief topography measurements of ageing skin using a light transmission method. *Skin Research and Technology* **9**, 193-194. [IF₂₀₀₃ = 0.790]
144. Elaut G., Laus G., Papeleu P., Breckx V., Van Hemel J., Erra M., Brosch G., Snykers S., Vanhaecke T. and Rogiers V. (2003) Benzamide-based Trichostatin A analogues are potent and metabolically stable inhibitors of histone deacetylase. *Toxicology Letters* **144 (1)**, 78. [IF₂₀₀₃ = 2.224]
145. Depreter M., Walker T., Beken S., De Smet K., Papeleu P., Tytgat T., Espeel M., Rogiers V. and Roels F. (2003) Modified peroxisomes in primary hepatocyte

- cultures. *Advances in Experimental Medicine and Biology* **544**, 255-264. [IF₂₀₀₄ = 0.642, no IF₂₀₀₃ available]
146. Van Ommeslaeghe K., Elaut G., Breckx V., Papeleu P., Iterbeke K., Geerlings P., Tourwé D. and Rogiers V. (2003) Amide-analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. *Bioorganic & Medicinal Chemistry Letters* **13**(11), 1861-1864. [IF₂₀₀₃ = 2.182]
 147. Snykers S., Vanhaecke T., Papeleu P., Elaut G., Van Riet I. and Rogiers V. (2003) *In vitro* pluripotency of human marrow mesenchymal stem cells. *Toxicology Letters* **144** (1), 196. [IF₂₀₀₃ = 2.224]
 148. Hellemans K., Rombouts K., Quartier E., Dittie A., Knorr A., Michalik L., Rogiers V., Schuit F., Wahli W. and Geerts A. (2003) PPAR β regulates vitamin A metabolism-related gene expression. *Journal of Lipid Research* **44**, 280-295. [IF₂₀₀₃ = 3.893]
 149. Elaut G., Török G., Papeleu P., Vanhaecke T., Laus G., Tourwé D. and Rogiers V. (2004) Rat hepatocyte suspensions as a suitable *in vitro* model for studying the biotransformation of histone deacetylase inhibitors. *Alternatives to Laboratory Animals (ATLA)* **32**(1), 105-112. [IF₂₀₀₄ = 1.533]
 150. Vanhaecke T., Papeleu P., Elaut G. and Rogiers V. (2004) Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. *Current Medicinal Chemistry* **11**(12), 1629-1643. [IF₂₀₀₄ = 4.382]
 151. Vanhaecke T., Henkens T., Kass G.E.N. and Rogiers V. (2004) Effect of the histone deacetylase inhibitor trichostatin A on spontaneous apoptosis in various types of adult rat hepatocyte cultures. *Biochemical Pharmacology* **68**(4), 753-760. [IF₂₀₀₄ = 3.436]
 152. De Paepe K., Weerheim A., Houben E., Roseeuw D., Ponc M. and Rogiers V. (2004) Analysis of the epidermal lipids of healthy human skin: Factors affecting the design of control population. *Skin Pharmacology and Physiology* **17**(1), 23-30. [IF₂₀₀₄ = 1.358]
 153. De Paepe K., Houben E., Adam R., Wiesemann F. and Rogiers V. (2004) Applicability of the closed unventilated VapoMeter to assess transepidermal water loss (TEWL) on nasolabial skin areas. *Skin Research and Technology* **10**, 1-16. [IF₂₀₀₄ = 0.905]
 154. Papeleu P., Loyer P., Vanhaecke T., Henkens T., Elaut G., Guguen-Guillouzo C. and Rogiers V. (2004) Proliferation of epidermal growth factor-stimulated hepatocytes in a hormonally defined serum-free medium. *Alternatives to Laboratory Animals (ATLA)* **32**, suppl. 1, 57-64. [IF₂₀₀₄ = 1.533]
 155. Pauwels M. and Rogiers V. (2004) Safety evaluation of cosmetics in the EU reality and challenges for the toxicologist. *Toxicology Letters* **151**(1), 7-17. [IF₂₀₀₄ = 2.571]
 156. Pauwels M. and Rogiers V. (2004) Considerations in the Safety Assessment of Cosmetics (A Report). *Business Briefing Global Cosmetic Manufacturing*, 2-3. [no IF₂₀₀₄]
 157. Rogiers V. (2004) ECOPA: The European Consensus Platform on three Rs alternatives. *Alternatives to Laboratory Animals (ATLA)* **32**, 349-353. [IF₂₀₀₄ = 1.533]
 158. De Paepe K., Houben E., Adam R., Wiesemann F. and Rogiers V. (2005) Validation of the VapoMeter, a closed unventilated chamber system to assess transepidermal water loss vs. the open chamber Tewameter. *Skin Research and Technology* **11**(1), 61-69. [IF₂₀₀₅ = 1.280]

159. Hachem J.P., Man M.Q., Crumrine D., Uchida Y., Brown B.E., Rogiers V., Roseeuw D., Feingold K.R. and Elias P.M. (2005) Sustained serine proteases activity by prolonged increase in pH to degradation of lipid degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. *Journal of Investigative Dermatology* **125**(3), 510-520. [IF₂₀₀₅ = 4.406]
160. Barel A., Calomme M., Timchenko A., De Paepe K.D., Demeester N., Rogiers V., Clarys J.P and Vanden Berghe D. (2005) Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skin. *Archives of Dermatological Research* **297**(4), 147-153. [IF₂₀₀₅ = 1.219]
161. Diembeck W., Eskes C., Heylings J.R., Langley G., Rogiers V., van de Sandt J.J.M. and Zuang V. (2005) Chap. 3.5. "Skin absorption and penetration". *Alternatives to Laboratory Animals (ATLA)* **33**, suppl. 1, 105-107. [IF₂₀₀₅ = 0.670]
162. Coecke S., Blauboer B.J., Elaut G., Freeman S., Freidig A., Gensmantel N., Hoet P., Kapoulas V.M., Ladstetter B., Langley G., Leahy D., Mannens G., Meneguz A., Monshouwer M., Nemery B., Pelkonen O., Pfaller W., Prieto P., Proctor N., Rogiers V., Rostami-Hodjegan A., Sabbioni E., Steiling W. and van de Sandt J.J.M. (2005) Chap. 3.9. "Toxicokinetics and metabolism". *Alternatives to Laboratory Animals (ATLA)* **33**, suppl. 1, 147-175. [IF₂₀₀₅ = 0.670]
163. Elaut G., Vanhaecke T., Vander Heyden Y. and Rogiers V. (2005) Spontaneous apoptosis, necrosis, energy status, glutathione levels and biotransformation capacities of isolated rat hepatocytes in suspension: effect of the incubation medium. *Biochemical Pharmacology* **69**(12), 1829-1838. [IF₂₀₀₅ = 3.617]
164. Papeleu P., Vanhaecke T., Elaut G., Vinken M., Henkens T., Snykers S. and Rogiers V. (2005) Differential effects of histone deacetylase inhibitors in tumor and normal cells. What is the toxicological relevance? *Critical Reviews in Toxicology* **35**(4), 363-378. [IF₂₀₀₅ = 5.000]
165. Rogiers V. (2005) Recent developments in the way forward for alternative methods: formation of national consensus platforms in Europe. *Toxicology and Applied Pharmacology* **207** (suppl. 2) S408-S413. [IF₂₀₀₅ = 3.148]
166. Rogiers V. and Pauwels M. (2005) Good science must be the key factor in the development and use of alternative methods for safety assessment of cosmetics. *ALTEX - Alternativen zu Tierexperimenten* **23** (Special Issue), 346-352. [IF₂₀₀₅ = 0.667]
167. Papeleu P., Vanhaecke T. and Rogiers V. (2006) Histone deacetylase inhibition: A differentiation therapy for cultured hepatocytes? *Current Enzyme Inhibition* **2**, 91-104. [no IF₂₀₀₆]
168. Houben E., De Paepe K. and Rogiers V. (2006) Skin condition associated with intensive use of alcoholic gels for hand disinfection: a combination of biophysical and sensorial data. *Contact Dermatitis* **54** (5): 261-267. [IF₂₀₀₆ = 2.446]
169. Houben E., Holleran W.M., Yaginuma T., Mao C., Obeid L.M., Rogiers V., Takagi Y., Elias P.M. and Uchida Y. (2006) Differentiation-associated expression of ceramidase isoforms in cultured keratinocytes and epidermis. *Journal of Lipid Research*. **47** (5): 1063-1070. [IF₂₀₀₆ = 4.357]
170. Vinken M., Vanhaecke T., Papeleu P., Snykers S., Henkens T. and Rogiers V. (2006) Connexins and their channels in cell growth and cell death. *Cellular Signalling* **18**(5): 592-600. [IF₂₀₀₆ = 4.887]
171. Vinken M., Papeleu P., Rogiers V. and Vanhaecke T. (2006) Histone deacetylase inhibitors as potent modulators of cellular contacts. *Current Drug Targets* **7**, 773-787. [IF₂₀₀₆ = 4.274]

172. Vinken M., Henkens T., Vanhaecke T., Papeleu P., Van Rossen E., A. Geerts, Chipman J.K., Meda P. and Rogiers V. (2006) Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes. *Toxicological Sciences* **91**(2): 484-492. [IF₂₀₀₆ = 3.598]
173. Snykers S., Vanhaecke T., Papeleu P., Henkens T., Vinken M., Elaut G., Van Riet I. and Rogiers V. (2006) *In vitro* multipotency of human bone marrow (mesenchymal) stem cells. *ALTEX - Alternativen zu Tierexperimenten* **23** (Special Issue), 400-405. [IF₂₀₀₆ = 0.640]
174. Snykers S., Vanhaecke T., Papeleu P., Luttun A., Jiang Y., Vander Heyden Y., Verfaillie C. and Rogiers V. (2006) Sequential exposure to cytokines reflecting embryogenesis: the key for *in vitro* differentiation of adult bone marrow cells into functional hepatocyte-like cells. *Toxicological Sciences* **94**(2): 330-341. [IF₂₀₀₆ = 3.598]
175. Vanhaecke T., Vinken M., Henkens T., Snykers S., Elaut G., Papeleu P. and Rogiers V. (2006) Effects of Trichostatin A on apoptosis-regulating proteins during hepatocyte isolation. *ALTEX - Alternativen zu Tierexperimenten* **23** (Special Issue) 441-444. [IF₂₀₀₆ = 0.640]
176. Vinken M., Vanhaecke T., Papeleu P., Snykers S., Henkens T., Chipman J.K. and Rogiers V. (2006) A study of connexin expression in monolayer cultures of primary rat hepatocytes. *ALTEX - Alternativen zu Tierexperimenten* **23** (Special Issue) 456-460. [IF₂₀₀₆ = 0.640]
177. Vinken M., Papeleu P., Snykers S., De Rop E., Henkens T., Chipman J.K, Rogiers V. and Vanhaecke T. (2006) Involvement of cell junctions in hepatocyte culture functionality. *Critical Reviews in Toxicology* **36**, 299-318. [IF₂₀₀₆ = 3.707]
178. Elaut G., Henkens T., Papeleu P., Snykers S., Vinken M., Vanhaecke T. and Rogiers V. (2006) Molecular mechanisms the underlining dedifferentiation process of isolated hepatocytes and their cultures. Review Article. *Current Drug Metabolism* **7**(6): 629-660. [IF₂₀₀₆ = 5.762]
179. Papeleu P., Wullaert A., Elaut G., Henkens T., Vinken M., Laus G., Tourwé D., Beyaert R., Rogiers V. and Vanhaecke T. (2006) Inhibition of NF- κ B activation by the histone deacetylase inhibitor 4-Me₂N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes. *Cell Proliferation* **40**(6): 640-655. [IF₂₀₀₆ = 4.492]
180. Houben E., De Paepe K. and Rogiers V. (2007) A keratinocyte's course of life. *Skin Pharmacology and Physiology* **20** (3): 122-132. [IF₂₀₀₇ = 1.760]
181. Elaut G., Laus G., Alexandre E., Vanhaecke T., Papeleu P., Richert L., Tourwé D. and Rogiers V. (2007) A metabolic screening study of Trichostatin (TSA) and TSA-like histone deacetylase inhibitors in rat and human primary hepatocyte cultures. *Journal of Pharmacology and Experimental Therapeutics* **321**(1): 400-408. [IF₂₀₀₇ = 4.003]
182. Houben E., Uchida Y., Nieuwenhuizen W.F., De Paepe K., Vanhaecke T., Holleran W., Elias P. and Rogiers V. (2007) Kinetic characteristics of acidic and alkaline ceramidase in human epidermis. *Skin Pharmacology and Physiology* **20**(4), 187-194. [IF₂₀₀₇ = 1.760]
183. De Paepe K., Houben E., Adam R., Rogiers V. (2007) Effective protection of the nasolabial skin by using lotion-impregnated paper handkerchiefs during an acute viral cold. *International Journal of Cosmetic Science* **29**(3): 219-238. [No IF₂₀₀₇]

184. Henkens T., Papeleu P., Elaut G., Vinken M., Rogiers V. and Vanhaecke T. (2007) Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes. *Toxicology and Applied Pharmacology* **218**(1): 64-71. [IF₂₀₀₇ = 3.846]
185. Snykers S., R Henkens T., Papeleu P., Elaut G., Vinken M., Rogiers V. and Vanhaecke T. (2007) Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes. *Toxicology and Applied Pharmacology* **218**, 64-71. [IF₂₀₀₇ = 3.846]
186. Snykers S, Vinken M., Rogiers V. and Vanhaecke T. (2007) Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical *in vitro* toxicology and clinical therapy. *Archives of Toxicology* **81**(8), 533-544. [IF₂₀₀₇ = 1.756]
187. Snykers S., Vanhaecke T., De Becker A., Papeleu P., Vinken M., Van Riet I. and Rogiers V. (2007) Chromatin remodelling: a key-factor in the endogenic differentiation of human mesenchymal stem cells. *BMC Developmental Biology* **7**, 24. [IF₂₀₀₇ = 3.337]
188. Vinken M., Henkens T., Snykers S., Lukaszuk A., Tourwé D., Rogiers V. and Vanhaecke T. (2007) The novel histone deacetylase inhibitor 4-ME₂N-BAVAH differentially affects cell junctions between primary hepatocytes. *Toxicology* **236**, 92-102. [IF₂₀₀₇ = 2.919]
189. Elaut G., Rogiers V. and Vanhaecke T. (2007) The pharmaceutical potential of histone deacetylase inhibitors. *Current Pharmaceutical Design* **13**, 2584-2620. [IF₂₀₀₆ = 5.270]
190. Pauwels M., Rogiers V. (2007) Database search for safety information on cosmetic ingredients. *Regulatory Toxicology and Pharmacology* **49**, 208-216 [IF₂₀₀₇ = 1.968]
191. Pauwels M., Rogiers V. (2007) EU legislations affecting availability of safety data of cosmetic ingredients. *Regulatory Toxicology and Pharmacology* **49**, 308-315 [IF₂₀₀₇=1.968).
192. Henkens T., Vinken M., Vanhaecke T., Rogiers V. (2007) Modulation of CYP1A1 and CYP2B1 expression upon cell cycle progression in cultures of primary rat hepatocytes *Toxicology in Vitro* **21**(7): 1253-1257. [IF₂₀₀₇ = 2.193]
193. Snykers S., De Kock J., Vanhaecke T., Rogiers V. (2007) Differentiation of neonatal rat epithelial cells from biliary origin into immature hepatic cells by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development. *Toxicology In Vitro* **21**(7):1325-1331. [IF₂₀₀₇ = 2.193]
194. Henkens T., Vinken M., Lukaszuk A., Tourwé D., Vanhaecke T., Rogiers V. (2008) "Differential effects of hydroxamate histone deacetylase inhibitors on cellular functionality and gap junctions in primary cultures of mitogen-stimulated hepatocytes". *Toxicology Letters*, **178**(1): 37-43. [IF₂₀₀₈ = 3.249]
195. Houben E., Hachem J.P., De Paepe K., Rogiers V. (2008) Epidermal ceramidase activity regulates epidermal desquamation via stratum corneum acidification. *Skin Pharmacology and Physiology* **21**(2): 111-118. [IF₂₀₀₈=2.308]
196. Vinken M., Vanhaecke T., Rogiers V. (2008) Junctional structures and hepatocellular carcinoma: from the lab to the clinic? *Liver International* **28**(4): 432-434. [IF₂₀₀₈=2.908]
197. Vinken M., Henkens T., De Rop E., Fraczek J., Vanhaecke T., Rogiers V. (2008) Biology and pathobiology of gap junctional channels in hepatocytes. *Hepatology* **47**(3): 1077-1088. [IF₂₀₀₈ = 11.355]

198. Vandenbroucke RE., De Geest BG., Bonn  S., Vinken M., Vanhaecke T., Heimberg H., Wagner E., Rogiers V., De Smedt SC., Demeester J., Sanders NN. (2008) Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly β -amino esters. *The Journal of Gene Medicine* **10**(7): 783-794. [IF₂₀₀₈ = 3.141]
199. Vinken M., Doktorova T., Ellinger-Ziegelbauer H., Ahr Hans-J rger, Lock E., Carmichael P., Roggen E., van Delft J., Kleinjans J., Castell J., Bort R., Donato T., Ryan M., Corvi R., Keun H., Ebbels T., Athersuch T., Sansone S.A., Rocca-Serra P., Stierum R., Jennings P., Pfaller W., Gmuender H., Vanhaecke T., Rogiers V. (2008) The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based *in vitro* carcinogenicity screening assays. *Mutation Research Reviews* **659**(3): 202-210. [IF₂₀₀₈ = 5.912].
200. De Kock J., Vanhaecke T., Rogiers V., Snykers S. (2008), Chromatin remodelling, a novel strategy to expedite the hepatic differentiation of adult bone marrow stem cells *in vitro*. In: *Proceedings of 6th World Congress on Alternatives & Animal Use in the Life Sciences - Review progress made towards the 3Rs. AATEX 14, Special Issue*, pp. 605-611. [IF₂₀₀₈ = 1.309]
201. Rogiers V., Vinken M., Snykers S., Henkens T., Fraczek J., De Rop E., De Kock J., Doktorova T., Lukaszuk A., Tourw  D., Vanhaecke T. (2008), Histone deacetylase inhibitors: Opening a new field of research in the development of alternative methods? In: *Proceedings of 6th World Congress on Alternatives & Animal Use in the Life Sciences - Review progress made towards the 3Rs, AATEX 14, Special Issue*, pp. 613-617. [IF₂₀₀₈ = 1.309]
202. De Paepe K., De Rop E., Houben E., Adam R., Rogiers V. (2008) Effects of lotioned disposable handkerchiefs on skin barrier recovery after tape stripping. *Skin Research and Technology* **14**(4):440-447. [IF₂₀₀₈ = 1.348]
203. Houben E., Adam R., Hachem, J.P., Roseeuw D., Rogiers V., De Paepe K. (2008) Clinical scoring and biophysical evaluation of nasolabial skin barrier damage caused by rhinorrhea. *Contact Dermatitis* **59**(5): 296-300 [IF₂₀₀₈ = 3.470]
204. Pauwels M., Rogiers V. (2008) The incorporation of 3R alternatives in the safety evaluation of cosmetic ingredients by the SCC(NF)P. In: *Proceedings of the 15th Congress on Alternatives to Animal Testing. ALTEX 25*(Suppl.1): 52-53. [IF₂₀₀₈ = 1.309]
205. Devolder T., Reid K., Rogiers V., Webb S., Wilkins D. (2008) A review of national public funding programmes in European countries. *ALTEX 25*(3): 233-242. [IF₂₀₀₈ = 1.309]
206. Deleu S., Fraczek J., Lukaszuk A., Doktorova T., Tourwe D., Geerts A., Van Camp B., Vanhaecke T., Rogiers V., Vanderkerken K. (2008) Screening on Trichostatin analogues based on cellular potency in the ST33MM model. *Journal of Cancer Molecules*, **4**(4): 117-121. [no IF₂₀₀₈]
207. Vinken M., De Rop E., Decrock E., De Vuyst E., Leybaert L. Vanhaecke T., Rogiers V. (2009) Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet? *Biomechanica et Biophysica Acta - Reviews on Cancer*, **1795**(1):53-61. [IF₂₀₀₉ = 11.685]
208. De Paepe K., Houben E., Adam R., Hachem J.P., Roseeuw D., Rogiers V. (2009) Seasonal Effects on the Nasolabial Skin Condition. *Skin Pharmacology and Physiology* **22**(1):8-14. [IF₂₀₀₉ = 2.117]

209. Decrock E., De Vuyst E., Van Moorhem M., Van Laeken L., De Bock M., Vinken M., Rogiers V., D'Herde K., Evans H., Naus C., Leybaert L. (2009) Connexin 43 hemichannels contribute to the propagation of apoptotic cell death in a rat C6 glioma cell model. *Cell Death and Differentiation*, **16**(1): 151-163. [IF₂₀₀₉ = 8.387]
210. Pauwels M., Dejaegher B., Vander Heyden Y., Rogiers V. (2009). Critical analysis of the SCCNFP/SCCP safety assessment of cosmetic ingredients (2000-2006). *Food and Chemical Toxicology*, **47**(4): 898-905. [IF₂₀₀₉ = 2.114]
211. Vinken M., Decrock E., De Vuyst E., Leybaert L., Vanhaecke T., Rogiers V. (2009) Biochemical characterization of an *in vitro* model of hepatocellular apoptotic cell death. *ATLA*, **37**(2):209-218. [IF₂₀₀₉ = 1.580]
212. De Vocht C., Ranquin A., Willaert R., Van Ginderachter JA, Vanhaecke T., Rogiers V., Versées W., Van Gelder P., Steyaert J. (2009) “Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE”. *Journal of controlled release: official journal of the Controlled Release Society*, **137**(3):246-254. [IF₂₀₀₉ = 5.949]
213. Fraczek J., Deleu S., Lukaszuk A., Doktorova T., Tourwé D., Geerts A., Vanhaecke T., Vanderkerken K., Rogiers V. (2009) “Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes : search for potent and safe HDAC inhibitors”. *Investigational New Drugs*, **27**(4): 338-346. [IF₂₀₀₉ = 3.072]
214. Marx-Stoelting P., Adriaens E., Ahr HJ., Bremer S., Garthoff B., Gelbke HP, Perisma A., Pellizzer C., Reuter U., Rogiers V., Schenk B., Schwengberg S., Seiler A., Spielmann H., Steemans M., Stedman B., Vanparys P., Vericat JA., Verwei M., van de Water F., Weimer M., Schwarz M. (2009) “A review of the implementation of the embryonic Stem Cell Test (EST)”. *ATLA*, **37**(3): 313-328. [IF₂₀₀₉ = 1.580]
215. Vinken M., Doktorova T., Decrock E., Leybaert L., Vanhaecke T., Rogiers V. (2009) “Gap junctional intercellular communication as a target for liver toxicity and carcinogenicity”. *Critical Reviews in Biochemistry and Molecular Biology*, **44**(4): 201-222. [IF₂₀₀₉ = 10.216]
216. De Paepe K., Wibaux C., Ward C., Rogiers V. (2009) “Skin efficacy and Biophysical Assessment of Glycerol-Containing Hydrocolloid Patches” *Skin Pharmacology and Physiology* **22**(5): 258-265. [IF₂₀₀₉ = 2.117]
217. Deleu S., Menu E., Van Valckenborgh E., Van Camp B., Fraczek J., Vande Broek I., Rogiers V., Vanderkerken K. (2009) Histone deacetylase inhibitors in multiple myeloma. *Hematology Reviews*, **1**(e9): 46-55. [no IF]
218. Snykers S., Henkens T., De Rop E., Vinken M., Fraczek J., De Kock J., De Prins E., Geerts A., Rogiers V., Vanhaecke T. (2009) Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation, and stem cell reprogramming. *J. Hepatology*, **51**(1): 187-211. [IF₂₀₀₉ = 7.818].
219. De Vuyst E., Decrock E., DeBock M., Wang N., Vinken M., Van Moorhem M., Lai Ch., Culot M., Rogiers V., Cecchelli R., Naus C.C., Evans W.H., Leybaert L. (2009) Ca²⁺ regulation of Cx43 hemichannel mediated ATP release. *Cell Calcium*, **46**(3): 176-187. [IF₂₀₀₉ = 4.288]
220. Decrock E*, Vinken M.*, De Vuyst E., Krysko D., D'Herde K., Vanhaecke T., Vandenabeele P., Leybaert L., Rogiers V. (2009) Connexin-related signaling in cell death: to live or let die? *Cell Death and Differentiation*, **16**: 524-536. [IF₂₀₀₉ = 8.387] (* equal contribution)
221. Snykers S., De Kock J., Rogiers V., Vanhaecke T. (2009) *In vitro* differentiation of embryonic and adult stem cells into hepatocytes: state of the art. *Stem Cells*, **27**(3): 577-605. [IF₂₀₀₉ = 7.747]

222. Vanhaecke T., Snykers S., Rogiers V., Garthoff B., Castell J.V., Hengstler J.G. (2009) "EU research activities in alternative testing strategies: current status and future perspectives". *Archives of Toxicology* **83**(12): 1037-1042. [IF₂₀₀₉ = 3.312]
223. De Kock J., Vanhaecke T., Biernaskie J., Rogiers V., Snykers S. (2009) Characterization and hepatic differentiation of skin-derived precursors from adult foreskin by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development. *Toxicology in Vitro*, **23**(8): 1522-1527. [IF₂₀₀₉ = 2.473]
224. Ellis J.K., Chan P.H., Doktorova T., Athersuch T.J., Cavil R., Vanhaecke T., Rogiers V., Vinken M., Nicholson J.K., Ebbels T.M.D., Keun H.C. (2010) "The effect of the histone deacetylase inhibitor Trichostatin A on the metabolome of cultured primary hepatocytes". *Journal of Proteome Research* **9**(1): 413-419. [IF₂₀₁₀ = 5.460]
225. Vinken M.*, Snykers S.*, Fraczek J., Decrock E., Leybaert L., Rogiers V., Vanhaecke T. (2010) DNA methyltransferase 3a expression decreases during apoptosis in primary cultures of hepatocytes. *Toxicology in Vitro* **24**(2): 445-451. [IF₂₀₁₀ = 2.546] (*equal contribution).
226. Fraczek J., van Grunsven L.A., Vinken M., Snykers S., Deleu S., Vanderkerken K., Vanhaecke T., Rogiers V. (2010) Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. *Journal of Cellular and Molecular Medicine*, **13**(9B): 2990-3005. [IF₂₀₁₀ = 4.608]
227. Pauwels M., Rogiers V. (2010) Human health safety evaluation of cosmetics in the EU: A legally imposed challenge to science. *Toxicology and Applied Pharmacology* **243**(2): S1260-274. [IF₂₀₁₀ = 3.993]
228. Vinken, M., Decrock E., De Vuyst, E., De Bock M., Vandenbroucke RE., De Geest BG., Demeester J., Sanders NN., Vanhaecke T., Leybaert L., Rogiers V. (2010) Connexin32 hemichannels contribute to the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death. *Cellular and Molecular Life Sciences* **67**(6): 907-918. [IF₂₀₁₀ = 7.047]
229. Mannaerts I., Nuytten N., Rogiers V., Vanderkerken K., Van Grunsven L., Geerts A. (2010) Chronic administration of valproic acid inhibits activation of Mouse hepatic stellate cells *in vitro* and *in vivo*. *Hepatology*, **51**(2): 603-614 [IF₂₀₁₀=4.608]
230. Pauwels M., Rogiers V. (2010) "In vitro dermal toxicity testing of cosmetic ingredients: an iterative approach to complete regulatory acceptance". *ALTEX – Alternatives to Animal Testing*, **27**: 241-246. [IF₂₀₁₀ = 4.429]
231. Peters SJAC, Vanhaecke T., Papeleu P., Rogiers V., Haagsman HP, van Norren K. (2010) Co-culture of primary rat hepatocytes with rat liver epithelial cells enhances interleukin-6-induced acute-phase protein response. *Cell & Tissue Research*, **340**(3): 451-457. [IF₂₀₁₀ = 2.804]
232. Vinken M., Vanhaecke T., Rogiers V. (2010) 'The emerging roles of connexin hemichannels in gastrointestinal and liver pathophysiology' *World Journal of Gastrointestinal Pathophysiology*, **1**(4): 115-117. [no IF₂₀₁₀]
233. Vinken M., Ceelen L., Vanhaecke T., Rogiers V. (2010) "Inhibition of gap junctional intercellular communication by toxic metals". *Chemical Research in Toxicology*, **23**(12): 1862-1867. [IF₂₀₁₀ = 4.148]
234. Vinken M., Decrock E., Leybaert L., Vanhaecke T., Rogiers V. (2010) Proteolytic cleavage of adherens junction components during Fas-dependent cell death in primary cultures of rat hepatocytes. *ALTEX* **27**: 151-157 [IF₂₀₁₀=4.429]

235. Vinken M., Decrock E., De Vuyst E., Ponsaerts R., D'Hondt C., Bultynck G., Ceelen L., Vanhaecke T., Rogiers V. (2011) "Connexins: sensors and regulators of cell cycling". *Biochimica et Biophysica Acta – Reviews on Cancer* **1815**(1): 13-25. [IF₂₀₁₁ = 9.380]
236. Henkens T*, Snykers S*, Vinken M., Fraczek J., Lukaszuk A., Tourwé D., Verheyen G., Van Gompel J.V., Vanparys P., Rogiers V., Vanhaecke T. (2011) "Preservation of hepatocellular functionality in cultures of primary rat hepatocytes upon exposure to 4-Me(2)N-BAVAH, a hydroxamate-based HDAC-inhibitor" *Toxicology in Vitro* **25**(1): 100-109. [IF₂₀₁₁ = 2.546] (*Equal contribution).
237. D'Hondt C., Ponsaerts R., De Smedt H., Vinken M., De Vuyst E., De Bock M., Wang N., Rogiers V., Leybaert L., Himpens B., Bultynck G. (2011) "Pannexin channels in ATP release and beyond: an unexpected rendez-vous at the endoplasmic reticulum" *Cellular Signalling* **23**(2): 305-316. [IF₂₀₁₁ = 4.058]
238. Schroeder K., Bremm KD., Alépée N., Bessems JGM., Blaauboer B., Boehn SN., Burek C., Coecke S., Gombau L., Hewitt NJ., Heylings J., Huwyler J., Jaeger M., Jagelavicius M., Jarrett N., Ketelslegers H., Kocina I., Koester J., Kreysa J., Note R., Poth A., Radtke M., Rogiers V., Scheel J., Schultz T., Steinkellner H., Toeroek M., Whelan M., Winkler P., Diembeck W. (2011) "Report from the EPAA workshop: *In vitro* ADME in safety testing used by EPAA industry sectors" *Toxicology in Vitro* **25**(3): 589-604. [IF₂₀₁₁ = 2.775]
239. Ceelen L., De Spiegelare W., David M., De Craene J., Vinken M., Vanhaecke T. and Rogiers V. (2011) Critical selection of reliable reference for gene expression study in the HepaRG cell line. *Biochemical Pharmacology* **81**(10): 1255-1261. [IF₂₀₁₁ = 4.705]
240. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen KE., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois FY., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfulher S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., Tähti H., van Delft J., van Loveren H., Vinken M., Woerth A., Zaldivar JM. (2011) "Alternative (non-animal) methods for cosmetics testing: current status and future prospects – 2010". *Archives of Toxicology* **85**(5):367-385. [IF₂₀₁₁ = 4.674]
241. Vanhaecke T., Pauwels M., Vinken M., Ceelen L., Rogiers V. (2011) "Towards an integrated *in vitro* strategy for repeated dose toxicity testing". *Archives of Toxicology*: **85**(5): 365-366. [IF₂₀₁₁ = 4.674]
242. Rogiers V. (2011) "Is the replacement strategy, as it exist today in the EU for cosmetics, the way forward?". *Archives of Toxicology (ATOX)* **85**(5): 363-364. [IF₂₀₁₁ = 4.674]
243. De Kock J., Ceelen L., De Spiegelare W., Casteleyn C., Claes P., Vanhaecke T., Rogiers V. (2011) "Simple and quick method for whole liver decellularization: a novel *in vitro* three-dimentional bioengineering tool?". *Archives of Toxicology*: **85**(6): 607-612. [IF₂₀₁₁ = 4.674]
244. De Vocht C., Ranquin A., Van Ginderachter J., Vanhaecke T., Rogiers V., Van Gelder P., Versées W. and Steyaert J. (2011) "Polymeric nanoreactors for enzyme replacement therapy by MNGIE". *Journal of Controlled Release*, **148**(1): E19-20. [IF₂₀₁₁ = 5.732]

245. Ceelen L., Haesenbrouck F., Vanhaecke T., Rogiers V. and Vinken M. (2011) "Modulation of connexin signalling by bacterial pathogens and their toxins". *Cellular and Molecular Life Sciences*, **68**(18): 3047-3064. [IF₂₀₁₁ = 6.570]
246. Al Battah F.*, De Kock J.*, Ramboer E., Heymans A., Vanhaecke T., Rogiers V., Snyckers S. (2011) "Evaluation of the multipotent character of human adipose tissue-derived stem cells isolated by ficoll gradient centrifugation and red blood cell lysis treatment". *Toxicology in Vitro*, **25**(6): 1224-1230. [IF₂₀₁₁ = 2.775] (*equal contribution)
247. Al Battah F., De Kock J., Vanhaecke T., Rogiers V. (2011) "Current status of human adipose-derived stem cells: Differentiation into hepatocyte-like cells". *The Scientific World Journal*, **11**: 1568-1581 [IF₂₀₁₁=1.836]
248. Bolleyn J., Fraczek J., Vinken M., Lizaraga D., Gaj S., Joost H.M., van Delft J., Rogiers V. and Vanhaecke T. (2011) "Effect of Trichostatin A on miRNA expression in primary rat hepatocytes". *Toxicology in Vitro*, **25**: 1173-1182. [IF₂₀₁₁ = 2.775]
249. Decrock E., Vinken M., Bol M., D'Herde K., Rogiers V., Vandenaabeele P., Krysko D.V., Bultynck G., Leybaert L. (2011) "Calcium and connexin-based intercellular communication, a deadly catch?" *Cell Calcium*, **50**: 310-321. [IF₂₀₁₁ = 3.766].
250. De Bock M., Culot M., Wang N., Bol M., Decrock E., De Vuyst E., da Costa A., Dauwe I., Vinken M., Simon A.M., Rogiers V., De Ley G., Bultynck G., Evans W.H., Dupont G., Cecchelli R., Leybaert L. (2011) "Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood brain barrier permeability". *Journal of Cerebral Blood Flow and Metabolism*, **31**(9): 1942-1957. [IF₂₀₁₁ = 5.008].
251. Vinken M., Decrock E., Doktorova T., Ramboer E., De Vuyst E., Vanhaecke T., Leybaert L., Rogiers V. (2011) "Characterization of spontaneous cell death in monolayer cultures of primary hepatocytes". *Archives of Toxicology* **85**: 1589-1596. [IF₂₀₁₁ = 4.674].
252. De Kock J.*, Snyckers S.*, Ramboer E., Demeester S., Heymans A., Branson S., Vanhaecke T., Rogiers V. (2011) "Evaluation of the multipotent character of human fore skin-derived precursor cells". *Toxicology in Vitro*, **25**(6): 1191-1202. [IF₂₀₁₁ = 2.775] (*equal contribution).
253. Vinken M.*, Pauwels M*., Ates G., Vivier M., Vanhaecke T., Rogiers V. (2012) "Screening of repeated dose toxicity data present in SCC(NF)/SCCS safety evaluations of cosmetic ingredients". *Archives of Toxicology*, **86**(3): 405-412. [IF₂₀₁₂ = 5.215] (*equal contribution).
254. Vinken M., Vanhaecke T., Rogiers V. (2012) "Primary hepatocyte cultures as *in vitro* tools for toxicity testing: quo vadis?". *Toxicology in Vitro*, **26**(3): 541-544. [IF₂₀₁₂ = 2.650].
255. Ates H., Desmedt B., Vander Heyden Y. (2012) Test-set reduction in the screening step definition of a chiral separation strategy in polar organic solvents chromatography" *Journal of Chromatography B*, **910**: 95-102.
256. Dollé L., Best J., Empsen C., Mei J., Van Rossen E., Roelandt P., Snyckers S., Najimi M., Al Battah F., Theise N.D., Streetz K., Sokal E., Leclercq I., Verfaillie C., Rogiers V., Geerts A., van Grunsven L.A. (2012) "Successful Isolation of Liver Progenitor Cells by Aldehyde Dehydrogenase Activity in naïve mice" *Journal of Hepatology*, **55**(2): 540-552. [IF₂₀₁₂ = 9.858].

257. Vinken M., Buyl K., Vanhaecke T., Rogiers V. (2012) “Effects of RNA interference-mediated suppression of connexin43 production on the expression of differentiation markers in cultures of adult primary rat hepatocytes” proceedings of the 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25 August, 201, *ALTEX*, **1**: 155-164 [IF₂₀₁₂=4.093].
258. De Kock J., Rodrigues R.M., Bolleyn J., Vanhaecke T., Rogiers V. (2012) “Focus on Stem Cells as sources of human target cells for *in vitro* research and testing”. *ALTEX*, **29**: 541-548. [IF₂₀₁₂ = 4.093]
259. De Kock J., Najar M., Bolleyn J., Al Battah F., Raicevic G., Govaere O., Branson S., Jagtap S., Gaspar J.A., Roskams T., Sachinidis A., Lagneaux, Vanhaecke T., Rogiers V. (2012) “Assessment of the intrinsic pluripotency of mesoderm-derived stem cells from different niches”. *ALTEX*, **1**(12): 531-539. [IF₂₀₁₂ = 4.093]
260. Doktorova T., Pauwels M., Vinken M., Vanhaecke T., Rogiers V. (2012) “Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment”. *Critical Reviews in Toxicology*, **42**(2): 91-106. [IF₂₀₁₂=6.253]
261. Decrock E., Krysko D.V., Vinken M., Kaczmarek A., Crispino A., Bol M., Wang N., De Bock M., De Vuyst E., Naus C.C., Rogiers V., Vandenamee P., Erneux C., Mammano F., Bultynck G., Leybaert L. (2012) “Transfer of IP₃ through gap junctions is critical, but not sufficient, for the spread of apoptosis”. *Cell Death and Differentiation*, **19**(6): 947-957. [IF₂₀₁₂ = 8.371]
262. Vinken M., Decrock E., Leybaert L., Bultynck G., Himpens B., Vanhaecke T., Rogiers V. (2012) “Non-channel functions of connexins in cell growth and cell death”. *Biochimica et Biophysica Acta Biomembranes*, **1818**(8): 2002-2008. [IF₂₀₁₂ = 3.398]
263. Vinken M., Decrock E., Vanhaecke T., Leybaert L., Rogiers V. (2012) “Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes”. *Toxicological Sciences*, **125**(1): 175-186. [IF₂₀₁₂ = 4.328]
264. Vinken M., De Kock J., Oliveira A.G., Menezes G.B., Cogliati B., Dagli M.L., Vanhaecke T., Rogiers V. (2012) “Modifications in connexin expression in liver development and cancer”. *Cell Communication and Adhesion* **19**(3-4): 55-62. [IF₂₀₁₂ = 1.048]
265. Bolleyn J., De Kock J., Mertens H., Fraczek F., Vinken M., Govaere O., Roskams T., Rogiers V. and Vanhaecke T. (2012) “Liver-Specific miR-122 does Not Affect mRNA Levels of Cytochrome P450 Enzymes and Nuclear Receptors in Primary Rat Hepatocyte Cultures”. *ALTEX* **29**(S1): 165-172. [IF₂₀₁₂ = 4.093]
266. Doktorova T.Y., Ellinger-Ziegelbauer H., Vinken M., Vanhaecke T., van Delft J., Kleinjans J., Ahr H.J., Rogiers V. (2012) “Comparison of genotoxicant-modified transcriptomic responses in conventional and epigenetically-stabilized primary rat hepatocytes with *in vivo* rat liver data”. *Archives of Toxicology* **86**(11): 1703-1715. [IF₂₀₁₂ = 5.215]
267. Ceridono, M., Siviglia E., Bauer D., Barroso J., Alépée N., Corvi R., De Smedt A., Fellows M.D., Gibbs N.K., Heisler E., Jacobs A., Jirova D., Jones D., Kandarova H., Kasper P., Akunda J.K., Krul C., Learn D., Liebsch M., Lynch A.M., Muster W., Nakamura K., Nash J.F., Pfannenbecker U., Phillips G., Robles C., Rogiers V., Van De Water F., Liminga U.W., Vohr H.W., Watrelos O., Woods J., Zuang V., Kreysa J., Wilcox P. (2012) “The 3T3 neutral uptake phototoxicity test: Practical experience and implications for phototoxicity testing – the report of an ECVAM-EFPIA workshop”. *Regulatory Toxicology and Pharmacology*, **63**(3): 480-488. [IF₂₀₁₂ = 2.132]

268. Doktorova T.Y., Ellinger-Ziegelbauer H., Vinken M., Vanhaecke T., van Delft J., Kleinjans J., Ahr H.J., Rogiers V. (2012) "Comparison of hepatocarcinogen-induced gene expression profiles in conventional primary rat hepatocytes with in vivo rat liver". *Archives of Toxicology* 86(9): 1399-1411. [IF₂₀₁₂ = 5.215]
269. De Kock J., Snykers S., Branson S., Jagtap S., Gaspar J.A., Sachinidis A., Vanhaecke T., Rogiers V. (2012) "A liver-derived rat epithelial cell line from biliary origin acquires hepatic functions upon sequential exposure to hepatogenic growth factors and cytokines". *Current Medicinal Chemistry*, **19**(26): 4523-4533. [IF₂₀₁₂ = 4.070]
270. Fraczek J., Vinken M., Tourwé D., Vanhaecke T., Rogiers V. (2013) "Synergetic effect of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes". *Investigational New Drugs*, **30**(4): 1715-1724. [IF₂₀₁₃ = 2.927].
271. De Kock J., Najar M., Bolleyn J., Al Battah F., Rodrigues R.M., Buyl K., Raicevic G., Govaere O., Branson S., Meganahan K., Gaspar J.A., Roskams T., Sachinidis A., Lagneaux L., Vanhaecke T., Rogiers V. (2013) "Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential". *Stem Cells and Development*, **10**,21(18): 3309-3323. [IF₂₀₁₃ = 4.202].
272. Wang N., De Bock M., Decrock E., Bol M., Gadicherla A., Vinken M., Rogiers V., Bukauskas F., Bultynck G., Leybaert L. (2013) "Paracrine signaling through plasma membrane hemichannels". *Biochimica et Biophysica Acta Biomembranes*, **1828**(1): 35-50. [IF₂₀₁₃ = 3.431]
273. Wang N., De Vuyst E., Ponsaerts R., Boengler K., Palacios-Prado N., Wauman J., Lai C.P., De Bock M., Decrock E., Bol M., Vinken M., Rogiers V., Tavernier J., Evans W.H., Naus C.C., Bukauskas F.F., Sipido K.R., Heusch G., Schulz R., Bultynck G., Leybaert L. (2013) "Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury". *Basic Research in Cardiology*, 108: 309. [IF₂₀₁₃ = 5.955]
274. Oliveira A.G., Marques P.E., Amaral S.S., Dias Quintao J.L., Cogliati B., Zaidan Dagli M.L., Rogiers V., Vanhaecke T., Vinken M., Menezes G.B. (2013) "Purinergic signaling in sterile liver injury". *Liver International*, **33**(3): 353-361. [IF₂₀₁₃ = 4.412].
275. Fraczek J., Bolleyn J., Vanhaecke T., Rogiers V., Vinken M. (2013) "Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various antidedifferentiation strategies" *Archives of Toxicology*, **87**(4): 577-610. [IF₂₀₁₃ = 5.078]
276. Bolleyn J., De Kock J., Mertens H., Fraczek J., Vinken M., Govaere O., Roskams T., Rogiers V., Vanhaecke T. (2013) "Liver-Specific miR-122 does not affect mRNA levels of Cytochrome P450 enzymes and nuclear receptors in primary rat hepatocyte cultures". *ALTEX-Alternatives to Animal Experimentation* **29**, 165-172. [IF₂₀₁₃ = 3.630]
277. Vinken M., Maes M., Cavill R., Valkenborg D., Ellis J.K., Decrock E., Leybaert L., Staes A., Gevaert K., Oliveira A.G., Menezes G.B., Cogliati B., Zaidan Dagli M.L., Ebbels T.M.D., Witters E., Keun H.C., Vanhaecke T., Rogiers V. (2013) "Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte cultures. *Archives of Toxicology*, **87**: 883-894. [IF₂₀₁₃ = 5.078].
278. Ramboer E., Vanhaecke T., Rogiers V., Vinken M. (2013) "Primary hepatocyte cultures as prominent *in vitro* tools to study hepatic drug transporters". *Drug Metabolism Reviews*, **45**(2): 196-217. [IF₂₀₁₃ = 6.286].

279. Fraczek J., Vanhaecke T., Rogiers V. (2013) “Toxicological and Metabolic Considerations for HDAC inhibitors”. *Expert Opinion on Drug Metabolism and Toxicology*, **9**(4): 441-457. [IF₂₀₁₃ = 2.934]
280. Desmedt B., Rogiers V., Courselle P., De Beer J.O., De Paepe K., Deconinck E. (2013) “Development and validation of a chromatographic method for screening and quantification of legal and illegal whitening agents”. *Journal of Pharmaceutical and Biomedical Analysis*, **83**(2013): 82-88. [IF₂₀₁₃ = 2.829]
281. Doktorova T., Yildirimman R., Vinken M., Vilardell M., Vanhaecke T., Gmuender H., Bort R., Brolen G., Chesne C., van Delft J., Kleinjans J., Castell J., Bjorquist P., Herwig R., Rogiers V. (2013) “Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based *in vitro* models”. *Carcinogenesis*, **34**(6): 1393-1402. [IF₂₀₁₃ = 5.266]
282. Vinken M., Maes M., Vanhaecke T., Rogiers V. (2013) “Drug-induced liver injury: mechanisms types and biomarkers”. *Current Medicinal Chemistry*, **20**(24): 3011-3021. [IF₂₀₁₂ = 3.715]
283. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. (2013) “Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury”. *Toxicological Sciences*, **136**(1): 97-106. [IF₂₀₁₃ = 4.478].
284. Godoy P., Hewitt N.J., Albrecht U., Andersen M.E., Ansari N., Bhattacharya S., Bode J.G., Bolleyn J., Borner C., Böttger J., Braeuning A., Budinsky R.A., Burkhardt B., Cameron N.R., Camussi G., Cho C.S., Choi Y.J., Craig Rowlands J., Damm G., Dirsch O., Donato M.T., Dong J., Dooley S., Drasdo D., Eakins R., Ferreira K.S., Fonsato V., Fraczek J., Gebhardt R., Gibson A., Glanemann M., Goldring C.E., Gomez-Lechon M.J., Groothuis G.M., Gustavsson L., Guyot C., Hallifax D., Hammad S., Hayward A., Haussinger D., Hellerbrand C., Hewitt P., Hoehme S., Holzhütter H.G., Houston J.B., Hrach J., Ito K., Jaeschke H., Keitel V., Kelm J.M., Kevin Park B., Kordes C., Kullak-Ublick G.A., Lecluyse E.L., Lu P., Luebke-Wheeler J., Lutz A., Maltman D.J., Matz-Soja M., McMullen P., Merfort I., Messner S., Meyer C., Mwinyi J., Naisbitt D.J., Nussler A.K., Olinga P., Pampaloni F., Pi J., Pluta L., Przyborski S.A., Ramachandran A., Rogiers V., Rowe C., Schelcher C., Schmich K., Schwarz M., Singh B., Stelzer E.H., Stieger B., Stöber R., Sugiyama Y., Tetta C., Thasler W.E., Vanhaecke T., Vinken M., Weiss T.S., Widera A., Woods C.G., Xu J.J., Yarborough K.M., Hengstler J.G. (2013) “Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME”. *Archives of Toxicology* **87**(8): 1315-1530. [IF₂₀₁₃ = 5.078].
285. D’hondt C., Iyyathurai J., Vinken M., Rogiers V., Leybaert L., Humpens B., Bultynck G. (2013) “Regulation of connexin- and pannexin-based channels by post-translational modifications”. *Biology of the Cell*, **105**(9):373-398. [IF₂₀₁₃ = 3.872]
286. Doktorova T., Gamze A., Vanhaecke T., Rogiers V. (2013) “Way forward in case of a false positive *in vitro* genotoxicity result for a cosmetic substance?” *Toxicology In Vitro*, **28**(1): 54-59. [IF₂₀₁₃ = 3.207].
287. De Kock J.*, Buyl K.*, Najar M., Lagneaux L., Branson S., Vanhaecke T., Rogiers V. (2013) “Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells”. *Toxicology In Vitro*, **28**(1): 113-119 (*equal contribution) [IF₂₀₁₃ = 3.207].

288. Lemper M., Snykers S., Vanhaecke T., De Paepe K., Rogiers V. (2014) “Current status of healthy human skin models: Can histone deacetylase inhibitors potentially improve the present replacement models?” *Skin Pharmacology and Physiology*, **27**: 36-46. [IF₂₀₁₃ = 1.964]
289. Desmedt E., Van Hoeck V., Rogiers V., Courselle P., De Beer J.O., De Paepe K., Deconinck E. (2014) “Characterization of suspected illegal skin whitening cosmetics”. *Journal of Pharmaceutical and Biomedical Analysis*, **90**: 85-91. [IF₂₀₁₄ = 2.366]
290. Vinken M., Whelan M., Rogiers V. (2014) “Adverse outcome pathways: hype or hope?”. *Archives of Toxicology*, **88**(1): 1-2. [IF₂₀₁₄ = 5.980]
291. Rodrigues R.M., De Kock J., Branson S., Vinken M., Meganathan K., Chaudhari U., Sachinidis A., Govaere O., Roskams T., De Boe V., Vanhaecke T., Rogiers V. (2014) “Human skin-derived stem cells as a novel cell source for *in vitro* hepatotoxicity screening of pharmaceuticals”. *Stem Cells and Development*, **23**(1): 44-55. [IF₂₀₁₄ = 3.727]
292. Vinken M., Maes M., Oliveira A.G., Cogliati B., Elias P., Menezes G.B., Zaidan Dagli M.L., Vanhaecke T., Rogiers V. (2014) “Primary hepatocytes and their cultures in liver apoptosis research”. *Archives of Toxicology*, **88**(2): 199-212. [IF₂₀₁₄ = 5.980].
293. De Paepe K., Sieg A., Le Meur M., Rogiers V. (2014) “Silicones as Nonocclusive Topical Agents”. *Skin Pharmacology and Physiology* **27**: 164-171. [IF₂₀₁₄ = 2.366]
294. Ates G., Doktorova T.Y., Pauwels M., Rogiers V. (2014) “Retrospective analysis of the mutagenicity/genotoxicity data of the cosmetic ingredients present on the Annexes of the Cosmetic EU legislation (2000-12)”. *Mutagenesis* **29**(2): 115-121. [IF₂₀₁₄ = 2.793].
295. Buyl K., De Kock J., Najar M., Lagneaux L., Branson S., Rogiers V., Vanhaecke T. (2014) “Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells” *Toxicology in Vitro* **28**: 113-119. [IF₂₀₁₄ = 2.903].
296. Govaere O., Komuta M., Berkers J., Spee B., Janssen C., de Luca F., Katoonizadeh A., Wouters J., van Kempen L., Durnez A., Verslype C., De Kock J., Rogiers V., van Grunsven L., Topal B., Pirenne J., Vankelecom H., Nevens F., van den Oord J., Pinzani M., Roskams T. (2014) “Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. *Gut* **63**(4): 674-685. [IF₂₀₁₄ = 14.660].
297. Lemper M., De Paepe K., Rogiers V. (2014) “Practical problems encountered during the cultivation of an open source reconstructed human epidermis”. *Skin Pharmacol. Physiol.* **27**(2): 106-112. [IF₂₀₁₄ = 2366].
298. Najar M., Rodrigues R.M., Buyl K., Branson S., Vanhaecke T., Lagneaux L., Rogiers V., De Kock J. (2014) “Proliferative and phenotypical characteristics of human adipose tissue-derived stem cells : comparison of Ficoll gradient centrifugation and red blood cell lysis buffer treatment purification methods”. *Cytotherapy* **16**(9): 1220-1228. [IF₂₀₁₄ = 3.293].
299. De Kock J., Meuleman P., Raicevic G., Rodrigues R.M., Branson S., Meganathan K., De Boe V., Sachinidis A., Leroux-Roels G., Vanhaecke T., Lagneaux L., Rogiers V.,* Najar M.*(2014) “Human-skin-derived precursor cells are poorly immunogenic and modulate the allogeneic immune response”. *Stem Cells* **32**(8): 2215-2228. [IF₂₀₁₄ = 6.523]. (* equally contributing)
300. Ramboer E., De Craene B., De Kock J., Vanhaecke T., Berx G., Rogiers V., Vinken M. (2014) “Strategies for immortalization of primary hepatocytes”. *Journal of Hepatology*, **6**: 925-943. [IF₂₀₁₄ = 11.336].

301. Madden J.C., Rogiers V., Vinken M. (2014) “Application of *in silico* and *in vitro* methods in the development of adverse outcome pathway constructs in wildlife”. *Philosophical Transactions of The Royal Society B Biological Sciences*, **369**, pages not yet known. [IF₂₀₁₄ = 7.055].
302. Maes M.I., Decrock E., Cogliati B., Oliveira A.G., Marques E., Zaidan Dagli M.L., Menezes G.B., Menecier G., Leybaert L., Vanhaecke T., Rogiers V., Vinken M. (2014) “Connexin and pannexin (hemi)channels in the liver”. *Frontiers in Membrane Physiology and Membrane Biophysics*, **4**:405. [no IF₂₀₁₄]
303. Desmedt B., Van Hoeck E., Rogiers V., Courselle P., De Beer J. O., Deconinck E., De Paepe K (2014) “Illegal cosmetics on the EU market: a threat for human health?”. *Archives of Toxicology*, **88**, 1765–1766.[IF₂₀₁₄ = 5.980]
304. Doktorova T. Y., Yildirimman R., Ceelen L., Vilardell M., Vanhaecke T., Vinken M., Ates G., Heymans A., Gmuender H., Bort R., Corvi R., Phrakonkham P., Li R., Mouchet N., Chesne C, van Delft J., Kleinjans J., Castell J., Herwig R., Rogiers V. (2014) “Testing chemical carcinogenicity by using a transcriptomics HepaRG-based model?”. *EXCLI Journal* **13**:623-637. [IF₂₀₁₄ = 0.857].
305. Grinberg M., Stöber R.M., Edlund K., Rempel E., Godoy P., Reif R., Widera A., Madjar K., Schmidt-Hek W., Marchan R., Sachinidis A., Spitkovsky D., Hescheler J., Carmo H., Arbo M.D., van de Water B., Wink S., Vinken M., Rogiers V., Escher S., Hardy B., Mitic D., Myatt G., Waldmann T., Mardinoglu M., Damm G., Seehofer D., Nüssler A., Weiss T.S., Oberemm A., Lampen A., Schaap M.M. Luijten M., van Steeg H., Thasler W.E., Kleinjans J.C., Stierum R.H., Leist M., Rahnenführer J., Hengstler J.G. (2014) “Toxicogenomics directly of chemically exposed human hepatocytes”. *Archives of Toxicology*, **88**(12): 2261-2287 [IF₂₀₁₄= 5.980].
306. Kirkland D.J., Zeiger E., Madia F., Gooderham N., Kasper P., Lynch A., Morita T., Ouedraogo G., Parra Morte J. M., Pfuhler S., Rogiers V., Schulz M., Thybaud V., van Benthem J., Vanparys P., Worth A. P., Corvi R., (2014) “Can *in vitro* mammalian cell genotoxicity test results be used to complement positive results in the Ames test and help predict carcinogenic or *in vivo* genotoxic activity?”. I. Reports of individual databases presented at a EURL ECVAM Workshop. *Mutation Research – Genetic Toxicology and Environment Mutagenesis*, **775-776**: 55-68 [IF₂₀₁₄ = 3.521].
307. Desmedt B., Canfyn M., Pype M., Baudewyns S., Hanot V., Courselle P., De Beer J.O., Rogiers V., De Paepe K., Deconinck E.(2015) “HS-GC-MS method for the analysis of fragrance allergens in complex cosmetic matrices” *Talanta*, **131**: 444-451. [IF₂₀₁₄=3.545]
308. Desmedt B., Rogiers V., Courselle P., De Beer J.O., Deconinck E., De Paepe K. (2015) “*In vitro* Dermal Absorption: Sample Application and Seal Quality in a Franz Diffusion Cell System” *Skin Pharmacology and Physiology*, **28**: 245-249. [IF₂₀₁₄= 2.366]
309. Nelms M. D., Ates G., Madden J.C., Vinken M., Cronin M. T., Rogiers V., Enoch S. J. (2014) “Proposal of an *in silico* profiler for categorisation of repeat dose toxicity data of hair dyes. *Archives of Toxicology*, **89**(5): 733-741 [IF₂₀₁₄=5.980].
310. Rodrigues R. M., Sachinidis A., De Boe V., Rogiers V., Vanhaecke T.* and De Kock J.* (2014) “Identification of potential biomarkers of acute liver failure in human skin-derived precursors upon hepatogenic differentiation”. *Toxicology In Vitro*, **29**(6): 1231-1239 (*equal contribution) [IF₂₀₁₄ = 2.903].

311. Rodrigues R.M., Branson S., De Boe V., Sachinidis A., Rogiers V. (2015) “*In vitro* assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells”. *Archives of Toxicology* [Epub ahead of print] [IF₂₀₁₄=5.980].
312. Rodrigues R.M., Branson S., De Boe V., Rogiers V., De Kock J.* and Vanhaecke T.* (2014) “Sodium valproate induces steatotic effects in hepatic cells obtained from human skin-derived precursors”. *Archives of Toxicology*, under review. (*equal contribution) [IF₂₀₁₄ = 5.980]
313. Ramboer E., Vanhaecke T., Rogiers V., Vinken M. (2015) “Effects of Trichostatin A on drug uptake transporters in primary rat hepatocyte cultures”. *EXCLI*, **14**: 567-576 [IF₂₀₁₄ = 0.857].
314. Buyl K., Vanhaecke T., Desmae T., Lagneaux L., Rogiers V., Najar M.* and De Kock J.*(2015) “Influence of the isolation protocol on the expression of hepatic markers and transcription factors of human umbilical cord-derived stem cells”.*Toxicology In Vitro*, **29**(6): 1254-1262 (*equal contribution) [IF₂₀₁₄=2.903].
315. Bolleyn J., De Kock J., Rodrigues R. M., Vinken M., Rogiers V., Vanhaecke T. (2015) “MicroRNA’s as key regulators of xenobiotic biotransformation and drug response”. *Archives of Toxicology*, **89**: 1523-1541 [IF₂₀₁₄ = 5.980].
316. Ramboer E., De Craene B., De Kock J., Berx J., Rogiers V., Vanhaecke T., Vinken M. (2015) “Development and characterizaion of a new human hepatocyte-based cell line”. *Experimental and Clinical Sciences* **14**: 875-889 [IF₂₀₁₄=0.857].

In press:

317. Rodrigues R.M., Heymans A., De Boe V., Sachinidis A., Govaere O., Roskams T., De Kock J., Vanhaecke T., Rogiers V. (2015) “Toxicogenomics-based prediction of drug-induced liver injury using hepatic in vitro cell systems“. *Toxicology Letters*,: in press [IF₂₀₁₄=3.262]
318. Doktorova T., Yildirimman R., Ceelen L., Vilardell M., Vanhaecke T., Vinken M., Heymans A., Gmuender H., Bort R., Corvi R., Li R., Mouchet N., Chesne C., van Delft J., Kleinjans J., Castell J., Herwig R., Rogiers V. (2015) “Evaluation of the robustness of classification of carcinogen-modified transcriptomic responses in HepaRG cells and the interlaboratory reproducibility of the model”. *Carcinogenesis*, in press [IF₂₀₁₄ = 5.334]
319. Herwig, R., Gmuender H., Corvi R., Bloch K.M., Brandenburg, A., Castell J., Ceelen L., Chesne C., Doktorova T.Y., Jennen D., Jennings P., Limonciel A., Lock E.A., McMorro, T., Phrakonkham P., Radford R., Slattery C., Stierum R., Vilardell M., Wittenberger, T., Yildirimman R., Ryan M., Rogiers V., Kleinjans J. (2015) “Interlaboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective”. *Archives of Toxicology*, in press [IF₂₀₁₄=5.980]

Submitted:

320. Desmedt B., Courselle P., De Beer J.O., Rogiers V., Grosber M., Deconinck E., De Paepe K. (2015) "Overview of skin whitening agents with an insight into the illegal cosmetic market in Europe" *Journal of the European Academy of Dermatology and Venereology*, submitted [IF₂₀₁₄=2.826]
321. Desmedt B., Courselle P., De Beer J.O., Rogiers V., Deconinck E., De Paepe K. (2015) "In vitro dermal absorption of hydroquinone: protocol validation and applicability on illegal skin whitening cosmetics". *Toxicology in Vitro*, submitted [IF₂₀₁₄=2.903]

10.2. Articles in peer-reviewed national journals

322. Rogiers V. (1980) Bijdrage tot de studie van het patroon der niet-veresterde langketenvetzuren in plasma en de vetzuursamenstelling van de fosfolipidenfrakties der erythrocytaire membranen bij kinderen - Uitgewerkt bij cystic fibrosis. Doctoral Thesis, May 1980, Vrije Universiteit Brussel, Brussels, Belgium.
323. Rogiers V. (1986) Beschouwingen bij de huidige wetgeving betreffende cosmetica. *Farmaceutisch Tijdschrift voor België* **6**, 445-45.
324. Rogiers V. (1990) Liposomen: een nieuwe galenische vorm in de dermatocosmetologie. *Chemie Magazine* **16**, 19-22.
325. Rogiers V. (1991) Dossier: Les différents types de peaux et les soins journaliers à y apporter. Dossier: Huidtypes en hun dagelijkse verzorging. *Pharma Horizon, Le périodique d'Upjohn pour les pharmaciens/Farma Horizon, Upjohn's tijdschrift voor apothekers* **1**, 1-10.
326. Rogiers V. (1995) Notions de base concernant les shampooings et nouveaux développements dans l'évaluation des réactions irritatives /
327. Rogiers V. (1995) Basisbegrippen van shampoo's en nieuwe ontwikkelingen in het evalueren van irritatieve reacties. *Journal d'Actualités Dermatologiques Belges/Tijdschrift voor Belgische Dermatologische Actualiteit* **18**, 17-23.
328. De Paepe K. and Rogiers V. (1995) Mise au point d'une lotion hydratante pour peau sèche: capacité hydratante et effet sur la fonction de barrière de la couche cornée. *Journal d'Actualités Dermatologiques Belges*, **17**, 16a-16d.
329. Rogiers V., De Paepe K. and Roseeuw D. (1996) Considérations pratiques concernant la mesure de la perte d'eau transépidermique./Practische overwegingen ten aanzien van TEWL-metingen. *Journal d'Actualités Dermatologiques Belges /Tijdschrift voor Belgische Dermatologische Actualiteit* **28**, 23-28.
330. Rogiers V. (1996) Les acides hydroxy dans les cosmétiques: considérations et matière de sécurité/Alpha-hydroxyzuren in cosmetica: enkele veiligheidsoverwegingen. *Journal d'Actualités Dermatologiques Belges/ Tijdschrift voor Belgische Dermatologische Actualiteit* **25**, 14-18.
331. De Paepe K., Roseeuw D., Rogiers V. La fonction de barrière de la peau: considération critiques/De barrière functie van de huid: enkele kritische beschouwingen. *Journal d'Actualités Dermatologiques Belges/Tijdschrift voor Belgische Dermatologische Actualiteit* **28**, 4-15.
332. De Paepe K. and Rogiers V. (1997) Ethisch-wetenschappelijke en praktische aspecten van het galenisch dermatologisch voorschrift. *Farmaceutisch Tijdschrift voor België* **4**, 3-15.

333. Van Damme P., De Paepe K. and Rogiers V. (1997) Pour des soins cutanés raisonnables chez l'enfant et le nouveau-né./Een verantwoorde huidverzorging bij de baby en het kind. *Journal d'Actualités Dermatologiques Belges/Tijdschrift voor Belgische Dermatologische Actualiteit* **31**, 16-22.
334. Rogiers V. (1999) Cosmetische verzorging van acne: een ondersteunende rol bij de behandeling. Soins cosmétiques de l'acné: un rôle de soutien dans le traitement. *Skin* **2/2**, 54-57. [no IF₁₉₉₉]
335. Rogiers V. (1999) Huidhydratatie: een claim die wetenschappelijk moet ondersteund worden in de Europese en de nieuwe nationale wetgeving betreffende cosmetica. *Tijdschrift voor Belgische Dermatologische Actualiteit* **45**, 23-26. [no IF₁₉₉₉]
336. De Paepe K., Roseeuw D., Derde M.P. and Rogiers V. Vergelijkende studie van dermato-cosmetische producten voor de droge tot zeer droge huid: objectieve evaluatie aan de hand van efficiëntiemetingen. *Tijdschrift voor Geneeskunde* **55**, 268-277. [no IF₁₉₉₉]
337. De Paepe K. and Rogiers V. (2000) De huidefficiëntie van dermatocosmetische producten. *Farma Sfeer* **47**, 17-19. [no IF₂₀₀₀]
338. Rogiers V. (2001) Hoe specifiek zijn cosmetische producten voor mannen? *Antwerps Farmaceutisch Tijdschrift* **79/7**. [no IF₂₀₀₁]
339. Rogiers V. (2003) Zijn de zonneproducten veilig? Les produits solaires présents sur le marché européen sont-ils sûrs? *Percentiel/Percentile* **8/2**, 51-53. [no IF₂₀₀₃]
340. Vinken M., Vanhaecke T. and Rogiers V. (2003) "The role of gap junctional intercellular communication in disease: an overview." *Nederlands Tijdschrift voor Geneeskunde* **147**, 50 2463-2466. [IF₂₀₀₃ = 0.566]
341. Vinken M., Vanhaecke T. and Rogiers V. (2003) De integratie van "omics" in de genesmiddelenontwikkeling van de 21ste eeuw. *Farmaceutisch Tijdschrift voor België* **2**, 11-18. [no IF₂₀₀₃]
342. Desmedt B., Rogiers V., Courselle P., De Beer J.O., De Paepe K., Deconinck E. (2013) «Illegale huidblekende cosmetica op de Belgische markt (Des cosmétiques dépigmentants illégaux sur le marché Belge)» *Skin*, **16**: 1-4. [IF₂₀₁₃=]
343. Desmedt B., Van Hoeck E., Rogiers V., Courselle P., De Paepe, K., Deconinck E., (2014) "Illegal skin whitening cosmetics on the Belgian market" Official Report WIP-ISP, 2014.

10.3. Books, articles in books

1. Rogiers V., Mozes F., Geeraerts F., Vertongen F. and Dab I. Fatty acid transport in the red blood cell membrane phospholipids of cystic fibrosis patients and heterozygotes. In: *Monographs in Pediatrics*, (Eds. M. Schönland and Kraemer R.), Bern, vol. 14,1981, p. 53
2. Rogiers V. *Fatty acids in cystic fibrosis*. Monography, in the series: Monographies Pédiatriques (Ed. Vis H.L.), Editions de l'Université de Bruxelles, 1983 - ISBN 2-8004-0796-4
3. Rogiers V., Paeme G., Vercruyse A. and Bouwens L. Procyclidine metabolism in isolated rat liver cells. In: *Pharmacological, morphological and physiological aspects on liver aging. Topics in aging research in Europe*. Vol. I, (Ed. van Bezooijen C.F.A.), Eurage, Rijswijk, The Netherlands, 1984, pp. 121-126 - ISBN 90 71021 077

4. Rogiers V., Callaerts A., Sonck W. and Vercruyssen A. Biotransformation of sodium valproate in isolated rat hepatocytes. In: *Liver cells and drugs*, (Ed. Guillouzo A.), Colloque Inserm, John Libbey Eurotext Ltd, vol. 164, 1998, pp. 329-333.
5. Rogiers V. and Vercruyssen A. Isolated hepatocytes as a suitable *in vitro* model for biotransformation and toxicity studies of xenobiotics. In: *Proceedings of Symposium on Alternatives to animal experiments in risk assessment*. Ed. Tierversuchsgegner Berlin E.V. and Schering AG, West-Germany, 1988, pp. 37-45
6. Rogiers V., Vandenberghe Y., Cornet M., Callaerts A., Sonck W., Guillouzo A. and Vercruyssen A. The use of cultures and co-cultures of rat hepatocytes for the study of the effects of valproate on phase I and II biotransformation systems of xenobiotics. In: *The liver, metabolism and ageing*, (Eds Woodhouse K.W., Yelland C. and James O.F.W.) in Series: Topics in aging research in Europe, vol. 13, 1989, pp. 75-82
7. Vandenberghe Y., Morel F., Ratanasavanh D., Rogiers V., Ketterer B., Vercruyssen A. and Guillouzo A. Changes in the expression of rat liver glutathione S-transferase *in vitro*. In: *The liver, metabolism and ageing*, (Eds. Woodhouse K.W., Yelland C. and James O.W.F.), in Series: Topics in aging research in Europe, Vol. 13, 1989, pp. 83-94
8. Rogiers V., Derde M.P., Verleye G. and Roseeuw D. Assessment of skin surface hydration: the need for standardized conditions in capacitance measurements. In: *Conference Proceedings Cosmetic Ingredients Europe* (Ed. Ziolkowsky H.), Verlag für Chemische Industrie, Augsburg, Germany, 1990, pp. 1255-1272
9. Rogiers V. and Claes V. *Schoonheidsmiddelen: een blik achter de facade*, (Ed. Lemonnier M.) Socialistische Vrouwen, Brussels, Belgium, 1991 - D/1991/51 34/3.
10. Cornet M., Callaerts A., Segaert A., van Bezooijen C.F.A., Vercruyssen A. and Rogiers V. Epoxide metabolizing enzymes in liver of young and old brown Norway rats. In: *Topics in aging research in Europe: drug metabolism, liver injury and ageing*, (Eds. Woodhouse K.W. and O'Mahony M.S.O.), Eurage, Leiden, The Netherlands, vol. 16, 1991, pp. 93-100.
11. Coecke S., Rogiers V., Callaerts A., Soetaert H., van Bezooijen C.F.A., Guillouzo A. and Vercruyssen A. Effect of the ageing process on gender and phenobarbital dependent glutathione S-transferase activity, subunit composition and steady state mRNA in brown Norway rat liver. In: *Topics in aging research in Europe: drug metabolism, liver injury and ageing*, (Eds. Woodhouse K.W. and O'Mahony M.S.O.), Eurage, Leiden, The Netherlands, vol. 16, 1991, pp. 155-163.
12. Mertens K., Rogiers V., Cornet M., Soetaert H., Segaert A., van Bezooijen C.F.A. and Vercruyssen A. Glutathione-dependent detoxication in liver tissue of aging rats. In: *Topics in aging research in Europe: drug metabolism, liver injury and ageing*, (Eds. Woodhouse K.W. and O'Mahony M.S.O.), Eurage, Leiden, The Netherlands, Vol. 16, 1991, pp. 165-171.
13. Rogiers V. Alternative methods in pharmaco-toxicological research and testing: advantages and disadvantages. In: *Proceedings of the 19th B.C.L.A.S. Symposium: New animal models and alternative methods*, Brussels, UCL, 29/4/1992, pp. 13-26.

14. Geerts A., Greenwel P., Cunningham M., De Bleser P., Rogiers V., Wisse E. and Rojkind M. Identification of collagen, fibronectin and laminin gene transcripts in freshly isolated liver cells. In: *Cellular and molecular aspects of cirrhosis*, (Ed. Clément B. and Guillouzo A.), Colloque Inserm, John Libbey Eurotext 216, 1992, pp. 215-218.
15. Rogiers V. Cultures of human hepatocytes in *in vitro* pharmaco-toxicology. In: *Human cells in in vitro pharmaco-toxicology*, (Eds. Rogiers V., Sonck W., Shephard E. and Vercruysse A.), VUB Press, Brussels, Belgium, 1993, pp. 77-115.
16. Geerts A., De Bleser P., Niki T., Rogiers V., Rojkind M. and Wisse E. Connective tissue gene transcripts in freshly isolated parenchymal, endothelial, Kupffer and fat-storing cells of CCl₄ treated rats. In: *Cells of the hepatic sinusoid* (Eds. Knook D.L. and Wisse E.), Kupffer Cell Foundation, Leiden, The Netherlands, Vol. 4, 1993, pp. 209-213.
17. Rogiers V., Akrawi M., Vercruysse A., Shephard E. and Phillips I.R. Co-cultured rat hepatocytes: a suitable tool for the study of the cytochrome P-450 dependent metabolism and toxicity of sodium valproate. In: *European Medicines Research - Perspectives in pharmacotoxicology and pharmacovigilance*, IO Press, Amsterdam, 1994, pp. 224-252.
18. Akrawi M., Rogiers V., Verdruysse A., Phillips I.R. and Shephard E.A. Long-term preservation and induction of cytochromes P450 in co-cultured rat hepatocytes. In: *Cytochrome P450*, (Ed. Lechner M.C.), 8th International Conference, John Libbey Eurotext, Paris, France, 1994, pp. 737-740.
19. Rogiers V., Akrawi M., Vandenberghe Y., Shephard E., Phillips I. and Vercruysse A. New strategies: The use of long-term cultures of hepatocytes in toxicity testing and metabolism studies of chemical products other than pharmaceuticals. In: *Toxicology of industrial compounds*, (Eds. Thomas H., Hess R. and Waechter F.), Taylor & Francis, London, UK, 1995, pp. 211-224
20. Beken S. and Rogiers V. Three-dimensional cultures of hepatocytes as suitable *in vitro* systems for metabolism studies of cosmetic ingredients. In: *Alternatives to animal testing. Proceedings of an International Scientific Conference organised by the European Cosmetic Industry*, (Eds. Lisansky S., MacMillan R. and Dupuis J.), COLIPA, Clp Press, 1995, pp. 243-245.
21. Rogiers V. TEWL measurements in patch test assessment: the need for standardisation. In: *Irritant Dermatitis. New clinical and experimental aspects*, (Eds. Elsner P. and Maibach H.) Current Problems in Dermatology, Vol. 23, Karger, Basel, Switzerland, 1995, pp. 152-158.
22. Roels F., Tytgat T., Beken S., Giros M., Espeel M., De Prest B., Kerckaert I., Pampols T. and Rogiers V. Peroxisome mosaics in the liver of patients and the regulation of peroxisome expression in rat hepatocyte cultures. In: *Peroxisomes - Biology and role in toxicology and disease*, Vol. 804, (Eds. Reddy J.K., Suga T., Mannaerts G.P., Lazarow P.B. and Subramani S.), Annals of the New York Academy of Sciences, 1996, pp. 502-515.
23. De Paepe K., Van Damme P., Roseeuw D. and Rogiers V. Ceramides/cholesterol/free fatty acids containing cosmetics: the effect on barrier function. In: *Conference Proceedings - In Cosmetics* (Ed. Ziolkowsky H.), Verlag für Chemische Industrie GmbH, Augsburg, 1996, pp. 333-346

24. De Paepe K., Van Damme P., Derde M.P., Roseeuw D. and Rogiers V. Ceramides/cholesterol/FFA containing body-lotions: effects on the TEWL of aged and SDS-damaged skin. In: *Conference Proceedings of the Active Ingredients Conference* (Ed. Ziolkowsky H.), Verlag für Chemische Industrie GmbH, Augsburg, 1996, pp. 97-111.
25. De Paepe K., Taelman M.C., Roseeuw D. and Rogiers V. Ceramides in dermatocosmetic products. In: *Conference Proceedings - In Cosmetics* (Ed. Ziolkowsky H.), Verlag für Chemische Industrie GmbH, Augsburg, 1997, pp. 101-108.
26. Rogiers V. and Vercruyssen A. Hepatocyte cultures in drug metabolism and toxicological research and testing. In: *Cytochrome P450 Protocols*, Vol. 107, in series *Methods in Molecular Biology* (Eds. Phillips I. and Shephard E.), Humana Press, Totowa, 1998, pp. 279-194.
27. De Smet K., Beken S., Vanhaecke T., Pauwels M., Vercruyssen A. and Rogiers V. Isolation of rat hepatocytes. In: *Cytochrome P450 Protocols*, Vol. 107, in series *Methods in Molecular Biology*, (Eds. Phillips I. and Shephard E.), Humana Press, Totowa, 1998, pp. 295-301.
28. Beken S., Vanhaecke T., De Smet K., Pauwels M., Vercruyssen A. and Rogiers V. Collagen gel cultures of rat hepatocytes: collagen gel sandwich and immobilisation cultures. In: *Cytochrome P450 Protocols*, Vol. 107, in series *Methods in Molecular Biology*, (Eds. Phillips I. and Shephard E.), Humana Press, Totowa, 1998, pp. 303-309.
29. Vanhaecke T., De Smet K., Beken S., Pauwels M., Vercruyssen A. and Rogiers V. Isolation of rat hepatocytes: conventional monolayer cultures and co-cultures with rat liver epithelial cells. In: *Cytochrome P450 Protocols*, Vol. 107, in series *Methods in Molecular Biology*, (Eds. Phillips I. and Shephard E.), Humana Press, Totowa, 1998, pp. 311-317.
30. De Paepe K., Roseeuw D. and Rogiers V. Effect of ceramides-containing lotions on the barrier function of the skin. In: *Conference Proceedings - Active Ingredients*, Step Publishing, Step Exhibitions Ltd, Turnbridge Wells, 1998, pp. 121-132.
31. Beken S. and Rogiers V. The Belgian Platform for Alternative Methods (BPAM). Alternatives to animal testing II. *Proceedings of the Second International Scientific Conference organised by the European Cosmetic Industry (Colipa)* (Eds. Clark G.D., Lisansky S.G. and MacMillan R.), CLP Scientific Publishing Services Ltd, Berkshire, UK, 1999, p. 266 - ISBN 1 872691 129.
32. Rogiers V. Training product safety assessors. Alternatives to animals testing II. *Proceedings of the Second International Scientific Conference organised by the European Cosmetic Industry (COLIPA), Brussels, Belgium.* (Eds. Clark D.G., Lisansky S.G. and MacMillan R.), CLP Scientific Publishing Services Ltd, Berkshire, UK, 1999, pp. 100-106 - ISBN 1 872691 129.
33. Rogiers V. and Roseeuw D. Welke is de rol van de schoonheidsspecialiste bij acne-behandeling? Wat kan men verwachten van cosmetische producten bij acne vulgaris. In: *De 25 meest gestelde vragen rond acne* (Eds. Degreef H., Lachapelle J.M. and Piérard G.E.), Medipress Services NV, Brussels, Belgium, 1999, pp. 169-180.

34. Asiru O.O., Vanhaecke T., Vercruysse A. and Rogiers V. Long-term culture of rat hepatocytes and prevention of oxidative stress by addition of high concentrations of pyruvate to the culture medium. In: *Progress in the reduction, refinement and replacement of animal experimentation*, Vol. 31B (Eds. Balls M., Zeller A.M. and Halder M.), Elsevier Science BV, Amsterdam, The Netherlands, 2000, pp. 159-171.
35. Rogiers V., De Greeve P., Garthoff B. The role of National Platforms. In: *Progress in the reduction, refinement and replacement of animal experimentation*, Vol. 31B (Eds. Balls M., Zeller A.M. and Halder M.), Elsevier Science BV, Amsterdam, The Netherlands, 2000, pp. 1713-1718.
36. Rogiers V. and Beken S. (Eds.) *Alternative methods to animal experiments. Actual status, development and approach in Belgium*. VUBPress, Brussels, Belgium, 2000 ISBN 90 5487 264 0.
37. Beken S. and Rogiers V. Alternatieven voor experimenten op levende dieren. De actuele situatie in Europa. In: *Mensen en andere dieren. Hun onderlinge relaties meervoudig bekeken*. (Ed. Cazaux G.), Garant, Leuven-Apeldoorn, Belgium, 2001, PP. 199-226 - ISBN 90 441 1071 3.
38. De Paepe K., Derde M.P., Roseeuw D. and Rogiers V. The effect of topically applied ceramide containing lotions on the barrier function of the skin. In: *Conference Proceedings of Perspectives in Percutaneous Penetration* (Eds. Brain K.R. and Walters K.A.), STS Publishing, Cardiff, UK, 2000, Vol. 6B, pp. 64-67.
39. De Paepe K., Hachem J.P., Janssens K., Vanpee E., Roseeuw D. and Rogiers V. The effect of a moisturising body lotion in the treatment and prevention of irritant and allergic contact dermatitis. In: *Conference Proceedings of Perspectives in Percutaneous Penetration* (Eds. Brain K.R. and Walters K.A.), STS Publishing, Cardiff, UK, 2000, Vol. 6b, pp. 64-67.
40. Rogiers V., Houben E. and De Paepe K. Safety and efficacy of cosmetics in the EU. In: *Conference Proceedings of Perspectives in Percutaneous Penetration* (Eds. Brain K.R. and Walters K.A.), STS Publishing, Cardiff, UK, vol. 7a, 2000, p.146.
41. Rogiers V., Houben E. and De Paepe K. Safety and efficacy of cosmetics in the EU. In: *Conference Proceedings of Cosmetic & Household Ingredients* (Ed. Ziolkowsky H.), Verlag für die Chemische Industrie, Augsburg, Germany, 2001, pp. 3-11.
42. De Paepe K. and Rogiers V. Analytical techniques for skin lipids. In: *Cosmetic Lipids and the Skin Barrier* (Ed. Förster T.), Marcel Dekker, London-Berlin, UK, 2001, pp. 149-183.
43. Lambert J., Rogiers V. and Roseeuw D. Huidaandoeningen. In: *Geriatric dagelijkse praktijk en klinische aspecten* (Eds. Afschrift M., Leners J.C., Mets T., Nève P., Pelemans W., Petermans W., Smits S., Swine C. and Vandewoude M.), Pfizer NV, Belgium, 2nd Ed., 2002, pp. 309-314 - ISBN 908042924 4
44. Elaut G., Papeleu P., Rogiers V. and Vanhaecke T. Practical aspects of *in vitro* biotransformation studies during early drug development. In: *Recent research developments in drug metabolism and disposition*, Vol. 1 (Ed. Pandalai S.G.), Transworld Research Network, Kerala, India, 2002, pp. 199-234 - ISBN 81 7895 038 3.

45. Papeleu P., Elaut G., Rogiers V. and Vanhaecke T. Cell cultures as *in vitro* tools for biotransformation studies. In: *Recent research developments in drug metabolism and disposition*, Vol. 1 (Ed. Pandalai S.G.), Transworld Research Network, Kerala, India, 2002, pp. 199-234 - ISBN 81 7895 038 3.
46. De Paepe K., Hachem J.P., Vanpee E., Roseeuw D. and Rogiers V. Beneficial corneotherapeutic effects of skin-tolerance tested moisturising creams. In: *The essential stratum corneum* (Eds. Marks R., Lévêque J.L. and Voegeli R.), Martin Dunitz Ltd, London, UK, 2002, pp. 369-371.
47. De Paepe K., Hachem J.P., Janssens K., Vanpee E., Roseeuw D. and Rogiers V. The effect of a topically applied lignoceric acid and behenic acid on the barrier recovery of irritated skin. In: *Conference Proceedings of Perspectives in Percutaneous Penetration* (Eds. Brain K.R. and Walters K.A.), STS Publishing, Cardiff, UK, Vol. 8a, 2002, p.37.
48. Rogiers V. (Ed.) *Ecopa: the European Consensus Platform on 3R-Alternatives. Fourth World Congress on Alternatives and Animal Use in the Life Sciences* (Book), 2003, pp. 349-353.
49. Rogiers V., Houben E. and De Paepe K. Transepidermal water loss (TEWL) measurements in dermato-cosmetic sciences. In: *Water and the stratum corneum* (Eds. Fluhr J., Elsner P., Berardesca E. and Maibach H.I.), CRC Press, Boca Raton, Copenhagen, 2004, pp. 63-76.
50. Pauwels M., Rogiers V., Considerations in the Global Cosmetics Manufacturing In: *Business Briefing: Global Cosmetics Manufacturing 2004* (Ed. Touch Briefings, London ,UK), accessible through <http://www.touchbriefings.com/cdps/cditem.cfm?NID=846> (consulted Dec. 2006)
51. Vanhaecke T. and Rogiers V. Hepatocyte cultures in drug metabolism and toxicological research and testing: In: *Methods in Molecular Biology. Cytochrome P450 protocols*, 2nd edition (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 25, pp. 209-227, 2006.
52. Papeleu P., Vanhaecke T., Henkens T., Elaut G., Vinken M., Snykers S. and Rogiers V. Isolation of rat hepatocytes. In: *Methods in Molecular Biology. Cytochrome P450 protocols* (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 26, pp. 229-237, 2006.
53. Henkens T., Vanhaecke T., Papeleu P., Elaut G., Vinken M., Snykers S. and Rogiers V. Rat hepatocyte cultures: conventional monolayer cultures and co-cultures with rat liver epithelial cells. In: *Methods in Molecular Biology. Cytochrome P450 protocols*, 2nd edition (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 27, pp. 239-246, 2006.
54. Vinken M., Elaut G., Henkens T., Papeleu P., Snykers S., Vanhaecke T. and Rogiers V. Rat hepatocyte cultures. Collagen gel sandwich and immobilization cultures. In: *Methods in Molecular Biology. Cytochrome P450 protocols*, 2nd edition (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 28, pp. 247-254, 2006.
55. Elaut G., Papeleu P., Vinken M., Henkens T., Snykers S., Vanhaecke T. and Rogiers V. Hepatocytes in suspension. In: *Methods in Molecular Biology. Cytochrome P450 protocols*, 2nd edition (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 29, pp. 255-263, 2006.

56. Snykers S., Vanhaecke T. and Rogiers V. Isolation of rat bone marrow stem cells. In: *Methods in Molecular Biology. Cytochrome P450 protocols*, 2nd edition (Eds. Phillips I.R. and Shephard E.A.), Humana Press, Totowa, NJ, USA, Vol. 320, Chap. 30, pp. 265-272, 2006.
57. Vera Rogiers and Marleen Pauwels (Eds.). *Current Problems in Dermatology Vol.36:2008. Safety Assessment of Cosmetics in Europe*. S. Karger, Basel, Switzerland, 2008, ISBN 978-3-8055-8655-9.
58. Pauwels M., Rogiers V., The current EU regulatory context. In: *Handbook of Cosmetic Science and Technology*, 3rd Edition (Eds. Barel A, Maibach H and Paye M), in press, 2009.
59. Rogiers V., "START-UP: Scientific and technological issues in 3Rs alternatives research in the process of drug development and Union politics" in: *Alternative Testing Strategies, Progress report 2009* (ed. E.M. Nogueiro), pp 251-252, ISBN 978-92-79-11949-1, 2009.
60. Lemper M., De Paepe K., Rogiers V. "Baby care products" in *Handbook of Cosmetic Science and Technology*, 3rd Ed. (Barel A., Maibach H., Paye M. (eds) Informa Healthcare USA, New York, pp. 613-23. ISBN 978-1-4200-6963-1, 2009.
61. Doktorova T.Y., Vanhaecke T., Rogiers V., Vinken M. "Epigenetically stabilized primary hepatocyte cultures: a potential sensitive screening tool for non-genotoxic carcinogenicity." In: *Methods in Bioengineering: Alternative Technologies to Animal Testing* (Maguire T. and Novik E., eds.), Artech House, Boston, USA, pp. 133-146. ISBN-13: 978-1-60807-011-4, 2010.
62. Rogiers, V., START-UP "Scientific and technological issues in 3Rs alternatives research in the process of drug development and Union politics", in: *Alternative Testing Strategies, Progress report 2010*, (Ed. H. Spielmann et al.) pp. 248-254. ISBN: 978-3-9814126-0-4, 2010.
63. Snykers S.*, De Kock J*, Vanhaecke T., Rogiers V. "Hepatic differentiation of mesenchymal stem cells: *in vitro* strategies" in: *Methods in Molecular Biology, Mesenchymal Stem Cell Assays and Applications*, Vernuri MH, Rao MS and Chase L. (Eds.) publ. by Humana Press Inc., USA, vol.698 pp.305-314, 2011 (* equal contribution)
64. Rogiers V., Pauwels M., Vinken M., Vanhaecke T. "The SEURAT-1 Research Initiative: Towards a more realistic integrated *In vitro* strategy for repeated dose toxicity testing of cosmetic products and their ingredients" in: *Towards the Replacement of *in vivo* repeated dose systemic toxicity testing, Toxicology in the 21th century: mechanism-driven toxicology defines the safe dose*, COACH, Annual Report, vol. 1, 2011.
65. Vinken M., Rogiers V., Vanhaecke T. "The interplay between epigenetics and gap junctional intercellular communication" in *The Cellular Response to the Genotoxic Insult: The Question of Threshold for Genotoxic Carcinogens*, Greim H. and Albertini R.J. (Eds.), The Royal Society, London, pp. 293-311, 2012.
66. De Bruyne E., Maes K., Deleu S., Van Valckenborgh E., Menu E., Vande Broek I., Fraczek J., Van Grunsven L., Rogiers V., Jernberg-Wilkund H., Vanderkerken K. (2013) "Epigenetic modulation of myeloma within its bone marrow microenvironment" in *Advances in Biology and Therapy of Multiple Myeloma*, p. 255-282.

67. De Paepe K., Vander Heyden Y., Rogiers V. "Biophysical Assessment of Skin Desquamation and Scaliness Usin Tape Strips and Adhesive Discs" in *Non Invasive Techniques in Clinical Dermatology* Eds. E. Berardesca, H. Maibach, KP Wilhelm, Springer Berlin Heidelberg, 2014.
68. Desmedt B., De Paepe K., Rogiers V., Adam R. "Baby Care products" in *Handbook of Cosmetic Science and Technology*. Third Edition. Eds. A.O. Barel, M. Paye, H.I. Maibach. CRC Press, Taylor 1 Francis Group, New York pp. 487-500, 2014.
69. Vinken M., Landesmann B., Rogiers V. (2014) "Focus on hepatotoxic modes-of-action in SEURAT-1: rationale and strategy" In: *Towards the replacement of in vivo repeated dose systemic toxicity testing volume 4*, COACH (Ed.) Mouzet Imprimerie, France, pp. 114-125, 2014.
70. Rogiers V. "Validated alternative methods available for human health safety assessment of cosmetics products and their ingredients in the European Union" CRC Press, Taylor & Francis Group, New York pp. 647-663, 2014.
71. Rodrigues R.M., Bremer-Hoffmann S., De Kock J., Escher S., Hengstler J., Jennings P., Keun H., Kleinjans J., Kolde R., Kopp-Schneide A., Ringwald A., Rogiers V., Sachinidis A., Sickmann A., Spitkovsky D., Vanhaecke T., Vinken M., van de Water B., Hescheler J. "DETECTIVE: detection of endpoints and biomarkers for repeated dose toxicity testing using *in vitro* systems, in: *Towards the replacement of in vivo repeated dose systemic toxicity testing volume4*, COACH (Ed.), Mouzet Imprimerie, France, pp. 166-185, 2014.
72. Vinken M., Rogiers V. "Challenging the predictive power and robustness of an adverse outcome pathway construct from bile salt export pump inhibition to cholestatic liver injury, in: *Towards the replacement of in vivo repeated dose systemic toxicity testing volume4*, COACH (Ed.), Mouzet Imprimerie, France, pp. 93-96, 2014.
73. Buyl K., De Kock J., Bolleyn J., Rogiers V. and Vanhaecke T. "Measurement of albumin secretion as functionality test in primary hepatocyte cultures". In: *Methods in molecular biology Vol. 1250: protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) Springer Protocols-Human Press, New York pp. 303-308, 2014.
74. Rodrigues R.M., De Kock J., Doktorova T., Rogiers V., Vanhaecke T. "Measurement of Cytochrome P450 Enzyme Induction and inhibition in Human Hepatoma Cells". *Protocols in In Vitro Hepatocyte Research*, Editors: Rogiers V. and Vinken M., Humana Press, *Methods in Molecular Biology* 1250 pp. 279-285, 2014.
75. De Kock J., Rodrigues R.M., Buyl K., Vanhaecke T., Rogiers V. "Human skin-derived precursor cells: isolation, expansion and hepatic differentiation". *Protocols in In Vitro Hepatocyte Research*, Eds.: Rogiers V. and Vinken M., Humana Press, *Methods in Molecular Biology*, Vol. 1250 pp.113-122, 2014.
76. Vinken M., Maes M., Crespo Yanguas S., Willebrords J., Vanhaecke T., Rogiers V. "Establishment and characterization of an *in vitro* model of Fas-mediated hepatocyte cell death" *Protocols in in vitro hepatocyte research*. In: *Protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) Springer Protocols-Humana Press, New York, pp. 95-104, 2015.

77. Maes M., Vanhaecke T., Cogliati B., Crespo Yanguas S., Willebrords J., Rogiers V., Vinken M. ("Measurement of apoptotic and necrotic cell death in primary hepatocyte cultures" *Protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) *Springer Protocols-Humana Press, New York*, pp. 349-362, 2015.
78. Ramboer E., Vanhaecke T., Rogiers V., Vinken M. "Immortalized human hepatic cell lines for *in vitro* testing and research purposes" In: *Protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) *Springer Protocols-Humana Press, New York*, Vol. 1250 pp. 53-76, 2015.
79. Bolleyn J., Fraczek J., Rogiers V., Vanhaecke T. "Epigenetic modifications as anti-differentiation strategy for primary hepatocytes in culture" In: *Protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) *Springer Protocols-Humana Press, New York*, Vol. 1250 pp.203-211, 2015.
80. Bolleyn J., Rogiers V., Vanhaecke T. "Functionality testing of primary rat hepatocytes by the measurement of urea synthesis", In: *Protocols in in vitro hepatocyte research*, Vinken M. and Rogiers V. (Eds.) *Springer Protocols-Humana Press, New York*, Vol. 1250 pp.317-321, 2015.
81. Vinken M., Rodrigues R.M., Rogiers V. "Challenging the predictive power and robustness of an adverse outcome pathway construct from bile salt export pump inhibition to cholestatic liver injury", in: *Towards the replacement of in vivo repeated dose systemic toxicology testing*, Vol. 5, COACH (Ed.) Mouzet Imprimerie, France, pp. 75-96, 2015.
82. Wink S., van de Water B., Reif R., Hammad S., Stöber R., Widera A., Hengstler J.G., Limonciel A., Jennings P., Escher S., Keun H., Kleinjans J., Kopp-Schneider A., Peterson H., Ringwald A., Rogiers V., Sachinidis A., Sickmann A., Vinken M., Spitkovsky D., Hescheler J. "DETECTIVE: detection of endpoints and biomarkers for repeated dose toxicity testing using *in vitro* systems", in *Towards the replacement of in vivo repeated dose systemic toxicity*, Vol. 5, COACH (Ed.) Mouzet Imprimerie, France, pp. 136-165.

11. ACTIVE PARTICIPATION IN CONGRESSES

11.1. Organisation of congresses

1. Organisation of the 11th Congress of the European Working Group of Cystic Fibrosis, June 1982, Brussels. Member of the Scientific Committee responsible for the selection of the oral presentations and posters. My responsibility was the section "Function of membranes".
2. Chairperson of the 11th Congress of the European Working Group of Cystic Fibrosis for the section "Basic Research".
3. Organisation of the symposium "Reduction of experimental animals in the laboratory", at the VUB in collaboration with the "Vlaamse Vereniging voor Biologie", Brussels, Belgium, 16/03/1988.
4. Organisation of the symposium "Trends in Dermatology" at the VUB, in collaboration with Prof. A. Barel and Prof. D. Roseeuw, Brussels, Belgium, 7/05/1988.

5. Member of the scientific and organising committee of "The International Workshop on *In Vitro* Toxicology" (every two year in an European country), from 1988 on.
6. Organisation of the BADECOS symposia (2 per year), at the VUB Medical Campus, Brussels, from 1990 until now.
7. Invited as expert for panel session in the Congress "Toxicology *in vitro*", organised by Rhone-Poulenc, Annecy, France, 17-19/10/1990.
8. Organisation of the European Symposium "Alternative Methods in Pharmacotoxicological Research", together with Prof. M. Roberfroid (UCL) under the auspices of HRH Prince Laurent of Belgium, Brussels, Belgium, 11/01/1991.
9. Organisation of the "Seventh International Workshop on *In Vitro* Toxicology", De Haan, Belgium, 05-09/10/1992.
10. Organisation of the EC symposium "Human Cells in Pharmacotoxicology", responsible for the scientific programme, 23-24/09/1993.
11. Member of the Scientific Board of the Congress "Second International Symposium on Irritant Contact Dermatitis", Zürich, Switzerland, 14-16/04/1993.
12. Member of the Scientific Board of the "First Tricontinental Meeting of Hair Research Societies", Brussels, Belgium, 08-10/10/1995.
13. Organisation of an EC preparatory meeting on "Hepatocyte-based *in vitro* models and their application in pharmacotoxicology", Brussels, Belgium, 23-24/10/1995
14. Chairperson of the session "Acids and skin rejuvenation" at the 4th Congress of the European Academy of Dermatology and Venerology, Brussels, Belgium, 10-15/10/1995.
15. Member of the Jury of the European Association for the Study of the Liver (EASL) Congress 1997, review of 25 abstracts for the category Toxicology-Pharmacology, London, UK, 09-14/04/1997.
16. Chairperson and organiser of the Workshop "Tissue-specific culture models for pharmacotoxicology" during the 42th International Congress of the European Tissue Culture Society, Mainz, Germany, 12-15/10/1997.

17. Chairperson of the session "Latest techniques, future marketing trends; Competitive marketing strategies in Europe" of the 1st Annual International Conference 'Successfully competing in the cosmetics, skin care and toiletries markets in Europe', Paris, France, 30-31/10/1997.
18. Local organiser of the 7th Meeting of the Hepatocyte User Group (HUG), Sheraton Brussels Airport, Brussel, Belgium, 12-13/08/1997.
19. Organisation and chairperson of task force meetings of ECVAM "Hepatocytes and Other Systems with Metabolic Competence", at the VUB, Brussels, Belgium, 25-27/02/1998.
20. Organisation and chairperson of EEMCO-ECVAM Workshop "Non-invasive methods in efficacy measurements and their potential use in safety assessment", Salons Waerboom, Brussels, Belgium, 10-12/03/1998.
21. Member of the Advisory Committee of the 3rd World Congress on "Alternatives and Animal Use in the Life Sciences", Chairperson of Workshop 25: The Role of National Platforms. V. Rogiers, B. Garthoff and P. De Greeve, Bologna, Italy, 29/08/1999.
22. Organisation of the ISBN and EEMCO Joint Meeting "Turning the tide against skin ageing - Hopes and setbacks through bioengineering", Liège, Belgium, 10-12/09/1999.
23. Chairperson of the Plenary Session II of the ISBN and EEMCO Joint Meeting "Turning the tide against skin ageing - Hopes and setbacks through bioengineering", Liège, Belgium, 10-12/09/1999.
24. Organisation, V. Rogiers and S. Beken, of all BPAM scientific session meetings taking place in 1999 at the VUB, Brussels.
25. Chairperson of the session "Cosmétologie - Les derniers progrès. Le traitement des complications dermatologiques et Médecine Esthétique, 2ème Congrès Européen de Médecine Esthétique et de Chirurgie Dermatologique et Esthétique, Brussels, Belgium, 25-26/09/1999.
26. Organisation of the 1st ecopa Workshop (European Workshop of National Platforms on Alternative Methods) "Impact of Platforms on the 3Rs in the EU", Sheraton Brussels, Belgium, 14-15/10/2000.
27. Organisation of all EEMCO meetings taking place in 1997, 1998, 1999, 2000 and 2001 at the VUB, Brussels, Belgium.
28. Organisation of the 2nd ecopa Workshop (European Workshop of National Platforms on Alternative Methods) "The White Book on Chemicals", Sheraton Brussels, Belgium, 27-28/10/2001.
29. Co-chairperson of Session A6 "Organ Studies I" (Liver and Drug Metabolism) of the 4th World Congress on Alternatives, New Orleans, Louisiana, USA, 11-15/08/2002.
30. Organisation of the 3rd ecopa Workshop (European Workshop of National Platforms on Alternative Methods) "Introducing and implementing 3R-alternatives into national, European and supra-national/OECD guidelines more efficiently", Sheraton Brussels, Belgium, 09-10/11/2002.
31. Co-organiser of the Intensive Training Course EU-candidate Countries "Implementation of the EU Cosmetics Directive/Safety and Control of Cosmetic Products in the EU in the scope of Enlargement", in collaboration with Colipa (The European Cosmetic Toiletry and Perfumery Association) and Taiex Office (Technical Assistance Information Exchange Office - DG Enlargement European Commission), Centre Albert Borschette, Brussels, Belgium 06-11/01/2003.

32. Organisation of the 4th *ecopa* Workshop (European Workshop of National Platforms on Alternative Methods) "Alternative Methods Development - Pipeline: Sufficient Projects in Face of EU Chemical White Paper and Cosmetic Legislation?" Sheraton, Brussels, Belgium, 28-29/11/2003.
33. Organisation of the 29th BADECOS Symposium, at the VUB, in collaboration with iPAVUB on "Deodorants, antiperspirants", Brussels, Belgium, 15/3/2004.
34. Local organiser of the ECVAM Meeting on "Alternative Methods", Sheraton Brussels, Belgium, 17/03/2004.
35. Chairperson of session "Alternative methods in toxicology", 10th ICTX Congress (International Congress of Toxicology), Tampere, Finland, 11-16/07/2004.
36. Chairperson of the European Toxicology Forum, Zürich, Switzerland, 19-21/07/2004.
37. Chairperson of session IV on "New Approaches in toxicology and risk assessment, Annual European Meeting of the Toxicology Forum 2004, Brussels, Belgium, 19-21/10/2004.
38. Organisation of the 30th BADECOS Symposium, at the VUB, in collaboration with iPAVUB on "Teeth whitening", Brussels, Belgium, 21/10/2004
39. Co-organisation of the eSI (*ecopa* Science Initiative) Workshop - moderator of session on "Novel technologies and techniques", Pueblo Acanilado (Alicante), Spain, 28-30/10/2004.
40. Co-organisation of the 5th Annual *ecopa* Workshop European Workshop of National Platforms on Alternative Methods) "SCALE after REACH and alike: Consequences for the development of alternative methods, respectively animal use", Sheraton Brussels, Belgium, 26-27/11/2004.
41. Member of the Organising Committee and Member of the Scientific Committee, of the 5th World Congress on Alternatives & Animal Use in the Life Sciences, Berlin, Germany, 21-25/08/2005.
42. Organisation of the 31st BADECOS Symposium, at the VUB, in collaboration with iPAVUB on "Safe sun exposure. What's new?", Brussels, Belgium, 1/10/2005
43. Chair of the Organising Committee of the 6th annual *ecopa* Workshop on "Nanotech, Biotech and other new technologies: safety testing and research requirements". Brussels, 17-18/12/2005
44. Chair of the Organising Committee of the *ecopa* Workshop on "REALity CHECK (REACH): Proposals, Amendmends and Conclusions from an alternative point of view", Brussels Sheraton, 01/02/2006.
45. Organisation of the Agenda Meeting of Predictomics, at VUB, campus Jette, Brussels 21-23/02/2006.
46. Organisation of the 32nd BADECOS Meeting on "Modern technology to counteract skin ageing", VUB Campus Jette, Brussels, 06/05/2006.
47. Organisation of a Course on Toxicology (Part I) and Ecotoxicology (Part II) in collaboration with VITO, for the Belgian Federal Government, Division Security of the Food Chain and Environment, at VUB campus Jette, Brussels, 29/5-02/06/2006.
48. Chair of the Organising Committee of the eSI (European Science Initiative) Workshop providing the possibility for young scientists to meet top senior scientists in developing fields of new science and technology, Alicante, 29-30/09/2006.

49. Member of the Local Organising Committee of INVITOX 2006 (14th International Workshop on *In Vitro* Toxicology), Ostend, Belgium, 02-05/10/2006, Participation in the European Society of *In Vitro* toxicology (ESTIV) General Assembly, Ostend, 04/10/2006.
50. Chair of the Organising Committee of the 7th Annual *ecopa* Workshop, Brussels Sheraton, 25-26/11/2006.
51. Member of the Advisory Board of the joint meeting of the 2nd World Congress on Work-Related and Environmental Allergy (WOREAL) and the 6th International Symposium on Irritant Contact Dermatitis (ISICD), Weimar, Germany, 13-16/06/2007.
52. Co-organiser of Session:Theme 8 on "Applying new science and Technology from basic research for the 3Rs", World Congress on Alternatives and Animal Use in the Life Sciences, Tower Hall Funabory, Tokyo, Japan, 21-25/08/2007.
53. Member of the Scientific Advisory Board of the 14th Congress on Alternatives to Animal Testing, and 11th Annual Meeting of MEGAT (Middle European Society for Alternative Methods to Animal Testing, Linz, Austria, 27-28/09/2007.
54. Organiser of the Safety Course – Follow-Up at the VUB, 04-06/02/2008.
55. Chair of the START-UP Project of the Workshop "Refinement in drug development process" of the 3Refinement: bottlenecks in pharmaceutical investigations, Rome, 26-27/02/2009.
56. Chair of session on Stem cells in 8th World Congress on Alternatives and Animal Use in the Life Sciences, WC8, Montréal, Canada, 21-25/08/2011.
57. Co-chair of Symposium on Replacement, the ultimate 3R concept, Hirschberg, Grossachen, Germany, 27-28/10/2011.
58. Organiser together with Prof. M. Vinken of the second HeMiBio winterschool for young scientists, Barcelona, Spain, 13/01/2013.
59. Organisation of the Safety Course - Follow-Up at the VUB Brussels, 27-28/05/2013.
60. Organisation of the yearly postacademic iPAVUB course "Intensive course in Dermato-Cosmetic Sciences", together with Prof. A. Barel and Prof. D. Roseeuw, from 1992 onwards, at the VUB.
61. Organisation of the yearly post academic iPAVUB training course "Safety Assessment of Cosmetics in EU", from 2000 onwards, at the VUB.

11.2. Invited speaker/Lecturer

1. Rogiers V. "Vergelijkende *in vitro* studie betreffende de inkorporatie en de transfer van NEFA in de erythrocytaire membraanfosfolipiden en hun afgifte aan autoloog serum bij cystic fibrosis patiënten en gezonde kinderen". Seminar at the State University of Utrecht, The Netherlands, Dept. of Prof. L. L. M. Van Deenen, 17/01/1980.
2. Rogiers V. "*In vitro* study concerning the incorporation and the transfer NEFAs into the phospholipids of the erythrocyte membranes of cystic fibrosis patients in comparison with healthy children". Seminar at the Université Libre de Bruxelles, Belgium, Dept. of Prof. J. Christophe, 30/09/1980.

3. Rogiers V. "Study of the fatty acid metabolism in cystic fibrosis patients in comparison with healthy children. Seminar at the University of Cardiff, Wales, Dept. of Pediatrics of Prof. J.A. Dodge, 24-26/11/1980.
4. Rogiers V. "Dietary fats and their metabolism". Plenary lecture during the 9th International CF Congress, Brighton, Great-Britain, 09-15/06/1984.
5. Rogiers V. "Biotransformation of valproic acid in isolated hepatocytes of rats". Seminar at the first SANOFI, Toulouse, France, 26-27/09/1984.
6. Rogiers V. "Use of isolated rat hepatocytes for the study of the toxicity and biotransformation of xenobiotics". Seminar at the Katholieke Universiteit Leuven, Belgium, Dept. of Toxicology Prof. Roberfroid.
7. Rogiers V. "Short-term culture of hepatocytes as an '*in vitro*' model for biotransformation and toxicity studies of xenobiotics". Seminar at the University of Berlin, West-Germany, Institut Max von Pettenkofer, invited by Prof. H. Spielmann, BGA, 10-12/12/1986.
8. Rogiers V. "Isolated hepatocytes as a suitable '*in vitro*' model for biotransformation and toxicity studies of xenobiotics". Seminar at the University of Dortmund, West-Germany, Dept. of Physiology and Toxicology, Prof. H.M. Bolt, 9/2/1987.
9. Rogiers V. "Isolated hepatocytes and their short-term culture as a suitable *in vitro* model for biotransformation and toxicity studies of xenobiotics". Plenary lecture during the Symposium "Alternatives to animal experiments in risk assessment", Berlin, West-Germany, 26-27/03/1987.
10. Rogiers V. "Geïsoleerde hepatocyten in de toxicologische studie van valproïnezuur". Seminar at the University of Utrecht, The Netherlands, Dept. of Pharmaceutical Sciences and Toxicology of Prof. B. Blaauboer; 16/04/1987.
11. Rogiers V. "Isolated hepatocytes in studies of xenobiotic metabolism". Seminar at I.C.I. Macclesfield, Great-Britain, invited by Dr. O. Flint, Director of the Dept. "*In vitro* Systems", 06/06/1987.
12. Rogiers V., A. Callaerts, W. Sonck and A. Vercruyse "Biotransformation of sodium valproate in isolated rat hepatocytes". International Symposium on Liver Cells and Drugs, Rennes, France, 07-10/07/1987.
13. Rogiers V. "Isolated hepatocytes as a suitable *in vitro* model for biotransformation and toxicity studies of xenobiotics". Seminar at l'Oréal, Paris, France, invited by Prof. K.G. Dossou, Director of the Dept. of Control and Security, 12/07/1987.
14. Rogiers V. "Experiments on living animals and alternative methods in scientific research". Plenary lecture during the colloquia held in Brussels for the 125th Anniversary of the Veeweyde Association, the Belgian Foundation for the Protection of Animals and Society against Cruelties, 21/04/1988-16/05/1988.
15. Rogiers V.: "Alternatives in toxicity testing" Plenary lecture during the study day on Product Toxicology, held in Brussels by the V.C.V., I.H.E., Brussels, Belgium, 22/02/1989.
16. Rogiers V. "Toxicologische aspecten verbonden met het veelvuldige gebruik van zepen en syndets door ziekenhuispersoneel". Lecture during the Congress of the Vlaamse Vereniging van Intensieve Zorgen Verpleegkundigen, U.I.A., Antwerp, Belgium, 12/11/1990.
17. Rogiers V. "Legislation concerning experimental animals: Implementation in Belgium". Lecture during BELTOX Meeting "Laboratory animals: ethical, legal and practical aspects", at Janssen Pharmaceutica, Beerse, Belgium, 28/11/1990.
18. Rogiers V. "Liposomen in dermato-cosmetische toepassingen". Plenary lecture during the Second Badecos Symposium at the VUB, Brussels, Belgium, 08/12/1990.

19. Rogiers V. "Alternative methods in pharmaco-toxicological research: an overview". Plenary lecture during the International Symposium on Alternative methods in Pharmacological Research, organised by the Group for reflexion on the quality of life and the environment, under the auspices of HRH Prince Laurent, Brussels, Belgium, 11/01/1991.
20. Rogiers V. "Effects of valproate on phase I and phase II biotransformation systems of xenobiotics". Plenary lecture during the Valproate Workshop organised at the University of Nijmegen, The Netherlands, 25-26/01/1991.
21. Rogiers V. "Cultures and co-cultures of hepatocytes as *in vitro* models for biotransformation and toxicity studies of xenobiotics". Plenary lecturing during the *In vitro* Toxicology Meeting, at the University of Padova, Italy, Dept. of Biology, 20/06/1991.
22. Rogiers V. "Hepatocytes as biotransformation model". Plenary lecture during the 3rd International (International Society for the Study of Xenobiotics) Meeting on Drug Metabolism 1991, Amsterdam, The Netherlands, 24-28/06/1991.
23. Rogiers V. "Liposomes: a new galenic form". Seminar at the Firm Merck, Sharp & Dohme, Antwerp, Belgium, 12/09/1991.
24. Rogiers V. "Use of rat hepatocyte cultures and co-cultures in biotransformation studies of xenobiotics". Plenary lecture during the meeting of the European Society of Biochemical Pharmacology: Application of Cellular Systems in Drug Metabolism and Toxicity Studies, at Otzenhausen, Germany, 21-24/07/1991.
25. Rogiers V. "Freshly isolated hepatocytes, their cultures and co-cultures as *in vitro* models for biotransformation and toxicity studies". Seminar at the Vrije Universiteit Brussel, Medical Research, Brussels, Belgium, 11/10/1991.
26. Rogiers V. "Safety and composition of dermato-cosmetic preparations for babies". Seminar at the Firm Galenco, Paal, Belgium, 08/11/1991.
27. Rogiers V. "Use of cultured hepatocytes for toxicity and biotransformation studies". Seminar at Searle, Mont-Saint-Guibert, Belgium. Invited by Dr. J. Roba, Director of Product Safety, 28/11/1991.
28. Rogiers V. "Liposomen, een nieuwe galenische vorm voor topische applicatie". Plenary lecture in the 11th Bijscholingscursus voor Apothekers: Trends in Galenica, Vrije Universiteit Brussel, Brussels, Belgium, 13/12/1991.
29. Rogiers V. "Alternative methods in pharmaco-toxicological research and testing: advantages and disadvantages". BCLAS Meeting, Brussels, Belgium, 29/04/1992.
30. Rogiers V. "Development of *in vitro* methods for local toxicity". Workshop "Research and Development of *In Vitro* Pharmaco-toxicology, organised by EC DG XIII, F6, Brussels, Belgium, 09-10/07/1992.
31. Rogiers V. "Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P-450-mediated monooxygenase". BRIDGE sectoral Meeting "Development of *in vitro* toxico-pharmacological tests", organised by the National Pharmaceutical Biotechnology Centre, Trinity College, Dublin, and the CEC Biotechnology Programme, Dublin, Ireland, 08-10/12/1992.
32. Rogiers V. "Hydratatiemetingen van de huid: noodzaak tot standaardisatie". 1ste Nascholingscursus van de Stichting Nederlandstalige Nascholing voor Dermatologie en Venereologie "Niet-chirurgische cosmetische raadgevingen", Maastricht, The Netherlands, 28-29/10/1993.

33. Rogiers V. "Co-cultured rat hepatocytes: a suitable tool for the study of the cytochrome P-450 dependent metabolism and toxicity of sodium valproate". First European Conference on Medicines Research "Perspectives in Pharmacotoxicology and Pharmacovigilance, Brussels, Belgium, 06-07/12/1993.
34. Rogiers V. "Co-cultures of adult hepatocytes: a suitable model for xenobiotic biotransformation". Annual BEMS Meeting 1993 (Belgian Environmental Mutagen Society) on Metabolic Activation and Mutagenesis, ULg, Liège, Belgium, 10/12/1993.
35. Rogiers V.: "Expression and induction of the cytochrome P-450-mediated monooxygenase system". NATO advanced course on "Molecular aspects of liver carcinogenesis", organised by G.G. Skouteris, G.K. Michalopoulos and P. Skett, Delphi, Greece, 08-18/01/1994.
36. Rogiers V. "Use of human hepatocytes in pharmaco-toxicology. Actual status within Europe". NATO advanced course on "Molecular aspects of liver carcinogenesis", organised by G.G. Skouteris, G.K. Michalopoulos and P. Skett, Delphi, Greece, 8-18/01/1994.
37. Rogiers V. "Expression and induction of phase I and II biotransformation in mono-cultured and co-cultured rat hepatocytes". Seminar at Bayer AG, Wuppertal, Germany, 26/01/1994.
38. Rogiers V. "TEWL measurements in patch test assessment: the need for standardisation". Second International Symposium on Irritant Contact Dermatitis (ISICD), Zürich, Switzerland, 14-16/04/1994.
39. Rogiers V. "New strategies: the use of long-term cultures of hepatocytes in toxicological research and testing of xenobiotics" European (International Society for the Study of Xenobiotics) Workshop 1994, Toxicology of Industrial Compounds, Schluchsee, Germany, 12-15/06/1994.
40. Rogiers V. "Métabolisme de la peau". EC-Course: Utilisation des peaux reconstituées en pharmaco-toxicologie cutanée, Université de Montpellier, Montpellier, France, 27/06-1/07/1994.
41. Rogiers V. "The use of human hepatocytes in pharmaco-toxicology. A review". International Workshop on Human *In vitro* Liver Preparations for Metabolism Studies in Drug Development (HUG 94), University of Utrecht, Nederland, 6-08/09/1994.
42. Rogiers V., K. De Paepe and D. Roseeuw "Are hydrating cosmetics effective?". Skin Club, Gemeentekrediet, Brussels, Belgium, 09/01/1995.
43. Rogiers V. "Perspectives in the use of hepatocyte cultures in pharmaco-toxicology". EC preparatory meeting on "Hepatocyte-based *in vitro* models and their application in pharmaco-toxicology", Brussels, Belgium, 23-24/01/1995.
44. Rogiers V. "The use of cultures of human hepatocytes in pharmacotoxicology. A review" 5th Hepatocyte User Group (HUG) Meeting, Veterinary Centre of Glasgow, UK, 10-11/09/1995.
45. Rogiers V. "The hormonal regulation of flavin-containing monooxygenase and glutathione S-transferase in co-cultured hepatocytes and *in vitro* approach". 5th Hepatocyte User Group (HUG) Meeting, Veterinary Centre of Glasgow, UK, 10-11/09/1995.
46. Rogiers V.: "Alpha hydroxy acids: a critical review of skin effects". Fourth congress of the European Academy of Dermatology and Venereology, Brussels, Belgium, 10-15/10/1995.

47. Rogiers V. "Long-term cultures of hepatocytes in metabolism studies of pharmaceuticals and other chemical products". Plenary lecture at the 10th Anniversary of the Irish Society of Toxicology, Dublin, Ireland, 20/10/1995.
48. Rogiers V. "Huidtypes en hun verzorging". Derde Dermatologisch Symposium Schering-Plough, Lederle, KULAK, Kortrijk, Belgium, 09/11/1995.
49. Rogiers V. "Wat is nieuw in cosmetica?". Congress of the Medical Women's Association of Belgium "Women are in medicine to stay", Nieuwe aanwinsten, nieuwe uitdagingen, Brussel, België, 11/11/1995.
50. Rogiers V.: "Effecten van TEWL van body lotions met ceramiden, cholesterol en vrije vetzuren". 2nd BADECOS Symposium on "Ceramide and Dermato-Cosmetics. Pregnancy and Dermato-Cosmetics", Brussels, Belgium, 02/12/1995.
51. Rogiers V. "Efficacy claims of cosmetics in Europe: need for standardisation of non-invasive measurements on the skin". Conference Zyma Nyon, Department of Dr. B. Schmid, Nyon, Switzerland, 25/01/1996.
52. Rogiers V. "Questions d'actualité en cosmétologie" Journée rencontre EVIC-CEBA, Hilton Paris, France, 21/03/1996.
53. Rogiers V. "Dermato-cosmetic formulations and objective evaluation of their efficacy on the skin". Education course for pharmacists "Dermatica in der Apotheke. Patienten-orientierte Pharmazie in Theorie und Praxis", University of Basel, Basel, Switzerland, 26/04/1996.
54. Rogiers V. "AHA, leur action dans le vieillissement cutané". Journée Européenne d'Echange en Cosmétologie dermatologique, Hôtel Nikko, Paris, France, 10/05/1996
55. Rogiers V. "Up-dating of ECVAM News". Werkgroep Dierproeven in de Farmaceutische Sector, Brussel, België, 14/05/1996.
56. Rogiers V. "Overview of alternative methods in pharmaco-toxicology: possibilities and limitations of alternatives". Proefdierkunde NIDO, Brussel, België, 20-31/05/1996.
57. Rogiers V. "Survey of alternatives - Possibilities and limitations". Course on Laboratory Animal Sciences, Belgian Council for Laboratory Animal Science (BCLAS), Brussels, Belgium, 20-31/05/1996.
58. Rogiers V., Beken S., Vanhaecke T., Coecke S., Vercruyssen A., Phillips I. and Shephard E.A. "Dependency of glutathione S-transferase (GST) expression in long-term hepatocyte culture on condition factors" in session "The Role of Extracellular Matrix in Pharmaco-toxicological Testing *In Vitro*" of the World Congress on *In Vitro* Biology "Biotechnology: from fundamental concepts to reality", San Francisco, USA, 22-27/06/1996.
59. Rogiers V. "Effects of ceramides containing creams on the barrier function of the skin". 5th Congress of the European Academy of Dermatology and Venereology (EADV), Lissabon, Portugal, 13-17/10/1996
60. Rogiers V. "Huidveroudering, wat cosmetisch eraan te doen?". Uitstraling permanente vorming VUB, in samenwerking met het Academisch Ziekenhuis VUB, Lessenreeks "Dokter mag ik U wat vragen?", Brussels, Belgium, 09/12/1996.
61. Rogiers V. "Zon en huid". Uitstraling permanente vorming VUB, in samenwerking met het Academisch Ziekenhuis VUB, Lessenreeks "Dokter mag ik U wat vragen?". Brussels, Belgium, 24/02/1997.
62. Rogiers V., Beken S., Vanhaecke T., Coecke S., Vercruyssen A., Phillips I. and Shephard E. "The use of co-culture models and the collagen sandwich technique for the investigation of xenobiotic metabolism and hepatotoxicity *in vitro*". British Toxicology Societies (BTS) Annual Congress, Warwick, UK, 24-26/03/1997.

63. Rogiers V. "Expression of key phase 1 and phase 2 drug metabolism enzymes in collagen gel cultures of rat hepatocytes". 42nd International Congress of the European Tissue Culture Society, Mainz, Germany, 12-15/10/1997.
64. Rogiers V. "Survey and alternatives: possibilities and limitations". 2nd Course on Laboratory Animal Sciences, Belgian Council for Laboratory Animal Science (BCLAS), Brussels, Belgium, 29/10/1997 - 07/11/1997 - 28/11/1997.
65. Rogiers V. "Proeven op dieren" Uitstraling permanente vorming VUB, Vrijzinnig Cultureel Centrum, Kortrijk, België, 14/11/1997.
66. Rogiers V. "Senioren: zon en huid". Zenith - Uitstraling permanente vorming VUB, Brussels, Belgium, 07/12/1997.
67. Rogiers V. "Alternatives to animal use". First course of ICLAS/FELASA Associations, Educational Programme on Laboratory Animal Science in Central Europe, Budapest, Hungary, 12-13/01/1998.
68. Rogiers V. "Cosmetica en huidveroudering". Vereniging voor Dermato-Chirurgie (Glaxo-Wellcome), Zeist, België, 13/06/1998.
69. Rogiers V. "Ceramides in dermato-cosmetic preparations"; section Dermo-Cosmétologie, 22^e Congrès National de Médecine Esthétique et de Chirurgie Dermatologique, Paris, France, 22-27/11/1998.
70. Rogiers V. "De huid". Centrum voor Beroepsvervolmaking Leraren (CBL), Universitaire Instelling Antwerpen, België, 30/11/1998.
71. Rogiers V. "Technieken om proeven op dieren te vervangen in geneesmiddelenonderzoek". Wetenschapsweek 1998, VUB, October 1998.
72. Rogiers V. "Non-invasive methods in efficacy testing of cosmetic products on human volunteers". XXV^{ème} Journées Européennes de Cosmétologie. Le Cosmétologue Européen aux exigences du XXI^{ème} siècle. Hôpital Laënnec, St. Herblain, Nantes, France, 17-19/11/1998.
73. Rogiers V. "Ceramides-containing dermato-cosmetic emulsions and barrier function recovery of damaged skin". First World Congress of the International Academy of Cosmetic Dermatology, St. Julian's, Malta, 28-31/01/1999
74. Rogiers V. "Training product safety assessors" 2nd Colipa Symposium on Alternatives to Animal Testing. Section 3: Cosmetic Product Safety Assessment. The role of alternative methods, Brussels, Belgium 24-25/03/1999.
75. Rogiers V. "The use of hepatocyte cultures for investigating the interaction between metabolism and toxicity". IBC 2nd International Two Day Conference on *in vitro* Toxicology, IBC Global Conferences Ltd, London, UK, 12-13/04/1999.
76. Rogiers V., B. Garthoff and P. De Greeve "The role of national platforms". Third World Congress on Alternatives and Animal Use in the Life Sciences, Bologna, Italy, 29/08-02/09/1999.
77. Rogiers V. "A light transmission method for the study of microrelief and ageing". ISBS and EEMCO Joint Meeting "Turning the tide against skin ageing. Hopes and setbacks through bioengineering", Liège, Belgium, 10-12/09/1999.
78. Rogiers V. "Skin types and their daily care: some basic concepts". Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 17-21/09/1999.
79. Rogiers V. "Liposomes in dermato-cosmetology". Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 17-21/09/1999.
80. Rogiers V. "Xenobiotic metabolism of the skin". Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 17-21/09/1999.
81. Rogiers V. "Side-effects of cosmetics". Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 17-21/09/1999.

82. Rogiers V. "Measurements of skin hydration and TEWL". Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 17-21/09/1999.
83. Rogiers V. "De huid". 5de Vlaams Congres van Leraars-Wetenschappen, RUCA, Antwerpen, België, 20/11/1999.
84. Rogiers V. "The use of animal and human derived cell culture systems for metabolic studies". 10th EUROTOX Training & Discussion Session. Organised by the Eurotox: Specialty Section Carc inogenesis and Graduate Course Toxicology and Environmental Hygiene at the Heinrich-Heine University, Düsseldorf, Dortmund, Germany, 16/12/1999.
85. Rogiers V. "Long-term hepatocyte cultures and their potential use for drug metabolism enzyme induction" Course "Improved predictive *in vitro* screening" by Vision in Business, Euston Plaza Hotel, London, UK, 29-30/03/2000.
86. Rogiers V. "Hazard, risk: important considerations in safety assessments of cosmetics". Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, 10-15/04/2000.
87. Rogiers V. "Notes of Guidance for testing of cosmetic ingredients for their safety evaluation". Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, 10-15/04/2000.
88. Rogiers V. "New challenges in safety assessment of cosmetics", plenary lecture in section Safety Assessment "New challenges in safety assessment of cosmetics" of the 21st IFSCC (International Federation of Societies of Cosmetic Chemists) Congress on "Cosmetic Science for the next Century", Berlin, Germany, 11-14/09/2000.
89. Rogiers V. "Skin types and their daily care: some basic concepts", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 17-21/09/2000.
90. Rogiers V. "Drug metabolism of the skin", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 17-21/09/2000.
91. Rogiers V. "Notes of guidance of SCCNFP in the safety evaluation of cosmetic ingredients and finished products", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 17-21/09/2000.
92. Rogiers V. "Side effects of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 17-21/09/2000.
93. Rogiers V. "The use of skin hydration and TEWL measurements in efficacy testing of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 17-21/09/2000.
94. Rogiers V. "The role of National Platforms and ecopa" First ecopa Workshop on "Impact of Platforms on the 3Rs in the EU", Sheraton Airport Brussels, Brussels, Belgium, 14-15/10/2000.
95. Rogiers V. "Factual and bibliographical scientific data", Colipa Information Day on Cosmetic Efficacy, Brussels, Belgium, 07/02/2001.
96. Rogiers V. "Hazard, risk: important considerations in safety assessment of cosmetics", Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 02-07/04/2000.
97. Rogiers V. "Legislation of cosmetics in the EU", Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 02-07/04/2000.
98. Rogiers V. "Notes of Guidance of the SCCNFP", Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 02-07/04/2000.

99. Rogiers V. "Evaluation of the water diffusion barrier by TEWL measurements", IFSCC Conference "Quality of Cosmetics, An explosive myth?" Stockholm, Sweden, 07-09/05/2001.
100. Rogiers V. "Claim substantiatie van cosmetica gebaseerd op literatuur- en leveranciersgegevens", 23th BADECOS Symposium "Claims and efficacy of dermato-cosmetic products", VUB, Brussel, België, 19/05/2001.
101. Rogiers V., 4hr lecture "Development of dermato-cosmetic products according to the new concepts on structure and function of the stratum corneum" and 40 min course "Training course on the safety assessment of cosmetics in the EU", 15th Brazilian Congress of Cosmetology, Sao Paulo, Brazil, 24-26/07/2001.
102. Rogiers V., lecture in CEC (Continuing Education Courses) under CEC3 "Collagen gel cultures of hepatocyte and their use in metabolism-linked toxicity studies", EUROTOX 2001, the 39th Congress of the European Societies of Toxicology, Istanbul, Turkeu, 13-16/09/2001.
103. Rogiers V. "Skin types and their daily care", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 16-20/09/2001.
104. Rogiers V. "Notes of guidance of SCCNFP in the safety evaluation of cosmetic ingredients and finished products", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 16-20/09/2001.
105. Rogiers V. "Side effects of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 16-20/09/2001.
106. Rogiers V. "The use of skin hydration and TEWL measurements in efficacy testing of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, 16-20/9/2001.
107. Rogiers V. "Assessment of safety and efficacy of cosmetics in the EU", Czech Society of Cosmetology, Polish Society of Cosmetic Chemists: Symposium on Cosmetic & Household Ingredients (CHI Conference), Prague, Czech Republic, 28-29/11/2001.
108. Rogiers V. "Wat te geloven van huidverzorgingsproducten?" Actueel Denken en Leven Kortrijk, Kortrijk, Belgium, 21/02/2002.
109. Rogiers V. "Hazard, risk, risk perception: important considerations in safety assessment of cosmetics", Training course in "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 08-13/04/2002.
110. Rogiers V. "Alternatives for experimental animal testing: where are we to-day?", Nederlandse Vereniging voor Cosmetische Chemisten (NVCC)), Hoevelaken, The Netherlands, 19/04/2002.
111. Rogiers V. "Hazard, risk and risk perception: their importance for the cosmetic industry", Société Française de Cosmetologie (SFC), Paris, France, 25/04/2002.
112. Rogiers V. "The suntan story - UV filters and estrogenic activity", The Toxicology Forum 2002, Annual European Meeting, Session IV: Timely Issues in Cosmetology Data, Brussels, Belgium, 27-29/05/2002.
113. Rogiers V. "Ecopa: a powerful concept in the way forward", the 18th ESAC Meeting. The ECVAM Status Seminar, European Commission, Directorate General JRC (Joint Research Centre), Ispra, Italy, 03-06/06/2002.
114. Rogiers V. "Specific risk assessments for children products", Colipa Scientific Forum and General Assembly 2002, Venice, Italy, 26-29/06/2002.

115. Rogiers V. "Contribution of the SCCNFP and the animal health and animal welfare committees to the three Rs", Conference "The Three Rs, state of the art: research, development and implementation of alternative methods", jointly organised by DG Research and DG Joint Research Centre (JRC), European Commission/Charlemagne, Brussels, Belgium, 09-10/07/2002.
116. Papeleu P., Loyer P., Vanhaecke T., Kass G., Guguen-Guillouzo C. and Rogiers V. "Cell signalling in Trichostatin A-treated primary hepatocyte cultures: Effect on proliferation and apoptosis", Key-speaker Session A2: Immortalization versus Redifferentiation of cell lines, Fourth World Congress on Alternatives and Animal Use in the Life Sciences, New Orleans, Louisiana, US, 11-15/08/2002.
117. Rogiers V., G. Elaut, et al. "Major phase I biotransformation pathways of Trichostatin A in rat hepatocytes and rat and human liver microsomes", Key-speaker Session A6: Organ Studies I (Liver and Drug Metabolism), Fourth World Congress on Alternatives and Animal Use in the Life Sciences, New Orleans, Louisiana, US, 11-15/08/2002.
118. Rogiers V. "The initiative of ECOPA: the way forward", Key-speaker Session C4: Putting policy into practice: ethical analysis and national standards, Fourth World Congress on Alternatives and Animal Use in the Life Sciences, New Orleans, Louisiana, US, 11-15/08/2002.
119. Rogiers V. "Skin types and daily care", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 16-20/09/2002.
120. Rogiers V. "Safety aspects of UV-filters", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 16-20/09/2002.
121. Rogiers V. "Notes of Guidance of SCCNFP in the safety evaluation of cosmetic ingredients and finished products", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 16-20/09/2002.
122. Rogiers V. "Side effects of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 16-20/09/2002.
123. Rogiers V. "The use of skin hydration and TEWL measurements in efficacy testing of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 16-20/09/2002.
124. Rogiers V. "Ecopa: actual status and plans", Major lecture in Session 8: Regulatory Issues, INVITOX 2002, 12th International Workshop on *In Vitro* Toxicology, Formia, Italy, 16-19/10/2002.
125. Rogiers V. "Hepatocytes and their cultures as alternative models in toxicological research and testing", Meeting of the Fondation de Biotechnologie-Biotechnologie Stichting and the VUB, in collaboration with the Belgian Bioindustries Association "The University talks to the Industry", VUB, Medical Campus Jette, Brussel, Belgium, 28/11/2002.
126. Rogiers V. "Safety evaluation of cosmetics in Europe", International Symposium on Efficacy and Safety of Cosmetics, Cosmetic Scientists, of Korea, Seoul, December 2002.
127. Rogiers V. "Hazard, risk and risk perception in safety assessment of cosmetics", TAIEX Office (Technical Assistance Information Exchange Office-DG Enlargement European Commission) - Intensive Training Course EU-candidate Countries "Implementation of the EU Cosmetics Directive/Safety and Control of Cosmetic Products in the EU in the Scope of Enlargement", Centre A. Borschette, Brussels, Belgium, 06-10/01/2003.

128. Rogiers V. "Notes of Guidance of SCCNFP", TAIEX Office (Technical Assistance Information Exchange Office-DG Enlargement European Commission) - Intensive Training Course EU-candidate Countries "Implementation of the EU Cosmetics Directive/Safety and Control of Cosmetic Products in the EU in the Scope of Enlargement", Centre A. Borschette, Brussels, Belgium, 06-10/01/2003.
129. Rogiers V. "Skin and eye irritation: clinical picture, basic mechanism, *in vivo* and *in vitro* tests", TAIEX Office (Technical Assistance Information Exchange Office-DG Enlargement European Commission) - Intensive Training Course EU-candidate Countries "Implementation of the EU Cosmetics Directive/Safety and Control of Cosmetic Products in the EU in the Scope of Enlargement", Centre A. Borschette, Brussels, Belgium, 06-10/01/2003.
130. Rogiers V. "Safety assessment of cosmetic ingredients by SCCNFP", Personal Care Ingredients Europe (PCIE), Philipshalle, Düsseldorf, Germany, 04-06/02/2003.
131. Rogiers V. "Hazard, risk, risk perception: important considerations in safety assessment of cosmetics", Training course in "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 07-12/04/2003.
132. Rogiers V. "'Validated' and 'valid' alternative methods available today for testing of cosmetic products and their ingredients", Training course in "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 07-12/04/2003.
133. Rogiers V. "'Validated' and 'valid' alternative methods available today for testing of cosmetic products and their ingredients", 27th BADECOS Symposium on "The 7th Amendment: What does it mean in practical terms?"
134. VUB Medical Campus, Brussels, Belgium, 09/09/2003.
135. Rogiers V. "Le visiomètre", Société Francophone d'Ingénierie Cutanée (SFIC), Séminaire "Relief Cutané", Besonçon, France, 02-03/10/2003.
136. Rogiers V. "Skin types and daily care", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
137. Rogiers V. "Safety aspects of UV-filters", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
138. Rogiers V. "New notes of Guidance of SCCNFP in the safety evaluation of cosmetic ingredients", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
139. Rogiers V. "Side effects of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
140. Rogiers V. "Alternative methods for irritation and sensitisation testing of cosmetic ingredients and finished products", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
141. Rogiers V. "Skin hydration and TEWL measurements in efficacy testing of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, VUB, Brussels, Belgium, 15-29/09/2003.
142. Rogiers V. "EU cosmetic directive and requirements for toxicological evaluation of cosmetic ingredients", Lecture in CEC 2 (Safety testing of cosmetic ingredients and cosmetic formulations), EUROTOX 2003, the 41st Congress of the European Societies of Toxicology, Florence, Italy, 28/09-01/10/2003.
143. Rogiers V., P. Papeleu *et al.* "Effects of histone deacetylase inhibitors on the cell cycle properties of hepatocytes", Session 7 "Development and validation of advanced *in vitro* methods", 21st Annual SSCT (Scandinavian Society of Cell Toxicology) Workshop on *In Vitro* Toxicology, Tampere, Finland, 19-21/11/2003.

144. Rogiers V. "Ecopa: actual status and activities", Session 8 "New aspects of European co-work on alternative methods", 21st Annual SSCT (Scandinavian Society of Cell Toxicology) Workshop on *In Vitro* Toxicology, Tampere, Finland, 19-21/11/2003.
145. Rogiers V. "Al-derivatives in perspirants: pro and contra", 29th BADECOS Symposium on "Deodorants and antiperspirants: Do they cause breast cancer?", VUB, Brussels, Belgium, 09/03/2004.
146. Rogiers V. "Dermatologische en cosmetische bereidingen in de nabije toekomst", Brusselse Vereniging voor Dermatologie/Société Bruxelloise de Dermatologie, VUB, Brussels, Belgium, 25/03/2004.
147. Rogiers V. "Recent developments in the way forward for alternative methods: formation of national consensus platforms in Europe", 10th ICTX (International Congress of Toxicology) Congress on New developments in Europe: Building of national consensus platforms on alternatives, Tampere, Finland, 11-16/07/2004.
148. Rogiers V. "Hazard, risk, risk perception: important considerations in safety evaluation of cosmetics", Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 04-09/09/2004 Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 04-09/09/2004.
149. Rogiers V. "'Validated' and 'valid' alternative methods available today for testing of cosmetic products and their ingredients", Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 04-09/09/2004.
150. Rogiers V. "Safety of sunscreens", International Skin Cancer Conference, Zürich, Switzerland, 22-24/07/2004.
151. Rogiers V. "Skin types and daily care", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 13-17/09/2004.
152. Rogiers V. "Safety aspects of UV-filters", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 13-17/09/2004.
153. Rogiers V. "Notes of Guidance of SCCP (former SCCNFP) for testing of cosmetic ingredients for their safety evaluation", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 13-17/09/2004.
154. Rogiers V. "Side-effects of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 13-17/09/2004.
155. Rogiers V. "Skin hydration and TEWL measurements in efficacy testing of cosmetics", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 13-17/09/2004.
156. Rogiers V. "Key importance of risk assessment and risk perception for the cosmetic industry", Key note lecture in the CTFA Autumn Conference, Tothworth Court Hotel, Bristol, UK, 11-12/10/2004.
157. Rogiers V. "Deodorants/antiperspirants and breast cancer", CHI (Cosmetic & Household Ingredients) Exhibition & Conference, Place of Culture & Science, Warsaw, Poland, 15-16/11/2004.
158. Rogiers V. "Present and future challenges of European science and regulatory policy", Plenary Session IV: Competing priorities: future commitment to the advancement of health and environmental sciences, 6th LRI Members Workshop 2004 on Commitment to Health & Environmental Sciences & Policies, Méridien Hotel Brussels, Belgium, 17-18/11/2004.
159. Rogiers V. "Why do we need alternatives? An introduction to ecopa (European Consensus Platform for Alternatives), the objectives and opportunities for creating national platforms", Meeting on the formation of the Hungarian Consensus Platform for Alternatives, Budapest, Hungary, 03/12/2004.

160. Rogiers V. "Validated" and "valid" alternative methods available today for testing of cosmetic products and their ingredients", Session 6. Technical dossier of cosmetics, Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 04-09/04/2004.
161. Rogiers V. "Differentiation of stem cells and stabilisation of phenotypical properties of primary cells - patent PCT/EP2004/0012134)", in Seminariereeks "Patents: Burdens or Benefits? Publiceren én octrooieren: Wat is je creativiteit waard in de praktijk?", Workshop Farma, organised by R&D, VUB Interface, VUB Gebouw H, Brussels, Belgium, 01/02/2005.
162. Rogiers V. "De zon en onze huid", BDF Belgium, Plantentuin Meise, Belgium, 03/02/2005.
163. Rogiers V. "Issues and News in Dermato-Cosmetics", - Use of pharmacologically active ingredients in cosmetics - Inorganic Pigments - Subpopulations in risk assessment, BDF Hamburg, Germany, 14-15/02/2005.
164. Rogiers V. "Hazard, risk, risk assessment and risk perception: key factors in the safety evaluation of cosmetics", Session I. Introduction and key issues in safety assessment of cosmetics, Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 04-09/04/2005.
165. Rogiers V. in "O & O samenwerkingsmodellen tussen bedrijven en kennisinstellingen", Workshop organised by the Flemish Government and IWT, Brussel, 18/04/2005.
166. Rogiers V. "Safety of organic sun screens in Europe", Sun Protection 2010 - A Sun Odyssey, The Royal Society, London, UK, 08-09/06/2005.
167. Rogiers V. "Building NCPs and the Slovenian initiative", *ecopa* Ethical Workshop, Ljubljana, Slovenia, 09-12/06/2005.
168. Rogiers V. "Good science must be the key factor in the development and use of alternative methods for safety assessment of cosmetics" Session 5.14: "Meeting the challenge of the 7th amendment to the EU cosmetics directive", Theme 5: Toxicology, Safety Evaluation, Validation and Policy, of the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, 21-25/08/2005.
169. Vanhaecke T., Papeleu P. and Rogiers V. "Use of chromatin remodelling as a new way to create differentiated primary hepatocyte cultures", Session 7.6: Novel Cell Culture Techniques, of the 5th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin, Germany, 21-25/08/2005.
170. Rogiers V. "Skin types and daily care", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 12-16/09/2005.
171. Rogiers V. "Notes of Guidance of SCCP (former SCCNFP) for testing of cosmetic ingredients for their safety evaluation", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 12-16/09/2005.
172. Rogiers V. "Safety aspects of UV-filters", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 12-16/09/2005.
173. Rogiers V. in "O & O samenwerkingsmodellen tussen bedrijven en kennisinstellingen", Workshop organised by the Flemish Government and IWT, Brussel, 13/10/2005.
174. Rogiers V. "Hazard, risk, risk assessment and risk perception: key factors in the safety assessment of cosmetics", Colipa (The European Cosmetic Toiletry and Perfumery Association) Workshop: meeting with Chinese authorities on cosmetic legislation, Brussels, Belgium, 17-18/10/2005.

175. Rogiers V. "Exposure to cosmetics: general consideration, calculations of exposure to different classes of cosmetics according to the SCCNFP Note of Guidance", Colipa (The European Cosmetic Toiletry and Perfumery Association) Workshop: meeting with Chinese authorities on cosmetic legislation, Brussels, Belgium, 17-18/10/2005.
176. Rogiers V. "Safety of organic UV filters in Europe", International Congress on New technologies in preventing photo-induced skin cancer and photo-ageing, Sienna, 19-21/10/2005.
177. Rogiers V. "Implications for EU Scientific Committees", Session III. "Safety without animal testing: reality or fantasy?" of the 2005 Annual European Meeting of the Toxicology Forum, Brussels Hilton, Belgium, 08-10/11/2005.
178. Rogiers V. Member of Panel in 7th LRI (Long-Range Research Initiative, coordinated by CEFIC, the European Chemical Industry Council) Members Workshop on "Health and Environment Advocacy and Sciences: Gaps, Future demands and Directions", Brussels SAS Radisson, Belgium, 17/11/2005.
179. Rogiers V, SusChem 3rd Stakeholder Meeting (European Technology Platform for Sustainable Chemistry), London, UK, 25/11/2005.
180. Rogiers V. Chair of Session I "New technologies require different thinking", 6th annual ecopa Workshop on "Nanotech, Biotech and other new technologies: safety testing and research requirements", 17-18/12/2005.
181. Rogiers V. Welcome and Opening, plus Chairperson of Session 2 "What's next", ecopa Workshop on "REALity CHECK: Proposals, Amendments and Conclusions - from an alternative point of view", Brussels, Belgium, Sheraton-Airport Hotel, 01/02/2006.
182. Rogiers V. "Risk assessment and implementation of alternative methods", Grow (Maastricht Research Institute Growth & Development) Mini-Symposium on "Three R's of alternatives to animal testing: refinement, reduction and replacement", Maastricht, 03/02/2006.
183. Rogiers V. "Hazard, risk, risk assessment and risk perception: key factors in the safety evaluation of cosmetics", Session I. Key issues in safety assessment of cosmetics, Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 02-07/04/2006.
184. Rogiers V. "Validated' and 'valid' alternative methods available today for testing of cosmetic products and their ingredients", Session 5: Systemic toxicity of cosmetics, Training course "Safety Assessment of Cosmetics in EU", VUB, Brussels, Belgium, 02-07/04/2006.
185. Rogiers V. Presentation of the CONAM project by co-ordinator V. Rogiers, Session II on the Latest progresses in EU-funded research on alternatives. Workshop "EU-funded research on alternatives to animal experimentation: stocktaking from FP6 and views for the future", Brussels, Belgium, 13-14/06/2006.
186. Rogiers V. 4th SusChem Stakeholder Workshop (European Technology Platform for Sustainable Chemistry) on "Sustainable Chemistry in European Research - Preparing for Implementation), Budapest, Hungary, 27/08/2006.
187. Rogiers V. "Skin types and daily care". Main lecture on Session 1 on "Skin and hair care", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 11-15/09/2006.
188. Rogiers V. "Notes of Guidance of SCCP for testing of cosmetic ingredients for their safety evaluation" in Session 4 on "Legislative aspects of dermato-cosmetics", Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 11-15/09/2006.

189. Rogiers V. invited expert at the first meeting of the Mirror Group of the EPAA (European Partnership for Alternative Approaches to Animal Testing), European Parliament, Brussels, 12/10/2006.
190. Rogiers V. "Risk assessment practices in the European Union (SCCP)", 2006 Safety Seminar of the CTFA (Cosmetic, Toiletry and Fragrance Association) on "Current Risk Assessment Practices in the Cosmetic Industry, Newark, NJ, 26/10/2006.
191. Rogiers V. "Safety evaluation of cosmetics in the EU: role of SCCP", PIRA Global Regulations for Cosmetics Conference, Prague, Czechoslovakia, 08-09/11/2006.
192. Rogiers V. "Safety of cosmetics in the EU: risk assessment approach and implementation of alternative methods", Russian Seminar on Animal Alternatives and Safety, Moscow, Russia, 09-10/11/2006.
193. Rogiers V. Invited at round-table discussion on "Animal test ban/Claim "Not Animal Tested" - Consequences to raw material manufacturers." of *EFfCI* (The European Federation for Cosmetic Ingredients), Paris, France, 15/11/2006.
194. Rogiers V. "3R in general". Main Lecture of Session 1 on "3R", Symposium of the Belgian Council for Laboratory Animal Science (BCLAS), Louvain-la-Neuve, Belgium, 16/11/2006.
195. Rogiers V. "A Stakeholder's Assessment" *epaa* (The European Partnership for Alternative Approaches to Animal Testing) Conference on Alternative Approaches to Animal Testing "Europe goes alternative", European Commission, Brussels, 18/12/2006.
196. Rogiers V. "La santé publique et les produits chimiques: Comment la question est-elle traitée au niveau de l'Europe?" Colloque de GIRCOR (Groupe Interprofessionnel de Réflexion et de Communication sur la Recherche) sur "L'expérimentation animale en toute transparence", Paris, France, 31/01/2007.
197. Rogiers V. "Hepatocytes from established stem cells" Kick-Off Meeting of the IUAP-VI network HEPRO, Medical Campus VUB, Brussels, Belgium, 16/02/2007.
198. Rogiers V. "Alternative testing under REACH", REACH Seminar of FEDICHEM (Federation of the Belgian Chemical Industries), Brussels, Belgium, 9/03/2007.
199. Rogiers V. "Hazard, risk, risk assessment and risk perception: key factors in the safety evaluation of cosmetics" Session 1: Key issues in safety assessments of cosmetics. Safety Assessment of Cosmetics in the EU Training Course, Brussels, 01-06/04/2007.
200. Rogiers V. "Validated" and "valid" alternative methods available today for testing of cosmetic products and their ingredients" Session 6: Alternatives to animal testing. Safety Assessment of Cosmetics in the EU Training Course, Brussels, 01-06/04/2007.
201. Rogiers V. "Huid, haar: interacties met cosmetische producten". Tweedaags trainingsprogramma. Pilips NV, Drachten, NL, 09-10/05/2007
202. Rogiers V. "Alternative methods or additional animal use during REACH?", Aapistie, Oulu, Finland 14-16/05/2007.
203. Rogiers V. "Identification of requirements for acceptance for regulatory safety testing: IV. Cosmetics" *epaa* (European Partnership for Alternative Approaches to Animal Testing) Workshop on Regulatory Acceptance of 2R Methods and Strategies, Brussels 18-19/06/2007.
204. Rogiers V. "Histone deacetylase inhibitors: opening of a new research field in the development of alternative methods?", Theme 8: Applying new science and technology from basic research for the 3Rs, 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan 21-24/08/ 2007.

205. Rogiers V. "*ecopa's* EU FP7 project START-UP: Scientific and technological issues in 3Rs alternatives research in the process of drug development and Union politics", 14th Congress on Alternatives to Animal Testing and 11th Annual Meeting of MEGAT (Middle European Society for Alternative Methods to Animal Testing), Linz, 28-30/09/2007.
206. Rogiers V. "Future of safety assessment of cosmetics in Europe" (*Sobre o futuro da comprovação da segurança dos produtos cosméticos na Europa*), Lisboa, Portugal, 19/10/2007.
207. Rogiers V. " Safety evaluation of cosmetic ingredients in Europe: role of SCCP" or "Alternative methods for safety evaluation of cosmetic ingredients: a critical view", IntertechPira Conference on Global Regulations for Cosmetics, Nice, France, 14-15/11/2007.
208. Rogiers V. "Development of alternatives for animal experimentation in toxicology: The 3 R", 16th EUROTOX Training and Discussion Session, Development in Industrial and Occupational Toxicology – with special emphasis on carcinogenesis, Dortmund, Germany, 31/01/2008.
209. Rogiers V. "How good are validated methods to predict toxicity of different substances and products?" International Congress i-SUP2008, Bruges, Belgium, 22-25/04/2008.
210. Rogiers V. "How good are validated methods to predict toxicity of different substances and products?" "International Conference i-SUP 2008 – Innovation for Sustainable Production 2008", Bruges, Belgium, 22-25/04/2008.
211. Rogiers V. "EU Project START-UP, Goals, presentation status, output of the meeting (flow of information", START-UP 2nd Expert Meeting, Scientific and Technological issues in 3Rs Alternatives Research in the process of drug development and union politics, Novartis Campus Basel, Switzerland, 05/09/2008.
212. Rogiers V. "Evaluation of cosmetics' safety. Cosmetic's Safety Report" Challenge for the cosmetics industry. New legislation in the EU conference, Warsaw, Poland, 05-06/11/2008.
213. Rogiers V. "ADME toxicology in the view of the SCCP" EEPA Workshop on *In vitro* ADME in Safety Testing, Düsseldorf, Germany, 24-25/11/2008.
214. Rogiers V. Event Greek Authorities and Greek Cosmetics Association, Athens, Greece, 11/12/2008.
215. Rogiers V. "Hepatocyte-based *in vitro* models for pharmaco-toxicological purposes" Universiteit van Namen, Dienst Cell & Tissue Laboratory" Prof. Y. Poumay, 17/12/2008.
216. Rogiers V. "Ecopa and ecopa workshops as tools for promoting the 3Rs", Congress "Towards a common understanding of the meaning of the 3Rs", Vilvorde, Denmark organised by Dakopa, 22-23/01/2009.
217. Rogiers V. Boardmeeting ECOPA and Workshop Replacement, Education Refinement: bottlenecks in pharmaceutical investigations, Rome, 25/02-01/03/2009.
218. Rogiers V. "Functional and stable culture models are key factors in the risk assessment process of carcinogens" Pre-congress of VII World Congress on Alternatives & Animal Use in the Life Sciences, Workshop: Genomics in Cancer Risk Assessment, Venetië, San Servolo, Italy, 28/08/2009.

219. Rogiers V. - “Realisations and future perspectives” Session: Associations: ecopa
 - “What did we learn up to now by a project such as START UP?”
 Session: Pharmaceuticals.
 - “Repeated dose toxicity testing in the cosmetic sector”
 Session: Developments in the field of alternative methods.
 - “Regulatory requirements for cosmetics in the EU and status of non-animal tests”
 Session: Cosmetics
 - “An iterative approach to complete regulatory acceptance”.
 Session: Skin and eye toxicity I.
 VII World Congress on Alternatives & Animal Use in the Life Sciences, Rome,
 30/08-03/09/2009
220. Rogiers V. “Safety of cosmetics in the EU” International Society for Biophysics and
 imaging of the Skin. Besançon, France, 09-12/09/2009.
220. Vinken M., Doktorova T., Vanhaecke T., Rogiers V. “Functional and stable culture
 models are key factors in the risk assessment process of carcinogens” Workshop:
 Genomics in Cancer Risk Assessment, San Servolo Island, Venice, Italy,
 27-28/08/2009.
221. Rogiers V., Pauwels M. “An iterative approach to complete regulatory acceptance”
 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome, Italy,
 30/08-02/09/2009.
222. Rogiers V. “What did we learn up to now by a project such as START-UP?” 7th
 World Congress on Alternatives & Animal Use in the Life Sciences, Rome, Italy,
 30/08-02/09/2009.
223. Rogiers V. “Cell systems for liver toxicity” BELTOX-INVITROM congress,
 Edegem, Belgium, 25/11/2009.
224. Rogiers V. “Key-topic: Is there a single “gold standard”? Chair of Break out group 1,
 LRI Workshop “Applicability of skin sensitization testing methods for regulatory
 purposes”, Brussels, Belgium, 03/02/2010.
225. Rogiers V. “Risico-evaluatie van cosmetica in Europa” Brusselse Sociëteit voor
 Dermatologie, UZ Brussel, Belgium, 25/03/2010.
226. Rogiers V. 2-Day training “Safety assessment of cosmetics in the EU” at FDA lab of
 Dr. R. L. Bronaugh, USA, May 2010.
227. Rogiers V. “Actual status of alternative methods for human health risk assessment”
 State-of-the-Art Lectures in Biomedicine, IUA, Antwerp, Belgium, 16/11/2011.
228. Rogiers V. “Alternatives for animal testing (3R)” BRAS Advances course: CTD
 Mod 4, Brussels, Sheraton Hotel, Belgium, 24/02/2011.
229. Rogiers V. “The expected outcome after 5 years” SEURAT, kick-off meeting,
 Cascais, Portugal, 01-03/03/2011.
230. Rogiers V. “Pre-validation studies with liver cells *in vitro* using transcriptomics”,
 during the BTS Annual Congress, British Toxicology Society and the Dutch Society
 of Toxicology, Durham University, UK, 27-30/03/2011.
231. Rogiers V. “Relevance of actual endpoint(s) of reconstructed human skin models for
 skin imitation testing of color ingredients and hair dyes” IVTIP-ESTIV-CAAT
 Spring 2011 Meeting, “*In vitro* reconstructed human tissue models as alternatives to
 animal testing: applicability and limitations” Monaco, 26-28/04/2011.
232. Rogiers V. “Cell systems for liver toxicity studies” 2011 Life Technologies
 Hepatocyte Expert ProgrammeTM, Life technologies Customer Experience Centre,
 Darmstadt, Germany, 14-16/06/2011.

233. Rogiers V. "Focus on stem cells as sources of human target cells for *in vitro* research and testing", 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011.
234. Rogiers V. "Skin-derived precursor cells, a promising source for hepatic progeny" 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011.
235. Rogiers V.: "Validated 3R-Alternatives in the risk assessment of cosmetic ingredients" EAGG, Brussels, Belgium, 06/10/2011.
236. Rogiers, V. "Valid versus validated 3R-alternatives: their current status and their general use in different sectors" Symposium in Replacement, the ultimate step of the 3R concept: How to handle the ban of animal experiments enforced legally by the EU in cosmetics? Hirschberg-Grosssachsen, Germany, 26-28/10/2011.
237. Rogiers V. "Annual Meeting of epaa: Integrated Testing Strategies and their impact on the 3R's, Session 6, Conclusions and way forward." Brussels, Belgium, 09/11/2011.
238. Rogiers V. "Normal aging and skin care" Belgian Interuniversity Course in Geriatric Medicine" interuniversitaire opleiding geriatrie – BVGG, 17/12/2011.
239. Rogiers V. "2-day training "Safety assessment of cosmetics in the EU" at Health Canada, Montréal, Canada, March 2012.
240. Rogiers V. "Safety assessment of cosmetics and their ingredients in the EU: Updates in the notes of guidance of the SCCS" Cosmetics Europe General Assembly 2012, Brussels, Belgium, 13-15/06/2012.
241. Rogiers V. "Illegale cosmetische bleekmiddelen op de Belgische markt" Emeritaatsviering van Prof. Dr. Diane Roseeuw, Jette, 21/09/2010
242. Rogiers V. "Safety evaluation of cosmetic products and their ingredients for babies and children" Seminar Cosmetics Technical exchange meeting, Beijing, China, 22-26/10/2012.
243. Rogiers V. "Safety evaluation of cosmetics in Europe" Congresso Nazionale SICC, Milano, Italy, 31/10/2012.
244. Rogiers V. "EU Cosmetic ingredients risk assessment" and "EU cosmetic product risk assessment" Training on "Cosmetics Safety Risk Assessment and Risk Surveillance" SFDA, Paris, France, 31/10/2012.
245. Rogiers V., "Use of the Threshold of Toxicological Concern (TTC) approach for human safety assessment with focus on cosmetics" 10^{ème} Congrès Parfums & Cosmétiques, Chartres, France, 28/11/2012.
246. Rogiers V. "Safety evaluation of cosmetics in Europe without animal testing" World Congress of the International Society for Biophysics & Imaging of the Skin (ISBS), Copenhagen, Denmark, 28-30/11/2012.
247. Rogiers V. "Illegale huidblekende cosmetic op de Belgische Markt" Koninklijke Belgische Vereniging voor Dermatologie en Venerologie. What's News in Dermatology. Dolce, Terhulpen, Belgium, 01/12/2012.
248. Rogiers V. "Alternative methods; State of the art and applications for safety evaluation of cosmetics and their ingredients" Brasilia, 03-06/12/2012.
249. Rogiers V., ECVAM Workshop on Genotoxicity, Ispra, Italy, 23-25/01/2013.
250. Rogiers V. NCS TOX Project, 1^e Meeting of the Scientific Committee, Paris, France, 14/02/2013.
251. Rogiers V. "Safety Evaluation of Cosmetics and their ingredients in Europe: New Challenges Ahead" 2013 SOT Annual Meeting, San Antonio, Texas, USA, 11-14/03/2013.

252. Rogiers V. "Safety Assessment for Cosmetic Products" Workshop 52089 concerning the EU Legislation on Cosmetics Products. Ankara, Turkey, 25-26/04/2013.
253. Rogiers V. "Compiling Product Information Files" Workshop 52089 concerning the EU Legislation on Cosmetics Products. Ankara, Turkey, 25-26/04/2013.
254. Rogiers V. "Do we have the required *in vitro* methodology to adequately respond to the EU Cosmetics Regulation 1223/2009?" IVTD Spring meeting: "Ready for regulation?" 2013: State of the art on *in vitro* alternative methods from an industrial point of view. Southampton, UK, 15-16/05/2013.
255. Rogiers V. "Sunscreen Safety in the EU" Sun Protection Conference 2013, London, UK, 03-05/06/2013.
256. Rogiers V. "Safety assessment of cosmetics: What's new in the SCCS Notes of Guidance?" Ready, steady, go! New chapter in the EU cosmetic legislation, Conference by the Polish Union of Cosmetics Industry, Warsaw, Poland, 27-28/06/2013.
257. Rogiers V. "Safety assessment of cosmetics products: how to prepare and where to find data"? Unions Conference, Warsaw, Poland, 27-28/07/2013.
258. Rogiers V. "Safety Assessment of Cosmetics- Cosmetic Particular Product Groups" and "Alternative Tests for animal Testing for Cosmetics" Multidisciplinary approaches to cosmetics and sectoral consideration symposium, Ankara, Turkey, 08/07/2013.
259. Rogiers V. "What we are bringing to the dossier concerning skin metabolism" 2nd Skin Metabolism Meeting, Valbonne, France, 10-11/10/2013.
260. Rogiers V. "Sunscreen Safety in the EU" Conference for Société Française de Cosmétologie – Scientific Days. Maison Internationale – Cité Universitaire, Paris, France, 02-03/12/2013.
261. Rogiers V. "Cosmetics Safety Assessment" Cosmetic congress, Antalya, Turkey, 14-16/02/2014.
262. Rogiers V. "The AOP concept applied to skin sensitization" 5th Symposium of the Latin American Society of Toxicologic Pathology (LASTP), Sao Paulo, 11-14/4/2014.
263. Rogiers V. "Validated 3R-alternative methods available for risk assessment in the EU" 5th Symposium of the Latin American Society of Toxicologic Pathology (LASTP), Sao Paulo, 11-14/04/2014.
264. Rogiers V "New technologies in the safety assessment of cosmetic ingredients" 'Cosmetics at the Crossroads of Science and Regulation', Cosmetics Europe Conference 2014, Brussels, 10-11/06/2014.
265. Rogiers V. "How safe is safe enough for market presence?", Cosmetics Business Regulatory Summit, Brussels, 17-18/06/2014.
266. Rogiers V. "Toxicogenomics as a WoE tool to investigate false positive responses obtained in the LLNA" 9th World Congress on Alternatives and Animal use in the Life Sciences – WC9, Prague, Czech Republic, 24-28/08/2014.
267. Rogiers V. Chair of Break out Group I "Combination of omics and *in vivo* methods – a way forward to get more information from toxicity studies?" BfR Workshop on Application of Omics Data in Regulatory Toxicology at BfR, Berlin, 09-10/10/2014.
268. Rogiers V. "The war on drugs". Science Bar Brussels, Belgium, 14/10/2014.
269. Rogiers V. "Alternatives methods in risk assessment of cosmetics in Europe" IFSCC 28th Congress, Paris, 27-30/10/2014.

270. Ates G. and Rogiers V. "Misleading positive mutagenicity/genotoxicity of cosmetic ingredients: alternative solutions?" Bundesinstitut für Risikobewertung (BfR), Berlin, 05/11/2014.
271. Ates G. and Rogiers V. "What are hair dyes? Is genotoxicity a potential issue?" WIV-ISP, BEMS meeting "Carcinogens@Home 2014", Brussels, 14/11/2014.
272. Doktorova T., Ates G., Rogiers V. "Genotoxicity testing of cosmetic ingredients: current status and possible alternatives" WIV-ISP, BEMS meeting "Carcinogens@Home 2014", Brussels, 14/11/2014.
273. Van Bossuyt M., Van Hoeck E., Schüürman, Ates G., Vanhaecke T., Mertens B., Rogiers V. WIV-ISP, BEMS meeting "Carcinogens@Home 2014", Brussels, 14/11/2014.
274. Rogiers V. "10th EPAA – Annual Conference of the European Partnership for Alternative Approaches to Animal Testing – How to facilitate the use of alternative methods by regulators", Brussels, 19/11/2014.
275. Rogiers V. "Progress in anti-ageing and dermato-esthetic procedures" New developments in cosmetics organized by Prof. J. Gutermuth, Dept. Dermatology UZ Brussels, 29/11/2014.
276. Rogiers V. "The case of cosmetics: *in vitro* embryotoxicity testing is a key element in the risk assessment process". Symposium Fish and Amphibian Embryos and Alternatives Models in Toxicology and Teratology, Paris, 01-02/12/2014.
277. Rogiers V. "The role of skin penetration and metabolism in risk assessment" Annual meeting of the German Society of Toxicology (DGPT), Germany, Kiel, 10-12/03/2015.
278. Rogiers V. "Pigmentation and depigmentation of the skin: illegal skin bleaching cosmetics on the Belgian market" Host speaker at the PhD-day, Edition 2015, Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy, Campus Jette, Brussels, 31/03/2015.
279. Rogiers V. "Genotoxicity testing of active ingredients. What to expect in the context of the cosmetic regulation?" Cosmetics Business Regulatory Summit 2015, Brussels, 19/05/2015.
280. Rogiers V. "Challenges in safety evaluation of cosmetics and their ingredients in the EU" Cosmetics Europe 2015, Brussels 16-19/06/2015.
281. Rogiers V. "Importance of dermal absorption testing for cosmetic active ingredients" QACSLtd. – Cosmetics, Regulation issues update – Safety evaluation of cosmetics products. Athens, Greece, 03/07/2015.
282. Rogiers V. "Safety Evaluation of skin care products for babies" QACSLtd. – Cosmetics, Regulation issues update – Safety evaluation of cosmetics products. Athens, Greece, 03/07/2015.
283. Rogiers V. "Quantitative Risk Assessment in the EU of Cosmetics for Babies and Children" EUROTOX 2015, 51th Congress of the European Societies of Toxicology, Porto, Portugal, 13-16/09/2015.
284. Rogiers V. "Cosmetics as a test case for completely non-animal toxicity testing" 51th Congress of the European Societies of Toxicology, Porto, Portugal, 13-16/09/2015.
285. Rogiers V. "Differentiated human skin-derived stem cells as a novel cell source for *in vitro* screening of drug-induced injury (DILI)" EUSAAT symposium, session "stem cells", Linz, 21-23/09/2015.
286. Rogiers V. "Use of stem cells in Toxicology" Johnson & Johnson, in Priorij van Corsendonk, Belgium, 07/10/2015.

287. Mertens B., Van Bossuyt M., Fraselle S., Ost N., Schüürman G., Vanhaecke T., Verschaeve L., Rogiers V., Van Hoeck E. "Development of a strategy to assign priority to substances migrating from non-plastic food contact materials based on genotoxic potential: A case study with substances related to coatings" EFSA's 2nd Scientific Conference Shaping the Future of Food Safety, Together, Milan, Italy, 14-16/10/2015.
288. Rogiers V. "Often misunderstood safety aspects of cosmetics and their ingredients" Chanel Symposium on Products Safety, Paris, 27/10/2015.
289. Rogiers V. "Transformation of safety information, into an argued safety assessment", "Principles of Cosmetic Safety Assessment" and Relevant sources of safety information" Invited expert on Safety assessment of cosmetics in the EU, Beijing, China, 01-06/11/2015.
289. Rogiers V. "Safety assessment of cosmetic products – General Principles" International GAZI Pharma Symposium (GPSS), Antalya, Turkey, 12-13/11/2015.
290. Rogiers V. "Update of validated *in vitro* methods for cosmetic ingredients testing in the EU" Congrès Parfums & Cosmétiques, Chartres, France, 18-19/11/2015.

11.3. Oral and poster communications

1. Rogiers V. "Determination of the non-esterified fatty acids in plasma of children", National Congress of the Belgian Society for Pharmaceutical Sciences, Heverlee, Belgium, 16-17/03/1979 (lecture)
2. Rogiers V. "Gas chromatographic determination of the fatty acid composition of the red cell membrane plasmalogens of healthy children and of children under pathological conditions", Third European Congress of Clinical Chemistry, Brighton, UK, 03-08/06/1979 (poster)
3. Rogiers V. "Abnormal NEFA pattern in plasma and abnormal fatty acid spectrum in the various phospholipid fractions in erythrocyte membranes of pancreatic CF patients", IXth Meeting of the European Working Group for Cystic fibrosis, Noordwijkerhout, The Netherlands, 12-13/06/1979 (oral)
4. Rogiers V., Mozes N. and Vertongen F. "Fatty acid incorporation and transport in red cell membranes of CF patients", 8th International Congress of Cystic Fibrosis, Toronto, Canada, 26-30/05/1980 (oral)
5. Rogiers V., Dab R., Crokaert R. and Vis H.L. "Changes in the plasma NEFA pattern and in the fatty acid composition of the various phospholipid fractions of red blood cell membranes in cystic fibrosis patients", Meeting of the Belgian Association for Cystic Fibrosis, Brussels, Belgium, 12/01/1980 (oral)
6. Rogiers V., Dab I., Crokaert R. and Vis H. L. "5th International Congress of the Belgian Society for Pharmaceutical Sciences", Université Libre de Bruxelles, Brussels, Belgium, 14-15/03/1980 (oral)
7. Rogiers V. "Altered fatty acid pattern of the plasma and red blood cell lipids of CF patients", Meeting of the "Foundation Queen Elisabeth", Brussels, 10/05/1980 (lecture)
8. Rogiers V. "Incorporation and transport of fatty acids in the phospholipids of red blood cell membranes of CF patients", Scientific Meeting of the Belgian Association for Cystic Fibrosis, Brussels, Belgium, 24/01/1981 (lecture)

9. Rogiers V., Mozes N. and Vertongen F. "Incorporation and transport of fatty acids in the red blood cells of CF patients", 6th National Congress of the Belgian Society for Pharmaceutical Sciences, Brussels, Belgium, 14/03/1981 (poster)
10. Rogiers V., Mozes N., Geeraerts F., Vertongen F., Dab I. and Vercruyssen A. "Fatty acid patterns in plasma cholesterol esters of CF patients and heterozygotes", 10th Meeting of the European Working Groups for Cystic Fibrosis, Bern, Switzerland, 22-23/09/1981 (poster).
11. Rogiers V., Dab I., Baran D. and Vercruyssen A. "Fatty acid patterns in plasma cholesterol esters of CF patients with and without pancreatic insufficiency", 11th Annual Meeting of the European Working Group for Cystic Fibrosis, 02-04/05/1982 (poster)
12. Rogiers V. and Vercruyssen A. "Abnormalities in the fatty acid renewal process of the red blood cell membranes of CF patients; *In vitro* study", 13th International Colloquium on lipid metabolism and its pathology", Lisbon, Portugal, 22-25/11/1982 (lecture)
13. Rogiers V. and Geeraerts F. "Use of labelled compounds in biochemistry and toxicology", 15th FEBS Meeting, 24-29/07/1983 (Projection of slides with synchronized text and music in "Didactic Section")
14. Rogiers V., Paeme G., Vercruyssen A. and Bouwens L. "Procyclidine in isolated rat liver cells", Eurage Workshop on "Pharmacological, morphological and physiological aspects of liver aging", Lommersbergen, Reuver, The Netherlands, 25-28/11/1983 (oral)
15. Rogiers V., Dab I., Vercruyssen A., Crockaert R. and Vis H.L. "Intrinsic abnormal fatty acid turnover in the red cell membranes of cystic fibrosis", 9th International Cystic Fibrosis Congress, Brighton, UK, 9-15/6/1984 (poster)
16. Rogiers V., Paeme G. and Vercruyssen A. "Use of isolated hepatocytes of rats for biotransformation and toxicity studies of drugs and toxic compounds", VCV-Kekulé cycle, UIA, Wilrijk, Belgium, 10/01/1984 (poster)
17. Paeme G., Rogiers V., Vercruyssen A. and Bouwens L. "Phenobarbital induction of the procyclidine metabolism in isolated rat hepatocytes", 9th European Workshop on Drug Metabolism, Pont-à-Mousson, France, 11-15/06/1984 (oral)
18. Rogiers V., Paeme G. and Vercruyssen A. "Use of isolated hepatocytes of rats in the study of procyclidine metabolism", Forum of Pharmaceutical Sciences, RUG, Ghent, Belgium, 14/03/1984 (poster)
19. Rogiers V., Paeme G. and Vercruyssen A. "Evidence for vicinal diol formation arising from two cytochrome P-450 catalyzed hydroxylations", 6th International Symposium on Microsomes and Drug Oxidation, Brighton, Great-Britain, 05-11/08/2984 (poster)
20. Rogiers V., Dab I. and Vercruyssen A. "Abnormal fatty acid turnover in the red cell membranes of CF patients", Meeting of the Belgian Association for Cystic Fibrosis, Brussels, Belgium, 19/05/1984 (oral)
21. Rogiers V., Vandenberghe Y. and Vercruyssen A. "Effect of sodium valproate and its metabolites on gluconeogenesis in isolated rat hepatocytes", Contact Group "Drug Metabolism and Pharmacokinetics", Janssen Pharmaceutica, Beerse, Belgium, 23/11/1984 (oral)

22. Rogiers V., Vandenberghe Y. and Vercruysse A. "Effect of sodium valproate and its metabolites on gluconeogenesis in isolated rat hepatocytes", Contact Group "Drug Metabolism and Pharmacokinetics", Janssen Pharmaceutica, Beerse, Belgium, 23/11/1984 (oral)
23. Rogiers V., Adriaenssens L., Vandenberghe Y. and Vercruysse A. "Determination of 7-ethoxycoumarin O-deethylase (ECD) activity in intact isolated rat hepatocytes", International Symposium on Clinical and Basic Aspects of Enzyme Induction and Inhibition, Essen, West-Germany, 05-06/07/1985 (poster)
24. Rogiers V., Adriaenssens L., Vandenberghe Y. and Vercruysse A. "A critical view on the determination of 7-ethoxycoumarin", Joint Meeting of the Belgian, Dutch and German Pharmacological and Toxicological Societies, Aachen, West-Germany, 23-26/09/1985 (oral)
25. Dedobbeleer P., Rogiers V., Sonck W. and Vercruysse A. "Synthesis of valproic acid metabolites and their quantitative determination in biological media", 2nd International Symposium on Drug Analysis, 27-30/5/1985 (poster)
26. Rogiers V., Maes V., Van der Linden M. and A. Vercruysse "Inducing and inhibiting properties of sodium valproate studied with isolated rat hepatocytes", 10th European Drug Metabolism Workshop, Surrey, Guilford, England, 06/11/1986 (poster)
27. Rogiers V., Vandenberghe Y., Maes V. and Vercruysse A. "Effect of sodium valproate on the biotransformation systems of xenobiotics in isolated hepatocytes", 4th International Workshop on *In Vitro* Toxicology, Crieff, Scotland, 08-12/09/1986 (oral)
28. De Valck V., Geerts A., Theunissen J., Thielemans K., Rogiers V. and Wisse E. "Monoclonal antibodies against rat liver fat storing cells: production and their use for immunocytochemical localisation in tissue sections", NFWO Contact Group "Monoclonal Antibodies", Katholieke Universiteit Leuven, Leuven, Belgium, 29/11/1986 (poster)
29. Rogiers V., Vandenberghe Y., Sonck W. and Vercruysse A. "Inducing and inhibiting properties of valproate studies with isolated hepatocytes", NFWO Contact Group "Liver", Vrije Universiteit Brussel, Brussels, Belgium, 14/02/1987 (oral)
30. Rogiers V., Callaerts A., Sonck W. and Vercruysse A. "Biotransformation of sodium valproate in isolated rat hepatocytes", International Symposium on Liver Cells and Drugs, Rennes, France, 07-10/07/1987 (poster)
31. Rogiers V. "Isolated hepatocytes as a suitable *in vitro* model for biotransformation and toxicity studies of xenobiotics", Symposium "Alternatives to Animal Experiments in Risk Assessment", International Conference Centre, Berlin, West-Germany, 26-27/03/1987 (lecture)
32. Rogiers V. "Toxicity of cosmetics", Visit of the UCB at the Vrije Universiteit Brussel, Brussels, Belgium (lecture)
33. Rogiers V. "Isolated hepatocytes as a suitable *in vitro* model for biotransformation and toxicity studies of xenobiotics", Symposium van de Nederlandse Vereniging U.B., Medical Department, 24/11/1987 (lecture)
34. Mertens K., Rogiers V., Vandenberghe Y. and Vercruysse A. "Determination of reduced and oxidized glutathione in isolated rat hepatocytes", FGWO Contact Group "Experimental Toxicology", VUB, Brussels, Belgium, 18/03/1988 (poster)

35. Rogiers V. "Progress in *in vitro* techniques and possibilities for reduction of experimental animals", Symposium on Reduction of Experimental Animals in the Laboratory", VUB, Brussels, 16/04/1988 (lecture)
36. Rogiers V. "Effects of sodium valproate on phase I and II biotransformation systems of xenobiotics studied in rat hepatocytes under various culture conditions", Symposium "Trends in Dermatology" , VUB, 14/05/1998 en voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, 01/10/1988 (lecture)
37. Mertens K., Rogiers V., Vandenberghe Y. and Vercruysse A. "Determination of reduced and oxidized glutathione in different culture systems of rat hepatocytes", Symposium "Trends in Dermatology" , VUB, 14/05/1998 en voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, 01/10/1988 (poster)
38. Rogiers V. "The use of cultures and co-cultures of rat hepatocytes for the study of the effects of valproate on phase I and II biotransformation systems of xenobiotics", 5th International Workshop on *In vitro* Toxicology, Schloss Elmau, West-Germany, 02-04/11/1988 (lecture)
39. Vandenberghe Y., Rogiers V., Guillouzo A. and Vercruysse A. (Glutathione S-transferase in cultured rat hepatocytes and the influence of phenobarbital treatment", 5th International Workshop on *In vitro* Toxicology, Schloss Elmau, West-Germany, 02-04/11/1988 (poster)
40. Rogiers V., Vandenberghe Y., Cornet M., Callaerts A., Sonck W., Guillouzo A. and Vercruysse A. "Inducing and inhibiting effects of sodium valproate on some biotransformation systems of xenobiotics in cultured and co-cultured rat hepatocytes", 11th European Workshop on Drug Metabolism, University of Konstanz, West-Germany, 11-16/09/1988 (poster)
41. Rogiers V., Mertens K., Vandenberghe Y., Cornet M., Callaerts A., Sonck W., Guillouzo A. and Vercruysse A. "Phase I biotransformation systems of xenobiotics in rat hepatocytes, cultured under various conditions", 11th European Workshop on Drug Metabolism, University of Konstanz, West-Germany, 11-16/09/1988 (poster)
42. Vandenberghe Y., Kiekens R., Rogiers V., Guillouzo A. and Vercruysse A. "Effect of phenobarbital on glutathione S-transferase activity in conventionally and co-cultured rat hepatocytes", 11th European Workshop on Drug Metabolism, University of Konstanz, West-Germany, 11-16/09/1988 (poster)
43. Vandenberghe YK, Kiekens R., Morel F., Rogiers V., Ketterer B., Guillouzo A. and Vercruysse A. "Effect of phenobarbital on glutathione S-transferase subunit composition *de novo* synthesis and mRNA levels of conventionally and co-cultured rat hepatocytes", 11th European Workshop on Drug Metabolism, University of Konstanz, West-Germany, 11-16/09/1988 (poster)
44. Rogiers V., Vandenberghe Y., Callaerts A., Guillouzo A. and Vercruysse A. "Phase I and phase II biotransformation systems of xenobiotics in cultured and co-cultured rat hepatocytes", 36th Meeting of the European Tissue Culture Society, Ghent, Belgium, 31/8-02/09/1988 (oral)
45. Rogiers V., Vandenberghe Y., Mertens K., Cornet M., Callaerts A., Sonck W., Guillouzo A. and Vercruysse A. "The use of cultures and co-cultures of rat hepatocytes for the study of the effects of valproate on phase I and II biotransformation systems of xenobiotics", Eurage Meeting, Nerja, Spain, 17-19/11/1988

46. Rogiers V., Vandenberghe Y., Callaerts A., Sonck W., Guillouzo A. and Vercruysse A. "Phase I and phase II biotransformation systems of xenobiotics in cultured and co-cultured rat hepatocytes under different conditions", 2nd Meeting of the FGWO Contact Group "Experimental Toxicology", Brussels, Belgium, 15/12/1988 (oral)
47. Grether T., Rogiers V. and Laib R.J. "Analysis of genotoxicity of hydroxylated and chlorinated biphenyl derivatives *in vitro* and *in vivo*", Deutsche Gesellschaft für Pharmakologie und Toxikologie, Mainz, West-Germany, 14-17/03/1989 (poster)
48. Rogiers V., Vandenberghe Y., Callaerts A., Sonck W. and Vercruysse A. "Effect of DMSO on phase I and II biotransformation in cultured rat hepatocytes", 2nd International Conference on Practical *In Vitro* Toxicology, Nottingham, Great-Britain, 23-27/07/1989 (oral)
49. Rogiers V., Vandenberghe Y., Callaerts A., Sonck W. and Vercruysse A. "Effects of dimethylsulphoxide on phase I and II biotransformation in cultured rat hepatocytes", 37th Annual Meeting of the European Tissue Culture Society, Graz, Austria, 29/08-01/09/1989 (oral)
50. Vandenberghe Y., Rogiers V. and Vercruysse A. "Effect of phenobarbital on the expression of GST cultured adult rat hepatocytes", 1st Annual BELTOX Meeting, Brussels, Belgium, 12/05/1989 (oral).
51. Mertens K., Rogiers V., Sonck W. and Vercruysse A. "Influence of fetal calf serum, nicotinamide, selenite and dimethyl-sulfoxide supplementation on glutathione levels in rat hepatocytes *in vitro*", 1st Annual BELTOX Meeting, Brussels, Belgium, 12/05/1989 (poster)
52. Vandenberghe Y., Morel F., Rogiers V., Ketterer A., Guillouzo A. and Vercruysse A. "The expression of GST in cultured adult rat hepatocytes", 3rd International GST Conference, Edinburgh, Scotland, 28-30/08/1989 (poster)
53. Laib R.J., Hindermeier U., Cornet M. and Rogiers V. "Metabolism and toxicology of 2-methylpropene (isobutene); comparison to other alkenes", 31st Meeting of the Deutsche Gesellschaft für Pharmakologie und Toxikologie, Mainz, West-Germany, 20/03/1990 (poster)
54. Cornet M., Laib R. J., Vercruysse A. and Rogiers V. "Biotransformation of 2-methylpropene (isobutene) in mice", Tweede Forum der Farmaceutische Wetenschappen, Den Haan, Belgium, 23-24/03/1990 (oral)
55. Rogiers V., Coecke S., Vandenberghe Y., Verleye G., Callaerts A., van Bezooijen C.F.A. and A. Vercruysse "Effects of ageing, gender and phenobarbital treatment on GST activity and subunit composition of rat liver", Eurage Meeting "Drugs and the liver", Noordwijk a/zee, The Netherlands, 22-25/03/1990 (oral)
56. Rogiers V., Schoon K. and Roseeuw D. "Assessment of skin surface hydration: the need for standardized conditions in capacitance measurements", International Conference and Exhibition on Raw Materials and Ingredients for Perfumers, Cosmetics and Toiletries, Wiesbaden, West-Germany, 21-23/03/1990 (oral)
57. Coecke S., Vandenberghe Y., Verleye G., Callaerts A., van Bezooijen C.F.A., Vercruysse A. and Rogiers V. "Effects of ageing, gender and phenobarbital treatment on GST activity and subunit composition of rat liver", Belgian Week of Gastroenterology, Brussels, Belgium, 09/03/1990 (oral)

58. Cornet M., Laib R.J., Vercruysse A. and Rogiers V. "*In vitro* biotransformation of 2-methylpropene in liver tissue of mice", 2nd Annual Meeting of the Belgian Society of Toxicology, KUL, Leuven, Belgium, 31/03/1990 (poster)
59. Mertens K., Rogiers V., Sonck W. and Vercruysse A. "Effects of culture system and media conditions on the reduced and oxidized glutathione contents of adult rat hepatocytes", 2nd Annual Meeting of the Belgian Society of Toxicology, KUL, Leuven, Belgium, 31/03/1990 (poster)
60. Coecke S., Vandenberghe Y., Verleye G., Callaerts A., van Bezooijen C.F.A., Vercruysse A. and Rogiers V. "Effects of ageing, gender and phenobarbital treatment on GST activity and subunit composition of rat liver", 2nd Annual Meeting of the Belgian Society of Toxicology, KUL, Leuven, Belgium, 31/03/1990 (poster)
61. Rogiers V., De Bisschop C. and Roseeuw D. "Assessment of skin surface hydration by capacitance measurements: the need for standardized conditions", 8th International Symposium on Bioengineering and the Skin, Stresa, Italy, 3-16/06/1990 (poster)
62. Geerts A., Greenwel P., Cunningham M., De Bleser P., Rogiers V., Wisse E. and Rojkind M. "Localisation of collagen a(I), collagen a1(IV), fibronectin and laminin gene transcripts in freshly isolated parenchymal endothelial, Kupffer and fat-storing cells by Northern hybridization analysis", 5th International Symposium on Cells of the Hepatic Sinusoid, Tucson, AZ, USA, 26-30/08/1990 (oral)
63. Coecke S., Vandenberghe Y., Verleye G., Callaerts A., van Bezooijen C.F.A., Vercruysse A. and Rogiers V. "Effects of ageing, gender and phenobarbital treatment on GST activity and subunit composition of rat liver", Eurage Meeting "Drugs and the Liver", Scheveningen, The Netherlands, 13-16/09/1990 (oral)
64. Roseeuw D., De Coninck A., Neven A.M., Vandenberghe Y., Kets E. and Rogiers V. "Use of cultured keratinocytes in wound healing", 6th International Workshop on *In vitro* Toxicology, INVITOX 1990, Seillac, France, 01-06/10/1990 (oral)
65. Mertens K. and Rogiers V. "Glutathione-dependent detoxication in adult rat hepatocytes under various culture conditions", 6th International Workshop on *In Vitro* Toxicology, INVITOX 1990, Seillac, France, 01-06/10/1990 (oral)
66. Cornet M., Castelain P., Laib R., Vercruysse A. and Rogiers V. "Mutagenic activity of 2-methylpropene (isobutene) and its epoxide in the Ames Salmonella assay modified for volatile compounds", 3de Forum der Farmaceutische Wetenschappen, Houffalize, Belgium, 15-16/03/1991 (oral)
67. Coecke S., Callaerts A., Vercruysse A. and Rogiers V. "Spectrophotometric assessment of flavin containing monooxygenase in freshly isolated hepatocytes", 3de Forum der Farmaceutische Wetenschappen, Houffalize, Belgium, 15-16/03/1991 (oral)
68. Akrawi M., Rogiers V., Vandenberghe Y., Shephard E. and Philips I. "Expression and induction of the cytochrome P-450 mediated monooxygenase system in co-cultured rat hepatocytes", 7th Tenovus - Scotland Symposium on "Eukaryotic genes and their expression", Glasgow, Scotland, 20-22/03/1991 (poster)

69. Akrawi M., Rogiers V., Vandenberghe Y., Shephard E. and Phillips I. "The expression and induction, in rat co-cultured hepatocytes, of components of the cytochrome P-450 mediated mono-oxygenase", 1st Symposium on "Gene expression during liver differentiation and disease", IRBM, Sorrento, Italy, 6-09/06/1991 (poster)
70. Cornet M., Laib R.J., Vercruyssen A. and Rogiers V. "Study of the mutagenicity of 2-methylpropene and its epoxide in the Ames assay, modified for volatile compounds", 3rd International (International Society for the Study of Xenobiotics) Meeting, Amsterdam, The Netherlands, 24-28/06/1991 (poster)
71. Mertens K., Sonck W., Vercruyssen A. and Rogiers V. "Effects of culture system, medium supplementation and oxygen availability during perfusion on the glutathione-dependent detoxication system in adult rat hepatocytes", 3rd International ISSX (International Society for the Study of Xenobiotics) Meeting, Amsterdam, The Netherlands, 24-28/06/1991 (poster)
72. Cornet M., Sonck W., Laib R.J., Vercruyssen A. and Rogiers V. "Epoxide formation during the biotransformation of 2-methylpropene in liver tissue of mice", 12th European Workshop on Drug Metabolism, Basel, Switzerland, 16-21/09/1990 (poster)
73. Mertens K., Rogiers V. and Vercruyssen A. "Glutathione-dependent detoxication in adult rat hepatocytes under various culture conditions", 12th European Workshop on Drug Metabolism, Basel, Switzerland, 16-21/09/1990 (poster)
74. Coecke S., Vandenberghe Y., Verleye G., Callaerts A., van Bezooijen C.F.A., Vercruyssen A. and Rogiers V. "Effects of ageing, gender and phenobarbital treatment on GST activity and subunit composition of rat liver", 12th European Workshop on Drug Metabolism, Basel, Switzerland, 16-21/09/1990 (oral)
75. Geerts A., Greenwel P., Cunningham M., De Bleser P., Rogiers V., Wisse E. and Rojkind M. "Connective tissue gene transcripts in freshly isolated liver cells", Eurage Meeting, Liver and Drugs Section, Cardiff, Wales, UK, 21-24/11/1991 (oral)
76. Cornet M., Mertens K., Soetaert H., Callaerts A., van Bezooijen C.F.A., Laib R.J., Vercruyssen A. and Rogiers V. "The biotransformation of 2-methylpropene (isobutene) as a function of age and gender in brown Norway rat liver", Eurage Meeting, Liver and Drugs Section, Cardiff, Wales, UK, 21-24/11/1991 (poster)
77. Mertens K., Rogiers V., Cornet M., Soetaert H., van Bezooijen C.F.A. and Vercruyssen A. "Glutathione-dependent detoxication in liver tissue of aging rats", Eurage Meeting, Liver and Drugs Section, Cardiff, Wales, UK, 21-24/11/1991 (oral)
78. Coecke S., Rogiers V., Callaerts A., Soetaert H., van Bezooijen C.F.A., Guillouzo A. and Vercruyssen A. "Effect of the aging process on gender and PB dependent glutathione S-transferase activity, subunit composition and steady state in mRNA in brown Norway rat liver", Eurage Meeting, Liver and Drugs Section, Cardiff, Wales, UK, 21-24/11/1991 (poster)
79. De Bleser P., Geerts A., Lazou J.M., Seynaeve C., Niki T., Rogiers V. and Wisse E. "Distribution of TGF- β 1 gene transcripts in cells of normal and CCl₄-treated rat liver", Forum of the Belgian Week of Gastroenterology, Namur, Belgium, 27-29/02/1992 (oral)

80. Rogiers V., Vandenberghe Y., Geerts A., Callaerts A., Carleer J., Roba J. and Vercruyssen A. "Effect of milacemide *in vivo* on xenobiotic biotransformation and lipid metabolism studied with isolated rat hepatocytes", VIth International Congress of Toxicology, Rome, Italy, 28/06-03/07/1992 (poster)
81. Cornet M., Callaerts A., Laib R.J. and Vercruyssen A. "Species differences in epoxide formation after *in vitro* exposure to 2-methylpropene (isobutene)", 7th Internal Workshop on *In Vitro* Toxicology, De Haan, Belgium, 5-9/10/1992 (poster)
82. Mertens K., Rogiers V. and Vercruyssen A. "Measurement of malondialdehyde in cultures of adult rat hepatocytes", 7th Internal Workshop on *In Vitro* Toxicology, De Haan, Belgium, 05-09/10/1992 (poster)
83. Coecke S., Rogiers V. and Vercruyssen A. "Flavin-containing monooxygenase activity in conventional cultures and co-cultures of adult rat hepatocytes under various culture conditions", 7th Internal Workshop on *In Vitro* Toxicology, De Haan, Belgium, 05-09/10/1992 (poster)
84. Shephard E., Akrawi M., Phillips I., Vercruyssen A. and Rogiers V. "Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P-450-mediated monooxygenase", 7th Internal Workshop on *In Vitro* Toxicology, De Haan, Belgium, 05-09/10/1992 (poster)
85. Nicolas F., de Sousa G., Placidi M., Rahmani R., Benicourt M., Fournex R., Lorenzon G., Mertens K., Coecke S., Callaerts A., Rogiers V., Fautrel A., Chesne C. and Guillouzo A. "Cryopreserved monkey and dog hepatocytes in pharmaco-toxicological studies of drugs", 7th Internal Workshop on *In Vitro* Toxicology, De Haan, Belgium, 05-09/10/1992 (poster)
86. Rogiers V., Vandenberghe Y., Geerts A., Callaerts A., Carleer J., Vercruyssen A. and Roba J. "Effects of milacemide *in vivo* on xenobiotic biotransformation and lipid metabolism, studied with isolated hepatocytes", 4th North American (International Society for the Study of Xenobiotics) Meeting, Florida, USA, 2-06/11/1992 (poster), ISSX Proceedings, vol. 2, p. 69 - ISSN 1061-3439
87. Rogiers V. "Facteurs influençant la détermination de la perte d'eau transépidermique", 3ème Congrès de la SICMP, Paris, France, 29-30/11/1993 (oral)
88. Rogiers V. and Roseeuw D. "TEWL measurement: the need for standardisation", Koninklijke Vereniging voor Dermatologie en Venerologie, VUB, Brussels, Belgium, 14-15/11/1992 (lecture)
89. Castelain Ph., Criado B., Cornet M., Laib R., Rogiers V. and Kirch-Volders M. "Comparative mutagenicity of structurally related epoxides in a modified Salmonella microsome assay", Belgian Environmental Mutagen Society, in collaboration with the FNRS-NFWO Contact Group "Genotoxicity Test Protocols: International Regulatory Requirements" Annual Meeting, VUB, Brussels, Belgium, 20/11/1992 (oral)
90. Geerts A., De Bleser P., Niki T., Lazou J.M., Seynaeve C., Rogiers V., Rojkind M. and Wisse E. "Connective tissue mRNAs in normal and fibrotic rat liver", Joint Meeting of the Dutch and Belgian Societies for Electron Microscopy and the Belgian Society for Cell Biology, Antwerpen, Belgium, 10-11/12/1992 (oral)
91. Cornet M., Callaerts A., Vercruyssen A. and Rogiers V. "Species differences in the biotransformation of 2-methylpropene", 4de Forum der Farmaceutische Wetenschappen, Blankenberge, Belgium, 26-27/03/1993 (oral)

92. Mertens K., Rogiers V. and Vercruyssen A. "Measurement of malondialdehyde in cultures of adult rat hepatocytes", 4de Forum der Farmaceutische Wetenschappen, Blankenberge, Belgium, 26-27/03/1993 (oral).
93. Jorritsma U., Van Hummelen P., Kirsch-Volders M., Cornet M. and Rogiers V. "Mutagenicity of 2-methylpropene (isobutene) and its epoxide in the '*in vitro*' micronucleus test using human lymphocytes", Deutsche Gesellschaft für Pharmakologie und Toxikologie (DGPT) Meeting, Mainz, Germany, March 1993 (oral)
94. Akrawi M., Rogiers V., Shephard E. and Phillips I. "Expression in co-cultured rat hepatocytes of members of the cytochrome P-450 gene family", Congress on "Regulation of liver gene expression in health and disease", Cold Spring Harbor Laboratory, New York, USA, 05-09/05/1993 (poster)
95. Shephard E., Akrawi M., Rogiers V. and Phillips I. "Co-cultured rat hepatocytes - modulation of the cytochrome P-450 monooxygenase system by antiepileptic drugs", Symposium of the Hepatocyte User Group (HUG), York, UK, 08-09/1993 (oral)
96. de Sousa G., Nicolas F., Placidi M., Rahmani R., Benicourt M., Vannier B., Lorenzon G., Mertens K., Coecke S., Callaerts A., Rogiers V., Fautrel A., Chesne C. and Guillouzo A. "Cryopreservation and characterization of *Cynomolgus* monkey hepatocytes for use in pharmacotoxicological investigations", 5th European ISSX (International Society for the Study of Xenobiotics) Meeting, Tours, France, 26-29/09/1993 (poster)
97. Akrawi M., Rogiers V., Vercruyssen A., Phillips I.R. and Shephard E.A. "Long-term preservation and induction of cytochromes P450 in co-cultured rat hepatocytes", 8th International Conference on Cytochrome P450 "Biochemistry Biophysics and Molecular Biology", Lisbon, Portugal, 24-28/10/1993 (oral)
98. Rogiers V., Akrawi M., Vercruyssen A., Shephard E. and Phillips I. "Co-cultured rat hepatocytes: a suitable tool for the study of the cytochrome P450 dependent metabolism and toxicity of sodium valproate", World Congress on Alternatives and Animal Use in the Life Sciences, Baltimore, MD, USA, 14-19/11/1993 (oral)
99. Rogiers V. "Facteurs influençant la détermination de la perte d'eau transépidermique", IIIème Congrès de la SICMP, Paris, France, 29-30/11/1993 (lecture)
100. Akrawi M., Rogiers V., Vercruyssen A., Phillips I.R. and Shephard E.A. "Long-term preservation and induction of cytochromes P-450 in co-cultured rat hepatocytes", Meeting of the Biochemical Society, Imperial College London, UK, 20-21/12/1993 (poster)
101. Rogiers V. and Roseeuw D. "TEWL-measurements in patch test assessment: the need for standardisation", 2nd International Symposium on Irritant Contact Dermatitis (ISICD), Zürich, Switzerland, 14-16/04/1994 (poster)
102. Shephard E., Ciaramella G., Edwards M., Kramer K., Akrawi M., Rogiers V. and Phillips I. "Cultured liver cells: differentiation and *in vitro* toxicology", 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada, July 1994 (oral)
103. Debast G., Coecke S., Akrawi M., Vercruyssen A. and Rogiers V. "Effects of diethylalcohol on GST expression in co-cultured rat hepatocytes", Hepatocyte

- User Group Meeting (HUG '94), Lunteren, Utrecht, The Netherlands, 08-09/09/1994 (poster).
104. Debast G., Coecke S., Akrawi M., Vercruyssen A. and Rogiers V. "Effect of diethylalcohol on GST expression in co-cultured rat hepatocytes", 8th International Workshop on *In Vitro* Toxicology (INVITOX 1994), Kartause, Ittingen, Switzerland, 20-23/09/1994 (poster)
 105. Coecke S., Debast G., Akrawi M., Foiriers A., Vercruyssen A. and Rogiers V. "Hormonal regulation of GST in co-cultured rat hepatocytes", 8th International Workshop on *In Vitro* Toxicology (INVITOX 1994), Kartause Ittingen, Switzerland, 20-23/09/1994 (poster)
 106. Rogiers V. "Niet-chirurgische raadgeving: hydratatie en TEWL-meting", 2de Nascholingscursus Stichting Nederlandse Nascholing voor Dermatologie en Venerologie: Huidannexen, Rotterdam, The Netherlands, 03-05/11/1994 (oral)
 107. Rogiers V. "Hormonal regulation of FMO and GST in co-cultured rat hepatocytes", 5de Congres Vrouwen in Geneeskunde: "Focus op Preventie", Medicinal Women's Association of Belgium/Wetenschappelijke Vereniging van Vlaamse Huisartsen, Blankenberge, Belgium, 26/11/1994 (poster)
 108. Rogiers V., De Paepe K. and Roseeuw D. "Are hydrating cosmetics effective?", Skin Club, Brussels, Belgium, 09/01/1995 (lecture)
 109. Beken S., Pauwels M., Pahernik S., Koebe H.G., Vercruyssen A. and Rogiers V. "Glutathione S-transferase activities in collagen gel sandwich and immobilisation cultures of rat hepatocytes under various conditions: a critical review", International ISSX(International Society for the Study of Xenobiotics) Workshop on "Glutathione S-transferase", Noordwijkerhout, The Netherlands, 22-25/04/1995 (poster)
 110. Rogiers V., Coecke S., Debast G., Akrawi M., Foiriers A., Phillips I., Shephard E. and Vercruyssen A. "Hormonal regulation of GST in co-cultured rat hepatocytes", International (International Society for the Study of Xenobiotics) Workshop on "Glutathione S-transferase", Noordwijkerhout, The Netherlands, 22-25/04/1995 (poster)
 111. Beken S., Mauwels M., Pahernik S., Koebe H.G., Vercruyssen A. and Rogiers V. "Glutathione S-transferase activities in collagen gel sandwich and immobilisation cultures of rat hepatocytes under various conditions: a critical review", BELTOX Meeting "Toxicology and Sensitization", Brussels, Belgium, 12/05/1995 (poster)
 112. Vanhaecke T., Rogiers V., Debast G., Akrawi M., Foiriers A. and Vercruyssen A. "Hormonal regulation of glutathione S-transferase in co-culture of rat hepatocytes", BELTOX Meeting: "Toxicology and Sensitization", Brussels, Belgium, 12/05/1995 (poster)
 113. Tytgat T., Beken S., Giros M., Espeel M., De Prest B., Rogiers V. and Roels F. "Peroxisome mosaics in the liver of patients and in cultured rat hepatocytes", International Symposium on "Peroxisomes: Biology and Role in Toxicology and Disease", The Aspen Institute, Aspen, Co, USA, 28/06-02/07/1995 (oral)
 114. Linday S., Rogiers V. and Shephard E. "Induction of human cytochromes P450 by anti-epileptic drugs in cultured human hepatocytes", XIth Interantional Symposium on "Microsomes and Drug Oxidations", University of California LA, Ca, USA, 21-24/07/1995 (poster)

115. De Paepe K., Vandamme P., Hachem H.J., Derde M.P., Roseeuw D. and Rogiers V. "Effects of ceramides/cholesterol/FFA-containing body lotions on the TEWL of aged and SLS-damaged skin", Gordon Research Conference on "Barrier Function of Mammalian Skin", Andover, NH, USA, 14-18/08/1995 (poster)
116. Beken S., De Smet K., Pahernik S., Vandamme P., Callaerts A., Foriers A., Koebe H.G., Vercruyse A. and Rogiers V. 'Collagen gel sandwich and immobilised cultures as suitable *in vitro* models for the study of GST expression", HUG 1995 (Hepatocyte User Group), Glasgow, Scotland, 10-11/09/1995 (oral and poster)
117. Vanhaecke T., Geerts A., Callaerts A., Vercruyse A. and Rogiers V. "The hormonal regulation of flavin-containing monooxygenase and glutathione S-transferase", HUG 1995 (Hepatocyte User Group), Glasgow, Scotland, 10-11/09/1995 (oral)
118. Vanhaecke T. Geerts A., Callaerts A., Roba J., Vercruyse A. and Rogiers V. "Toxic effects of milacemide in a combined *in vivo/in vitro* rat model", HUG 1995 (Hepatocyte User Group), Glasgow, Scotland, 10-11/09/1995 (poster)
119. De Paepe K., Vandenbussche K., Derde M.P., Roseeuw D. and Rogiers V. "Effects of ceramides/cholesterol/FFA-containing body lotions on the TEWL of aged and SLS-damaged skin", 4th Congress of the European Academy of Dermatology and Venereology, 10-15/10/1995, Brussels, Belgium (oral)
120. De Paepe K., Rogiers V., Roseeuw D. "Hydratatie en barrièrefunctie van de huid: noodzaak tot standaardisatie", Workshop Nascholingscursus van de Stichting Nederlandstalige Nascholing voor Dermatologie en Venereologie, Brugge, Belgium, 26-28/10/1995 (oral)
121. De Paepe K., Vandenbussche K., Derde M.P., Roseeuw D. and Rogiers V. "Effects of ceramides/cholesterol/FFA-containing body lotions on the TEWL of aged and SLS-damaged skin", Congress of the Medical Women's Association of Belgium (MWABe) on "Women are in medicine to stay", Brussels, Belgium, 11/11/1995 (poster)
122. De Paepe K., Roseeuw D. and Rogiers V. "Analysis of the epidermal lipids of healthy human skin: use of the thin-layer chromatography scanner 3 from CAMAG", Studiedag HPTCL - Texturometrie Studiedag in Cosmetologie (Workshops), Mettler-Toledo, Dworp, Belgium, 06/11/1995 (oral)
123. Beken S. and Rogiers V. "Three-dimensional cultures of hepatocytes as suitable *in vitro* models for metabolism studies of cosmetic ingredients", Colipa (The European Cosmetic Toiletry and Perfumery Association) Symposium on Alternatives to Animal Testing, Brussels, Belgium, 29-30/11/1995 (poster)
124. De Paepe K., Roseeuw D. and Rogiers V. "Effecten van TEWL van body lotions met ceramiden, cholesterol en vrije vetzuren", 12th BADECOS Symposium on "Ceramides and Dermato-Cosmetics. Pregnancy and Dermato-Cosmetics", VUB Brussels, Belgium, 21/12/1995 (oral)
125. De Paepe K., Vandamme P., Roseeuw D. and Rogiers V. "Ceramides/cholesterol/free fatty acids containing cosmetics: the effect on barrier functions", International Cosmetics Congress on "Physiological Active Ingredients", Milan, Italy, 28/02-01/03/1996 (oral)
126. Tytgat T., Depreter M., Nardacci R., Espeel M., Beken S. and Roels F. "The expression of peroxisomes in rat liver and in cultured hepatocytes", Annual Immunocytochemistry Meeting, 1996 (poster)

127. De Bleser P.J., Xu G., Niki T., Rogiers V. and Geerts "Localization and cellular sources of activins in normal and fibrotic rat liver", VIIth Belgian Week of Gastroenterology, Belgium, 29/02-02/03/1996 (oral)
128. Vanhaecke T., Vercruysse A. and Rogiers V. "The effect of pyruvate and triiodothyronine on glutathione S-transferase in primary cultures of rat hepatocytes", 6de Forum der Farmaceutische Wetenschappen, Blankenberge, Belgium, 03-04/05/1996 (oral)
129. Beken S., Pahernik S., Koebe H.G., Vercruysse A. and V. Rogiers V. "Three-dimensional culture of hepatocytes: an opportunity for progress in the development of *in vitro* biotransformation models", INVITOX 1996, 9th International Workshop on *In Vitro* Toxicology, Utrecht, The Netherlands, 24-28/06/1996 (oral)
130. Vanhaecke T., Vercruysse A. and Rogiers V. "The effect of pyruvate and triiodothyronine on glutathione S-transferase expression in primary cultures of rat hepatocytes", INVITOX 1996, 9th International Workshop on *In Vitro* Toxicology, Utrecht, The Netherlands, 24-28/06/1996 (poster)
131. De Smet K., Vercruysse A. and Rogiers V. "Ethoxycoumarin O-deethylase activity in collagen gel sandwich and immobilisation cultures of rat hepatocytes", INVITOX 1996, 9th International Workshop on *In Vitro* Toxicology, Utrecht, The Netherlands, 24-28/06/1996 (poster)
132. Depreter M., Nardacci R., Tytgat T., Espeel M., Beken S., Stefanini S. and Roels F. "Regulation of peroxisome expression in embryonic rat liver and in cultured rat hepatocytes", Xth International of Histochemistry and Cytochemistry, Kyoto, Japan, 18-23/08/1996 (poster)
133. Beken S., Pahernik S., Callaerts A., Foriers A., Koebe H.G., Vercruysse A. and Rogiers V. "Cell morphology, albumin secretion and glutathione S-transferase expression in collagen gel sandwich and immobilisation cultures of rat hepatocytes", HUG 1996 (Hepatocyte Users Group), Surrey, UK, 30-31/08/1996 (poster)
134. Vanhaecke T., Vercruysse A. and Rogiers V. "The effect of pyruvate and triiodothyronine on glutathione S-transferase in primary cultures of rat hepatocytes", HUG 1996 (Hepatocyte Users Group), Surrey, UK, 30-31/08/1996 (poster)
135. De Smet K., Vercruysse A. and Rogiers V. "Phenobarbital-mediated induction of 7-ethoxycoumarin-O-dethylase activity in three-dimensional cultures of rat hepatocytes" HUG 1996 (Hepatocyte Users Group), Surrey, UK, 30-31/08/1996 (poster)
136. Tytgat T., Depreter M., Beken S., Espeel M. and Roels F. "Extracellular matrix and regulation of liver peroxisome expression", Joint Meeting of the Belgian Society for Cell Biology and NFWO Research Community on Cell-Matrix Interactions, Ghent, Belgium, 07-08/09/1996 (poster)
137. Rogiers V., Beken S. and Vercruysse A. "Effect of the extracellular matrix protein collagen I on glutathione S-transferase expression of adult rat hepatocytes in primary cultures", International Congress on "Hepatocytes - Application in Cell Biology, Toxicology and Medicine", Tübingen, Germany, 25-28/09/1996 (oral)

138. Rogiers V., Linday S., Beken S., De Smet K., Pauwels M., Vanhaecke T. and Shephard E.A. "Induction of human cytochromes P450 by sodium valproate in cultured human hepatocytes", International Congress on "Hepatocytes - Application in Cell Biology, Toxicology and Medicine", Tübingen, Germany, 25-28/09/1996 (poster)
139. Vanhaecke T., Vercruyssen A. and Rogiers V. "Glutathione S-transferase expression in primary cultures of rat hepatocytes supplemented with pyruvate and triiodothyronine", International Congress on "Hepatocytes - Application in Cell Biology, Toxicology and Medicine", Tübingen, Germany, 25-28/09/1996 (poster)
140. De Smet K., Callaerts A., Vercruyssen A. and Rogiers V. "Induction of ethoxycoumarin-O-deethylase and epoxide hydrolase activity by phenobarbital in collagen I extracellular matrix models of rat hepatocytes", International Congress on "Hepatocytes - Application in Cell Biology, Toxicology and Medicine", Tübingen, Germany, 25-28/09/1996 (poster)
141. Rogiers V., Linday S., Beken S., De Smet K., Pauwels M., Vanhaecke T. and Shephard E.A. "Sodium-valproate mediated induction of human cytochromes P450 in cultured human hepatocytes", 2nd World Congress on Alternatives and Animal Use in the Life Sciences, Utrecht, The Netherlands, 20-24/10/1996 (lecture)
142. Beken S., Pahernik S., De Pauw G., Foriers A., Koebe H.G., Vercruyssen A. and Rogiers V. "Cell morphology, albumin secretion and glutathione S-transferase expression in collagen gel sandwich and immobilisation cultures of rat hepatocytes", 2nd World Congress on Alternatives and Animal Use in the Life Sciences, Utrecht, The Netherlands, 20-24/10/1996 (oral)
143. Vanhaecke T., Vercruyssen A. and Rogiers V. "The use of pyruvate supplemented monolayer cultures of hepatocytes to study the effect of triiodothyronine on glutathione S-transferase expression in rat liver", 2nd World Congress on Alternatives and Animal Use in the Life Sciences, Utrecht, The Netherlands, 20-24/10/1996 (poster)
144. De Smet K., Callaerts A., Vercruyssen A. and Rogiers V. "Induction of ethoxycoumarin-O-deethylase and epoxide hydrolase activities by phenobarbital in collagen I extracellular matrix models of rat hepatocytes", 2nd World Congress on Alternatives and Animal Use in the Life Sciences, Utrecht, The Netherlands, 20-24/10/1996 (poster)
145. Moens K., Van Schravendijk C., Foriers A., Pipeleers D., Rogiers V., Flamez D. and Schuit F. "Glucagon and GLP-1 receptors on β -cells and hepatocytes", EASD (European Associated Society of Diabetes) Congress, Wenen, Austria, 01-05/11/1996 (poster)
146. De Paepe K., Vandamme P., Derde M.P., Roseeuw D. and Rogiers V. "Ceramides/cholesterol/free fatty acids containing body lotions: effect on TEWL of aged and SLS-damaged skin", International Conference featuring active ingredients for the care of healthy and damaged skin: modern active materials, Paris, France, 13-14/11/1996 (lecture)
147. Rogiers V., Beken S., De Smet K. and Vercruyssen A. "Co-cultures and collagen sandwich cultures of hepatocytes for the investigation of drug metabolism and hepatotoxicity *in vitro*", BTS (British Toxicology Society) Annual Congress on "Human and Experimental Toxicology", Warwick, UK, 24-26/03/1997 (oral)

148. De Paepe K. and Rogiers V. "Ethisch-wetenschappelijke en praktische aspecten van het galenisch dermatologisch voorschrift", 15de BADECOS Symposium, Brussels, Belgium, 19/04/1997 (lecture)
149. De Smet K., Callaerts A., Vercruysse A. and Rogiers V. "Effect of phenobarbital on 7-ethoxycoumarin-O-deethylase and microsomal epoxide hydrase in collagen gel cultures of rat hepatocytes", 7de Forum der Farmaceutische Wetenschappen, Blankenberge, België, 24-25/04/1997 (lecture)
150. De Paepe K., Taelman M.C., Roseeuw D. and Rogiers V. "Ceramides in dermatocosmetic products", In-Cosmetics 1997 (Evaluation of Cosmetic Formulation; Experimental and Dermatological Approaches, part II), Düsseldorf, Germany, 05-07/05/1997 (lecture)
151. De Paepe K., Taelman M.C., Vandamme P., Derde M.P., Roseeuw D. and Rogiers V. "Ceramides in dermatocosmetic products: effects on the TEWL of aged skin and SLS-induced scaly skin", Gordon Research Conference on Barrier Function of Mammalian Skin, Tilton, NH, USA, 10-15/08/1997 (poster)
152. Beken S., Slaus K., Vercruysse A. and Rogiers V. "Effect of the extracellular matrix composition on the expression of glutathione S-transferase isoenzymes in organotypical hepatocyte cultures", HUG 1997 (Hepatocytes Users Group), Brussels, Belgium, 12-13/09/1997 (poster)
153. De Smet K., Callaerts A., Vercruysse A. and Rogiers V. "Induction of phase I drug metabolism enzymes in collagen gel cultures of rat hepatocytes", HUG 1997 (Hepatocytes Users Group), Brussels, Belgium, 12-13/09/1997 (oral and poster).
154. Depreter M., Beken S., Tytgat T., Hallez F., Espeel M., Rogiers V. and Roels F. "Hepatocytes polarity to differentiation", HUG 1997 (Hepatocytes Users Group), Brussels, Belgium, 12-13/09/1997 (poster)
155. Rogiers V., Beken S., Domingo R.R., De Pauw G. and Vercruysse A. "Regulation of glutathione S-transferase isoenzymes in collagen gel sandwich and immobilisation cultures of rat hepatocytes", International Workshop on Glutathione Transferases, Rome, Italy, 07-10/11/1997 (poster)
156. Vanhaecke T., Derde M.P., Vercruysse A. and Rogiers V. "Regulation of glutathione S-transferase expression in co-cultured rat hepatocytes by thyroid hormones, administered via hydroxypropyl- β -cyclodextrin", International Workshop on Glutathione Transferases, Rome, Italy, 07-10/11/1997 (poster)
157. Barel A.O., De Paepe K. and Rogiers V. "Demonstration of non-invasive efficacy measurements of the efficiency of skin care products: hydration and barrier function of the skin", Workshop Intensive Course in Dermato-Cosmetic Sciences, Brussels, Belgium, 11/10/1997 (lecture)
158. Beken S., Slaus K., Vercruysse A. and Rogiers V. "Effect of the extracellular matrix composition on the expression of glutathione S-transferase isoenzymes in organotypical hepatocyte cultures", 16th European Workshop on Drug Metabolism, Copenhagen, Denmark, 21-26/06/1998 (poster)
159. De Smet K., Callaerts A., Vercruysse A. and Rogiers V. "Effect of EGF on pentoxyresorufin O-depentylase and ethoxyresorufin O-deethylase activities and DNA synthesis in collagen gel cultures of hepatocytes", 16th European Workshop on Drug Metabolism, Copenhagen, Denmark, 21-26/06/1998 (poster)

160. Vanhaecke T., Derde M.P., Vercruyssen A. and Rogiers V. "Hydroxypropyl- β -cyclodextrin as delivery system for thyroid hormones, regulating glutathione S-transferase expression in rat hepatocyte co-cultures", INVITOX '98, 10th International Workshop on *In Vitro* Toxicology, Sparsholt, Winchester, UK, 14-18/09/1998 (poster)
161. Beken S., Domingo R.R., De Pauw G., Vercruyssen A. and Rogiers V. "Regulation of glutathione S-transferase isoenzymes in collagen gel cultures of rat hepatocytes", INVITOX '98, 10th International Workshop on *In Vitro* Toxicology, Sparsholt, Winchester, UK, 14-18/09/1998 (poster)
162. Beken S. and Rogiers V. "The Belgian Platform for Alternative Methods (BPAM)", INVITOX '98, 10th International Workshop on *In Vitro* Toxicology, Sparsholt, Winchester, UK, 14-18/09/1998 (poster)
163. De Smet K., Callaerts A., Vercruyssen A. and Rogiers V. "Effect of EGF on pentoxyresorufin O-depentylase and ethoxyresorufin O-deethylase activities and DNA synthesis in collagen gel cultures of hepatocytes", INVITOX '98, 10th International Workshop on *In Vitro* Toxicology, Sparsholt, Winchester, UK, 14-18/09/1998 (poster)
164. De Paepe K., Derde M.P., Roseeuw D. and Rogiers V. "The effect of topically applied ceramide containing lotions on the barrier function of the skin", Perspectives in Percutaneous Penetration (PPP), Leiden, The Netherlands, 22-26/09/1998 (poster)
165. De Paepe K., Roseeuw D. and Rogiers V. "Ceramides in dermato-cosmetic preparations", 25th Congress of Aesthetic Medicine and Surgical Dermatology, Paris, France, 28-30/09/1998 (lecture)
166. De Paepe K., Derde M.P., Roseeuw D. and Rogiers V. "Effect of ceramide containing lotions on the barrier function of the skin", 7th Congress of the EADV (European Academy of Dermatology and Venereology), Nice, France, 07-11/10/1998 (lecture)
167. De Paepe K., Roseeuw D. and Rogiers V. "Effect of ceramide containing lotions on the barrier function of the skin", International Conference featuring Active Ingredients for the Care of Healthy and Damaged Skin, Paris, France, 17-18/11/1998, Paris, France (lecture)
168. De Raeve L., De Paepe K., Roseeuw D. and Rogiers V. "Effects of rice starch as a bath additive on skin barrier function", Clinical Dermatology Congress, Singapore, 18-20/06/1998 (poster)
169. Spatzenegger M., Van Obbergh L., Rogiers V. and Verbeeck R.K. "Comparison of hexafluoroisopropranol and fluoride formation kinetics by human liver microsomes", 12th International Symposium on Microsomes and Drug Oxidation, Montpellier, France, 1988 (poster)
170. Rogiers V. "Ceramides containing dermato-cosmetic emulsions and barrier function. Recovery of damaged skin", 1st World Congress of the International Academy of Cosmetic Dermatology, Roma, Italy, 28-31/01/1999 (lecture)
171. Depreter M., Walker T., Raes S., De Smet K., Espeel M., Rogiers V. and Roels F. "Hepatocyte polarity and peroxisome differentiation in three culture types and during development", Spring Meeting of the Belgische Vereniging voor Celbiologie (BVCB), Gent, Belgium, 6/03/1999 (poster)

172. Beken S. and Rogiers V. "The Belgian Platform for Alternative Methods (BPAM)", 2nd Colipa Symposium on Alternatives to Animal Testing, Section 3: Cosmetic Product Safety Assessment - The Role of Alternative Methods, Brussels, Belgium, 24-25/03/1999 (poster)
173. De Paepe K., Vandamme P., Hachen J.P., Derde M.P., Roseeuw D. and Rogiers V. "Effects of rice starch as a bath additive on the barrier function of SLS-damaged skin and skin of atopic patients", Gordon Research Conference on Barrier Function of Mammalian Skin, Il Ciocco, Barga, Italy, 18-23/4/1999 (poster)
174. Rogiers V. "Localisation of Ecto-ATPases and 5Nases as a tool to assess hepatocyte polarity", 2nd International Workshop on Ecto-ATPass and related ectonucleotidass, Diepenbeek, Belgium, 14-18/06/1999 (oral)
175. Beken S., Domingo R., De Pauw G., Vercruysse A. and Rogiers V. "Suitability of collagen gel sandwich cultures of rat hepatocytes for long-term induction studies", 3rd World Congress on Alternatives in Animal Use in the Life Sciences, Bologna, Italy, 29/08-2/09/1999 (poster)
176. Vanhaecke T., Lindros K.O., Oinonen T., Coecke S., Debast G., Phillips I.R., Shephard E.A., Vercruysse A. and Rogiers V. "Effect of ethanol on the expression of hepatic glutathione S-transferase: an *in vivo/in vitro* study", 3rd World Congress on Alternatives in Animal Use in the Life Sciences, Bologna, Italy, 29/08-2/09/1999 (poster)
177. De Smet K., Loyer P., Guguen-Guillouzo C., Vercruysse A. and Rogiers V. "Effect of EGF on CYP and cell cycle factor expression in collagen gel sandwich cultures of rat hepatocytes", 3rd World Congress on Alternatives in Animal Use in the Life Sciences, Bologna, Italy, 29/08-2/09/1999 (poster)
178. Slaus K., Coughtrie M., Sharp S., Vercruysse A. and Rogiers V. "Sulfotransferase and sulfatase expression in different culture models of male rat hepatocytes", 3rd World Congress on Alternatives in Animal Use in the Life Sciences, Bologna, Italy, 29/08-2/09/1999 (poster)
179. Asiru O. O., Vanhaecke T., Vercruysse A. and Rogiers V. "Long term-culture of rat hepatocytes and prevention of oxidative stress by addition of high concentrations of pyruvate to the culture medium", 3rd World Congress on Alternatives in Animal Use in the Life Sciences, Bologna, Italy, 29/08-02/09/1999 (poster)
180. Hachem J.P., De Paepe K., Vanpée E., Kaufman L., Rogiers V. and Roseeuw D. "Contact allergy patch (CAP) test combined with TEWL measurements, a suitable experimental model for human skin barrier function assessment", Joint Meeting of the 12th International Contact Dermatitis Symposium and the 1st International Symposium on the Prevention of Occupational Skin Disease in Hairdressers (ISPOSH), San Francisco, Ca, USA, 14-18/10/1999 (lecture)
181. Depreter M., Walker T., De Smet K., Beken S., Rogiers V. and Roels F. "Variable peroxisome expression in different types of primary hepatocyte cultures", 39th Annual Meeting the the American Society for Cell Biology, Washington, DC, USA, 11-15/12/1999 (poster)
182. Beken S., Domingo R., De Pauw G., Vercruysse A. and Rogiers V. "Suitability of collagen gel sandwich cultures of rat hepatocytes for long-term induction studies", Spring Meeting of the Belgian Society for Cell Biology on "Cellular Transdifferentiation, Medical Campus VUB, Brussels, Belgium, 18/03/2000 (poster)

183. De Smet K., Loyer P., Gilot D., Papeleu P., Guguen-Guillouzo C., Vercruyssen A. and Rogiers V. "Effects of epidermal growth factor on CYP inducibility, DNA replication and caspase activation in collagen type I gel sandwich cultures of adult rat hepatocytes", Spring Meeting of the Belgian Society for Cell Biology on "Cellular Transdifferentiation, Medical Campus VUB, Brussels, Belgium, 18/03/2000 (poster)
184. De Paepe K., Lagarde J.M., Gall Y., Vanhecke I., Roseeuw D. and Rogiers V. "Study of the human skin microrelief by a standardised light transmission method", 13th International Congress of the International Society of Bio-Engineering and Skin, Jerusalem, Israel, 26-31/03/2000 (oral)
185. Janssens K., De Paepe K., Roseeuw D. and Rogiers V. "Lack of correlation between stratum corneum hydration and scaling pattern: evaluated by corneometry and squamometry", 13th International Congress of the International Society of Bio-Engineering and Skin, Jerusalem, Israel, 26-31/03/2000 (poster)
186. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. "Combined therapy improves the recovery of the human skin barrier function: an experimental model using contact allergy patch test combined with TEWL measurements", 13th International Congress of the International Society of Bio-Engineering and Skin, Jerusalem, Israel, 26-31/03/2000 (oral)
187. De Smet K., Loyer P., Gilot D., Papeleu P., Guguen-Guillouzo C., Vercruyssen A. and Rogiers V. "Effects of EGF on CYP inducibility, DNA replication and caspase activation in collagen type I sandwich cultures of adult rat hepatocytes", 9de Forum der Farmaceutische Wetenschappen, Belgisch Genootschap voor Farmaceutische Wetenschappen, Blankenberge, Belgium, 06-07/04/2000 (oral)
188. Janssens K., De Paepe K., Roseeuw D. and Rogiers V. "Squamometry: a screening method for the evaluation of hydrating products", 9de Forum der Farmaceutische Wetenschappen, Belgisch Genootschap voor Farmaceutische Wetenschappen, Blankenberge, Belgium, 06-07/04/2000 (oral)
189. Elaut G., Vanhaecke T., Vercruyssen A. and Rogiers V. "Influence of oxygen concentration on specific zoned hepatocyte functions in primary cultures of periportal and perivenous rat hepatocytes", 9de Forum der Farmaceutische Wetenschappen, Belgisch Genootschap voor Farmaceutische Wetenschappen, Blankenberge, Belgium, 06-07/04/2000 (oral)
190. De Paepe K., Hachem J.P., Janssens K., Vanpee E., Roseeuw D. and Rogiers V. "The effect of a moisturising body lotion in the treatment and prevention of irritant and allergic contact dermatitis", Perspectives in Percutaneous Penetration (PPP), La Grande Motte, Languedoc, France, 25-29/04/2000 (poster)
191. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "The importance of cosmetic products in inflammatory skin pathologies", International Academy of Cosmetic Dermatology, on "Dermatology in the third millennium", Rome, Italy, 27-30/04/2000 (oral)
192. Depreter M., Walker T., De Smet K., Beken S., De Prest B., Kerckaert I., Rogiers V. and Roels F. "Are hepatocyte polarity and peroxisome expression related?", 35th Meeting of the EASL, Rotterdam, The Netherlands, 29/04-03/05/2000 (abstract)
193. Beken S., Elaut G., Domingo R., De Pauw G., Vercruyssen A. and Rogiers V. "Suitability of collagen gel sandwich cultures of rat hepatocytes for long-term

- induction studies", DMW/ISSX (International Society for the Study of Xenobiotics) Meeting 2000, St. Andrews, Fife, Scotland, 11-16/06/2000 (poster)
194. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "New insights in the treatment of skin inflammatory diseases", Regional Meeting of the International Society of Dermatology, on "Continuing medical education in dermatology & future trends in Mediterranean dermatology", Sorrento, Italy, 03-08/07/2000 (oral)
 195. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "Cosmetics in inflammatory dermatology", Cosmoderm 2000, European Society for Cosmetic & Aesthetic Dermatology (ESCAD), Mandelieu, Cannes, France, 06-09/07/2000 (oral)
 196. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. "Prevention of skin barrier damage in allergic contact dermatitis: An experimental model using contact allergy patch tests combined with TEWL measurements", 30th ESDR Annual Meeting, Berlin, Germany, 21-23/09/2000 (poster)
 197. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. "Prévention de l'altération de la barrière cutanée induite par un eczéma de contact allergique", Journées Dermatologiques de Paris 2000, Paris, France, 10/2000 (oral)
 198. Hachem J.P., De Paepe K., Vanpee E., Kaufman L., Rogiers V. and Roseeuw D. "Mesure de l'efficacité des corticoïdes locaux sur la barrière cutanée suite à l'induction d'un eczéma de contact allergique au nickel", Journées Dermatologiques de Paris 2000, Paris, France, Oct. 2000 (poster)
 199. Rogiers V., Elaut G. and Vanhaecke T. "Effect of oxygen concentration on the expression of GST in periportal and perivenous rat hepatocyte cultures", INVITOX 2000, 11th International Workshop on *In Vitro* Toxicology, Alicante, Spain, 25-28/10/2000 (poster)
 200. Vanhaecke T., Lindros K.O., Oinonen T., Vercruyse A. and Rogiers V. "Triiodothyronine downregulates the periportal expression of alpha class glutathione S-transferase in rat liver", INVITOX 2000, 11th International Workshop on *In Vitro* Toxicology, Alicante, Spain, 25-28/10/2000 (oral and poster)
 201. Vanhaecke T., Lindros K. O., Oinonen T., Vercruyse A. and Rogiers V. "Effect of oxygen concentration on the expression of glutathione S-transferase activity in periportal and perivenous rat hepatocytes in pyruvate-supplemented cultures", INVITOX 2000, 11th International Workshop on *In Vitro* Toxicology, Alicante, Spain, 25-28/10/2000 (poster)
 202. De Smet K., Loyer P., Gilot D., Papeleu P., Guguen-Guillouzo C., Vercruyse A. and Rogiers V. "Effect of epidermal growth factor on CYP inducibility, DNA replication and caspase activations in collagen type I gel sandwich cultures of adult rat hepatocytes", INVITOX 2000, 11th International Workshop on *In Vitro* Toxicology, Alicante, Spain, 25-28/10/2000 (poster)
 203. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "The efficacy of topical skin treatments in preventing and restoring skin barrier damage due to allergic contact dermatitis", 2nd World Congress of the International Academy of Cosmetic Dermatology, Rio de Janeiro, Brazil, 09-11/11/2000 (oral)

204. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "The epidermal barrier function in skin inflammatory diseases: clinical implications", Koninklijke Belgische Vereniging voor Dermatologie, Roche Brussels, Belgium, 18/01/2001 (oral)
205. Hachem J.P., De Paepe K., Vanpee E., Rogiers V. and Roseeuw D. "The role of corneotherapy in the treatment of allergic contact dermatitis", 62th Annual Meeting of the Society of Investigative Dermatology, Washington, USA, 08-12/05/2001 (poster)
206. De Paepe K., Hachem J.P., Vanpee E., Roseeuw D. and Rogiers V. "Barrier properties of a skin tolerance-tested moisturising cream", Gordon Research Conference on "Barrier function of mammalian skin", Bristol, RI, USA, 05-10/08/2001 (poster)
207. De Paepe K., Hachem J.P., Vanpee E., Roseeuw D. and Rogiers V. "Irritant and allergic contact dermatitis: beneficial corneotherapeutic effects of skin-tolerance tested moisturising cream", Stratum Corneum III, Basel, Switzerland, 12-14/08/2001 (poster)
208. Hachem J.P., De Paepe K., Rogiers V. and Roseeuw D. "Prevention of skin barrier damage in allergic contact dermatitis", 10th Congress of the European Association of Dermatology and Venereology (EADV) (Sub4: European Society for Cosmetic and Aesthetic Dermatology (ESCAD) and Arbeitsgemeinschaft für Aesthetische Dermatology und Kosmetologie), Munich, Germany, 10-14/10/2001 (oral)
209. Hachem J.P., De Paepe K., Rogiers V. and Roseeuw D. "Corneotherapeutic agents in the treatment of skin pathology", 10th Congress of the European Association of Dermatology and Venereology (EADV), Munich, Germany, 10-14/10/2001 (poster)
210. De Raeve L., De Paepe K., Rogiers V. and Roseeuw D. "Effects of rice starch as a bath additive on skin barrier function", 10 th Congress of the European Association of Dermatology and Venereology (Symposium of the European Task force on Atopic Dermatitis (ETFAD-1)), Munich, Germany, 10-14/10/2001 (oral)
211. Vanhaecke T., Kass G. and Rogiers V. "Apoptosis and necrosis in conventional monolayer and collagen gel sandwich cultures of rat hepatocytes", Université de Luxembourg, Signal Transduction 2002 "Cell signaling, transcription and translation as therapeutic targets", European Conference, Centre Kirchberg, Luxemburg, 30/01-02/02/2002 (poster)
212. Papeleu P., Loyer P., Elaut G., Guguen-Guillouzo C. and Rogiers V. "Mechanisms involved in Trichostatin A-mediated growth arrest in adult rat hepatocytes", Université de Luxembourg, Signal Transduction 2002 "Cell signaling, transcription and translation as therapeutic targets", European Conference, Centre Kirchberg, Luxemburg, 30/01-02/02/2002 (poster)
213. Elaut G., Török G., Vinken M., Papeleu P., Laus G., Tourwé D. and Rogiers V. "Phase I biotransformation of Trichostatin A, a histone deacetylase inhibitor, in human and rat liver microsomes and in suspensions of freshly isolated rat hepatocytes", Université de Luxembourg, Signal Transduction 2002 "Cell signaling, transcription and translation as therapeutic targets", European Conference, Centre Kirchberg, Luxemburg, 30/01-02/02/2002 (poster)

214. De Paepe K., Houben E., Hachem J.P., Roseeuw D. and Rogiers V. "The effect of topically applied lignoceric acid and behenic acid on the barrier recovery of experimentally-elicited irritated skin", 8th International Conference on "Perspectives in Percutaneous Penetration (PPP) 2002, Antibes, Juan-les-Pins, France, 02-06/04/2002 (poster)
215. De Paepe K., Hachem J. P., Houben E., Roseeuw D. and Rogiers V. "Corneotherapeutic effects of a moisturising cream in contact dermatitis", Section: New Therapies in Contact Dermatitis, 6th Congress of the European Society of Contact Dermatitis, Rome, Italy, 14-16/06/2002 (oral)
216. Depreter M., Walker T., Beken S., De Smet K., Papeleu P., Tytgat T., Espeel M., Rogiers V. and Roels D. "Modified peroxisomes in primary hepatocyte cultures" Internation Symposium of the Belgian Society for Cell and Developmental Biology (SBBCD-BVCOB) on "Peroxisomal disorders and regulation of genes", Ghent University, Ghent, Belgium, 25-28/09/2002 (oral)
217. Vanhaecke T., Kass G., Papeleu P., Elaut G., Vinken M., Henkens T., Snykers S., Guguen-Guillouzo C. and Rogiers V. "Signalling pathways involved in Trichostatin A-mediated inhibition of mitogenesis in cultured adult rat hepatocytes", INVITOX 2002, 12th International Workshop on *In Vitro* toxicology, Formia, Italy, 16-19/10/2002 (oral and poster)
218. Elaut G., Török G., Vinken M., Papeleu P., Vanhaecke T., Laus G., Tourwé D. and Rogiers V. "Phase I biotransformation of Trichostatin A, a histone deacetylase inhibitor, in human and rat liver microsomes and in suspensions of freshly isolated rat hepatocytes", INVITOX 2002, 12th International Workshop on *In Vitro* toxicology, Formia, Italy, 16-19/10/2002 (oral and poster)
219. Vanhaecke T., Kass G., Papeleu P., Elaut G., Vinken M., Henkens T., Snykers S., Guguen-Guillouzo C. and Rogiers V. "Trichostatin A inhibits the expression of early G1 and G1/S transition regulation proteins in primary cultures of mitogen-stimulated rat hepatocytes", INVITOX 2002, 12th International Workshop on *In Vitro* toxicology, Formia, Italy, 16-19/10/2002 (oral and poster)
220. Henkens T., Snykers S. and Rogiers V. "Effect of Trichostatin A on spontaneous apoptosis in organotypic adult rat hepatocyte cultures", BELTOX 2002, Annual Meeting on "Current Trends in Chemical Risk Assessment", Nationaal Congres, Brussels, Belgium, 29/11/2002 (poster)
221. Vanhaecke T., Kass G., Papeleu P., Elaut G., Henkens T., Snykers S. and Rogiers V. "Effect of Trichostatin A on spontaneous apoptosis in organotypic adult rat hepatocyte cultures", Congres "Apoptosis: from signaling pathways to therapeutic tools", European Conference Center Kirchberg, Luxemburg, 29/01-01/02/2003 (poster).
222. Vanhaecke T., Kass G., Papeleu P., Elaut G., Vinken M., Henkens T., Snykers S. and Rogiers V. "Effect of Trichostatin A on spontaneous apoptosis in organotypic adult rat hepatocyte cultures", HUG (Hepatocyte Users Group) Meeting 2003: Differentiated State of Primary Cultures, Aberdeen, UK, 28-29/03/2003 (oral)

223. De Paepe K., Hachem J.P., Houben E., Lagarde J.M., Gall Y., Roseeuw D. and Rogiers V. "Skin microrelief topography measurements of ageing skin using a light transmission method", Section: Imaging and measurement in normal skin, skin disease, cosmetic dermatology and skin pharmacology, of the 1st Joint Meeting of the 14th International Congress for Bioengineering and the Skin, and the 8th Congress of the International Society for Skin Imaging, CCH Convention Center, Hamburg, Germany, 21-24/05/2003 (poster)
224. De Paepe K., Houben E., Hachem J.P., Roseeuw D. and Rogiers V. "Skin barrier damage caused by rhinorrhea: clinical scoring and biophysical evaluation of the nasolabial skin", 8th Gordon Research Conference on Barrier Function of Mammalian Skin, Bristol, Rhode Island, NJ, USA, 02-08/08/2003 (poster)
225. Houben E., De Paepe K. and Rogiers V. "Biophysical measurements to evaluate changes in skin condition associated with intensive use of alcoholic gels for hand disinfection", 8th Gordon Research Conference on Barrier Function of Mammalian Skin, Bristol, Rhode Island, NJ, USA, 02-08/08/2003 (poster)
226. Elaut G., Laus G., Papeleu P., Breckx V., Van Hemel J., Erra M., Brosch G., Snykers S., Vinken M., Henkens T., Vanhaecke T., Tourwé D. and Rogiers V. "Benzamide-containing hydroxamates are potent and metabolically stable inhibitors of HDAC with selective toxicity towards tumor cells", EUROTOX 2003, The 41st Congress of the European Societies of Toxicology, Florence, Italy, 28/09-01/10/2003 (poster)
227. Snykers S., Vanhaecke T., Papeleu P., Elaut G., Van Riet I. and Rogiers V. "In vitro pluripotency of human marrow mesenchymal stem cells", EUROTOX 2003: Science for Safety, The 41st Congress of the European Societies of Toxicology, Florence, Italy, 28/09-01/10/2003 (poster)
228. Elaut G., Laus G., Papeleu P., Breckx V., Van Hemel J., Erra M., Brosch G., Snykers S., Vinken M., Henkens T., Vanhaecke T., Tourwé D. and Rogiers V. "Benzamide-containing hydroxamates are potent and metabolically stable inhibitors of HDAC with selective toxicity towards tumor cells", Congress on "Structure-Based Drug Design", Louvain-la-Neuve, Belgium, 18/11/2003 (poster)
229. De Paepe K., Pauwels M. and Rogiers V. "Kwaliteitsvolle preparaten in het licht van de recente evoluties in de magistrale receptuur", iPAVUB Postacademische Vorming, Brussel, Belgium, 15/03/2004 (oral)
230. Houben E., Uchida Y., De Paepe K., Elias P., Holleran W. and Rogiers V. "Acid ceramidase in human keratinocytes and epidermis: enzyme characteristics and altered activity and expression with differentiation", 9th International Congress on Perspectives in Percutaneous Penetration, La Grande Motte, France, 13-18/04/2004 (poster)
231. Uchida Y., Houben E., Rogiers V., Elias P. and Holleran W. "Ceramide hydrolysis is an important protective mechanism against ceramide-induced apoptosis in UV-B irradiated keratinocytes", Society for Investigative Dermatology 2004, Providence, Rhode Island, USA, 28/04-01/05/2004 (poster)
232. Uchida Y., Houben E., Rogiers V., Elias P.M., Holleran W.M. (2004) Ceramide hydrolysis is an important protective mechanism against ceramide-induced apoptosis in VUB irradiated keratinocytes. *Journal of Investigative Dermatology*, **122**(3) A72 (meeting abstract)

233. Houben E., Uchida Y., Yaginuma T., Mao C., Obeid L., Rogiers V., Elias P., Takagi Y. and Holleran W. "Altered expression of ceramidase isoforms with differentiation in human keratinocytes and epidermis", Society for Investigative Dermatology 2004, Providence, Rhode Island, USA, 28/04-01/05/2004 (poster)
234. De Paepe K., Houben E., Adam R., Wiesemann F. and Rogiers V. "Validation of the VapoMeter, a closed unventilated chamber system, versus the open chamber TewaMeter to assess transepidermal water loss", IVth Stratum Corneum Congress, Paris, France, 17-19/06/2004 (poster)
235. Houben E., Uchida Y., Yaginuma T., Mao C., Obeid L., Rogiers V., Elias P., Takagi Y. and Holleran W. "Expression of acid-, alkaline-, neutral- and phytoceramidase in human keratinocytes and epidermis", Gordon Research Conference 2004 on "Glycolipid and spingolipid biology", Hyogo, Japan, 25-30/07/2004 (poster)
236. De Paepe K., Houben E. and Rogiers V. "Applicability of the closed unventilated VapoMeter as a measuring tool to assess transepidermal water loss (TEWL) on nasolabial skin areas", 2004 US Symposium of the International Society for Bioengineering and the Skin", Orlando, FL, USA, 28-30/10/2004
237. Vanhaecke T., Papeleu P. and Rogiers V. "Use of chromatin remodelling as a new way to create differentiated primary hepatocyte cultures", eSI (ECOPA Science Initiative-Reaching the Young Scientist) Workshop, Pueblo Acantilado, Alicante, Spain, 28-30/10/2004 (oral)
238. Vanhaecke T., Papeleu P. and Rogiers V. "Effect of HDAC inhibition on proliferation- and apoptosis-related signalling in EGF-stimulated primary rat hepatocyte cultures", HUG 2004 (Hepatocyte Users Group) Meeting, Valencia, Spain, 12-13/11/2004 (oral)
239. Hachem J. P., Wagberg F., Schmuth M., Leonardsson G., Houben E., Jayakumar A., Clayman G.L., De Raeve L., Diabe R., Brattsand M., Egelrud T., Williams M., Feingold K.R. and Elias P.M. "Basis for the permeability barrier defect and abnormal stratum corneum integrity in Netherton's syndrome", Society for Investigative Dermatology, St. Louis, MI, USA, 04-07/05/2005 (oral and poster)
240. De Paepe K. and Rogiers V. "Corneofix F20, a new technology to define skin desquamation", In: Congress Proceedings of the 2005 World Congress on Non-Invasive Studies of the Skin, Philadelphia, p. 20, 2005 (oral)
241. Rogiers V. and Pauwels M. "Good science must be the key factor in the development and use of alternative methods for safety assessment of cosmetics". *ALTEX - Alternativen zu Tierexperimenten* **23**, 346-352. Workshop 5.14 Meeting the challenge of the 7th amendment to the EU cosmetics directive (Colipa Workshop), Proceedings of the 5th World Congress on Alternatives to Animal Experiment, Berlin, Germany, 21-25/08/2005 (oral)
242. Snykers S., Vanhaecke T., Papeleu P., Henkens T., Vinken M., Elaut G., Van Riet I. and Rogiers V. "*In vitro* multipotency of human bone marrow (mesenchymal) stem cells". *ALTEX - Alternativen zu Tierexperimenten* **23**, 441-444. Session 7.1 on Stem cell technology in toxicity testing, Proceedings of the 5th World Congress on Alternatives to Animal Experiment, Berlin, Germany, 21-25/08/2005 (oral)

243. Vanhaecke T., Vinken M., Henkens T., Snykers S., Elaut G., Papeleu P. and Rogiers V. (2006) "Effects of Trichostatin A on apoptosis-regulating proteins during hepatocyte isolation". *ALTEX - Alternativen zu Tierexperimenten* **23**, 441-444. Workshop 7.5 on Novel cell culture techniques, Proceedings of the 5th World Congress on Alternatives to Animal Experiment, Berlin, Germany, 21-25/08/2005 (oral)
244. Vinken M., Vanhaecke T., Papeleu P., Snykers S., Henkens T., Chipman J.K. and Rogiers V. (2006) "A study of connexin expression in monolayer cultures of primary rat hepatocytes". *ALTEX - Alternativen zu Tierexperimenten* **23**, 456-460. Session 7.6 on Non-genotoxic carcinogenicity: mechanistic perspectives for alternatives, Proceedings of the 5th World Congress on Alternatives to Animal Experiment, Berlin, Germany, 21-25/08/2005 (oral)
245. Snykers S., De Kock J., Vanhaecke T., Van Riet I. and Rogiers V. "Production of functional hepatocyte-like cells from postnatal progenitor cells". Ecopa Science Initiative (eSI) Meeting, Pueblo Acanilado (Alicante), Spain, 29-30/09/2006 (oral)
246. Henkens T., Papeleu P., Elaut G., Vinken M., Rogiers V. and Vanhaecke T. "Trichostatin A, a critical factor to maintain differentiation in primary cultures of rat hepatocytes". Session 3: New *in vitro* models and strategies. INVITOX 2006: 14th International workshop on In Vitro Toxicology, Ostend, 2-5/10/2006 (oral)
247. Snykers S., De Kock J., Vanhaecke T., Van Riet I. and Rogiers V. "Differentiation of postnatal progenitor cells into hepatocyte-like cells". Session 6: Stem cells *in vitro*, expectations and limitations. INVITOX 2006: 14th International workshop on In Vitro Toxicology, Ostend, 02-05/10/2006 (oral)
248. Castell J.V., Pfaller W., Rogiers V., Maurel P., Daha M., Ryan M., Ellinger-Ziegelbauer H., Wolf A., Simon L., Garcia L.F., Steeman M., Prieto P. and Garthoff G. "Predictomics: towards a feasible *in vitro* prediction of liver and kidney chronic toxicity elicited by drugs". Poster session on EU programmes. INVITOX 2006: 14th International workshop on *In Vitro* Toxicology, Ostend, 02-05/10/2006 (poster)
249. Houben E., Hachem J.P., De Paepe K., Uchida Y., Holleran W.M. and Rogiers V. "Epidermal ceramidase activity regulates desquamation through stratum corneum acidification". 2nd International Meeting of the International Society of Skin Pharmacology and Physiology (ISP) on "Skin Physiology: irritation and penetration pathways", Rome, Italy, 05-07/11/2006 (poster)
250. Deleu S., Tourwé D., Vanhaecke T., Rogiers V. and Vanderkerken K. "Screening of TSA-analogues in the 5T33vv multiple myeloma model". EHA (European Hematology Association) Scientific Workshop on the role of epigenetics in haematological malignancies, Mandelieu, France, 09-11/2/2007 (oral)
251. Vinken M., Henkens T., Vanhaecke T., Geerts A., Chipman JK., Meda P., Rogiers V. 'Les effets de la trichostatine A, un inhibiteur d'histone désacétylase, sur l'expression des connexines dans les cultures primaires d'hépatocytes du rat: resultants et perspectives". Journée exceptionnelle CONNEXINES, Paris, France, 25/05/2007 (oral).
252. De Kock J., Snykers S., Vanhaecke T., Rogiers V. "Differentiation of neonatal rat epithelial cells from biliary origin into immature hepatic cells by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development" Ghent, Belgium, 08/06/2007 (poster).

253. Vinken M., Henkens T., Vanhaecke T., Geerts A., Chipman JK, Meda P., Rogiers V. "Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes". Knowledge for Growth, Ghent, Belgium, 08/06/2007 (oral)
254. Chipman J.K., Vinken M., Edwards G., Vanhaecke T. and Rogiers V. "The role of connexin 32 in liver cell proliferation and differentiation". XIth International Congress of Toxicology (ICT), Montreal, Canada, 15-19/07/2007 (oral)
255. Devolder T., Gabrielson K., Garthoff B., Müller K., Pauwels M., Phillips B., Rogiers V., Spielmann H. and Webb S. "The impact of REACH upon animal use in the European Union"; Report of the *ecopa* CONAM Chemical Policy Working Group. World Congress on Alternatives and Animal Use in the Life Sciences, Tower Hall Funabory, Tokyo, Japan, 21-25/08/2007 (poster).
256. Devolder T., Reid K., Rogiers V., Webb S. and Wilkins D. "A Survey of National Research Expenditure on 3R Alternatives in Europe". World Congress on Alternatives and Animal Use in the Life Sciences, Tower Hall Funabory, Tokyo, Japan, 21-25/08/2007 (poster).
257. De Paepe K. and Rogiers V. "Comparative quantification of stratum corneum scaling and hydration state in young and aging skin". IFSCC (International Federation of Societies of Cosmetic Chemists) Conference, Amsterdam, 24-26/09/2007 (oral).
258. De Kock J., Snykers S., Vanhaecke T., Rogiers V. "Differentiation of neonatal rat epithelial cells from biliary origin into immature hepatic cells by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development" Dertiende Forum der Farmaceutische Wetenschappen (BGFW) Spa, Belgium, 11-12/10/2007 (oral).
259. Fraczek J., Deleu S., Vanhaecke T., Vanderkerken K., Rogiers V. "Growth inhibitory and differentiating properties of novel hydroxamate-based Histone Deacetylase Inhibitors in cultures of primary rat hepatocytes" Dertiende Forum der Farmaceutische Wetenschappen (BGFW) Spa, Belgium, 11-12/10/2007 (oral).
260. De Rop E., Papeleu P., Vanhaecke T., Rogiers V. "Synergetic effects of histon acetylation and DNA demethylation on proliferation and differentiation in EGF-stimulated primary rat hepatocytes" Dertiende Forum der Farmaceutische Wetenschappen (BGFW) Spa, Belgium, 11-12/10/2007 (oral).
261. Vinken M., Henkens T., Vanhaecke T., Geerts A., Chipman K.J., Meda P. and Rogiers V. "Trichostatin A enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes". Cambridge Healthtech Institute's Fifth Annual Discovery on Target 2007: histone deacetylase inhibitors Conference, Developing inhibitors for promising drug targets. Boston, USA, 16-17/10/2007 (poster).
262. Vinken M., Henkens T., Vanhaecke T., Geerts A., Chipman JK, Meda P., Rogiers V., "Trichostatin A enhances gap junctional intercellular communication in primary cultures of rat hepatocytes" 1st Annual carcinoGENOMICS consortium Meeting, Valencia, Spain, 06-08/11/2007 (oral + poster).
263. De Kock J., Vanhaecke T., Rogiers V., Snykers S. "Influence of Trichostatin A on the hepatic differentiation process of neonatal epithelial cells from biliary origin" 3rd UK Stem Cell Meeting, Abcam, Londen, UK, 11/03/2008 (poster presentation)

264. Fraczek J., Deleu S., Lukaszuk A., Vanhaecke T., Doktorova T., Vanderkerken K., Tourwé D., Rogiers V. "Structural analogues of Trichostatin A as effective inhibitors of histone deacetylases in cultured rat hepatocytes" The Adult Stem/Progenitor Cell Niche meeting, Brussels, Belgium, 13-15/03/2008 (poster).
265. Snykers S., De Kock J., De Prins E., Vanhaecke T., Rogiers V. "In vitro differentiation of progenitor cells into functional hepatocytes for pharmacology and toxicity testing" INVITROM Symposium- Stem Cells; from Petri Dish to Clinic, 's Hertogenbosch, The Netherlands, 26/03/2009 (oral presentation).
266. De Kock J., Vanhaecke T., Biernaskie J., Miller FD, Rogiers V., Snykers S. "Characterization and hepatic differentiation of skin-derived precursors from adult foreskin by sequential exposure to hepatogenic cytokines and growth factors reflecting liver development" ESTIV 15th International Congress on In Vitro Toxicology, Stockholm, Sweden, 25-28/09/2008 (poster presentation).
267. Doktorova T., Vinken M., Vanhaecke T., Rogiers V. "Non-genotoxic hepatocarcinogens specifically target mitochondria and gap junctions" ESTIV2008 (European Society for Toxicology *in Vitro*) Stockholm, Sweden, 25-28/09/2008. (oral)
268. Doktorova T., Vinken M., Vanhaecke T., Rogiers V. "TSA-stabilised hepatocytes in the study of genotoxic and non-genotoxic carcinogens" ECOPA Science Initiative (eSI) meeting, Alicante, Spain, 16-18/10/2008.(oral)
269. Vinken M., Decrock E., De Vuyst E., Leybaert L., Vanhaecke T., Rogiers V., "Establishment of an *in vitro* model of liver cell death" EPAA 2008 Conference - Research into Alternative Approaches [3Rs]: Are we on the right track?, Brussels, 03/11/2008 (poster).
270. Vanhaecke T., Henkens T., Rogiers V. "Development of a new strategy to stabilize liver cells in culture" EPAA Annual Conference Research into Alternative Approaches [3Rs]: in regulatory testing: Are we on the right track?, Brussels, Belgium, 03/11/2008 (poster).
271. De Kock J., Snykers S., De Prins E., Vanhaecke T., Rogiers V. "Hepatocyte-like cells from human skin: a promising tool for in vitro pharmaco-toxicological research and testing" EPAA Annual Conference Research into Alternative Approaches [3Rs]:in regulatory testing: Are we on the right track?, Brussels, Belgium, 03/11/2008 (poster).
272. Doktorova T., Vinken M., Vanhaecke T., Rogiers V. "Non-genotoxic hepatocarcinogens specifically target mitochondria and gap junctions" 2nd Annual carcinoGENOMICS meeting, Dublin, Ireland, 10-12/11/2008 (oral + poster)
273. Ellis, J.K., Chan P.H., Doktorova T., Athersuch T.J., Cavill R., Vanhaecke T., Rogiers V., Vinken M., Nicholson J.K., Ebbels T., Keun H.C. "The effect of the histone deacetylase inhibitor Trichostatin A on the Metabolome of Cultured Primary Hepatocytes" Workshop 'Genomics in Cancer Risk Assessment Workshop', Venetië, Italy, 27-28/08/2009 (abstract +poster).
274. De Kock J., De Prins E., Vanhaecke T., Rogiers V., Snykers S. "Hepatic differentiation of neonatal rat epithelial cells from biliary origin. Human Pluripotent Stem Cells Symposium, Dublin, Ireland, 22-24/04/2009 (poster).

275. Vinken M, Decrock E, De Vuyst E., De Bock M., Vandenbroucke R. E., De Geest B. G., Demeester J., Sanders N. N., Vanhaecke T., Leybaert L., Rogiers V. “Connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death” 7th World Congress on Alternatives and Animal Use in the Life Sciences”, Rome, 30/08-03/09/2009 (poster).
276. De Kock J., Snykers S., Vanhaecke T., Rogiers V. “In vitro differentiation of postnatal stem/progenitor cells into functional hepatic cells: differentiation strategy and *in vivo* transplantation”. Dag van het Farmaceutisch onderzoek, Mechelen, Belgium, 02/06/2009.
277. Decrock E., Van Moorhem M., De Vuyst E., Wang N., De Bock M., Vinken M., Rogiers V., Naus C.C., Erneux C., Leybaert L. “Cell death communication via connexin channels investigated in a C6 glioma cell model” 9th European Meeting on Glial Cells in Health and Disease”, Paris, 8-12/09/2009 (poster).
278. Vinken M., Decrock E., De Vuyst E., Leybaert L., Vanhaecke T., Rogiers V. “Establishment of an *in vitro*-model of liver cell death” EPAA congres 2008 gepubliceerd in ALTEX 26, 2009 p.140 (abstract+poster).
279. Vinken M., Decrock E., De Vuyst E., De Bock M., Vandenbroucke R.E., De Geest B.G., Demeester J., Sanders N.N., Vanhaecke T., Leybaert L., Rogiers V. “Connexin32 hemichannels facilitate the apoptotic-to-necrotic translation during Fas-mediated hepatocyte cell death” Journal Club, Universiteit Gent, 07/07/2009 (oral presentation).
280. Rogiers V. “Safety assessment practices – European Union (SCCS)” Personal Care Products Council’s 5th Annual Seminar, Newark, New Jersey, 29/10/2009 (oral presentation).
281. Vinken M., Doktorova T., Ellinger-Ziegelbauer H., Arh H.J., Lock E., Carmichael P., Roggen E., van Delft J., Kleinjans J., Castell J., Bort R., Donato T., Ryan M., Corvi R., Keun H., Ebbels T., Atersuch T., Sansone S.-A., Rocca-Serra P., Stierum R., Jennings P., Pfaller W., Gmuender H., Vanhaecke T., Rogiers V. “Data sharing on compound selection: a way to improve the outcome of research projects in the field of 3R-alternatives to animal testing” Annual EPAA conference, Brussel 06/11/2009 (poster).
282. Rogiers V. “Safety assessment of cosmetics in the EU” the 17th International Contact Dermatitis Symposium (ICDS) – The 10th Asia-Pacific Environmental and Occupational Dermatology Symposium (APEODS), Kyoto, Japan, 05-08/11/2009 (oral presentation).
283. Rogiers V., Vinken M., Snykers S., Vanhaecke T “Actual status of alternative methods for human health risk assessment: focus on available cell systems for liver toxicity testing” Seminarreeks ‘State-of-the-art lectures in biomedicine’ Universiteit Antwerpen, 01/12/2009 (oral presentation).
284. De Kock J., Vanhaecke T., Biernaskie J., Rogiers V., Snykers S. “Human skin, a promising source of stem cell-derived hepatic cells” BCLAS Symposium 2009, Blankenberge, Belgium 02/12/2009 (oral).
285. De Kock J., Snykers S., Vinken M., Vanhaecke T., Rogiers V. “The development of robust functional human-based cell systems for liver toxicity screening of new chemical entities”, Alternatieven voot Dierproeven, Leiden, The Netherlands, 22/03/2010 (oral).

286. Bolleyn J., De Kock J., Vanhaecke T., Rogiers V., Snykers S. "Isolation, characterisation and hepatic differentiation of adult stem/progenitor cells from easily accessible human sources". PhD Research Day VUB Brussels, 28/05/2010 (poster).
287. Michotte Y., Rombaut B., Rogiers V., Vander Heyden Y. "CePhar: Center for Pharmaceutical Research". PhD Research Day VUB Brussels, 28/05/2010.
288. De Kock J., Vanhaecke T., Biernaskie J., Rogiers V., Snykers S. "Skin-derived precursors, a promising source for hepatic progeny, Epigenetics and Stem Cells Conference, Abcam, Copenhagen, Denmark, 25-27/08/2010 (poster).
289. Vinken, M., Decrock E., De Vuyst E., De Bock M., Vandenbroucke R. E., De Geest, B. G., Demeester J., Sanders N.N., Vanhaecke T., Leybaert L., Rogiers V. "Connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death" 16th ESTIV International Conference on Toxicology in Vitro, Linz, Oostenrijk, 02-04/09/2010 (poster).
290. Snykers S., Al Battah F., De Kock J., Vanhaecke T., Rogiers V. "Optimized 2D and 3D isolation and expansion of multipotent human adipose-derived stem cells, 16th International Congress on *In Vitro* Toxicology (ESTIV 2010), Linz, Austria, 02-04/09/2010 (poster).
291. Bolleyn J., Fraczek J., Vinken M., Lizarrago D., Gaj S., Van Delft J.H.M., Rogiers V., Vanhaecke T. (2010) "Effect of Trichostatin A on miR-122 expression in cultures of primary rat hepatocytes". ESTIV 2010), 16th International Congress on *In Vitro* Toxicology (ESTIV 2010), Linz, Austria, 02-04/09/2010 (oral).
292. De Kock J., Al Battah F., Vanhaecke T., Rogiers V. and Snykers S. "Evaluation of the multipotent character of human skin-derived precursors" 16th International Congress on *In Vitro* Toxicology (ESTIV 2010), Linz, Austria, 02-04/09/2010 (poster).
293. Doktorova, T., Vanhaecke T., Rogiers V., Vinken M. "Epigenetically-stabilized primary hepatocyte cultures: a sensitive *in vitro* tool for hepatocarcinogenicity screening?" 4th Consortium and General Assembly Meeting, carcinoGENOMICS project, Arona, Italy, 08-10/11/2010 (poster).
294. Dollé L., Best J., Mei J., Empsen C., Van Rossen E., Najimi, M., Snykers S., Streetz K., Sokal E., Rogiers V., Leclercq I., Van Grunsven L. "Purification of liver progenitor cells by using aldehyde dehydrogenase activity" EASL, The International Liver Congress 2011, Berlin, Germany, 31/03-03/04/2011 (poster).
295. Doktorova, T., Vinken M., Vanhaecke T., Rogiers V. "Epigenetically-stabilized primary hepatocyte cultures: a sensitive *in vitro* tool for hepatocarcinogenicity screening?" PhD Research Day, Brussels, Belgium, 05/04/2011 (poster).
296. Vinken M., Decrock E., De Vuyst E., De Bock M., Vandenbroucke R.E., De Geest B. G., Demeester J., Sanders N. N., Vanhaecke T., Leybaert L., Rogiers V. "Connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during FAS-mediated hepatocyte cell death" Society of Toxicology Meeting, Washington, USA, 06-10/03/2011.
297. De Kock J., Snykers S., Vinken M., Vanhaecke T., Rogiers V. "The development of robust functional human-based cell systems for liver toxicity screening of new chemical entities" Alternatieven voor Proefdieren, Leiden, The Netherlands 22/03/2011 (oral presentation).

298. De Kock J., Vanhaecke T., Biernaskie J., Rogiers V., Snykers S. “Skin-derived precursors, a promising source for hepatic progeny, Research Unlimited, Brussels, Belgium, 05/04/2011 (poster).
299. De Kock J., Al Battah F., Vanhaecke T., Rogiers V., Snykers S. “Evaluation of the multipotent character of human skin-derived precursors, Research Unlimited, Brussels, Belgium, 05/04/2011 (poster).
300. De Kock J., Snykers S., Branson S., Rogiers V., Vanhaecke T. “Differentiation of neonatal rat liver epithelial cells from biliary origin into functional hepatocyte-like cells. ESNATS Summer School, Thessaloniki, Greece, 01-03/05/2011 (poster).
301. Decrock E., Kaczmarek A., Vinken M., Crispino G., Bol M., De Vuyst E., Naus C.C., Rogiers V., Vandenaabeele P., Erneux C., Mammano F., Krysko D.V., Bultynck G., Leybaert L. “The transfer of inositol trisphosphate through gap junctions is necessary, but not sufficient, to mediate spread of CytC-induced apoptosis” International Gap Junction Conference 2011, Ghent 06-11/08/2011 (poster).
302. De Vuyst E., Wang N., Ponsaerts R., Boengler K., Abudara V., Palacios-Prado N., Wauman J., Lai C.P., De Bock M., Decrock E., Bol M., Leurs K., Vinken M., Rogiers V., Tavernier J., Howard E.W., Naus C.C., Bukauskas F.F., Giaume C., Heusch G., Schulz R., Bultynck G., Leybaert L. “Gap19 inhibits connexin-43 hemichannels without inhibiting gap junctions and limits cardiac ischemia/reperfusion injury in mice”. International GAP Junction Conference 2011, Ghent, 06-11/08/2011 (poster)
303. Vinken M., Decrock E., Bultynck G., Vanhaecke T., Leybaert L., Rogiers V. “Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes”. International Gap Junction Conference 2011, Ghent, 06-11/08/2011 (poster)
304. Prieto P., Creton S., Boobis A., Dekant W., Kleinjans J., Komulainen H., Mazzatorta P., Orice A., Rogiers V., Schoeters G., Vinken M. “Alternative approaches for the evaluation of repeated dose toxicity and its use for quantitative risk assessment of cosmetic ingredients” 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (poster).
305. Doktorova T., Ellinger-Ziegelbauer H., Vinken M., Vanhaecke T., Ahr J.-J., Rogiers V. “Comparison of *in vitro* versus *in vivo* transcriptomics data of hepatocarcinogens” 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (poster).
306. Ceelen L., Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V. “Critical selection of reliable reference gene expression study in the HepaRG cell line” 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (poster).
307. De Kock J., Ceelen L., Rodrigues R.M., De Spiegelaere W., Casteleyn C., Claes P., Vanhaecke T., Rogiers V. “Decellularized liver matrix, a remarkable tool in the bio-engineering of three-dimensional *in vitro* liver systems” 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (poster).

308. Ramboer E., De Kock J., Al-Battah F., Heymans A., Vanhaecke T., Rogiers V., Snyckers S. "Optimized 1- and 3 dimensional isolation and expansion of multipotent human adipose tissue-derived stem cells evaluation of their multipotency" 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (oral + poster).
309. Vanhaecke T., Bolleyn J., Fraczek J., Vinken M., Rogiers V. "Stabilisation of primary hepatocyte cultures via interfering with epigenetic control mechanisms" 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (oral presentation).
310. Vinken M., Decrock E., Bultynck G., Vanhaecke T., Leybaert L., Rogiers V. "Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes" 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montréal, Canada, 21-25/08/2011 (poster).
311. Bolleyn J., Fraczek J., Vinken M., Lizarraga D., Gai S., van Delft J. H., Rogiers V., Vanhaecke T. "Effect of Trichostatin A on miRNA expression in cultures of primary rat hepatocytes. 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada, 21-25/08/2011 (poster)
312. De Kock J., Rodrigues R. M., Vanhaecke T., Rogiers V. "Whole Liver Decellularization: a novel *in vitro* 3D bioengineering tool". INVITROM, Utrecht, The Netherlands, 12/12/2011.
313. Vinken M., Decrock E., Bultynck G. Vanhaecke T., Leybaert L., Rogiers V. "Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes" Annual Meeting "Safety Evaluation Ultimately Replacing Animal Testing (SEURAT-1), project cluster, Lisboa, Portugal 08-09/02/2012 (poster)
314. Vinken M., Decrock E., Bultynck G. Vanhaecke T., Leybaert L., Rogiers V. "Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes" Annual Meeting "Safety Evaluation Ultimately Replacing Animal Testing (SEURAT-1), project cluster, Lisboa, Portugal, 08-09/02/2012 (oral presentation).
315. Rodrigues R., De Kock J., Vanhaecke T., Rogiers V. "Decellularized liver matrix: a remarkable tool in the development of 3D *in vitro* liver systems" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
316. Ramboer E., Vinken M., Vanhaecke T., Rogiers V. "Comparison of the expression and functionality of MRP2 and BSEP drug transporters in different primary hepatocyte culture systems" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
317. Buyl K., Vinken M., Vanhaecke T., Rogiers V. "Effects of RNA interference-mediated suppressions of connexin43 production on the expression of differentiation markers in cultures of adult primary rat hepatocytes" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
318. Desmedt B., Rogiers V., Courcells P., De Beer J., De Paepe K., Deconinck E. "Development and validation of a fast chromatographic method for screening and quantification of illegal whitening agents" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
319. Ates G., Vinken M., Pauwels M., Vivier M., Vanhaecke T., Rogiers V. "Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).

320. Bolleyn J., De Kock J., Mertens H., Fraczek J., Vinken M., Govaere O., Roskams T., Rogiers V., Vanhaecke T. "Liver-specific miR-122 does not affect mRNA levels of cytochrome P450 enzymes and nuclear receptors in primary rat hepatocyte cultures" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
321. De Kock J., Najar M., Bolleyn J., Al Battah F., Rodrigues R.M., Buyl K., Raicevic G., Govaere O., Branson S., Meganathan K., Gaspar J. A., Roskams T., Sachinidis A., Lagneaux L., Vanhaecke T., Rogiers V. "Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
322. Rodrigues, R.M., De Kock J., Vanhaecke T., Rogiers V. "Human skin derived progenitor cells: a new model for hepatic toxicity testing" Dag van de doctorandi, VUB Campus Jette, 27/03/2012 (poster).
323. Desmedt B., Deconinck E., De Beer J., De Paepe K., Rogiers V. "Illegal whitening cosmetics: development and validation of a fast chromatographic method for characterization and risk evaluation of skin penetrating actives" 13th Int. Perspectives in Percutaneous Penetration conference, La Grande-Motte, France, 10-14/04/2012 (poster).
324. Vinken M., Decrock E., Bultynck G., Vanhaecke T., Leybaert L., Rogiers V. "Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes" Summer School, van de "Safety Evaluation Ultimately Replacing Animal Testing (SEURAT-1)" project cluster, Lisboa, Portugal, 04-08/06/2012 (poster).
325. Doktorova T., Ellinger-Ziegelbauer H., Vinken M., Vanhaecke T., Ahr H.J., Rogiers V. "In vivo relevance of in vitro results using toxicogenomics approach?" 5th Consortium and General Assembly Meeting, carcinoGENOMICS Final Meeting, Maastricht, The Netherlands, 16-17/04/2012.
326. Doktorova T., Vinken M., Vanhaecke T., Rogiers V. "Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures" 5th Consortium and General Assembly Meeting, carcinoGENOMICS Final Meeting, Maastricht, The Netherlands, 16-17/04/2012.
327. Ramboer E., Vanhaecke T., Rogiers V., Vinken M. "The effect of epigenetic modification on drug transporters in primary cultured hepatocytes" Kick-off symposium inter-universitaire samenwerking UA-KULeuven-VUB, 27/06/2012 (oral presentation).
328. Rogiers, V., Gamze A., Doktorova T. (2012) "Genotoxicity testing in the safety assessment of cosmetic substances". ESTIV 2012, International Congress on in vitro toxicology, Lisbon, Portugal, 16-19/10/2012 (oral).
329. Bolleyn J., De Kock J., Rogiers V., Vanhaecke T. (2012) "Influence of miR-143 on the expression of cell cycle related genes in cultured primary hepatocytes. ESTIV 2012: International Congress on in vitro toxicology, Lisboa, Portugal, 16-19/10/2012 (poster).
330. Rodrigues R.M., De Kock J., Claes P., Vanhaecke T., Rogiers V. "Decellularized Liver Matrix: a remarkable tool in the development of three-dimensional in vitro liver systems. ESTIV 2012: International Congress on in vitro toxicology, Lisboa, Portugal, 16-19/10/2012 (poster).

331. Rodrigues R.M., De Kock J., Branson S., Vinken M., Meganathan K., Chaudhars U., Sachinidis A., Vanhaecke T., Rogiers V. "Human skin-derived stem cells as a novel cell source for *in vitro* hepatotoxicity testing of pharmaceuticals" SEURAT-1 Annual Meeting, Lisboa, 06-07/03/2013 (poster).
332. Ramboer E., Vanhaecke T., Rogiers V., Vinken M. "The effect of the histone deacetylase inhibitor Trichostatin A on the expression and activity of drug transporters in primary rat hepatocyte cultures", Dag van de Doctorandi 2013, VUB, campus Etterbeek, Brussels 31/05/2013 (poster).
333. Gamze A., Doktorova T., Pauwels M., Rogiers V. "Retrospective analysis of the mutagenicity/genotoxicity data of cosmetic ingredients present in the Annexes of the Cosmetic EU legislation", Dag van de Doctorandi 2013, VUB, campus Etterbeek, Brussels 31/05/2013 (poster).
334. Desmedt B., Rogiers V., Courselle P., De Beer J.O., De Paepe K., Deconinck E. « Detection of allergic fragrances in cosmetic formulations » Dag van de Doctorandi 2013, VUB, campus Etterbeek, Brussels 31/05/2013 (poster).
335. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. "Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury". The annual meeting of the "Safety Evaluation Ultimately Replacing Animal Testing" (SEURAT-1) Barcelo, Spain, 05-06/02/2014 (poster).
336. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. "Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury". Society of Toxicology (SOT) meeting, Phoenix-Arizona, 23-27/03/2014 (poster).
337. Maes M., Cogliati B., Zaidan Dagli ML, Rogiers V, Vinken M. "Protective effects of connexin43 signaling in experimental induced acute liver failure in mouse" PhD Research Day, Vrije Universiteit Brussel – Research Unlimited, Brussels, Belgium, 01/04/2014 (poster).
338. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. "Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury". NC3Rs workshop on Pathways-based approaches across the biosciences, London, UK, 08-09/05/2014 (poster).
339. Maes M., Cogliati B., Zaidan Dagli ML, Rogiers V., Vinken M. "Protective effects of connexin43 signaling in experimental induced acute liver failure in mouse" "Connexins-Pannexins: WOG FWO Meeting Ghent, Belgium, 22/05/2014 (oral).
340. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. "Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury". 18th International Congress on *In Vitro* Toxicology (ESTIV) that will take place in Egmond aan Zee, The Netherlands, 10-13/06/2014 (poster).
341. Desmedt B., Rogiers V., Courselle P., De Beer J.O., De Paepe K., Deconinck E. « Validation and application of a novel method for the detection of 24 allergenic fragrances in complex cosmetic formulations » 24th symposium on Pharmaceutical and Biomedical Analysis – Recent Developments in Pharmaceutical Analysis, Bologna, Italy, 07/2014 (poster).

342. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. "Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury". 9th World Congress on Alternatives and Animal Use in the Life Sciences, Prague, Czech Republic, 24-28/08/2014 (poster).
343. Bolleyn J., Nair N., De Kock J., Chuah M., VandenDriessche T., Rogiers V., Vanhaecke T. "Lentiviral transduction to drive a liver - derived rat epithelial cell line from biliary origin towards hepatocyte-like cells". 9th World Congress on Alternatives and Animal Use in the Life Sciences, Prague, Czech Republic, 24-28/08/2014 (poster).
344. Van Bossuyt M., Van Hoeck E., Schüürmann G., Ates G., Vanhaecke T., Mertens B., Rogiers V. "Annual Scientific Meeting of the Belgian Environmental Mutagen Society, Brussels, 14/11/2014 (oral)
345. Van Bossuyt M., Van Hoeck E., Schüürmann G., Vanhaecke T., Mertens, B., Rogiers V. "Use of (Q)SAR tools as a first step in a strategy to assign priority to substances migrating from printed paper and board food contact materials based on the genotoxic potential". Annual BELTOX meeting, Thomas More campus (KH Leuven) in Geel, 04/12/2014 (poster).
346. Van Bossuyt M., Van Hoeck E., Schüürmann G., Vanhaecke T., Mertens, B., Rogiers V. "Use of (Q)SAR tools as a first step in a strategy to assign priority to substances migrating from printed paper and board food contact materials based on the genotoxic potential". PhD Day VUB, Jette, 31/03/2015. (poster)
347. De Kock J., Meuleman P., Rodrigues R.M., Govaere O., Lootens L., Van Eenoo, Roskams T., Leroux-Roels G., Vanhaecke T., Rogiers V. "Human skin-derived cells as cellular therapy for end-stage liver disease". ISSCR 2015, 13th Annual Meeting of International Society for Stem Cell Research, Stockholm, Sweden, 24-27/06/2015 (oral)
348. Van Bossuyt M., Van Hoeck E., Raitano G., Ost N., Ates G., Schüürman G., Vanhaecke T., Benfenati E., Rogiers V., Mertens B. "Use if (Q)SAR tools as a first step in a strategy to assign priority to substances migrating from printed paper and board food contact materials based on genotoxic potential" EUROTOX 2015, 51th Congress of the European Societies of Toxicology, Porto, Portugal, 13-16/09/2015 (poster)
349. Benfenati E., Raitano G., Van Bossuyt M., Mertens B., Van Hoeck E., Rogiers V. "Screening tossicologico dei contaminanti alimentari attraverso metodi 'in silico'" Workshop: un ambiente pulito per cibi sani – EXPO 2015, Milan, Italy, 16/09/2015 (oral).

12. REFEREE FOR JOURNALS - MEMBER OF THE EDITORIAL BOARD

- Biochemical Pharmacology
- Cell Biology and Toxicity
- European Journal of Pharmacology, since 2000.
- Journal of Hepatology
- **Archives of Toxicology**, member of the Editorial Board since 1991, Associate Editor since 1994-now
- Life Sciences
- **Toxicology In Vitro**, member of the Editorial Board, since 2002
- European Journal of Biochemistry
- **ATLA** (Alternatives for Laboratory Animals), member of the Editorial Board, since 1998-now
- Tijdschrift voor Belgische Dermatologische Actualiteit.
- **Skin** - Medical Journal for Dermatologists, member of the Editorial Board since 1998.
- Journal of Cosmetic Dermatology, since 2000.

13. MENTIONS/CITATIONS IN THE MEDIA

- "Van hobby naar onderzoek", Echo Pharma, nr. 2, pp8-9, 1992, Rogiers V.
- "Nieuw hydratatieperiode", Kosmetiek, p. 36, 1992, Rogiers V.
- "Moderne vochtcrèmes voorkomen huidveroudering", Coiffure, pp. 24-25, 11/11/1992, Rogiers V.
- "Dermofarmacie: wetenschappelijk!", Het Apothekersblad, nr. 1, p 21, 1992, Rogiers V.
- "Specialisten aan het woord. Beter ouder Worden. Wat is veroudering?", Onze Tijd, pp 2-16/05/1992, Rogiers V.
- "Weefselkweekjes verminderen nood aan proefdieren", De Standaard, 23/09/1993, Rogiers V.
- "Van proefkonijn naar kippen", Het Belang van Limburg, 17/03/1993, Rogiers V.
- "Over mijn lijk?", Artsenkrant, pp 12-13, 15/10/1993, Rogiers V.
- "Vivisection: l'alternative", La Dernière Heure, 22/09/1993, Rogiers V.
- "Les cellules humaines à la place d'animaux", La Libre Belgique, 24/09/1993, Rogiers V.
- "Les cellules humaines mises en boîte", L'Hebdomadaire, nr. 201, 22/09/1993, Rogiers V.
- "Er is hoop voor proefdieren", Het laatste Nieuws, 24/09/1993, Rogiers V.
- "Il faut légiférer sur les tests *in vitro*", Le Soir, 25-26/09/1993
- Dossier "Ze bloost als een roosje maar 't komt allemaal uit een doosje", Top 21, pp 28-29, 1994, Rogiers V.
- "Cosmetica: illusies uit potjes zorgen voor rode kaken", Het Nieuwsblad, 24/12/1994, Rogiers V.
- "Vier deskundigen en het rimpel-debat", Fit en Gezond, juli-aug. 1994, Rogiers V.
- "Je haar kleuren, is dat wel gezond?", Goed Gevoel, pp 16-17, 1995, Rogiers V.

- Dossier "Bronzer protégée", Le monde médical de la femme/Medische wereld van de vrouw, nr. 8, 1995, Rogiers V.
- "Les cosmétiques sand fard", Le Sori, 10-11/02/1996, Rogiers V.
- "Luizen kunnen zwemmen", Dossier "Veilig bruinen", Knack Gezondheid, nr. 40, pp 40-41, 30/09/1998, Rogiers V.
- "Aandacht voor het team "apotheker-dermatoloog", Farmasfeer, nr. 27, p 10, 1998, Rogiers V.
- Rubriek: Onderzoek en Ontwikkeling "Belgisch Platform voor Alternatieve Methoden", Fedichem, nr. 3530, dec. 1998, Rogiers V. en Beken S.
- The creation and presentation of BPAM (Belgisch Platform voor Alternatieve Methoden - Plate-Forme Belge pour Méthodes Alternatives) - Organisation of a press conference in the presence of HH Prince Laurent - Presentation of the goals and objectives of BPAM by Rogiers V., Palais des Congrès, 09/02/1999.
- Interview met VRT Radio 1 "Actueel over het verminderen van dieren als proefkonijn", 09/02/1999, Rogiers V.
- Interview met VRT TV1 "Het journaal over het verminderen van dieren als proefkonijn", 09/02/1999, Rogiers V.
- Interview met VTM Nieuws over "Het verminderen van dieren als proefkonijn", 09/02/1999, Rogiers V.
- Interview met RTL TVI, Le Journal concernant "La diminution des animaux pour les expériences scientifiques", 09/02/1999, Rogiers V.
- Interview met RTBF, Le journal télévisé " concernant la dimunition des animaux pour les expériences scientifiques", 09/02/1999, Rogiers V.
- Interview met RTBF "'La première' concernant la dimunition des animaux pour les expériences scientifiques", 10/02/1999, Rogiers V.
- "Het Belgisch Onderzoek naar Alternatieven voor Proefdieren heeft zijn zetel ana de VUB", Akademos, Infirmatieblad van de VUB, nr 2/2, p 5, 1999.
- "Dierproeven in de geneeskunde. Nieuwste ontwikkelingen in België
- "Expérimentation animale en médecine: derniers développements en Belgique", Medi-Sfeer, nr. 94, p 17, 1999, Rogiers V.
- "Dieren in de wetenschap. Deel 3. Proefkonijn", Natuur en Techniek, nr. 67, pp 68-75, 1999, De Ron A., Beken S. & Rogiers V.
- "Dierproeven", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, in: De Morgen, 31/12/1999
- "La Plate-forme belge pour Méthodes Alternatives (BPMA), lancement et présentation du Livre Blanc", Vétérinaria II (Union professionnelle des Vétérinaires), 1999, Beken S. and Rogiers V.
- "Droits de l'homme et 'droits' des animaux", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie. Le Journal du Médecin, 19/01/1999, Beken S. and Rogiers V.
- "Mensenrechten en 'dieren'rechten", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Artsenkrant 22/01/1999, Beken S. & Rogiers V.
- "Dierproeven: alternatieven hartelijk welkom", Factua Newsletter nr. 90, feb. 1999.
- "Sur la plate-forme belge des méthodes alternatives et le recours à l'expérimentation animale", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Le Soir, 11/02/1999, Beken S. and Rogiers V.

- "On ne fait pas ça par plaisir", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Dernière Heure, 10/02/1999, Beken S. and Rogiers V.
- "Un Prince au secours des animaux de laboratoire", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Dernière Heure, 10/02/1999, Beken S. and Rogiers V.
- "Les tests sur les animaux ont du plomb dans l'aile", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Le Soir, 10/02/1999, Beken S. and Rogiers V.
- "Tests sur les animaux: des méthodes alternatives", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Libre Belgique, 10/02/1999, Beken S. and Rogiers V.
- "Les expériences doivent être limitées au strict nécessaire", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Libre Belgique, 10/02/1999, Beken S. and Rogiers V.
- "Un million d'animaux sacrifiés chaque année en laboratoire. Le long combat contre l'expérimentation animale", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Le Soir, 10/02/1999, Beken S. and Rogiers V.
- "Overlegplatform wil alternatieven voor dierproeven promoten", Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Financieel Economische Tijd, 10/02/1999, Beken S. and Rogiers V.
- "Goede vooruitzichten voor proefkonijnen" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Morgen, 10/02/1999, Beken S. and Rogiers V.
- "Platform ijvert voor alternatieven voor dierenproeven" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De De Standaard, 10/02/1999, Beken S. and Rogiers V.
- "Prins Laurent tegen proeven op dieren" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Standaard, 10/02/1999, Beken S. and Rogiers V.
- "Goede vooruitzichten voor proefkonijnen" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Het Nieuwsblad, 10/02/1999, Beken S. and Rogiers V.
- "Stichting Laurent wil alternatief voor deirenproeven" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Het Belang van Limburg, 10/02/1999, Beken S. and Rogiers V.
- "The realisation of BPAM in one working year", presentation by V. Rogiers of the scientific realisation, KINT, Brussels, Belgium
- Interview met RTBF "Matin Première" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, 27/10/1999, Beken S. and Rogiers V.
- Interview met RTBF "L'auditeur à la parole" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, 29/10/1999, Beken S. and Rogiers V.
- "Wetenschap gepaard aan dierenwelzijn" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Morgen, 01/12/1999, Beken S. and Rogiers V.

- "Dierproeven. Een verre toekomst zonder dierenleed" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Morgen (Aula-Wetenschap 32), 03/12/1999, Beken S. and Rogiers V.
- "Prins Laurent heeft alternatief klaar voor proeven op dieren" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Standaard, 01/12/1999, Beken S. and Rogiers V.
- "Vol huis voor proefdieren en astrokatten" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Het Laatste Nieuws, 01/12/1999, Beken S. and Rogiers V.
- "Les animaux sacrifiés ont diminué de moitié en trois ans" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Lanterne, 01/12/1999, Beken S. and Rogiers V.
- "Quatre ans d'activité et des projets d'avenir" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Libre Belgique, 01/12/1999, Beken S. and Rogiers V.
- "Expérimentation animale - Sept projets pour favoriser des alternatives" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Le Matin, 01/12/1999, Beken S. and Rogiers V.
- "Sept premières alternatives à l'expérimentation animale" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Le Soir, 01/12/1999, Beken S. and Rogiers V.
- "Pas le Prince des cabots. La croisade de Laurent contre l'expérimentation sur les animaux" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, La Dernière Heure, 01/12/1999, Beken S. and Rogiers V.
- "Le prince Laurent: son combat contre l'expérimentation animale" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, Revue "Comme Chien et Chat, nr. 25, Jan. 2000, Beken S. and Rogiers V.
- Organisation of two plenary meetings of the Scientific Section of BPAM with representatives of industry, ministries, animal welfare and universities in 1999 and one plenary meeting in 2000 at the Medical Campus VUB, Jette, Belgium
- Organisation of a BPAM Meeting with animal welfare/protection on budget planning - Budget planning, 10/02/2000, Rogiers V.
- "Minder dieren, betere proef" Belgisch Platform voor Alternatieve Methoden, Wetenschappelijke Sectie, VUB, Dienst Toxicologie, De Standaard, 13/03/2000, Beken S. and Rogiers V.
- "iPAVUB start 4-delige reeks over veiligheid en gebruik van cosmeticaproducten", Informatie aan de pers, 17/09/2002, Rogiers V.
- "Hoe gevaarlijk zijn cosmetica?", Tijdschrift Klasse, 07/10/2002, Rogiers V.
- "Cosmetica en dierproeven", De Morgen, 05/11/2002, Rogiers V.
- "Van ijdelheid en veiligheid", De Financieel Economische Tijd, 16/11/2002, Rogiers V.
- "Zijn zonneproducten veilig?", Medi-Sfeer, 19/02/2002, Rogiers V.
- "Bio-ethiek en levenskwaliteit", De Huisarts, 04/12/2003, Rogiers V.
- "The Interview: A discussion with Prof. Dr. Vera Rogiers", Vrije Universiteit Brussel, Dept. of Toxicology, Belgium, Euro-Cosmetics, vol. 11, pp 14-15, 2003

- Interview "Met de hulp van pillen? De fabeltjes bestaan: hele nachten studeren op koffie, pillen en cola", Rogiers V. , Knack Magazine, pp 66-67, 26/3/2003 (journalist R. Debeule).
- "Hoe veilig zijn mooimakers?", Rogiers V., Weekend Knack, nr. 15, p. 42, 9-15/04/2003 (journaliste S. Allbrecht).
- Interview "Kwalijke chemicaliën in kinderproducten", Rogiers V., De Morgen, p. 10, 21/10/2003 (eigen berichtgeving).
- Interview "Levenskwaliteit en gezondheidszorg", Post-academic formation, iPAVUB, Rogiers V., De Huisarts, p. 12, 29/10/2003.
- Interview "Onvermijdelijk gebruik van proefdieren is toegenomen", Rogiers V., Het Laatste Nieuws, p. 8, 31/10/2003.
- "Wat weten we over de gevoelige huid en hoofdhuid?", Rogiers V., Persontmoeting Firma Procter & Gamble "Head & Shoulders Sensitive - Omdat een gevoelige huid niet bij de haarlijn stopt", Museum David en Alice Van Buuren, Léopold II-laan 41, Brussels, Belgium, 06/11/2003.
- "VUB-onderzoek kan proefdieren sparen", Rogiers V., De Tijd, p. 21, 17/11/2003
- Interview "Deodorants en borstkanker" concerning the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 9/2/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., Het Belang van Limburg, p. 2, 20/01/2004.
- Interview "Berichten over borstkanker en deodorants zaaien paniek" referring to the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., De Morgen, p. 9, 13/01/2004 (eigen berichtgeving).
- Interview "Borstkanker wijten ana deodorants is paniekzaaierij" referring to the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., De Tijd, p. 13, 25/02/2004.
- Interview "Geen verband deodorant-borstkanker" referring to the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., Gazet van Antwerpen, p. 6, 25/02/2004.
- Interview Rubriek Diagnose "Hoe riskant is deodorant?" referring to the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., Algemeen Dagblad (NL), p. 20, 27/02/2004 (journaliste Frederike Geerdrink)
- Interview "Kanker uit de oksel" concerning the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., Knack Magazine, p. 11, 03/03/2004 (journalist Dirk Draulans).
- Interview Rubriek Science/Fiction "Deohype", Rogiers V., Krant Trouw (NL), p. 13, 08/03/2004 (journalist Sander Becker)
- "Onrust over deo's onterecht", Rogiers V., Natuurwetenschap & Techniek, 09/03/2004 (journalist Ernst Van Eijk).
- Mention of the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, in the article "Nederlandse journalist ontkracht knotsgekke wetenschappelijke onderzoeken", Rogiers V., Het Volk, p. 5, 10/03/2004 (journaliste Karen Torben Nielsen).

- Interview "Efficiëntie van Cosmetica", Dag van de Technologie, Rogiers V., Radio 2 Huisraad, 09/03/2004.
- Interview "Parabenen ten onrechte in het vizier" referring to the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, Rogiers V., De Huisarts, nr. 683, pp. 20-21, 24/03/2004 (journalist Johan Waelkens).
- Mention of the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, in the article "Parabènes accusés à tort", Rogiers V., Le Généraliste, nr. 683, p. 24, 24/03/2004 (journalist Johan Waelkens).
- "Wist U dat ... het verhaal dat deodorants borstkanker veroorzaken onzin is?" Akademos, Informatieblad van de VUB, jaargang 7, nr. 2, p.2, April 2004.
- Interview "Nederwiet mogelijk even schadelijk als hard drugs. Nederlandse ministers overwegen verbod op cannabis", Rogiers V., Het Belang van Limburg, p. 3, 07/04/2004 (journalist AdHe).
- Mention of the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, in the article "Geen verbant tussen anti-zweetmiddelen en borstkanker", Rogiers V., De Agenda Gynaecologie, nr. 35, p.16, April 2004 (journalist Johan Waelkens).
- Mention of the 29th Badecos Symposium "Deodorants and Antiperspirants: Do they cause Breast Cancer?" on 09/02/2004 at the Medical Campus VUB, Brussels, Belgium, in the article "Aucun lien entre sels d'aluminium et cancer du sein", Rogiers V., L'Agenda de Gynécologie, no.35, p.16, April 2004 (journalist J. Waelkens).
- Interview "De politiek zo beu", Rogiers V., Het Laatste Nieuws, pp. 10-11, 20/03/2004.
- "Kanker door deodorants? Over zwak onderzoek en een kettingsbrief", Rogiers V., EOS Magazine, pp. 20-23, 01/04/2004 (journalist H. Allemeersch).
- Interview "De gekleurde mens - Tatoeages", Rogiers V., Knack Magazine, Dossier Gezondheid, pp. 72-74, 05/05/2004 (journaliste M. Finoulst).
- "Anti-kanker geneesmiddelen moeten proefdierengebruik in labo's helpen verminderen", Informatie aan de pers, Interne & Externe Communicatie, VUB, August 2004.
- "Wat te geloven van cosmetische verzorgingsproducten?", Rogiers V., Voordracht voor Actueel Denken en Leven, Hadewych Stichting, Leuven, 8/11/2004.
- "Slak redt konijn", participation in documentary, Canvas, in series OverLeven (documentary), 24/03/2005.
- "Waar of niet? Hot news-analyse. Geurtjes met een reukje", Goed Gevoel, p. 122, June, 2005.
- "Nat van het zweet", Evita, pp. 104-105, 1 aug. 2005 (journalist Sarina Wijnen)
- "VUB-professor krijgt prijs voor onderzoek naar alternatieve methoden", Gazet van Antwerpen, p.104-105,14/10/2005.
- "Professor VUB wint prijs voor onderzoek", De Standaard, p. 51, 15-16/10/2005.
- "Wetenschappers moeten geen activisten zijn. Toxicologe Vera Rogiers (VUB) wint Europese prijs voor Dierenwelzijn in Wetenschappelijk Onderzoek", De Morgen, p. 7, 15/10/2005.
- "VUB-Professor krijgt prijs voor onderzoek naar alternatieve methoden", Het Belang van Limburg, 17/10/2005.

- "VUB-onderzoek naar alternatieve methoden bekroont", De Huisarts, rubriek Geneeskunde, 27/10/2005 (journalist J. Waelkens).
- "Animal Award", in Rubriek The Week in Brief, The Bulletin, nr. 05/40, p. 13, 20/10/2005.
- "VUB-onderzoek naar alternatieve methoden bekroont", De Huisarts, nr. 05/756, p. 44, 27/10/2005 (journalist J. Waelkens).
- Panelgesprek in "De 7de Dag" over o.m. carcinogeniciteit van cosmetica, VRT, 30/10/2005.
- "Zepen in geuren en kleuren" (journalist Annelies Ryckaert), Nest, jaargang 4, pp. 118-124, december 2005.
- "Wist u dat ... Vera Rogiers de wetenschappelijke prijs voor Europees onderzoek naar alternatieve methoden behaalde?", Akademos, jaargang 8, nr.5, p.2, december 2005.
- "Kandidaat-kankermedicijn beschermt celcultuur" Mens en Molecule (Magazine voor Chemie en Biowetenschappen), jaargang 1, nr. 10, p. 21, December 2005 (journalist Wim Daems).
- "Maximale veiligheid voor ons hoeft niet persé ten koste te gaan van dierenwelzijn" Goed Gevoel, nr. 06/2, p. 11, 01/02/2006 (journalist VatoLine De Ruyck).
- "DDT weer ingezet tegen malaria". De Standaard, p. 17, 28/07/2006 (journalist Kim De Rijck).
- "Experten Hinterfragen EU-Vision: REACH ohne Tiere". Chemische Rundschau, Deutschland, Aug. 1, 2006. (journaliste Susanne Donner).
- Bijdrage aan de brochure "Zeker van cosmetica", Uitgave van de Nederlandse Cosmetica Vereniging (NCV) (Voorzitter Henk Hogeveen), Zeist, 2006, ISBN 90 8109 911 6.
- Vermelding in artikel "Universiteiten werken aan alternatief voor dierenproeven" van persgroep anp in rubriek Kanaal Nieuws van internetsite www.hln.be op 19/12/2006.
- "Deodorant: zit er een geurtje aan? De waarheid over rollen, smeren & sprayen" Libelle, nr. 29/3212, p. 80-81, 19/07/2007 (journalist Anne Peeters).
- "Hepatocyten uit stamcellen: minder proefdieren" De Huisarts, 09/08/2007, p. 10 (journalist Johan Waelkens).
- "S.O.S. droge huid", Remedies voor gezicht en lichaam, Xtra Magazine, Antwerpen- Limburg nr. 23 p.43, 12/10/2007.
- "Deadline voor dierproeven", Mens en Molecule, Magazine voor chemie en biowetenschappen; jaargang 3 n° 8 p.18-21 (journalist Joef Slegers)
- "Schminkallergie haalt nieuwsanker Sigrid Spruyt voorgoed van het scherm" De Morgen, p. 2, 27/10/07.
- "In de prijzen" Mens en Molecule, p. 20-21, 9 November 2007.
- "Alternatieven voor dierproeven kampen met muizenissen".EOS Magazine n°12 p.38-43, 1 December 2007.
- "Kwikvervuiler gevonden" Het Volk (ed. Vlaams Brabant) 31 januari 2008 p. 19.
- "Veiligheid van dermocosmetische verzorgingsproducten" Esthetische Dermatologie, Skin vol. 11, 3, 2008.
- "La sécurité des soins dermocosmétiques" Dermatologie Esthétique" Skin, Vol. 11 n°3, 2008.
- "L'interdiction des tests sur les animaux menace l'innovation (VUB)" Belga, p. 178, 12/11/2008.

- "Verbod dierproeven bedreigt innovatie cosmetische sector (VUB)" Belga, p. 240, 12/11/2008.
- "Afschaffing dierproeven is gevaar voor nieuwe medicatie" Het Belang van Limburg, 13/11/2008.
- "Afschaffing dierproeven is gevaar voor nieuwe medicatie" Gazet van Antwerpen, 13/11/2008.
- "Verbod dierproeven bedreigt innovatie cosmetische sector", Standaard, 13/11/2008.
- "Verbod dierproeven bedreigt innovatie cosmetische sector", Nieuwsblad, 13/11/2008.
- "Geen vooruitgang in cosmetica door verbod dierenproeven" Het Laatste Nieuws, 13/11/2008.
- "Geen vooruitgang in cosmetica door verbod dierenproeven" De Morgen, 13/11/2008.
- "L'interdiction des tests sur les animaux menace l'innovation" 7 sur 7, 13/11/2008;
- "Verbod dierproeven heeft ernstige gevolgen voor cosmetische sector" Metro, Nederland p. 10, 13/11/2008.
- "Verbod op dierproeven bedreigt innovatie cosmetische sector", De Morgen, p. 11, 13/11/2008.
- "Des cosmétiques à la mode bio?", La Libre Belgique page 22 in "Memento", 13/12/2008.
- « Crèmes de Beauté : Promesses tenues ? », Equilibre, p.6-8, 01/03/2009.
- « Vals alarm ? », Feeling, p. 18, 01/06/2009.
- « Huidverzorging bij mannen is geen taboe meer », De Standaard p. 6 in 'Media Planet' 10/07/2009.
- "Zon helpt niet tegen acne", www.nieuwsblad.be van 23/07/2009.
- "Zon helpt niet tegen acne", Het Nieuwsblad p. 13 van 23/07/2009.
- "Zonlicht maakt acné erger", www.rnews.be van 23/07/2009.
- "Jongeren met acne kunnen zon best mijden", www.vandaag.be van 23/07/2009.
- "Zonlicht maakt acne erger", Het Laatste Nieuws p. 21 van 25/07/2009.
- "Vaak kammen leidt tot haarverlies" Het Laatste Nieuws p. 6 van 11/08/2009.
- "Conséquence (fâcheuse) de la pesanteur..." MediaPlanet p. 8 de 18/12/2009.
- "De houdbaarheid van Cosmetica" Het Nieuwsblad Magazine p. 28 van 12/12/2009.
- "Volwassen stamcellen als alternatief voor proefdierengebruik" Folium, XXIII ed. II p. 8-11, dec. 2009.
- "Le Scientific Committee on Consumer Safety européen (ex-SCCP) a publié un mémorandum sur les méthodes alternatives validées, encore trop peu nombreuses". Cosmétique Hebdo, n°442 p. 3 van 22/02/2010.
- "Nanotechnologie, een zegen of een vloek?" Weekend Knack p. 89-90 van 03/03/2010.
- "Zonnebaden heeft ook positieve effecten" Het Belang van Limburg, p.13 van 29/03/2010.
- "De l'utilité des produits cosmétiques masculins" Le Pharmacien p.8 van 29/03/2010.
- "Mannencosmetica, zin of onzin ?" de Apotheker p. 8 van 29/03/2010.
- "Zon niet goed voor Acne" Web, www.gezondheid.be van 19/08/2010.
- "Wetenschappelijke uitleg in cosmeticareclame kan beter" Het Laatste Nieuws van 16/10/2010.

- “EUREKA 48 Onderzoekers in de kijker” Poster Tentoonstelling – Brussel September 2010: aan alle Secundaire Scholen Brussel; Oktober 2010: in Warandapark Brussel, Sint-Gorikshallen en November 2010: aan Centraal Station en City2 Brussel.
- “De waarheid over huidverzorging” Magazine p.22-23 van 8 February 2011
- “Hoe kies je het juiste product, Gezichtscreme, Magazine p. 29 van 28 February 2011.
- “Getest op mensen” interview VRT op woensdag 16/02/2011.
- “Vloeibare cocaïne” VTM nieuws van donderdag 17/02/2011.
- “De waarheid over huidverzorging” Het Nieuwsblad Magazine, 05/02/2011 p.22-23.
- “Al die potjes, geuren en kleuren... Hoe kies je het juiste product” Het Nieuwsblad Magazine van 05/02/2011 p. 27-29.
- “Cosmétiques: potions ou poisons?” Le Vif Weekend p. 76-79 van 29/04/2011.
- “Hoe (on)veilig zijn cosmetica?” Stand van Zaken. Weekend Knack p. 26-30 van 27/04/2011.
- “Cosmetica: veiligheid voor alles” Topic Zomer 2011, Jaarlijks Themamagazine p. 109-110.
- “Antitransparant, DETIC REAGIT” La Dernière Heure, p.18 van 04/05/2011.
- Opinie: “Waarom onze wetenschappers zo goed scoren” V. Rogiers en M. Gevers, De Morgen, p. 16 van 26/03/2012.
- “Belgische wetenschappers zijn wereldtop” De Morgen p. 1 van 26/03/2012.
- “Pourquoi les chercheurs belges sont-ils si productifs?” Michel Gevers, V. Rogiers, Le Soir, 26/03/2012.
- Ter gelegenheid van het Belgisch EU-Voorzitterschap, verderzetting “EUREKA 48 Onderzoekers in de kijker” Poster Tentoonstelling - start 2010 – afsluiting UCL Brussel mei 2012.
- “De waarheid over deodorants” Vitaya Magazine, pag. 131 van 1 June 2012.
- “Hoe adviseren over zonnebescherming?” OTC Partner, 4^e ed. June 2012.
- “Hoe verslavend is een lippenbalsem?” Radio 2 op 09/01/2013.
- “Zon beschermers met benefits” Feeling, p. 50, 01/06/2013.
- “Schoonheid uit een plantje” Het Laatste Nieuws, pag. 78-79 van 12/10/2013.
- “Alle onderzoekers zijn bang om de pispaal te worden” De Standaard, pag. 28-29 van 01/02/2014.
- “Animal testing: In search of alternatives” Flanders Today, 13/02/2014.
- “An alternative to lab rats” Flanders Today, pag. 9, 19/02/2014.
- “Werken antirimpel” Goed Gevoel, pag. 42-45, 1 March 2014.
- “Uw badkamerkastje vol gif? Onzin” Het Laatste Nieuws pag.9 van 24/03/2014.
- “Les produits d’hygiène sont-ils si nocifs?” La Dernière Heure pag.13 van 24/03/2014.
- “Werken antirimpelcrèmes echt?” Goed Gevoel pag. 52-55 van 04/04/2014.
- “Consument: 96u zonder geurtje? Nieuwe deo’s beloven omogelijke” Het Laatste Nieuws p. 64-65 van 12/04/2014.
- “Zo mooi zijn we tegenwoordig op 69”, Het Laatste Nieuws van 28/11/2014.
- “Van huidstamcel naar levercel” Artsenkrant pag. 18 van 17/04/2015.
- “Regulations: Everything you need to know” in Soap, Perfumery & Cosmetics (SPC) 88(7): 58-65 van 07/2015.

An important remark is also that both the fundamental toxicological research and the more applied dermato-pharmaceutical and cosmetic research have received a large interest by the general public. Interviews appeared on television, radio and in several newspapers and magazines. Only some of these are mentioned above as illustrative examples.
